data_2mfs_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mfs _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.5 p . . . . . 0 N--CA 1.452 -0.334 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.535 HG23 ' SG ' ' A' ' 33' ' ' CYS . 21.2 m -106.84 167.4 3.45 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-O 121.184 0.516 . . . . 0.0 111.291 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.453 ' HB3' ' OE1' ' A' ' 20' ' ' GLN . 25.3 mt -107.41 175.97 5.31 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.174 -172.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 27.9 pt -61.07 134.99 26.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.438 0 CA-C-O 121.415 0.626 . . . . 0.0 112.394 -178.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.65 -13.3 60.97 Favored Glycine 0 C--N 1.312 -0.78 0 CA-C-N 115.486 -0.779 . . . . 0.0 112.622 -179.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -90.4 151.18 21.54 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 106.892 -1.522 . . . . 0.0 106.892 176.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 34.3 ptt180 -85.9 146.24 26.8 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.949 -0.7 . . . . 0.0 111.064 -173.156 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.4 p -139.09 176.91 8.29 Favored 'General case' 0 C--N 1.282 -2.331 0 CA-C-N 115.164 -0.926 . . . . 0.0 109.224 -174.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -152.11 117.31 5.24 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 174.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -57.08 -38.99 74.1 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 113.629 0.974 . . . . 0.0 113.629 -173.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -91.86 -47.58 7.25 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 113.628 0.973 . . . . 0.0 113.628 -175.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.0 mtm180 -89.48 -29.88 18.67 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -173.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.55 160.31 25.94 Favored Glycine 0 N--CA 1.435 -1.389 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -174.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -79.65 167.45 75.47 Favored 'Cis proline' 0 C--O 1.218 -0.475 0 CA-C-N 119.542 1.671 . . . . 0.0 111.987 1.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 88.0 mtm180 -122.01 156.25 33.87 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 33.6 m -70.2 149.25 47.7 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 124.825 1.25 . . . . 0.0 111.319 -175.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 85.4 m -68.43 143.74 54.95 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 175.229 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 11.4 t -54.3 -26.45 29.41 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 125.25 1.42 . . . . 0.0 113.039 -172.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -108.08 16.53 35.8 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.188 178.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.453 ' OE1' ' HB3' ' A' ' 3' ' ' LEU . 18.3 mm-40 -97.74 -68.1 0.82 Allowed 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -179.368 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -175.85 -179.18 46.2 Favored Glycine 0 CA--C 1.481 -2.089 0 C-N-CA 120.261 -0.971 . . . . 0.0 110.703 -176.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 52.4 t30 -93.29 139.6 30.46 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 177.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 49.9 t -79.47 98.13 6.68 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.62 120.09 69.53 Favored Pre-proline 0 C--N 1.302 -1.47 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -67.18 141.7 58.19 Favored 'Trans proline' 0 N--CA 1.449 -1.114 0 C-N-CA 122.431 2.087 . . . . 0.0 113.106 -176.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.4 mt -119.36 144.19 35.95 Favored Pre-proline 0 C--N 1.302 -1.5 0 CA-C-N 114.743 -1.117 . . . . 0.0 109.078 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_exo -40.26 -57.31 1.23 Allowed 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 124.731 3.621 . . . . 0.0 114.806 -176.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 30.4 p90 -119.18 -24.18 6.54 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -177.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 78.3 mt -79.9 0.49 31.02 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 179.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 87.57 -59.22 4.37 Favored Glycine 0 CA--C 1.499 -0.939 0 C-N-CA 121.149 -0.548 . . . . 0.0 111.871 177.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 171.64 170.79 36.07 Favored Glycine 0 N--CA 1.418 -2.512 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 9.2 p -147.3 146.15 18.59 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.986 0 CA-C-O 121.503 0.668 . . . . 0.0 109.992 177.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.535 ' SG ' HG23 ' A' ' 2' ' ' VAL . 74.1 m -80.06 118.4 21.75 Favored 'General case' 0 C--N 1.285 -2.223 0 CA-C-N 114.713 -1.13 . . . . 0.0 109.923 179.639 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -143.87 153.66 42.57 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 -177.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 52.4 t . . . . . 0 C--N 1.306 -1.32 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -179.109 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.3 p . . . . . 0 C--O 1.24 0.57 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.575 HG22 ' SG ' ' A' ' 33' ' ' CYS . 30.2 m -112.06 158.28 12.55 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-O 120.655 0.264 . . . . 0.0 111.504 -178.567 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 38.2 mt -99.57 -178.56 3.92 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.482 -176.554 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 34.0 pt -58.64 140.37 17.04 Favored 'Isoleucine or valine' 0 C--O 1.241 0.651 0 N-CA-C 113.023 0.749 . . . . 0.0 113.023 -179.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.8 -14.34 48.48 Favored Glycine 0 C--N 1.311 -0.86 0 CA-C-N 115.708 -0.678 . . . . 0.0 113.183 178.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 27.2 mt-30 -86.15 156.53 20.31 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 108.056 -1.091 . . . . 0.0 108.056 178.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 47.1 ttp180 -86.01 132.22 34.11 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 123.623 0.577 . . . . 0.0 109.962 -176.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.2 p -128.71 175.11 8.85 Favored 'General case' 0 C--N 1.278 -2.543 0 CA-C-N 115.069 -0.969 . . . . 0.0 109.197 -177.478 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -149.82 125.68 10.5 Favored 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 174.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . 0.405 ' OD1' ' HB3' ' A' ' 23' ' ' CYS . 43.6 m-80 -76.64 -23.11 53.31 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 120.531 0.205 . . . . 0.0 111.526 -175.84 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -84.87 -57.56 3.06 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.903 -175.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 63.2 mtt180 -103.07 -21.85 13.86 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 113.107 0.78 . . . . 0.0 113.107 -175.356 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 103.86 168.55 25.25 Favored Glycine 0 N--CA 1.433 -1.543 0 C-N-CA 120.121 -1.038 . . . . 0.0 110.609 -177.393 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -80.1 159.17 87.18 Favored 'Cis proline' 0 CA--C 1.535 0.549 0 CA-C-N 119.085 1.442 . . . . 0.0 112.065 0.217 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 -104.55 169.91 8.19 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 177.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.6 m -80.52 147.16 30.96 Favored 'General case' 0 C--N 1.297 -1.688 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.419 -176.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 39.5 m -72.77 153.28 41.19 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 175.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.1 t -67.77 120.12 13.59 Favored 'General case' 0 N--CA 1.435 -1.214 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 103.54 0.1 46.4 Favored Glycine 0 N--CA 1.437 -1.264 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -175.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 86.0 mm-40 -111.86 38.01 2.78 Favored 'General case' 0 C--N 1.31 -1.132 0 CA-C-O 121.496 0.665 . . . . 0.0 110.366 179.064 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 78.14 -156.58 43.77 Favored Glycine 0 N--CA 1.418 -2.554 0 CA-C-N 115.057 -0.974 . . . . 0.0 112.962 177.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 79.6 m-20 -123.74 153.75 40.47 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 106.123 -1.806 . . . . 0.0 106.123 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . 0.405 ' HB3' ' OD1' ' A' ' 10' ' ' ASN . 51.6 t -84.52 98.46 10.14 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.656 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.411 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 22.9 t -97.34 118.05 64.9 Favored Pre-proline 0 C--N 1.303 -1.456 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 -178.026 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 4.0 Cg_exo -70.76 129.84 17.16 Favored 'Trans proline' 0 N--CA 1.451 -0.99 0 C-N-CA 122.611 2.207 . . . . 0.0 110.113 177.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 85.2 mt -129.3 150.6 75.96 Favored Pre-proline 0 C--N 1.309 -1.154 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.951 -175.525 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -42.49 -67.37 0.12 Allowed 'Trans proline' 0 CA--C 1.545 1.044 0 C-N-CA 124.792 3.661 . . . . 0.0 115.679 -177.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 26.5 p90 -97.8 -23.58 15.82 Favored 'General case' 0 C--N 1.314 -0.975 0 N-CA-C 113.325 0.861 . . . . 0.0 113.325 -174.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 97.4 mt -83.13 -12.11 57.32 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.557 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 84.06 -65.65 4.06 Favored Glycine 0 CA--C 1.501 -0.813 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -178.23 134.79 2.48 Favored Glycine 0 CA--C 1.47 -2.773 0 N-CA-C 108.569 -1.812 . . . . 0.0 108.569 177.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.5 m -136.02 153.68 32.45 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.224 0 CA-C-O 121.505 0.669 . . . . 0.0 110.998 -178.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.575 ' SG ' HG22 ' A' ' 2' ' ' VAL . 84.1 m -79.15 117.27 20.02 Favored 'General case' 0 C--N 1.291 -1.957 0 CA-C-N 114.503 -1.226 . . . . 0.0 108.833 175.613 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -135.07 130.41 35.53 Favored 'General case' 0 N--CA 1.431 -1.399 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -177.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 N--CA 1.432 -1.338 0 O-C-N 123.306 0.378 . . . . 0.0 110.63 178.847 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 22.2 p . . . . . 0 N--CA 1.446 -0.673 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.565 HG21 ' SG ' ' A' ' 33' ' ' CYS . 15.7 m -101.29 163.22 3.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-O 121.17 0.51 . . . . 0.0 111.511 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 23.9 mt -107.88 179.99 4.06 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.454 -0.793 . . . . 0.0 111.108 -172.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 24.3 pt -55.11 134.34 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.42 -17.85 41.12 Favored Glycine 0 C--O 1.242 0.614 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.937 177.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' A' ' 32' ' ' VAL . 78.7 mt-30 -81.54 159.72 24.06 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.133 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.44 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 40.5 ttp180 -85.78 129.0 34.95 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.269 -173.802 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 30.3 p -128.17 172.43 11.01 Favored 'General case' 0 C--N 1.291 -1.949 0 CA-C-O 121.294 0.569 . . . . 0.0 110.677 -177.22 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -147.12 118.97 8.09 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 175.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -58.22 -42.03 85.4 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 124.192 0.997 . . . . 0.0 113.113 -173.241 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -91.93 -56.63 3.01 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -175.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -83.15 -31.0 27.42 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-O 121.133 0.492 . . . . 0.0 112.024 -171.046 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 104.85 165.0 24.16 Favored Glycine 0 N--CA 1.427 -1.906 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 -176.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -76.25 156.76 98.41 Favored 'Cis proline' 0 C--N 1.329 -0.468 0 C-N-CA 123.382 -1.507 . . . . 0.0 112.122 0.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 82.1 mtt180 -108.03 156.35 19.35 Favored 'General case' 0 C--N 1.289 -2.04 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.56 -179.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 58.8 m -76.23 144.03 40.65 Favored 'General case' 0 C--N 1.29 -1.99 0 C-N-CA 124.06 0.944 . . . . 0.0 110.79 -176.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.428 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 59.2 m -67.42 161.51 25.12 Favored 'General case' 0 C--O 1.243 0.743 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.543 177.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 37.6 t -46.96 -56.21 6.77 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.065 0.946 . . . . 0.0 113.414 -174.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -95.19 27.22 15.79 Favored Glycine 0 C--N 1.314 -0.672 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.825 -176.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.428 ' CG ' ' HB2' ' A' ' 17' ' ' CYS . 84.9 mm-40 -110.84 29.69 7.53 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-O 121.337 0.589 . . . . 0.0 110.707 -178.556 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.51 -140.5 18.2 Favored Glycine 0 N--CA 1.43 -1.712 0 C-N-CA 120.365 -0.921 . . . . 0.0 112.874 177.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -133.8 155.87 49.04 Favored 'General case' 0 C--N 1.287 -2.142 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 176.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 52.5 t -83.06 100.83 10.74 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.4 p -98.0 120.07 60.78 Favored Pre-proline 0 N--CA 1.419 -2.021 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.62 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_exo -69.42 139.9 42.57 Favored 'Trans proline' 0 N--CA 1.45 -1.034 0 C-N-CA 122.076 1.851 . . . . 0.0 112.62 -179.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 11.0 mp -119.49 134.92 23.81 Favored Pre-proline 0 C--N 1.304 -1.41 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.468 179.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_exo -39.93 -54.18 2.16 Favored 'Trans proline' 0 C--N 1.356 0.965 0 C-N-CA 124.58 3.52 . . . . 0.0 115.483 -175.464 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 75.5 m-85 -99.43 -40.88 7.66 Favored 'General case' 0 CA--C 1.504 -0.799 0 CA-C-O 121.079 0.466 . . . . 0.0 111.038 -178.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 14.0 mt -75.65 -14.58 60.37 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.872 -0.604 . . . . 0.0 112.594 -170.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.73 -64.53 0.75 Allowed Glycine 0 CA--C 1.486 -1.765 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 -179.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.44 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . 174.33 156.35 13.65 Favored Glycine 0 N--CA 1.425 -2.083 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 178.013 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 35.4 m -139.06 152.76 24.17 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-O 121.248 0.547 . . . . 0.0 109.925 177.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.565 ' SG ' HG21 ' A' ' 2' ' ' VAL . 60.4 m -82.55 125.01 30.65 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 115.426 -0.807 . . . . 0.0 108.964 176.751 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -146.82 135.74 22.34 Favored 'General case' 0 N--CA 1.439 -0.998 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.267 -176.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--N 1.301 -1.542 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 178.49 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 25.8 p . . . . . 0 C--O 1.24 0.59 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.491 HG22 ' SG ' ' A' ' 33' ' ' CYS . 30.1 m -103.84 168.68 2.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 120.902 0.382 . . . . 0.0 110.878 -179.508 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 24.8 mt -109.12 -179.48 3.86 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.771 -0.649 . . . . 0.0 109.695 -175.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.7 pt -57.68 134.02 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-O 121.643 0.735 . . . . 0.0 112.87 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 95.71 -23.99 31.58 Favored Glycine 0 N--CA 1.442 -0.945 0 CA-C-N 115.175 -0.92 . . . . 0.0 112.303 178.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 36.2 mt-30 -83.09 152.65 25.24 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 16.5 ptm180 -87.0 145.39 26.52 Favored 'General case' 0 C--N 1.297 -1.694 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.309 -176.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.418 ' HB2' ' O ' ' A' ' 14' ' ' PRO . 15.7 p -144.3 176.26 9.48 Favored 'General case' 0 C--N 1.285 -2.21 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.983 -174.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -145.0 116.78 8.2 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 177.64 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -62.32 -32.67 73.46 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 112.968 0.729 . . . . 0.0 112.968 -178.459 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -82.63 -56.59 3.77 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 121.186 0.517 . . . . 0.0 111.523 -172.597 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 77.5 mtm180 -96.95 -20.23 18.24 Favored 'General case' 0 C--N 1.295 -1.778 0 CA-C-N 115.614 -0.721 . . . . 0.0 112.788 -172.172 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 94.36 162.55 35.34 Favored Glycine 0 N--CA 1.43 -1.738 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -177.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.418 ' O ' ' HB2' ' A' ' 8' ' ' CYS . 97.9 Cg_endo -85.26 167.53 53.0 Favored 'Cis proline' 0 C--N 1.326 -0.649 0 CA-C-N 119.272 1.536 . . . . 0.0 110.979 0.254 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -115.94 178.33 4.35 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 175.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 32.7 m -68.12 146.12 53.74 Favored 'General case' 0 C--N 1.293 -1.881 0 C-N-CA 123.277 0.631 . . . . 0.0 110.884 178.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 71.3 m -70.89 154.9 41.42 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 171.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.7 t -60.68 113.31 2.4 Favored 'General case' 0 N--CA 1.436 -1.128 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 106.48 0.2 37.36 Favored Glycine 0 N--CA 1.441 -0.982 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.555 -178.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 86.3 mm-40 -107.93 33.86 3.87 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.168 0.509 . . . . 0.0 110.93 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 80.7 -140.35 21.67 Favored Glycine 0 N--CA 1.428 -1.867 0 C-N-CA 120.131 -1.033 . . . . 0.0 113.241 177.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 52.9 t30 -151.32 159.92 44.06 Favored 'General case' 0 C--N 1.288 -2.097 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 92.3 m -72.08 97.76 1.97 Allowed 'General case' 0 C--N 1.308 -1.199 0 O-C-N 123.884 0.74 . . . . 0.0 109.192 176.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.3 t -96.52 126.9 41.76 Favored Pre-proline 0 N--CA 1.42 -1.946 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 179.223 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_exo -58.84 127.0 22.79 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 122.764 2.309 . . . . 0.0 112.627 -177.659 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 47.5 tp -118.02 131.91 23.95 Favored Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 179.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -74.38 45.6 1.24 Allowed 'Trans proline' 0 N--CA 1.482 0.809 0 C-N-CA 123.636 2.891 . . . . 0.0 113.17 -176.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -148.98 -69.63 0.21 Allowed 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 124.143 0.977 . . . . 0.0 109.3 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 25.6 mt -95.66 1.53 53.6 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 114.285 -1.325 . . . . 0.0 111.516 -170.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.63 -77.14 0.63 Allowed Glycine 0 N--CA 1.435 -1.404 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -146.45 139.2 7.9 Favored Glycine 0 C--N 1.29 -2.015 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.051 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.8 m -134.38 157.09 41.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 178.693 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.491 ' SG ' HG22 ' A' ' 2' ' ' VAL . 81.4 m -73.78 124.54 26.26 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.103 179.622 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -144.5 143.24 30.75 Favored 'General case' 0 N--CA 1.425 -1.69 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.2 m . . . . . 0 C--N 1.301 -1.512 0 O-C-N 123.789 0.68 . . . . 0.0 111.124 178.767 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 19.9 p . . . . . 0 C--O 1.241 0.647 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.597 HG22 ' SG ' ' A' ' 33' ' ' CYS . 15.1 m -109.72 157.53 10.15 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.656 0 CA-C-O 121.131 0.491 . . . . 0.0 111.458 176.333 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 18.4 mt -111.98 179.34 4.03 Favored 'General case' 0 N--CA 1.432 -1.357 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.069 -172.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 23.7 pt -54.1 133.46 17.11 Favored 'Isoleucine or valine' 0 C--O 1.239 0.545 0 CA-C-O 121.76 0.791 . . . . 0.0 112.88 -179.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.57 -9.08 72.4 Favored Glycine 0 C--N 1.309 -0.954 0 CA-C-N 115.375 -0.83 . . . . 0.0 113.04 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 75.7 mt-30 -94.47 156.47 16.45 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 176.741 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 18.1 ptp180 -85.81 145.72 27.09 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-O 121.139 0.495 . . . . 0.0 111.504 -174.156 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.44 ' SG ' ' HA ' ' A' ' 15' ' ' ARG . 3.8 t -137.21 159.72 41.09 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.819 -1.082 . . . . 0.0 112.324 -172.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -150.86 117.54 5.79 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 113.277 -1.783 . . . . 0.0 107.062 176.137 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 48.2 m-80 -63.72 -43.04 97.71 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 113.671 0.989 . . . . 0.0 113.671 -173.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 17.4 m-20 -92.46 -35.88 13.4 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 113.678 0.992 . . . . 0.0 113.678 -174.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 54.8 mtm180 -100.99 -14.86 17.68 Favored 'General case' 0 C--N 1.309 -1.176 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -174.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.77 155.98 29.55 Favored Glycine 0 N--CA 1.442 -0.932 0 N-CA-C 111.081 -0.807 . . . . 0.0 111.081 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -84.91 159.33 66.08 Favored 'Cis proline' 0 CA--C 1.535 0.546 0 CA-C-N 119.206 1.503 . . . . 0.0 111.883 0.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.44 ' HA ' ' SG ' ' A' ' 8' ' ' CYS . 39.7 mtm180 -112.21 155.27 24.26 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-O 120.89 0.376 . . . . 0.0 110.083 -178.776 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.432 ' HA ' ' O ' ' A' ' 2' ' ' VAL . 36.8 m -78.02 142.01 38.52 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 123.882 0.873 . . . . 0.0 110.533 -176.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 m -67.05 153.37 43.82 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 119.144 -1.022 . . . . 0.0 111.312 172.006 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 12.3 p -48.74 -46.65 41.29 Favored 'General case' 0 C--O 1.241 0.622 0 N-CA-C 114.229 1.196 . . . . 0.0 114.229 -173.189 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -90.63 11.79 70.56 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.448 -0.882 . . . . 0.0 112.703 -179.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 78.7 mm-40 -105.28 37.19 2.25 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.276 0.56 . . . . 0.0 111.716 -178.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.48 -158.92 30.32 Favored Glycine 0 N--CA 1.423 -2.205 0 C-N-CA 120.091 -1.052 . . . . 0.0 112.32 177.02 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 -122.18 149.44 43.63 Favored 'General case' 0 C--N 1.282 -2.35 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 49.1 t -84.02 97.33 9.23 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.002 -1.111 . . . . 0.0 108.002 179.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.6 p -104.82 124.88 35.37 Favored Pre-proline 0 C--N 1.305 -1.34 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.52 -177.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -67.07 141.74 58.93 Favored 'Trans proline' 0 C--O 1.243 0.762 0 C-N-CA 122.645 2.23 . . . . 0.0 112.951 -176.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 87.9 mt -122.21 148.63 52.57 Favored Pre-proline 0 C--N 1.309 -1.181 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.601 -178.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo -49.29 -64.22 0.24 Allowed 'Trans proline' 0 CA--C 1.545 1.072 0 C-N-CA 123.715 2.943 . . . . 0.0 114.394 -178.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -97.16 -40.36 8.84 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.947 0.403 . . . . 0.0 110.987 -174.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 9.2 mp -78.98 0.74 26.38 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 113.737 1.014 . . . . 0.0 113.737 -174.681 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 86.28 -65.33 3.86 Favored Glycine 0 CA--C 1.501 -0.803 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.081 176.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -176.35 160.43 28.11 Favored Glycine 0 CA--C 1.477 -2.323 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 8.8 p -142.76 157.63 18.39 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 CA-C-N 117.73 0.765 . . . . 0.0 109.922 -178.265 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.597 ' SG ' HG22 ' A' ' 2' ' ' VAL . 59.9 m -88.0 108.73 19.36 Favored 'General case' 0 C--N 1.278 -2.514 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 174.547 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -149.88 163.84 36.97 Favored 'General case' 0 N--CA 1.435 -1.182 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 -175.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.9 p . . . . . 0 C--N 1.293 -1.852 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.653 178.786 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.4 p . . . . . 0 C--O 1.243 0.722 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 19.0 m -109.11 168.61 3.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 120.813 0.34 . . . . 0.0 111.147 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 29.3 mt -108.02 -176.24 3.0 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.327 -175.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 21.9 pt -56.78 138.83 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 N-CA-C 112.695 0.628 . . . . 0.0 112.695 179.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.29 -20.11 19.12 Favored Glycine 0 CA--C 1.506 -0.476 0 CA-C-N 115.707 -0.678 . . . . 0.0 112.694 178.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -80.5 153.73 27.98 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-O 121.252 0.549 . . . . 0.0 109.892 -179.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 4.2 tmt_? -86.31 130.14 34.61 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 114.657 -1.156 . . . . 0.0 109.038 -173.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.8 p -130.29 170.67 13.82 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.242 -176.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -147.42 124.59 11.47 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 177.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 14.6 m120 -71.56 -35.88 70.75 Favored 'General case' 0 C--N 1.298 -1.662 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.424 -175.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -76.3 -56.86 4.25 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.637 -0.71 . . . . 0.0 112.146 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 74.1 mtm180 -93.8 -21.3 19.38 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 115.872 -0.604 . . . . 0.0 112.511 -173.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 94.74 163.45 35.24 Favored Glycine 0 N--CA 1.427 -1.947 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -175.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -89.86 165.68 34.52 Favored 'Cis proline' 0 N--CA 1.451 -0.998 0 C-N-CA 123.353 -1.52 . . . . 0.0 110.76 -1.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 69.8 mtm180 -106.86 179.43 4.27 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 176.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 26.4 m -73.42 140.75 46.76 Favored 'General case' 0 C--N 1.293 -1.856 0 C-N-CA 122.914 0.486 . . . . 0.0 109.963 -179.085 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 60.9 m -67.83 155.03 40.25 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 173.25 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 29.1 t -60.98 113.5 2.57 Favored 'General case' 0 C--O 1.246 0.899 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 -178.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 102.36 14.39 28.21 Favored Glycine 0 N--CA 1.435 -1.389 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.657 -178.472 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.438 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 83.9 mm-40 -116.8 28.85 8.28 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 -178.421 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.33 -163.11 35.54 Favored Glycine 0 N--CA 1.433 -1.553 0 C-N-CA 119.689 -1.243 . . . . 0.0 111.756 178.529 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 52.8 m-80 -130.43 152.05 50.25 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 107.756 -1.202 . . . . 0.0 107.756 179.166 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 63.1 m -66.95 98.1 0.53 Allowed 'General case' 0 N--CA 1.439 -1.007 0 O-C-N 124.04 0.837 . . . . 0.0 110.713 176.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.4 m -92.99 111.81 53.19 Favored Pre-proline 0 N--CA 1.411 -2.378 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 175.449 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.37 141.4 31.78 Favored 'Trans proline' 0 N--CA 1.44 -1.634 0 C-N-CA 122.069 1.846 . . . . 0.0 112.977 -173.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 91.8 mt -137.3 117.34 10.47 Favored Pre-proline 0 C--N 1.292 -1.928 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -72.15 51.03 1.63 Allowed 'Trans proline' 0 N--CA 1.485 0.984 0 C-N-CA 124.393 3.395 . . . . 0.0 113.969 -171.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 70.8 m-85 -143.83 -60.51 0.4 Allowed 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.459 ' H ' HD21 ' A' ' 29' ' ' LEU . 2.1 pt? -106.95 0.22 23.6 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.922 -178.208 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 109.46 -76.76 0.22 Allowed Glycine 0 C--N 1.306 -1.123 0 C-N-CA 120.399 -0.905 . . . . 0.0 111.755 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 177.27 159.56 22.63 Favored Glycine 0 N--CA 1.425 -2.057 0 N-CA-C 109.984 -1.247 . . . . 0.0 109.984 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.2 m -133.9 157.14 41.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-O 120.927 0.394 . . . . 0.0 110.697 -179.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.438 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 86.3 m -83.67 108.63 16.87 Favored 'General case' 0 C--N 1.296 -1.74 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.77 176.519 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -141.45 155.38 45.86 Favored 'General case' 0 N--CA 1.429 -1.518 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 -178.662 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 49.0 t . . . . . 0 C--N 1.3 -1.572 0 N-CA-C 108.293 -1.002 . . . . 0.0 108.293 177.326 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 29.6 p . . . . . 0 CA--C 1.519 -0.246 0 N-CA-C 110.078 -0.341 . . . . 0.0 110.078 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.416 HG23 ' SG ' ' A' ' 33' ' ' CYS . 16.6 m -107.95 168.37 3.42 Favored 'Isoleucine or valine' 0 C--O 1.243 0.743 0 CA-C-O 121.113 0.482 . . . . 0.0 110.946 178.467 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 29.2 mt -108.2 178.54 4.47 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.185 -173.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.442 ' HA ' ' HB2' ' A' ' 33' ' ' CYS . 26.9 pt -59.49 136.27 23.25 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.131 177.073 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.99 -13.45 59.4 Favored Glycine 0 C--N 1.311 -0.856 0 CA-C-N 115.843 -0.617 . . . . 0.0 112.596 178.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.454 ' O ' ' HA ' ' A' ' 32' ' ' VAL . 89.9 mt-30 -92.09 159.7 15.56 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 179.582 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.58 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 41.9 ttm180 -85.34 124.61 32.15 Favored 'General case' 0 C--N 1.317 -0.839 0 O-C-N 123.729 0.643 . . . . 0.0 110.805 -175.266 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 23.6 p -123.34 176.26 6.23 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.795 -177.285 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -145.81 125.63 13.49 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 174.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 47.3 m-80 -71.78 -30.0 65.08 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 113.339 0.866 . . . . 0.0 113.339 -175.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -91.37 -47.1 7.66 Favored 'General case' 0 C--N 1.295 -1.761 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 -172.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 51.0 mtp180 -106.1 -23.1 12.7 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 112.593 0.59 . . . . 0.0 112.593 -176.065 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 98.96 169.7 30.94 Favored Glycine 0 N--CA 1.431 -1.689 0 C-N-CA 119.825 -1.179 . . . . 0.0 110.479 -176.373 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -72.49 152.39 97.51 Favored 'Cis proline' 0 C--N 1.333 -0.258 0 CA-C-N 119.474 1.637 . . . . 0.0 112.32 1.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 73.1 mtt180 -105.89 160.77 15.0 Favored 'General case' 0 C--N 1.289 -2.06 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.263 -179.16 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.0 m -69.81 143.32 52.95 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 123.665 0.786 . . . . 0.0 110.953 -177.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 85.2 m -63.3 155.78 27.61 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 176.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.7 m -63.57 106.13 0.9 Allowed 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -179.478 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 101.6 29.61 6.19 Favored Glycine 0 N--CA 1.439 -1.142 0 N-CA-C 110.687 -0.965 . . . . 0.0 110.687 -176.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 23.0 mm-40 -126.7 36.01 4.53 Favored 'General case' 0 CA--C 1.496 -1.098 0 CA-C-O 121.26 0.553 . . . . 0.0 111.506 178.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 76.14 -163.32 53.09 Favored Glycine 0 N--CA 1.42 -2.375 0 C-N-CA 120.469 -0.872 . . . . 0.0 113.138 178.299 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -110.45 145.49 37.55 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 177.444 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 50.3 t -75.69 98.02 3.97 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 176.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.421 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 20.8 t -98.87 126.51 38.3 Favored Pre-proline 0 N--CA 1.427 -1.604 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 -176.725 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 7.8 Cg_exo -72.94 126.45 11.28 Favored 'Trans proline' 0 N--CA 1.45 -1.071 0 C-N-CA 122.714 2.276 . . . . 0.0 112.296 178.468 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 10.6 mp -121.63 119.79 29.02 Favored Pre-proline 0 C--N 1.306 -1.315 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 176.373 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_exo -37.62 -49.69 1.9 Allowed 'Trans proline' 0 CA--C 1.553 1.438 0 C-N-CA 124.634 3.556 . . . . 0.0 116.673 -174.381 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -89.64 -26.34 20.8 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 120.151 -0.619 . . . . 0.0 112.228 -176.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -94.91 -4.88 46.06 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 121.464 0.65 . . . . 0.0 110.793 -174.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 84.53 -77.65 2.09 Favored Glycine 0 N--CA 1.431 -1.699 0 N-CA-C 109.109 -1.597 . . . . 0.0 109.109 -178.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.58 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -168.64 138.2 4.98 Favored Glycine 0 N--CA 1.413 -2.864 0 N-CA-C 107.816 -2.114 . . . . 0.0 107.816 178.258 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.454 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 35.9 m -134.8 146.95 29.83 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 CA-C-O 121.251 0.548 . . . . 0.0 109.796 -178.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.442 ' HB2' ' HA ' ' A' ' 4' ' ' ILE . 81.1 m -72.81 124.69 25.88 Favored 'General case' 0 C--N 1.294 -1.841 0 CA-C-N 115.305 -0.862 . . . . 0.0 109.138 176.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -142.19 133.94 26.98 Favored 'General case' 0 N--CA 1.425 -1.702 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 -176.031 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.7 m . . . . . 0 C--N 1.306 -1.318 0 O-C-N 123.54 0.525 . . . . 0.0 110.72 179.82 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.4 p . . . . . 0 N--CA 1.452 -0.332 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.546 HG23 ' SG ' ' A' ' 33' ' ' CYS . 19.6 m -107.58 162.82 5.72 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.876 0 CA-C-O 121.188 0.518 . . . . 0.0 112.076 -176.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.405 ' O ' ' HB2' ' A' ' 6' ' ' GLN . 16.4 mt -106.98 -177.11 3.27 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.145 -174.528 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 37.7 pt -59.65 139.42 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 N-CA-C 112.483 0.549 . . . . 0.0 112.483 -178.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 83.25 -16.74 27.37 Favored Glycine 0 C--N 1.316 -0.542 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.626 179.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.405 ' HB2' ' O ' ' A' ' 3' ' ' LEU . 78.2 mt-30 -82.02 156.83 24.44 Favored 'General case' 0 N--CA 1.428 -1.53 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 178.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.456 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 43.5 ttp180 -85.94 129.61 34.79 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-N 114.618 -1.173 . . . . 0.0 110.451 -173.185 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 24.6 p -126.35 176.16 7.32 Favored 'General case' 0 C--N 1.284 -2.26 0 CA-C-N 115.296 -0.866 . . . . 0.0 110.138 -177.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -146.76 123.09 10.95 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 105.896 -1.89 . . . . 0.0 105.896 173.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 18.7 m120 -58.44 -45.73 87.96 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.645 -1.162 . . . . 0.0 112.611 -173.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -92.65 -52.89 4.42 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -175.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -85.72 -24.99 26.72 Favored 'General case' 0 C--N 1.315 -0.9 0 C-N-CA 120.1 -0.64 . . . . 0.0 112.563 -173.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 98.18 169.75 32.01 Favored Glycine 0 N--CA 1.43 -1.743 0 C-N-CA 120.135 -1.031 . . . . 0.0 111.291 -177.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -74.57 164.0 89.1 Favored 'Cis proline' 0 C--N 1.332 -0.334 0 C-N-CA 123.342 -1.524 . . . . 0.0 112.351 0.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 77.0 mtt180 -117.7 164.26 15.24 Favored 'General case' 0 C--N 1.292 -1.895 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.076 -178.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 28.0 m -71.16 140.72 50.63 Favored 'General case' 0 C--N 1.289 -2.038 0 C-N-CA 123.829 0.852 . . . . 0.0 110.192 -177.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.429 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 59.0 m -67.26 151.98 46.54 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 176.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.3 t -67.15 103.66 1.26 Allowed 'General case' 0 N--CA 1.439 -1.005 0 C-N-CA 123.424 0.69 . . . . 0.0 109.181 -177.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 122.92 -12.3 8.67 Favored Glycine 0 N--CA 1.437 -1.267 0 N-CA-C 110.429 -1.068 . . . . 0.0 110.429 -177.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.429 ' CG ' ' HB2' ' A' ' 17' ' ' CYS . 84.2 mm-40 -85.78 -45.12 11.91 Favored 'General case' 0 CA--C 1.5 -0.96 0 CA-C-N 115.46 -0.37 . . . . 0.0 110.353 178.661 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 152.71 -161.62 29.61 Favored Glycine 0 N--CA 1.419 -2.45 0 C-N-CA 119.079 -1.534 . . . . 0.0 113.019 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -112.36 147.43 36.4 Favored 'General case' 0 C--N 1.279 -2.475 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 178.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 53.0 t -82.0 105.98 13.55 Favored 'General case' 0 C--N 1.294 -1.83 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -92.53 117.04 67.45 Favored Pre-proline 0 C--N 1.311 -1.078 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 176.184 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -74.36 148.25 38.13 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 122.025 1.817 . . . . 0.0 114.114 -174.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 8.1 mp -126.28 132.39 24.3 Favored Pre-proline 0 C--N 1.308 -1.198 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 176.573 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_exo -39.0 -57.2 1.01 Allowed 'Trans proline' 0 CA--C 1.543 0.933 0 C-N-CA 124.611 3.541 . . . . 0.0 115.299 -175.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -93.43 -46.4 7.35 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-O 121.801 0.81 . . . . 0.0 110.327 -178.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 26.7 mt -77.15 0.52 21.36 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 114.339 -1.3 . . . . 0.0 113.189 -167.439 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 87.03 -65.79 3.65 Favored Glycine 0 CA--C 1.492 -1.345 0 N-CA-C 112.201 -0.36 . . . . 0.0 112.201 175.069 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.456 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . 165.02 162.75 16.77 Favored Glycine 0 N--CA 1.412 -2.944 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.8 m -135.46 147.64 28.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 177.462 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.546 ' SG ' HG23 ' A' ' 2' ' ' VAL . 94.7 m -80.42 131.47 35.6 Favored 'General case' 0 C--N 1.293 -1.856 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.692 177.24 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.61 168.61 26.59 Favored 'General case' 0 N--CA 1.427 -1.596 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 -178.095 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 4.1 p . . . . . 0 C--O 1.259 1.586 0 C-N-CA 123.919 0.888 . . . . 0.0 113.101 -178.925 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 22.3 p . . . . . 0 N--CA 1.447 -0.606 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.563 HG21 ' SG ' ' A' ' 16' ' ' CYS . 23.8 m -94.15 178.42 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.594 -0.276 . . . . 0.0 110.586 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 27.3 mt -117.84 -176.01 2.95 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 112.667 0.617 . . . . 0.0 112.667 -172.669 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.523 HG13 ' OE1' ' A' ' 20' ' ' GLN . 66.4 mt -56.6 135.88 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 123.714 0.806 . . . . 0.0 110.764 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.04 -6.85 73.4 Favored Glycine 0 C--N 1.313 -0.704 0 C-N-CA 121.447 -0.406 . . . . 0.0 112.693 177.29 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -94.14 150.55 20.22 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 178.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.2 tmm_? -86.76 129.7 34.77 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.5 -172.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 18.5 p -128.33 175.45 8.48 Favored 'General case' 0 C--N 1.297 -1.694 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.175 -175.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -152.9 121.51 6.4 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 106.161 -1.792 . . . . 0.0 106.161 174.456 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -72.17 -26.27 62.01 Favored 'General case' 0 C--N 1.294 -1.843 0 CA-C-O 120.832 0.349 . . . . 0.0 111.091 -174.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -78.74 -56.8 4.14 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.788 -176.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 26.9 mmm180 -106.53 -9.61 16.55 Favored 'General case' 0 C--N 1.312 -1.043 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -174.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 90.64 165.51 40.39 Favored Glycine 0 C--N 1.297 -1.622 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -177.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -81.39 170.87 60.26 Favored 'Cis proline' 0 CA--C 1.534 0.486 0 C-N-CA 123.385 -1.506 . . . . 0.0 111.831 0.314 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 78.7 mtm180 -122.76 152.12 40.94 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.14 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.563 ' SG ' HG21 ' A' ' 2' ' ' VAL . 57.9 m -86.01 158.67 19.8 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.068 -176.345 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.457 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 26.4 m -67.28 153.81 42.79 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 178.295 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.7 m -46.86 -45.59 20.41 Favored 'General case' 0 CA--C 1.56 1.334 0 N-CA-C 115.188 1.551 . . . . 0.0 115.188 -172.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -97.0 22.01 43.06 Favored Glycine 0 C--N 1.318 -0.472 0 C-N-CA 120.501 -0.857 . . . . 0.0 112.559 -178.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.523 ' OE1' HG13 ' A' ' 4' ' ' ILE . 85.9 mm-40 -105.28 23.28 13.96 Favored 'General case' 0 C--N 1.311 -1.1 0 O-C-N 122.648 -0.324 . . . . 0.0 111.692 -178.602 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 92.65 -177.42 38.88 Favored Glycine 0 N--CA 1.43 -1.7 0 C-N-CA 120.451 -0.881 . . . . 0.0 112.774 177.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.467 ' O ' ' HA ' ' A' ' 33' ' ' CYS . 35.3 t30 -119.16 143.8 47.03 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 179.135 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 92.2 m -63.38 102.04 0.37 Allowed 'General case' 0 C--N 1.316 -0.872 0 O-C-N 123.871 0.732 . . . . 0.0 110.535 178.103 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.7 m -110.1 137.23 20.49 Favored Pre-proline 0 N--CA 1.421 -1.924 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 177.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -67.91 120.85 7.85 Favored 'Trans proline' 0 N--CA 1.448 -1.184 0 C-N-CA 121.699 1.6 . . . . 0.0 112.14 -178.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 56.5 tp -115.98 104.99 51.91 Favored Pre-proline 0 N--CA 1.42 -1.964 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 176.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -70.78 56.15 1.79 Allowed 'Trans proline' 0 N--CA 1.479 0.653 0 C-N-CA 124.056 3.171 . . . . 0.0 113.219 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -148.06 -63.54 0.26 Allowed 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 125.294 1.438 . . . . 0.0 108.09 179.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -104.03 -19.38 14.22 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.518 -179.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 121.76 -165.01 14.73 Favored Glycine 0 C--N 1.305 -1.167 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -177.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -72.91 125.43 9.82 Favored Glycine 0 CA--C 1.49 -1.481 0 C-N-CA 119.986 -1.102 . . . . 0.0 110.356 177.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 33.2 m -127.62 153.14 36.55 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.327 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -176.733 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.467 ' HA ' ' O ' ' A' ' 22' ' ' ASN . 74.1 m -85.84 116.55 24.16 Favored 'General case' 0 C--N 1.284 -2.246 0 C-N-CA 119.718 -0.793 . . . . 0.0 111.25 178.302 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.54 168.51 22.54 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.256 179.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.1 t . . . . . 0 C--N 1.307 -1.255 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 176.507 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.5 p . . . . . 0 C--O 1.244 0.808 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.406 HG22 ' SG ' ' A' ' 33' ' ' CYS . 27.9 m -116.35 159.44 16.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-O 120.916 0.389 . . . . 0.0 111.243 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 67.8 mt -105.41 -177.83 3.48 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 115.58 -0.737 . . . . 0.0 111.01 -175.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.5 pt -56.05 137.34 17.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 178.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.15 -14.42 60.79 Favored Glycine 0 C--N 1.316 -0.543 0 CA-C-N 115.761 -0.654 . . . . 0.0 113.288 177.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . 0.451 ' O ' ' HA ' ' A' ' 32' ' ' VAL . 78.0 mt-30 -87.73 162.06 17.26 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-O 121.031 0.443 . . . . 0.0 110.794 -178.453 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 37.6 ttt180 -84.88 123.59 30.66 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 114.753 -1.112 . . . . 0.0 109.092 -175.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -134.88 167.6 20.59 Favored 'General case' 0 C--N 1.294 -1.82 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.038 -176.702 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -146.55 130.54 17.27 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 175.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 35.7 m-80 -66.32 -40.33 89.86 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 114.753 -1.112 . . . . 0.0 112.977 -171.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -93.04 -52.01 4.78 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -175.113 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 78.4 mtp180 -84.46 -24.68 29.39 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.29 -173.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 99.58 163.17 29.22 Favored Glycine 0 N--CA 1.429 -1.818 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -175.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -81.15 159.73 82.94 Favored 'Cis proline' 0 N--CA 1.446 -1.311 0 CA-C-N 119.662 1.731 . . . . 0.0 111.296 0.267 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -107.94 149.93 27.72 Favored 'General case' 0 C--N 1.291 -1.972 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.017 -178.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 45.7 m -65.08 142.45 58.38 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.053 -0.976 . . . . 0.0 108.6 178.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 61.2 m -63.84 144.96 56.64 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 176.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.7 p -53.04 86.54 0.0 OUTLIER 'General case' 0 CA--C 1.546 0.818 0 N-CA-C 113.909 1.077 . . . . 0.0 113.909 -176.144 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.6 26.81 1.54 Allowed Glycine 0 N--CA 1.435 -1.392 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.3 -178.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 23.1 mm-40 -115.87 30.19 7.5 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.427 0.632 . . . . 0.0 111.87 179.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.64 -150.5 24.4 Favored Glycine 0 N--CA 1.425 -2.073 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.402 177.164 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.8 p-10 -130.64 159.35 37.46 Favored 'General case' 0 C--N 1.287 -2.127 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 179.064 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 85.5 m -77.5 99.27 5.61 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 123.572 0.545 . . . . 0.0 109.798 175.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 14.6 p -90.22 120.47 69.15 Favored Pre-proline 0 N--CA 1.421 -1.914 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 176.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -74.59 134.73 18.94 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 121.982 1.788 . . . . 0.0 113.222 -176.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.0 mt -135.94 129.92 18.34 Favored Pre-proline 0 C--N 1.301 -1.513 0 CA-C-N 115.046 -0.979 . . . . 0.0 108.573 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.79 54.23 2.01 Favored 'Trans proline' 0 CA--C 1.536 0.581 0 C-N-CA 124.031 3.154 . . . . 0.0 113.898 -174.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -143.06 -66.9 0.37 Allowed 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 178.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.486 HD22 ' H ' ' A' ' 29' ' ' LEU . 1.9 pt? -107.45 0.27 22.73 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.496 -0.774 . . . . 0.0 112.369 -178.458 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 109.94 -86.88 0.45 Allowed Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.393 -0.908 . . . . 0.0 111.39 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.54 148.83 20.19 Favored Glycine 0 CA--C 1.49 -1.518 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.451 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 28.4 m -128.79 145.79 35.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 120.834 0.349 . . . . 0.0 111.439 -178.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.406 ' SG ' HG22 ' A' ' 2' ' ' VAL . 79.7 m -71.72 121.68 19.31 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 175.598 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -142.33 136.49 29.74 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.025 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 58.1 t . . . . . 0 N--CA 1.438 -1.07 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 177.192 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.4 p . . . . . 0 C--O 1.242 0.694 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.436 HG21 ' SG ' ' A' ' 33' ' ' CYS . 26.1 m -108.87 162.68 6.55 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.166 0.508 . . . . 0.0 111.277 -179.038 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 54.3 mt -105.79 -175.28 2.75 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.737 -175.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.5 pt -58.02 129.03 19.48 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 N-CA-C 113.224 0.824 . . . . 0.0 113.224 -178.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.18 -13.92 65.02 Favored Glycine 0 CA--C 1.503 -0.664 0 CA-C-N 115.639 -0.71 . . . . 0.0 112.681 177.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -88.82 159.72 17.59 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 62.1 ttt180 -86.02 131.37 34.28 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.827 -173.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.7 p -126.2 156.67 39.86 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.813 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -137.38 126.57 24.58 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 176.202 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 46.9 m-80 -78.98 -31.62 44.96 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 120.485 -0.486 . . . . 0.0 111.893 -178.09 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -72.67 -52.86 13.55 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-O 121.097 0.475 . . . . 0.0 111.727 -174.7 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . 0.422 ' HA ' ' NE ' ' A' ' 12' ' ' ARG . 5.4 mmp_? -108.06 -17.58 14.0 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 113.398 0.888 . . . . 0.0 113.398 -176.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 91.26 168.28 41.5 Favored Glycine 0 N--CA 1.432 -1.6 0 C-N-CA 119.842 -1.17 . . . . 0.0 110.502 -177.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -79.25 159.9 89.53 Favored 'Cis proline' 0 C--N 1.329 -0.47 0 CA-C-N 119.082 1.441 . . . . 0.0 111.863 -1.143 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 83.0 mtm180 -109.6 177.0 4.87 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 178.514 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.2 m -70.51 144.45 51.35 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 86.3 m -68.17 145.02 54.73 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 173.585 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.5 t -50.93 99.0 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.236 1.015 . . . . 0.0 112.177 -175.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 118.01 -11.33 13.33 Favored Glycine 0 N--CA 1.443 -0.84 0 CA-C-N 115.83 -0.623 . . . . 0.0 112.123 179.3 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.462 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 23.7 mm-40 -86.17 23.55 1.52 Allowed 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 114.674 1.361 . . . . 0.0 114.674 -176.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 101.27 -176.63 26.86 Favored Glycine 0 N--CA 1.427 -1.946 0 C-N-CA 119.439 -1.362 . . . . 0.0 113.934 174.441 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 38.4 m-80 -113.4 150.31 32.88 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 179.407 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 89.1 m -74.52 98.18 3.29 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 123.193 0.308 . . . . 0.0 111.101 179.112 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.9 t -82.42 122.24 78.84 Favored Pre-proline 0 C--N 1.303 -1.42 0 N-CA-C 106.279 -1.749 . . . . 0.0 106.279 175.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -86.4 121.72 1.98 Allowed 'Trans proline' 0 N--CA 1.439 -1.686 0 C-N-CA 122.66 2.24 . . . . 0.0 113.679 -174.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -119.45 148.41 45.56 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 178.011 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_exo -41.19 -69.3 0.08 OUTLIER 'Trans proline' 0 CA--C 1.548 1.198 0 C-N-CA 124.74 3.627 . . . . 0.0 116.037 -175.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 24.6 p90 -93.01 -17.66 23.61 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 112.966 0.728 . . . . 0.0 112.966 -173.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 96.5 mt -86.64 -13.48 45.49 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.495 179.227 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 81.79 -79.46 1.84 Allowed Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.84 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -166.34 136.26 4.07 Favored Glycine 0 N--CA 1.426 -1.992 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 36.0 m -126.51 143.44 39.99 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 CA-C-O 120.909 0.385 . . . . 0.0 110.821 -179.006 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.462 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 74.8 m -71.42 114.08 9.12 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.792 178.696 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.43 156.41 42.45 Favored 'General case' 0 C--N 1.315 -0.912 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 178.561 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 39.3 t . . . . . 0 C--O 1.255 1.37 0 C-N-CA 123.684 0.794 . . . . 0.0 110.006 -179.315 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.5 p . . . . . 0 C--O 1.24 0.56 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 33.9 m -110.75 164.68 6.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 121.185 0.517 . . . . 0.0 110.866 -178.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 48.4 mt -102.47 -179.22 3.92 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.767 -178.286 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 27.3 pt -59.4 133.19 24.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.126 0.489 . . . . 0.0 112.213 178.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.1 -10.26 75.47 Favored Glycine 0 C--N 1.316 -0.536 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.98 178.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -94.85 157.53 15.88 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.124 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 2.7 tmm_? -85.96 124.55 32.53 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.367 -173.618 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.403 ' HB2' ' HA ' ' A' ' 15' ' ' ARG . 10.4 p -121.36 165.8 15.01 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.009 179.254 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -125.0 124.93 43.06 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 176.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -73.48 -33.43 64.82 Favored 'General case' 0 C--N 1.305 -1.365 0 N-CA-C 112.751 0.649 . . . . 0.0 112.751 -171.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -91.17 -50.56 5.77 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 120.542 -0.463 . . . . 0.0 111.928 -175.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 58.4 mtp180 -102.18 -8.67 21.14 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -172.177 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.14 168.36 44.57 Favored Glycine 0 C--N 1.31 -0.909 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.491 178.304 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -81.87 166.89 70.91 Favored 'Cis proline' 0 N--CA 1.474 0.327 0 C-N-CA 123.837 -1.318 . . . . 0.0 111.283 -0.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.403 ' HA ' ' HB2' ' A' ' 8' ' ' CYS . 73.4 mtm180 -121.49 -173.79 2.71 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 116.763 -0.199 . . . . 0.0 111.006 178.283 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 33.1 m -60.38 144.46 50.78 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 123.846 0.859 . . . . 0.0 112.142 -178.302 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 74.4 m -71.97 166.23 22.6 Favored 'General case' 0 C--O 1.243 0.731 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 170.541 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.7 t -67.83 109.82 3.55 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.056 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 101.16 26.68 7.71 Favored Glycine 0 N--CA 1.443 -0.886 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 -179.253 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.526 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 86.9 mm-40 -126.06 35.68 4.64 Favored 'General case' 0 C--N 1.318 -0.792 0 O-C-N 122.68 -0.306 . . . . 0.0 111.503 -179.239 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 70.81 -158.59 53.71 Favored Glycine 0 C--O 1.248 0.997 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.407 178.617 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -127.05 158.84 35.91 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 176.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 98.4 m -68.66 104.81 2.08 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 121.168 0.509 . . . . 0.0 110.779 178.616 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 59.9 t -91.83 120.06 68.14 Favored Pre-proline 0 N--CA 1.426 -1.647 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 175.608 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_exo -67.51 136.86 40.95 Favored 'Trans proline' 0 N--CA 1.445 -1.37 0 C-N-CA 122.459 2.106 . . . . 0.0 111.858 -179.461 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 24.0 tp -132.49 117.01 15.3 Favored Pre-proline 0 C--N 1.29 -2.017 0 N-CA-C 105.271 -2.122 . . . . 0.0 105.271 176.224 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -63.42 51.61 0.14 Allowed 'Trans proline' 0 N--CA 1.502 1.982 0 C-N-CA 125.029 3.819 . . . . 0.0 116.575 -170.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -144.34 -64.39 0.36 Allowed 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 177.531 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.465 HD22 ' H ' ' A' ' 29' ' ' LEU . 1.9 pt? -103.7 -3.4 25.11 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.213 -0.903 . . . . 0.0 112.88 -173.148 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 113.94 -103.91 1.39 Allowed Glycine 0 C--N 1.304 -1.216 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -177.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -139.78 152.48 22.63 Favored Glycine 0 N--CA 1.43 -1.724 0 C-N-CA 120.674 -0.774 . . . . 0.0 111.425 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 19.5 m -132.06 139.71 49.63 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.526 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 84.2 m -69.31 128.14 35.53 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.295 179.271 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -164.85 158.36 17.27 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 109.484 -0.562 . . . . 0.0 109.484 -178.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.2 t . . . . . 0 C--O 1.252 1.206 0 O-C-N 124.9 1.375 . . . . 0.0 111.603 177.329 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.6 p . . . . . 0 N--CA 1.456 -0.164 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.472 HG21 ' SG ' ' A' ' 33' ' ' CYS . 15.3 m -105.43 164.59 4.05 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-O 121.094 0.473 . . . . 0.0 111.846 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 21.4 mt -107.39 178.84 4.42 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.244 -173.652 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 40.0 pt -57.85 137.35 20.15 Favored 'Isoleucine or valine' 0 C--O 1.24 0.57 0 CA-C-O 121.571 0.7 . . . . 0.0 112.685 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.13 -23.98 24.18 Favored Glycine 0 C--N 1.306 -1.083 0 CA-C-N 115.645 -0.707 . . . . 0.0 112.795 178.661 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 92.3 mt-30 -82.8 155.79 24.01 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -178.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.9 tmm_? -85.75 127.18 34.47 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -173.512 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 21.8 p -122.52 172.92 8.02 Favored 'General case' 0 C--N 1.288 -2.107 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.376 -177.109 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -153.35 124.02 7.24 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 177.001 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 -72.96 -37.79 66.98 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 112.64 0.607 . . . . 0.0 112.64 -174.475 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -85.6 -47.3 9.98 Favored 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 120.072 -0.651 . . . . 0.0 112.533 -174.656 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 5.1 mmp_? -93.58 -29.21 15.6 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.891 -0.723 . . . . 0.0 112.196 -177.327 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 103.61 162.45 25.14 Favored Glycine 0 N--CA 1.434 -1.471 0 N-CA-C 109.826 -1.31 . . . . 0.0 109.826 -175.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -82.77 157.59 76.47 Favored 'Cis proline' 0 CA--C 1.535 0.536 0 CA-C-N 119.276 1.538 . . . . 0.0 112.432 1.278 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 63.7 mtm180 -107.23 157.04 18.21 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-O 120.853 0.359 . . . . 0.0 110.054 179.7 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 35.6 m -68.51 142.85 55.15 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 124.19 0.996 . . . . 0.0 110.282 -178.654 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . 0.441 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 54.7 m -67.78 154.4 41.61 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 174.032 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.1 p -54.55 -23.05 15.04 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 115.776 1.769 . . . . 0.0 115.776 -171.196 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -115.83 22.84 11.31 Favored Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 177.483 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.441 ' CG ' ' HB2' ' A' ' 17' ' ' CYS . 86.4 mm-40 -115.56 20.9 14.41 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.254 0.55 . . . . 0.0 110.91 -178.236 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 80.16 -151.6 33.46 Favored Glycine 0 N--CA 1.426 -2.002 0 C-N-CA 120.282 -0.961 . . . . 0.0 113.166 176.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -135.88 168.57 19.07 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 77.6 m -74.74 124.72 27.3 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 123.648 0.592 . . . . 0.0 111.234 -179.182 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 22.0 t -106.25 116.52 59.22 Favored Pre-proline 0 C--N 1.291 -1.954 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 173.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -80.72 125.01 5.34 Favored 'Trans proline' 0 N--CA 1.445 -1.371 0 C-N-CA 122.583 2.188 . . . . 0.0 112.953 -175.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 4.1 pp -118.72 153.96 52.52 Favored Pre-proline 0 C--N 1.302 -1.47 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.23 178.742 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_endo -83.54 49.66 2.99 Favored 'Trans proline' 0 C--O 1.236 0.396 0 C-N-CA 123.53 2.82 . . . . 0.0 113.935 -170.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -141.48 -77.59 0.28 Allowed 'General case' 0 C--N 1.314 -0.959 0 CA-C-O 120.878 0.37 . . . . 0.0 110.915 179.29 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.434 ' H ' HD13 ' A' ' 29' ' ' LEU . 0.0 OUTLIER -106.85 0.88 24.31 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -177.11 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 116.98 -138.62 14.44 Favored Glycine 0 N--CA 1.437 -1.266 0 C-N-CA 120.371 -0.919 . . . . 0.0 111.206 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -108.92 149.23 17.0 Favored Glycine 0 N--CA 1.428 -1.841 0 C-N-CA 120.395 -0.907 . . . . 0.0 112.52 -178.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.8 m -124.04 146.75 29.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 177.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.472 ' SG ' HG21 ' A' ' 2' ' ' VAL . 74.4 m -71.1 136.7 48.35 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.828 179.493 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -160.33 146.06 15.16 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.7 t . . . . . 0 C--N 1.307 -1.258 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 -179.063 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.5 p . . . . . 0 N--CA 1.443 -0.778 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.444 HG23 ' SG ' ' A' ' 33' ' ' CYS . 35.7 m -102.26 169.19 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-O 121.146 0.498 . . . . 0.0 111.088 -178.427 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 26.0 mt -109.84 -176.11 2.92 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.399 -0.818 . . . . 0.0 110.542 -175.432 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.507 HG13 ' OE1' ' A' ' 20' ' ' GLN . 61.5 mt -56.37 133.25 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 122.681 0.392 . . . . 0.0 111.029 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.26 -15.03 56.09 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 116.024 -0.534 . . . . 0.0 113.057 177.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -88.42 159.25 18.09 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 -178.662 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.55 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 85.9 mtm180 -86.63 134.53 33.62 Favored 'General case' 0 CA--C 1.496 -1.098 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.916 -175.523 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.413 ' HB3' ' CG2' ' A' ' 2' ' ' VAL . 24.0 p -139.49 171.34 14.4 Favored 'General case' 0 C--N 1.285 -2.205 0 CA-C-N 114.276 -1.329 . . . . 0.0 109.379 -178.148 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -145.51 125.7 13.8 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 174.427 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -65.79 -32.75 74.46 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -177.308 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -91.16 -52.34 4.87 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -172.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 55.3 mtp180 -92.46 -25.91 18.22 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -176.068 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 90.51 167.92 42.07 Favored Glycine 0 N--CA 1.437 -1.288 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -76.78 168.84 76.04 Favored 'Cis proline' 0 N--CA 1.475 0.387 0 CA-C-N 119.669 1.735 . . . . 0.0 110.517 -0.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 5.7 mpt_? -116.09 -179.18 3.59 Favored 'General case' 0 C--N 1.291 -1.943 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.267 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.7 m -70.71 148.59 47.82 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 178.161 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 60.9 m -69.85 142.86 53.01 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 106.04 -1.837 . . . . 0.0 106.04 170.526 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.6 m -62.23 99.23 0.13 Allowed 'General case' 0 C--O 1.243 0.749 0 CA-C-O 121.002 0.429 . . . . 0.0 111.111 -175.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 128.84 -6.59 6.49 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.204 -176.372 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.507 ' OE1' HG13 ' A' ' 4' ' ' ILE . 84.8 mm-40 -98.42 10.87 39.82 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 -178.478 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.4 ' HA2' ' HB ' ' A' ' 35' ' ' VAL . . . 103.73 -172.44 20.97 Favored Glycine 0 N--CA 1.442 -0.963 0 C-N-CA 120.009 -1.091 . . . . 0.0 113.442 176.138 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 -117.02 147.16 42.57 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 -179.301 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 96.1 m -72.67 102.21 3.26 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 123.884 0.74 . . . . 0.0 112.018 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.2 p -87.23 119.85 71.08 Favored Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 171.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -82.97 141.13 10.42 Favored 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 121.987 1.791 . . . . 0.0 114.606 -173.141 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 5.8 mp -122.83 122.97 26.98 Favored Pre-proline 0 C--N 1.3 -1.551 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 177.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_exo -36.34 -54.64 0.88 Allowed 'Trans proline' 0 N--CA 1.485 1.015 0 C-N-CA 124.957 3.772 . . . . 0.0 116.012 -175.398 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -111.05 -15.35 13.74 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 113.75 1.018 . . . . 0.0 113.75 -177.647 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -80.0 -30.13 39.58 Favored 'General case' 0 C--N 1.294 -1.836 0 C-N-CA 120.313 -0.555 . . . . 0.0 112.002 174.521 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 114.73 -99.0 0.9 Allowed Glycine 0 N--CA 1.431 -1.664 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.55 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -171.64 148.62 11.15 Favored Glycine 0 C--N 1.282 -2.471 0 N-CA-C 108.649 -1.78 . . . . 0.0 108.649 178.147 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 31.5 m -130.47 145.91 34.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 CA-C-N 117.928 0.864 . . . . 0.0 111.484 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.444 ' SG ' HG23 ' A' ' 2' ' ' VAL . 71.9 m -76.11 116.74 17.11 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.896 176.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -141.56 149.19 40.48 Favored 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -179.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.4 ' HB ' ' HA2' ' A' ' 21' ' ' GLY . 4.1 p . . . . . 0 C--N 1.3 -1.544 0 CA-C-O 118.74 -0.647 . . . . 0.0 109.485 177.232 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.0 p . . . . . 0 C--O 1.227 -0.118 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.524 HG23 ' SG ' ' A' ' 33' ' ' CYS . 16.5 m -110.13 161.21 8.68 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -177.54 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 36.0 mt -107.41 -178.96 3.78 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.09 -175.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 24.0 pt -61.13 128.81 23.03 Favored 'Isoleucine or valine' 0 C--O 1.238 0.489 0 N-CA-C 113.282 0.845 . . . . 0.0 113.282 -179.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.62 -5.35 73.57 Favored Glycine 0 N--CA 1.443 -0.859 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.767 -179.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 77.5 mt-30 -101.32 156.01 17.7 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 176.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 54.1 mtm180 -86.03 140.75 30.0 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.727 0.775 . . . . 0.0 112.606 -173.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.415 ' SG ' ' N ' ' A' ' 9' ' ' ASP . 1.6 t -133.16 171.68 13.68 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-N 113.68 -1.6 . . . . 0.0 109.321 -175.16 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.415 ' N ' ' SG ' ' A' ' 8' ' ' CYS . 17.1 t70 -161.86 118.73 2.13 Favored 'General case' 0 C--N 1.276 -2.59 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 172.363 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -57.68 -39.57 77.43 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 113.984 1.105 . . . . 0.0 113.984 -175.536 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -91.13 -47.78 7.33 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -175.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 29.1 mmt180 -80.7 -43.0 21.01 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.709 0.766 . . . . 0.0 111.592 -177.012 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 105.46 163.87 23.55 Favored Glycine 0 N--CA 1.425 -2.064 0 N-CA-C 108.337 -1.905 . . . . 0.0 108.337 -172.286 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -79.01 165.85 80.58 Favored 'Cis proline' 0 C--N 1.322 -0.865 0 CA-C-N 119.88 1.84 . . . . 0.0 111.891 -0.002 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 60.5 mtp180 -108.2 153.49 23.11 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 179.412 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 55.9 m -68.01 138.69 56.07 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 55.9 m -65.93 158.28 28.5 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 178.148 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.8 t -60.89 104.43 0.36 Allowed 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 123.194 0.597 . . . . 0.0 110.343 -179.342 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 108.85 17.35 10.4 Favored Glycine 0 N--CA 1.443 -0.897 0 N-CA-C 111.524 -0.631 . . . . 0.0 111.524 -178.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 83.6 mm-40 -111.18 52.19 0.75 Allowed 'General case' 0 C--N 1.307 -1.243 0 O-C-N 122.038 -0.684 . . . . 0.0 111.591 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 71.03 -143.4 36.15 Favored Glycine 0 N--CA 1.434 -1.492 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.376 178.079 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 46.4 m-80 -128.94 146.12 51.04 Favored 'General case' 0 C--N 1.289 -2.05 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 176.194 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 42.9 t -83.11 97.12 8.63 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.01 -1.107 . . . . 0.0 108.01 179.036 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.0 p -94.37 114.99 64.72 Favored Pre-proline 0 N--CA 1.432 -1.341 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.353 -179.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.45 ' HA ' ' CA ' ' A' ' 31' ' ' GLY . 73.9 Cg_endo -76.72 142.15 22.54 Favored 'Trans proline' 0 N--CA 1.449 -1.136 0 C-N-CA 122.557 2.172 . . . . 0.0 113.605 -176.107 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 5.8 mp -116.06 142.4 29.16 Favored Pre-proline 0 N--CA 1.422 -1.867 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 172.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_endo -74.57 53.99 3.3 Favored 'Trans proline' 0 C--N 1.326 -0.65 0 C-N-CA 123.164 2.576 . . . . 0.0 113.464 -177.247 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -139.17 -87.51 0.22 Allowed 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 178.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 4.5 mp -104.66 -28.27 11.33 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-O 121.589 0.709 . . . . 0.0 110.47 -176.181 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 167.41 -152.59 21.32 Favored Glycine 0 N--CA 1.418 -2.543 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -179.22 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.45 ' CA ' ' HA ' ' A' ' 25' ' ' PRO . . . -113.42 -172.75 18.36 Favored Glycine 0 N--CA 1.411 -3.033 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.3 p -138.06 152.59 26.22 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.24 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.061 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.524 ' SG ' HG23 ' A' ' 2' ' ' VAL . 63.7 m -89.12 119.43 29.62 Favored 'General case' 0 C--N 1.275 -2.633 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.297 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.04 139.56 24.83 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -176.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 C--N 1.306 -1.316 0 CA-C-O 118.867 -0.587 . . . . 0.0 109.978 -179.861 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.7 p . . . . . 0 CA--C 1.513 -0.45 0 N-CA-C 109.29 -0.634 . . . . 0.0 109.29 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.409 HG22 ' SG ' ' A' ' 33' ' ' CYS . 33.5 m -103.17 152.53 5.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-O 120.953 0.406 . . . . 0.0 111.076 -177.293 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 52.3 mt -97.68 -174.3 2.86 Favored 'General case' 0 N--CA 1.438 -1.043 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.667 -179.273 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 43.2 pt -59.28 142.06 15.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.059 0.457 . . . . 0.0 111.704 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.59 -26.07 8.67 Favored Glycine 0 C--N 1.311 -0.82 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.26 178.366 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 24.1 mt-30 -79.18 152.92 30.42 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -178.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 10.2 mpt_? -86.76 136.86 32.84 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.883 -175.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.5 p -130.02 168.27 16.98 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.984 -175.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -132.5 123.68 27.06 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.9 m120 -72.73 -26.59 61.63 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -175.685 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -84.17 -56.55 3.6 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-O 121.228 0.537 . . . . 0.0 111.4 -175.112 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 71.9 mtm180 -105.45 -24.14 12.69 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 -170.339 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 95.48 172.48 36.59 Favored Glycine 0 N--CA 1.426 -1.999 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 -172.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -72.21 160.54 93.94 Favored 'Cis proline' 0 C--O 1.235 0.373 0 CA-C-N 119.771 1.785 . . . . 0.0 111.574 -0.218 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 57.8 mtm180 -120.18 176.04 5.65 Favored 'General case' 0 C--N 1.291 -1.959 0 CA-C-N 116.495 -0.321 . . . . 0.0 110.17 179.281 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 20.5 m -68.02 144.45 55.12 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 123.607 0.567 . . . . 0.0 109.494 -178.501 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.9 m -67.9 145.67 54.36 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 105.977 -1.86 . . . . 0.0 105.977 171.333 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 14.6 p -56.43 107.75 0.41 Allowed 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 112.017 0.377 . . . . 0.0 112.017 -177.218 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 115.03 -11.46 20.32 Favored Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.497 -177.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.437 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 86.8 mm-40 -91.98 26.61 2.39 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-O 121.321 0.581 . . . . 0.0 111.45 -178.514 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.84 -168.02 37.17 Favored Glycine 0 N--CA 1.415 -2.73 0 C-N-CA 120.54 -0.838 . . . . 0.0 113.074 176.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 47.4 m-80 -129.9 153.07 48.68 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 -179.121 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 74.3 m -68.32 104.7 1.93 Allowed 'General case' 0 C--N 1.314 -0.946 0 O-C-N 123.895 0.747 . . . . 0.0 112.602 -176.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.53 117.5 61.78 Favored Pre-proline 0 N--CA 1.434 -1.259 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 175.248 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -77.98 122.36 5.76 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 122.125 1.884 . . . . 0.0 112.198 -179.051 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 34.9 tp -129.31 109.92 17.86 Favored Pre-proline 0 N--CA 1.427 -1.607 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 175.351 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -64.29 51.53 0.18 Allowed 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 125.122 3.881 . . . . 0.0 116.476 -172.464 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -139.16 -53.34 0.56 Allowed 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 174.009 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.499 HD22 ' H ' ' A' ' 29' ' ' LEU . 1.9 pt? -107.05 -18.37 13.92 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 114.595 -1.184 . . . . 0.0 111.842 -178.011 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 115.42 -154.97 16.61 Favored Glycine 0 N--CA 1.442 -0.954 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -101.81 123.94 8.05 Favored Glycine 0 CA--C 1.483 -1.965 0 N-CA-C 110.136 -1.186 . . . . 0.0 110.136 178.352 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 33.3 m -120.12 150.41 22.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.047 0 CA-C-O 121.157 0.503 . . . . 0.0 111.601 -174.101 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.437 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 82.0 m -75.13 116.43 15.86 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.152 176.12 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -130.86 136.3 48.51 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 55.2 t . . . . . 0 C--N 1.315 -0.933 0 CA-C-O 118.778 -0.629 . . . . 0.0 109.366 -179.518 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 28.4 p . . . . . 0 CA--C 1.51 -0.572 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.429 HG22 ' SG ' ' A' ' 33' ' ' CYS . 20.0 m -109.19 164.41 5.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.314 -178.333 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 38.8 mt -103.05 -179.83 4.06 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -177.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 34.2 pt -62.64 135.66 26.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.426 0.631 . . . . 0.0 112.683 -178.5 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.08 -12.77 66.68 Favored Glycine 0 C--N 1.314 -0.677 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.985 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -92.23 154.22 18.78 Favored 'General case' 0 N--CA 1.435 -1.211 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.368 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.0 mtm180 -86.16 143.41 28.02 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.545 -174.011 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.466 ' HB2' ' O ' ' A' ' 14' ' ' PRO . 26.4 p -144.46 176.13 9.61 Favored 'General case' 0 C--N 1.278 -2.519 0 CA-C-N 114.519 -1.219 . . . . 0.0 108.362 -177.681 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -130.23 124.14 31.8 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -69.29 -27.69 65.62 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 112.645 0.609 . . . . 0.0 112.645 -177.705 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -91.94 -57.05 2.86 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 111.688 0.255 . . . . 0.0 111.688 -175.683 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -96.75 -18.47 19.6 Favored 'General case' 0 C--N 1.312 -1.051 0 N-CA-C 112.756 0.65 . . . . 0.0 112.756 -172.315 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.02 172.99 47.53 Favored Glycine 0 N--CA 1.437 -1.283 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 -174.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.466 ' O ' ' HB2' ' A' ' 8' ' ' CYS . 80.6 Cg_endo -75.77 173.09 59.83 Favored 'Cis proline' 0 C--O 1.23 0.093 0 CA-C-N 120.013 1.907 . . . . 0.0 111.014 -0.538 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.412 ' HA ' ' HB2' ' A' ' 8' ' ' CYS . 73.2 mtm180 -126.59 -173.91 2.99 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.678 -0.237 . . . . 0.0 110.437 178.492 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.2 m -65.45 146.74 54.5 Favored 'General case' 0 C--N 1.294 -1.826 0 C-N-CA 124.08 0.952 . . . . 0.0 111.591 -179.037 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 62.9 m -66.75 149.65 50.24 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 171.131 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.9 t -62.05 100.48 0.16 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.762 0.315 . . . . 0.0 110.365 -178.075 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 121.35 1.23 11.2 Favored Glycine 0 N--CA 1.444 -0.824 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -177.481 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 27.3 mm-40 -109.76 39.6 2.08 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 120.976 0.417 . . . . 0.0 112.103 179.564 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 74.43 -159.21 52.28 Favored Glycine 0 N--CA 1.423 -2.172 0 C-N-CA 120.308 -0.949 . . . . 0.0 112.628 178.38 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -133.96 148.92 51.22 Favored 'General case' 0 C--N 1.278 -2.5 0 N-CA-C 109.338 -0.615 . . . . 0.0 109.338 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 88.4 m -64.78 112.69 3.36 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 124.112 0.883 . . . . 0.0 111.079 177.677 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.3 p -96.19 124.67 50.81 Favored Pre-proline 0 C--N 1.284 -2.242 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 172.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -78.39 145.86 21.52 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 C-N-CA 121.594 1.529 . . . . 0.0 112.585 -177.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -130.07 146.54 61.89 Favored Pre-proline 0 C--N 1.301 -1.534 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 178.003 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo -41.75 -68.19 0.1 Allowed 'Trans proline' 0 N--CA 1.481 0.791 0 C-N-CA 124.503 3.469 . . . . 0.0 115.111 -177.124 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 33.4 p90 -104.79 -25.22 12.74 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-O 121.074 0.464 . . . . 0.0 112.04 -176.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -66.05 -32.04 73.28 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.441 179.178 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 101.19 -88.12 0.7 Allowed Glycine 0 N--CA 1.429 -1.822 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 178.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -158.82 147.69 15.64 Favored Glycine 0 N--CA 1.427 -1.927 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 179.279 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.7 p -140.41 148.82 21.91 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 CA-C-O 121.197 0.522 . . . . 0.0 110.103 178.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.429 ' SG ' HG22 ' A' ' 2' ' ' VAL . 76.9 m -82.2 132.87 35.24 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.51 179.112 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.93 140.73 17.12 Favored 'General case' 0 N--CA 1.425 -1.678 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -178.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.1 m . . . . . 0 C--N 1.307 -1.282 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 176.125 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.3 p . . . . . 0 N--CA 1.445 -0.684 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 16' ' ' CYS . 30.8 m -96.67 169.2 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 120.936 0.398 . . . . 0.0 111.087 -179.562 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 42.5 mt -114.41 -176.14 2.84 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.788 -176.326 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.3 pp -51.92 145.01 2.56 Favored 'Isoleucine or valine' 0 C--O 1.246 0.917 0 N-CA-C 113.546 0.943 . . . . 0.0 113.546 176.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.32 -15.98 15.36 Favored Glycine 0 C--N 1.32 -0.348 0 CA-C-N 115.728 -0.669 . . . . 0.0 113.632 179.383 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 11.5 mt-30 -85.91 157.96 20.04 Favored 'General case' 0 C--N 1.307 -1.271 0 O-C-N 122.384 -0.48 . . . . 0.0 110.136 177.254 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -86.44 125.05 33.43 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.894 -177.245 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.4 p -119.07 163.48 16.93 Favored 'General case' 0 C--N 1.278 -2.538 0 CA-C-N 114.569 -1.196 . . . . 0.0 110.697 -175.318 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -148.15 126.32 12.17 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 174.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -77.78 -22.13 50.61 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -174.047 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -90.5 -54.81 3.84 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-O 121.255 0.55 . . . . 0.0 111.158 -175.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -100.04 -27.58 13.49 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.271 -172.424 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.0 169.93 27.32 Favored Glycine 0 N--CA 1.432 -1.599 0 N-CA-C 110.141 -1.184 . . . . 0.0 110.141 -174.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -79.85 155.53 88.16 Favored 'Cis proline' 0 N--CA 1.457 -0.655 0 CA-C-N 119.461 1.631 . . . . 0.0 111.704 -0.605 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 66.1 mtt180 -107.45 145.44 33.02 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 -179.358 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 2' ' ' VAL . 81.6 m -74.38 149.92 40.29 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.374 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 64.0 m -58.23 141.18 51.52 Favored 'General case' 0 C--N 1.317 -0.821 0 O-C-N 124.223 0.952 . . . . 0.0 109.693 -176.406 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 13.7 t -68.66 97.68 0.82 Allowed 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 141.01 -19.18 2.71 Favored Glycine 0 N--CA 1.435 -1.428 0 N-CA-C 108.559 -1.817 . . . . 0.0 108.559 -173.662 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 24.9 mm-40 -81.49 -178.98 7.18 Favored 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 123.681 0.792 . . . . 0.0 111.839 177.215 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.54 169.61 19.17 Favored Glycine 0 C--N 1.314 -0.681 0 CA-C-O 121.42 0.456 . . . . 0.0 114.083 -177.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . 0.526 ' O ' ' HA ' ' A' ' 33' ' ' CYS . 9.0 t30 -85.82 139.93 30.87 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 178.72 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 21.4 t -76.25 101.46 5.45 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 -178.276 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.6 t -99.9 113.95 65.41 Favored Pre-proline 0 N--CA 1.426 -1.652 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 -179.302 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.421 ' HA ' ' CA ' ' A' ' 31' ' ' GLY . 3.0 Cg_exo -71.87 121.38 7.56 Favored 'Trans proline' 0 N--CA 1.442 -1.545 0 C-N-CA 122.19 1.927 . . . . 0.0 110.706 179.257 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.1 mt -117.12 122.88 30.67 Favored Pre-proline 0 N--CA 1.425 -1.695 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 178.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -73.65 42.86 0.72 Allowed 'Trans proline' 0 CA--C 1.542 0.878 0 C-N-CA 123.716 2.944 . . . . 0.0 113.102 -176.721 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -135.2 -67.65 0.54 Allowed 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 -179.282 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . 0.467 HD22 ' H ' ' A' ' 29' ' ' LEU . 2.3 pt? -107.14 -5.72 17.8 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.669 -178.559 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 111.71 -172.76 15.12 Favored Glycine 0 N--CA 1.432 -1.595 0 N-CA-C 110.129 -1.188 . . . . 0.0 110.129 -175.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.421 ' CA ' ' HA ' ' A' ' 25' ' ' PRO . . . -90.64 132.78 11.45 Favored Glycine 0 CA--C 1.484 -1.894 0 C-N-CA 120.526 -0.845 . . . . 0.0 111.336 179.381 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.4 m -129.88 147.74 33.23 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.938 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -178.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.526 ' HA ' ' O ' ' A' ' 22' ' ' ASN . 96.4 m -82.25 120.07 24.9 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.132 178.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -119.76 137.71 53.78 Favored 'General case' 0 N--CA 1.427 -1.589 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 178.428 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--N 1.292 -1.898 0 C-N-CA 121.008 -0.277 . . . . 0.0 111.194 -177.472 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 25.8 p . . . . . 0 N--CA 1.446 -0.648 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.464 HG23 ' SG ' ' A' ' 33' ' ' CYS . 18.6 m -108.37 154.91 9.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 CA-C-O 121.134 0.492 . . . . 0.0 111.513 -179.605 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.409 ' HB3' ' OE1' ' A' ' 20' ' ' GLN . 57.7 mt -100.33 -176.96 3.37 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.52 -175.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.9 pt -61.13 130.49 25.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.503 0 CA-C-O 121.477 0.656 . . . . 0.0 112.438 -179.114 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 96.59 -22.64 39.12 Favored Glycine 0 C--N 1.311 -0.821 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.841 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -81.02 154.9 26.64 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 121.067 0.46 . . . . 0.0 109.794 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.1 tmt_? -86.34 138.15 32.04 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.349 -173.679 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 17.5 p -137.07 167.89 20.65 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.917 -177.364 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -141.66 120.49 12.7 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 175.41 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -63.37 -35.18 79.56 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.84 -0.618 . . . . 0.0 112.168 -170.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -92.44 -52.54 4.61 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 113.026 0.75 . . . . 0.0 113.026 -175.469 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.4 mtm180 -87.08 -27.81 22.92 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 121.133 0.492 . . . . 0.0 112.306 -174.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.0 163.42 26.76 Favored Glycine 0 N--CA 1.427 -1.966 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 -175.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -78.44 165.93 81.37 Favored 'Cis proline' 0 C--N 1.332 -0.323 0 C-N-CA 123.378 -1.509 . . . . 0.0 112.375 0.569 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 60.1 mtt180 -115.74 163.09 16.34 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.678 -179.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 58.4 m -70.14 142.33 52.55 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 123.638 0.775 . . . . 0.0 110.514 -177.39 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 81.9 m -67.39 157.48 34.0 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 174.667 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.1 p -57.64 96.6 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.818 0 C-N-CA 124.207 1.003 . . . . 0.0 112.477 -177.467 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 99.09 34.76 5.02 Favored Glycine 0 N--CA 1.433 -1.566 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.293 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.419 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 23.9 mm-40 -122.58 34.57 5.11 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-O 121.547 0.689 . . . . 0.0 111.013 177.184 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 78.47 -166.38 52.34 Favored Glycine 0 N--CA 1.419 -2.457 0 CA-C-N 114.928 -1.033 . . . . 0.0 112.169 178.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 40.4 m-80 -127.95 157.19 41.26 Favored 'General case' 0 C--N 1.29 -2.016 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 -179.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 99.3 m -68.13 97.92 0.74 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 123.819 0.7 . . . . 0.0 111.765 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.82 126.62 72.54 Favored Pre-proline 0 N--CA 1.425 -1.699 0 N-CA-C 106.153 -1.795 . . . . 0.0 106.153 174.082 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -70.3 129.99 17.94 Favored 'Trans proline' 0 N--CA 1.446 -1.288 0 C-N-CA 121.558 1.506 . . . . 0.0 114.283 -174.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -121.42 143.24 37.19 Favored Pre-proline 0 C--N 1.309 -1.187 0 CA-C-N 114.932 -1.031 . . . . 0.0 108.747 178.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_exo -44.26 -63.7 0.31 Allowed 'Trans proline' 0 CA--C 1.546 1.094 0 C-N-CA 123.731 2.954 . . . . 0.0 115.298 -176.744 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -89.65 -25.42 21.27 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 112.599 0.592 . . . . 0.0 112.599 -173.518 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -88.81 -17.97 28.66 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-O 121.362 0.601 . . . . 0.0 111.093 -175.434 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 88.89 -63.59 3.49 Favored Glycine 0 N--CA 1.429 -1.832 0 N-CA-C 109.389 -1.485 . . . . 0.0 109.389 -177.038 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -165.13 148.18 13.68 Favored Glycine 0 N--CA 1.419 -2.441 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 178.021 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.0 m -131.79 150.97 34.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 176.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.464 ' SG ' HG23 ' A' ' 2' ' ' VAL . 71.7 m -76.32 117.24 17.79 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -142.65 145.47 33.49 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 120.726 -0.389 . . . . 0.0 110.786 -179.733 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.6 m . . . . . 0 C--N 1.308 -1.22 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.603 176.963 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 23.4 p . . . . . 0 C--O 1.233 0.217 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.41 HG23 ' SG ' ' A' ' 33' ' ' CYS . 28.8 m -110.54 154.44 12.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-O 120.606 0.241 . . . . 0.0 111.367 -178.583 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 35.5 mt -99.69 -176.36 3.24 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.297 -177.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.423 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 33.8 pt -58.14 134.6 22.84 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.73 0 CA-C-O 121.477 0.656 . . . . 0.0 112.489 179.027 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.73 -18.72 55.98 Favored Glycine 0 C--N 1.311 -0.828 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.296 178.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 23.7 mt-30 -89.66 152.33 21.42 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -179.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.434 ' HA ' ' HA ' ' A' ' 32' ' ' VAL . 16.4 ptp180 -86.61 148.71 25.36 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.07 0.462 . . . . 0.0 111.106 -175.317 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.2 p -138.56 158.24 44.62 Favored 'General case' 0 C--N 1.298 -1.652 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.611 -174.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -129.06 124.03 33.8 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 176.152 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -79.17 -27.11 42.64 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 120.955 0.407 . . . . 0.0 111.626 -173.107 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -91.1 -42.08 10.68 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 115.723 -0.671 . . . . 0.0 112.154 -173.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 83.7 mtm180 -112.54 -13.3 13.35 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 -175.597 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 89.35 165.74 41.33 Favored Glycine 0 N--CA 1.44 -1.094 0 C-N-CA 120.055 -1.069 . . . . 0.0 110.805 -177.408 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -79.85 158.73 88.28 Favored 'Cis proline' 0 N--CA 1.463 -0.284 0 CA-C-N 119.227 1.513 . . . . 0.0 111.195 -0.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 80.9 mtm180 -113.49 172.67 6.83 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 121.03 -0.268 . . . . 0.0 110.502 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.7 m -68.01 141.0 56.37 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 123.634 0.583 . . . . 0.0 109.834 -179.228 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 55.8 m -67.33 140.86 57.29 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 172.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 5.9 p -58.4 94.77 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.73 0 CA-C-O 121.663 0.744 . . . . 0.0 112.794 -177.383 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 132.38 -5.32 5.26 Favored Glycine 0 N--CA 1.438 -1.179 0 CA-C-N 114.853 -1.067 . . . . 0.0 110.644 -176.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . 0.43 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 86.0 mm-40 -101.58 30.09 4.49 Favored 'General case' 0 C--N 1.323 -0.561 0 C-N-CA 123.348 0.659 . . . . 0.0 112.456 -177.483 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 84.44 -171.6 47.89 Favored Glycine 0 N--CA 1.436 -1.352 0 C-N-CA 120.103 -1.046 . . . . 0.0 113.9 175.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -113.44 162.59 15.94 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.747 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 98.8 m -76.87 97.23 4.51 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-O 121.553 0.692 . . . . 0.0 109.689 177.253 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.5 t -93.43 127.91 44.55 Favored Pre-proline 0 N--CA 1.416 -2.14 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 -179.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -85.0 121.01 2.34 Favored 'Trans proline' 0 N--CA 1.427 -2.421 0 C-N-CA 121.953 1.769 . . . . 0.0 112.018 -178.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 10.3 mp -110.39 124.52 33.08 Favored Pre-proline 0 C--N 1.29 -2.018 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 177.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -53.24 -17.38 8.46 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 C-N-CA 124.448 3.432 . . . . 0.0 115.564 -173.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -110.55 -22.74 11.49 Favored 'General case' 0 C--N 1.309 -1.164 0 C-N-CA 120.858 -0.337 . . . . 0.0 111.388 -179.167 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 6.1 mp -106.55 -16.89 14.41 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 112.177 0.436 . . . . 0.0 112.177 -173.76 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.94 -104.91 2.98 Favored Glycine 0 N--CA 1.426 -2.006 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 -176.449 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -147.35 127.9 2.79 Favored Glycine 0 C--N 1.295 -1.744 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 176.465 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.434 ' HA ' ' HA ' ' A' ' 7' ' ' ARG . 34.5 m -131.83 154.19 39.88 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 C-N-CA 122.926 0.49 . . . . 0.0 110.187 -175.809 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' CYS . . . . . 0.43 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 74.4 m -74.53 119.69 19.06 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.705 178.033 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -146.53 148.75 32.5 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.752 0.311 . . . . 0.0 110.551 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 17.9 m . . . . . 0 C--N 1.306 -1.291 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.007 176.663 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.5 p . . . . . 0 N--CA 1.452 -0.334 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.535 HG23 ' SG ' ' A' ' 33' ' ' CYS . 21.2 m -106.84 167.4 3.45 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-O 121.184 0.516 . . . . 0.0 111.291 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.453 ' HB3' ' OE1' ' A' ' 20' ' ' GLN . 25.3 mt -107.41 175.97 5.31 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.174 -172.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 27.9 pt -61.07 134.99 26.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.438 0 CA-C-O 121.415 0.626 . . . . 0.0 112.394 -178.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.65 -13.3 60.97 Favored Glycine 0 C--N 1.312 -0.78 0 CA-C-N 115.486 -0.779 . . . . 0.0 112.622 -179.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -90.4 151.18 21.54 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 106.892 -1.522 . . . . 0.0 106.892 176.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 34.3 ptt180 -85.9 146.24 26.8 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.949 -0.7 . . . . 0.0 111.064 -173.156 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.4 p -139.09 176.91 8.29 Favored 'General case' 0 C--N 1.282 -2.331 0 CA-C-N 115.164 -0.926 . . . . 0.0 109.224 -174.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -152.11 117.31 5.24 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 174.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -57.08 -38.99 74.1 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 113.629 0.974 . . . . 0.0 113.629 -173.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -91.86 -47.58 7.25 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 113.628 0.973 . . . . 0.0 113.628 -175.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.0 mtm180 -89.48 -29.88 18.67 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -173.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.55 160.31 25.94 Favored Glycine 0 N--CA 1.435 -1.389 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -174.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -79.65 167.45 75.47 Favored 'Cis proline' 0 C--O 1.218 -0.475 0 CA-C-N 119.542 1.671 . . . . 0.0 111.987 1.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 88.0 mtm180 -122.01 156.25 33.87 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 33.6 m -70.2 149.25 47.7 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 124.825 1.25 . . . . 0.0 111.319 -175.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 85.4 m -68.43 143.74 54.95 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 175.229 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 11.4 t -54.3 -26.45 29.41 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 125.25 1.42 . . . . 0.0 113.039 -172.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -108.08 16.53 35.8 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.188 178.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.453 ' OE1' ' HB3' ' A' ' 3' ' ' LEU . 18.3 mm-40 -97.74 -68.1 0.82 Allowed 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -179.368 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -175.85 -179.18 46.2 Favored Glycine 0 CA--C 1.481 -2.089 0 C-N-CA 120.261 -0.971 . . . . 0.0 110.703 -176.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 52.4 t30 -93.29 139.6 30.46 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 177.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 49.9 t -79.47 98.13 6.68 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.62 120.09 69.53 Favored Pre-proline 0 C--N 1.302 -1.47 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -67.18 141.7 58.19 Favored 'Trans proline' 0 N--CA 1.449 -1.114 0 C-N-CA 122.431 2.087 . . . . 0.0 113.106 -176.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.4 mt -119.36 144.19 35.95 Favored Pre-proline 0 C--N 1.302 -1.5 0 CA-C-N 114.743 -1.117 . . . . 0.0 109.078 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_exo -40.26 -57.31 1.23 Allowed 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 124.731 3.621 . . . . 0.0 114.806 -176.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 30.4 p90 -119.18 -24.18 6.54 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -177.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 78.3 mt -79.9 0.49 31.02 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 179.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 87.57 -59.22 4.37 Favored Glycine 0 CA--C 1.499 -0.939 0 C-N-CA 121.149 -0.548 . . . . 0.0 111.871 177.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 171.64 170.79 36.07 Favored Glycine 0 N--CA 1.418 -2.512 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 9.2 p -147.3 146.15 18.59 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.986 0 CA-C-O 121.503 0.668 . . . . 0.0 109.992 177.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.535 ' SG ' HG23 ' A' ' 2' ' ' VAL . 74.1 m -80.06 118.4 21.75 Favored 'General case' 0 C--N 1.285 -2.223 0 CA-C-N 114.713 -1.13 . . . . 0.0 109.923 179.639 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -143.87 153.66 42.57 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 -177.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 52.4 t . . . . . 0 C--N 1.306 -1.32 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -179.109 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.3 p . . . . . 0 C--O 1.24 0.57 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.575 HG22 ' SG ' ' A' ' 33' ' ' CYS . 30.2 m -112.06 158.28 12.55 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-O 120.655 0.264 . . . . 0.0 111.504 -178.567 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 38.2 mt -99.57 -178.56 3.92 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.482 -176.554 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 34.0 pt -58.64 140.37 17.04 Favored 'Isoleucine or valine' 0 C--O 1.241 0.651 0 N-CA-C 113.023 0.749 . . . . 0.0 113.023 -179.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.8 -14.34 48.48 Favored Glycine 0 C--N 1.311 -0.86 0 CA-C-N 115.708 -0.678 . . . . 0.0 113.183 178.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 27.2 mt-30 -86.15 156.53 20.31 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 108.056 -1.091 . . . . 0.0 108.056 178.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 47.1 ttp180 -86.01 132.22 34.11 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 123.623 0.577 . . . . 0.0 109.962 -176.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.2 p -128.71 175.11 8.85 Favored 'General case' 0 C--N 1.278 -2.543 0 CA-C-N 115.069 -0.969 . . . . 0.0 109.197 -177.478 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -149.82 125.68 10.5 Favored 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 174.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.405 ' OD1' ' HB3' ' A' ' 23' ' ' CYS . 43.6 m-80 -76.64 -23.11 53.31 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 120.531 0.205 . . . . 0.0 111.526 -175.84 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -84.87 -57.56 3.06 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.903 -175.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 63.2 mtt180 -103.07 -21.85 13.86 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 113.107 0.78 . . . . 0.0 113.107 -175.356 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 103.86 168.55 25.25 Favored Glycine 0 N--CA 1.433 -1.543 0 C-N-CA 120.121 -1.038 . . . . 0.0 110.609 -177.393 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -80.1 159.17 87.18 Favored 'Cis proline' 0 CA--C 1.535 0.549 0 CA-C-N 119.085 1.442 . . . . 0.0 112.065 0.217 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 -104.55 169.91 8.19 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 177.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.6 m -80.52 147.16 30.96 Favored 'General case' 0 C--N 1.297 -1.688 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.419 -176.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 39.5 m -72.77 153.28 41.19 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 175.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.1 t -67.77 120.12 13.59 Favored 'General case' 0 N--CA 1.435 -1.214 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 103.54 0.1 46.4 Favored Glycine 0 N--CA 1.437 -1.264 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -175.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 86.0 mm-40 -111.86 38.01 2.78 Favored 'General case' 0 C--N 1.31 -1.132 0 CA-C-O 121.496 0.665 . . . . 0.0 110.366 179.064 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 78.14 -156.58 43.77 Favored Glycine 0 N--CA 1.418 -2.554 0 CA-C-N 115.057 -0.974 . . . . 0.0 112.962 177.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 79.6 m-20 -123.74 153.75 40.47 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 106.123 -1.806 . . . . 0.0 106.123 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . 0.405 ' HB3' ' OD1' ' A' ' 10' ' ' ASN . 51.6 t -84.52 98.46 10.14 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.656 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.411 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 22.9 t -97.34 118.05 64.9 Favored Pre-proline 0 C--N 1.303 -1.456 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 -178.026 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 4.0 Cg_exo -70.76 129.84 17.16 Favored 'Trans proline' 0 N--CA 1.451 -0.99 0 C-N-CA 122.611 2.207 . . . . 0.0 110.113 177.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 85.2 mt -129.3 150.6 75.96 Favored Pre-proline 0 C--N 1.309 -1.154 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.951 -175.525 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -42.49 -67.37 0.12 Allowed 'Trans proline' 0 CA--C 1.545 1.044 0 C-N-CA 124.792 3.661 . . . . 0.0 115.679 -177.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 26.5 p90 -97.8 -23.58 15.82 Favored 'General case' 0 C--N 1.314 -0.975 0 N-CA-C 113.325 0.861 . . . . 0.0 113.325 -174.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 97.4 mt -83.13 -12.11 57.32 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.557 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 84.06 -65.65 4.06 Favored Glycine 0 CA--C 1.501 -0.813 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -178.23 134.79 2.48 Favored Glycine 0 CA--C 1.47 -2.773 0 N-CA-C 108.569 -1.812 . . . . 0.0 108.569 177.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.5 m -136.02 153.68 32.45 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.224 0 CA-C-O 121.505 0.669 . . . . 0.0 110.998 -178.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.575 ' SG ' HG22 ' A' ' 2' ' ' VAL . 84.1 m -79.15 117.27 20.02 Favored 'General case' 0 C--N 1.291 -1.957 0 CA-C-N 114.503 -1.226 . . . . 0.0 108.833 175.613 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -135.07 130.41 35.53 Favored 'General case' 0 N--CA 1.431 -1.399 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -177.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 N--CA 1.432 -1.338 0 O-C-N 123.306 0.378 . . . . 0.0 110.63 178.847 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 22.2 p . . . . . 0 N--CA 1.446 -0.673 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.565 HG21 ' SG ' ' A' ' 33' ' ' CYS . 15.7 m -101.29 163.22 3.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-O 121.17 0.51 . . . . 0.0 111.511 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 23.9 mt -107.88 179.99 4.06 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.454 -0.793 . . . . 0.0 111.108 -172.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 24.3 pt -55.11 134.34 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.42 -17.85 41.12 Favored Glycine 0 C--O 1.242 0.614 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.937 177.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' A' ' 32' ' ' VAL . 78.7 mt-30 -81.54 159.72 24.06 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.133 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.44 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 40.5 ttp180 -85.78 129.0 34.95 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.269 -173.802 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 30.3 p -128.17 172.43 11.01 Favored 'General case' 0 C--N 1.291 -1.949 0 CA-C-O 121.294 0.569 . . . . 0.0 110.677 -177.22 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -147.12 118.97 8.09 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 175.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -58.22 -42.03 85.4 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 124.192 0.997 . . . . 0.0 113.113 -173.241 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -91.93 -56.63 3.01 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -175.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -83.15 -31.0 27.42 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-O 121.133 0.492 . . . . 0.0 112.024 -171.046 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 104.85 165.0 24.16 Favored Glycine 0 N--CA 1.427 -1.906 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 -176.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -76.25 156.76 98.41 Favored 'Cis proline' 0 C--N 1.329 -0.468 0 C-N-CA 123.382 -1.507 . . . . 0.0 112.122 0.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 82.1 mtt180 -108.03 156.35 19.35 Favored 'General case' 0 C--N 1.289 -2.04 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.56 -179.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 58.8 m -76.23 144.03 40.65 Favored 'General case' 0 C--N 1.29 -1.99 0 C-N-CA 124.06 0.944 . . . . 0.0 110.79 -176.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.428 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 59.2 m -67.42 161.51 25.12 Favored 'General case' 0 C--O 1.243 0.743 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.543 177.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 37.6 t -46.96 -56.21 6.77 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.065 0.946 . . . . 0.0 113.414 -174.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -95.19 27.22 15.79 Favored Glycine 0 C--N 1.314 -0.672 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.825 -176.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.428 ' CG ' ' HB2' ' A' ' 17' ' ' CYS . 84.9 mm-40 -110.84 29.69 7.53 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-O 121.337 0.589 . . . . 0.0 110.707 -178.556 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.51 -140.5 18.2 Favored Glycine 0 N--CA 1.43 -1.712 0 C-N-CA 120.365 -0.921 . . . . 0.0 112.874 177.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -133.8 155.87 49.04 Favored 'General case' 0 C--N 1.287 -2.142 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 176.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 52.5 t -83.06 100.83 10.74 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.4 p -98.0 120.07 60.78 Favored Pre-proline 0 N--CA 1.419 -2.021 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.62 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_exo -69.42 139.9 42.57 Favored 'Trans proline' 0 N--CA 1.45 -1.034 0 C-N-CA 122.076 1.851 . . . . 0.0 112.62 -179.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 11.0 mp -119.49 134.92 23.81 Favored Pre-proline 0 C--N 1.304 -1.41 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.468 179.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_exo -39.93 -54.18 2.16 Favored 'Trans proline' 0 C--N 1.356 0.965 0 C-N-CA 124.58 3.52 . . . . 0.0 115.483 -175.464 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 75.5 m-85 -99.43 -40.88 7.66 Favored 'General case' 0 CA--C 1.504 -0.799 0 CA-C-O 121.079 0.466 . . . . 0.0 111.038 -178.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 14.0 mt -75.65 -14.58 60.37 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.872 -0.604 . . . . 0.0 112.594 -170.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.73 -64.53 0.75 Allowed Glycine 0 CA--C 1.486 -1.765 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 -179.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.44 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . 174.33 156.35 13.65 Favored Glycine 0 N--CA 1.425 -2.083 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 178.013 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 35.4 m -139.06 152.76 24.17 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-O 121.248 0.547 . . . . 0.0 109.925 177.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.565 ' SG ' HG21 ' A' ' 2' ' ' VAL . 60.4 m -82.55 125.01 30.65 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 115.426 -0.807 . . . . 0.0 108.964 176.751 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -146.82 135.74 22.34 Favored 'General case' 0 N--CA 1.439 -0.998 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.267 -176.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--N 1.301 -1.542 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 178.49 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 25.8 p . . . . . 0 C--O 1.24 0.59 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.491 HG22 ' SG ' ' A' ' 33' ' ' CYS . 30.1 m -103.84 168.68 2.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 120.902 0.382 . . . . 0.0 110.878 -179.508 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 24.8 mt -109.12 -179.48 3.86 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.771 -0.649 . . . . 0.0 109.695 -175.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.7 pt -57.68 134.02 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-O 121.643 0.735 . . . . 0.0 112.87 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 95.71 -23.99 31.58 Favored Glycine 0 N--CA 1.442 -0.945 0 CA-C-N 115.175 -0.92 . . . . 0.0 112.303 178.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 36.2 mt-30 -83.09 152.65 25.24 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 16.5 ptm180 -87.0 145.39 26.52 Favored 'General case' 0 C--N 1.297 -1.694 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.309 -176.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.418 ' HB2' ' O ' ' A' ' 14' ' ' PRO . 15.7 p -144.3 176.26 9.48 Favored 'General case' 0 C--N 1.285 -2.21 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.983 -174.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -145.0 116.78 8.2 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 177.64 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -62.32 -32.67 73.46 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 112.968 0.729 . . . . 0.0 112.968 -178.459 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -82.63 -56.59 3.77 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 121.186 0.517 . . . . 0.0 111.523 -172.597 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 77.5 mtm180 -96.95 -20.23 18.24 Favored 'General case' 0 C--N 1.295 -1.778 0 CA-C-N 115.614 -0.721 . . . . 0.0 112.788 -172.172 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 94.36 162.55 35.34 Favored Glycine 0 N--CA 1.43 -1.738 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -177.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.418 ' O ' ' HB2' ' A' ' 8' ' ' CYS . 97.9 Cg_endo -85.26 167.53 53.0 Favored 'Cis proline' 0 C--N 1.326 -0.649 0 CA-C-N 119.272 1.536 . . . . 0.0 110.979 0.254 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -115.94 178.33 4.35 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 175.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 32.7 m -68.12 146.12 53.74 Favored 'General case' 0 C--N 1.293 -1.881 0 C-N-CA 123.277 0.631 . . . . 0.0 110.884 178.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 71.3 m -70.89 154.9 41.42 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 171.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.7 t -60.68 113.31 2.4 Favored 'General case' 0 N--CA 1.436 -1.128 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 106.48 0.2 37.36 Favored Glycine 0 N--CA 1.441 -0.982 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.555 -178.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 86.3 mm-40 -107.93 33.86 3.87 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.168 0.509 . . . . 0.0 110.93 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 80.7 -140.35 21.67 Favored Glycine 0 N--CA 1.428 -1.867 0 C-N-CA 120.131 -1.033 . . . . 0.0 113.241 177.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 52.9 t30 -151.32 159.92 44.06 Favored 'General case' 0 C--N 1.288 -2.097 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 92.3 m -72.08 97.76 1.97 Allowed 'General case' 0 C--N 1.308 -1.199 0 O-C-N 123.884 0.74 . . . . 0.0 109.192 176.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.3 t -96.52 126.9 41.76 Favored Pre-proline 0 N--CA 1.42 -1.946 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 179.223 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_exo -58.84 127.0 22.79 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 122.764 2.309 . . . . 0.0 112.627 -177.659 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 47.5 tp -118.02 131.91 23.95 Favored Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 179.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -74.38 45.6 1.24 Allowed 'Trans proline' 0 N--CA 1.482 0.809 0 C-N-CA 123.636 2.891 . . . . 0.0 113.17 -176.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -148.98 -69.63 0.21 Allowed 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 124.143 0.977 . . . . 0.0 109.3 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 25.6 mt -95.66 1.53 53.6 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 114.285 -1.325 . . . . 0.0 111.516 -170.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.63 -77.14 0.63 Allowed Glycine 0 N--CA 1.435 -1.404 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -146.45 139.2 7.9 Favored Glycine 0 C--N 1.29 -2.015 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.051 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.8 m -134.38 157.09 41.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 178.693 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.491 ' SG ' HG22 ' A' ' 2' ' ' VAL . 81.4 m -73.78 124.54 26.26 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.103 179.622 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -144.5 143.24 30.75 Favored 'General case' 0 N--CA 1.425 -1.69 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.2 m . . . . . 0 C--N 1.301 -1.512 0 O-C-N 123.789 0.68 . . . . 0.0 111.124 178.767 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 19.9 p . . . . . 0 C--O 1.241 0.647 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.597 HG22 ' SG ' ' A' ' 33' ' ' CYS . 15.1 m -109.72 157.53 10.15 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.656 0 CA-C-O 121.131 0.491 . . . . 0.0 111.458 176.333 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 18.4 mt -111.98 179.34 4.03 Favored 'General case' 0 N--CA 1.432 -1.357 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.069 -172.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 23.7 pt -54.1 133.46 17.11 Favored 'Isoleucine or valine' 0 C--O 1.239 0.545 0 CA-C-O 121.76 0.791 . . . . 0.0 112.88 -179.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.57 -9.08 72.4 Favored Glycine 0 C--N 1.309 -0.954 0 CA-C-N 115.375 -0.83 . . . . 0.0 113.04 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 75.7 mt-30 -94.47 156.47 16.45 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 176.741 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 18.1 ptp180 -85.81 145.72 27.09 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-O 121.139 0.495 . . . . 0.0 111.504 -174.156 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.44 ' SG ' ' HA ' ' A' ' 15' ' ' ARG . 3.8 t -137.21 159.72 41.09 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.819 -1.082 . . . . 0.0 112.324 -172.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -150.86 117.54 5.79 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 113.277 -1.783 . . . . 0.0 107.062 176.137 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 48.2 m-80 -63.72 -43.04 97.71 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 113.671 0.989 . . . . 0.0 113.671 -173.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 17.4 m-20 -92.46 -35.88 13.4 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 113.678 0.992 . . . . 0.0 113.678 -174.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 54.8 mtm180 -100.99 -14.86 17.68 Favored 'General case' 0 C--N 1.309 -1.176 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -174.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.77 155.98 29.55 Favored Glycine 0 N--CA 1.442 -0.932 0 N-CA-C 111.081 -0.807 . . . . 0.0 111.081 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -84.91 159.33 66.08 Favored 'Cis proline' 0 CA--C 1.535 0.546 0 CA-C-N 119.206 1.503 . . . . 0.0 111.883 0.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.44 ' HA ' ' SG ' ' A' ' 8' ' ' CYS . 39.7 mtm180 -112.21 155.27 24.26 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-O 120.89 0.376 . . . . 0.0 110.083 -178.776 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.432 ' HA ' ' O ' ' A' ' 2' ' ' VAL . 36.8 m -78.02 142.01 38.52 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 123.882 0.873 . . . . 0.0 110.533 -176.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 m -67.05 153.37 43.82 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 119.144 -1.022 . . . . 0.0 111.312 172.006 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 12.3 p -48.74 -46.65 41.29 Favored 'General case' 0 C--O 1.241 0.622 0 N-CA-C 114.229 1.196 . . . . 0.0 114.229 -173.189 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -90.63 11.79 70.56 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.448 -0.882 . . . . 0.0 112.703 -179.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 78.7 mm-40 -105.28 37.19 2.25 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.276 0.56 . . . . 0.0 111.716 -178.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.48 -158.92 30.32 Favored Glycine 0 N--CA 1.423 -2.205 0 C-N-CA 120.091 -1.052 . . . . 0.0 112.32 177.02 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 -122.18 149.44 43.63 Favored 'General case' 0 C--N 1.282 -2.35 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 49.1 t -84.02 97.33 9.23 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.002 -1.111 . . . . 0.0 108.002 179.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.6 p -104.82 124.88 35.37 Favored Pre-proline 0 C--N 1.305 -1.34 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.52 -177.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -67.07 141.74 58.93 Favored 'Trans proline' 0 C--O 1.243 0.762 0 C-N-CA 122.645 2.23 . . . . 0.0 112.951 -176.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 87.9 mt -122.21 148.63 52.57 Favored Pre-proline 0 C--N 1.309 -1.181 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.601 -178.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo -49.29 -64.22 0.24 Allowed 'Trans proline' 0 CA--C 1.545 1.072 0 C-N-CA 123.715 2.943 . . . . 0.0 114.394 -178.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -97.16 -40.36 8.84 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.947 0.403 . . . . 0.0 110.987 -174.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 9.2 mp -78.98 0.74 26.38 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 113.737 1.014 . . . . 0.0 113.737 -174.681 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 86.28 -65.33 3.86 Favored Glycine 0 CA--C 1.501 -0.803 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.081 176.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -176.35 160.43 28.11 Favored Glycine 0 CA--C 1.477 -2.323 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 8.8 p -142.76 157.63 18.39 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 CA-C-N 117.73 0.765 . . . . 0.0 109.922 -178.265 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.597 ' SG ' HG22 ' A' ' 2' ' ' VAL . 59.9 m -88.0 108.73 19.36 Favored 'General case' 0 C--N 1.278 -2.514 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 174.547 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -149.88 163.84 36.97 Favored 'General case' 0 N--CA 1.435 -1.182 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 -175.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.9 p . . . . . 0 C--N 1.293 -1.852 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.653 178.786 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.4 p . . . . . 0 C--O 1.243 0.722 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 19.0 m -109.11 168.61 3.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 120.813 0.34 . . . . 0.0 111.147 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 29.3 mt -108.02 -176.24 3.0 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.327 -175.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 21.9 pt -56.78 138.83 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 N-CA-C 112.695 0.628 . . . . 0.0 112.695 179.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.29 -20.11 19.12 Favored Glycine 0 CA--C 1.506 -0.476 0 CA-C-N 115.707 -0.678 . . . . 0.0 112.694 178.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -80.5 153.73 27.98 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-O 121.252 0.549 . . . . 0.0 109.892 -179.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 4.2 tmt_? -86.31 130.14 34.61 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 114.657 -1.156 . . . . 0.0 109.038 -173.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.8 p -130.29 170.67 13.82 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.242 -176.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -147.42 124.59 11.47 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 177.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 14.6 m120 -71.56 -35.88 70.75 Favored 'General case' 0 C--N 1.298 -1.662 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.424 -175.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -76.3 -56.86 4.25 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.637 -0.71 . . . . 0.0 112.146 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 74.1 mtm180 -93.8 -21.3 19.38 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 115.872 -0.604 . . . . 0.0 112.511 -173.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 94.74 163.45 35.24 Favored Glycine 0 N--CA 1.427 -1.947 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -175.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -89.86 165.68 34.52 Favored 'Cis proline' 0 N--CA 1.451 -0.998 0 C-N-CA 123.353 -1.52 . . . . 0.0 110.76 -1.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 69.8 mtm180 -106.86 179.43 4.27 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 176.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 26.4 m -73.42 140.75 46.76 Favored 'General case' 0 C--N 1.293 -1.856 0 C-N-CA 122.914 0.486 . . . . 0.0 109.963 -179.085 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 60.9 m -67.83 155.03 40.25 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 173.25 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 29.1 t -60.98 113.5 2.57 Favored 'General case' 0 C--O 1.246 0.899 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 -178.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 102.36 14.39 28.21 Favored Glycine 0 N--CA 1.435 -1.389 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.657 -178.472 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.438 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 83.9 mm-40 -116.8 28.85 8.28 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 -178.421 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.33 -163.11 35.54 Favored Glycine 0 N--CA 1.433 -1.553 0 C-N-CA 119.689 -1.243 . . . . 0.0 111.756 178.529 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 52.8 m-80 -130.43 152.05 50.25 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 107.756 -1.202 . . . . 0.0 107.756 179.166 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 63.1 m -66.95 98.1 0.53 Allowed 'General case' 0 N--CA 1.439 -1.007 0 O-C-N 124.04 0.837 . . . . 0.0 110.713 176.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.4 m -92.99 111.81 53.19 Favored Pre-proline 0 N--CA 1.411 -2.378 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 175.449 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.37 141.4 31.78 Favored 'Trans proline' 0 N--CA 1.44 -1.634 0 C-N-CA 122.069 1.846 . . . . 0.0 112.977 -173.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 91.8 mt -137.3 117.34 10.47 Favored Pre-proline 0 C--N 1.292 -1.928 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -72.15 51.03 1.63 Allowed 'Trans proline' 0 N--CA 1.485 0.984 0 C-N-CA 124.393 3.395 . . . . 0.0 113.969 -171.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 70.8 m-85 -143.83 -60.51 0.4 Allowed 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.459 ' H ' HD21 ' A' ' 29' ' ' LEU . 2.1 pt? -106.95 0.22 23.6 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.922 -178.208 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 109.46 -76.76 0.22 Allowed Glycine 0 C--N 1.306 -1.123 0 C-N-CA 120.399 -0.905 . . . . 0.0 111.755 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 177.27 159.56 22.63 Favored Glycine 0 N--CA 1.425 -2.057 0 N-CA-C 109.984 -1.247 . . . . 0.0 109.984 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.2 m -133.9 157.14 41.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-O 120.927 0.394 . . . . 0.0 110.697 -179.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.438 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 86.3 m -83.67 108.63 16.87 Favored 'General case' 0 C--N 1.296 -1.74 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.77 176.519 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -141.45 155.38 45.86 Favored 'General case' 0 N--CA 1.429 -1.518 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 -178.662 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 49.0 t . . . . . 0 C--N 1.3 -1.572 0 N-CA-C 108.293 -1.002 . . . . 0.0 108.293 177.326 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 29.6 p . . . . . 0 CA--C 1.519 -0.246 0 N-CA-C 110.078 -0.341 . . . . 0.0 110.078 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.416 HG23 ' SG ' ' A' ' 33' ' ' CYS . 16.6 m -107.95 168.37 3.42 Favored 'Isoleucine or valine' 0 C--O 1.243 0.743 0 CA-C-O 121.113 0.482 . . . . 0.0 110.946 178.467 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 29.2 mt -108.2 178.54 4.47 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.185 -173.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.442 ' HA ' ' HB2' ' A' ' 33' ' ' CYS . 26.9 pt -59.49 136.27 23.25 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.131 177.073 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.99 -13.45 59.4 Favored Glycine 0 C--N 1.311 -0.856 0 CA-C-N 115.843 -0.617 . . . . 0.0 112.596 178.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.454 ' O ' ' HA ' ' A' ' 32' ' ' VAL . 89.9 mt-30 -92.09 159.7 15.56 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 179.582 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.58 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 41.9 ttm180 -85.34 124.61 32.15 Favored 'General case' 0 C--N 1.317 -0.839 0 O-C-N 123.729 0.643 . . . . 0.0 110.805 -175.266 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 23.6 p -123.34 176.26 6.23 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.795 -177.285 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -145.81 125.63 13.49 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 174.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 47.3 m-80 -71.78 -30.0 65.08 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 113.339 0.866 . . . . 0.0 113.339 -175.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -91.37 -47.1 7.66 Favored 'General case' 0 C--N 1.295 -1.761 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 -172.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 51.0 mtp180 -106.1 -23.1 12.7 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 112.593 0.59 . . . . 0.0 112.593 -176.065 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 98.96 169.7 30.94 Favored Glycine 0 N--CA 1.431 -1.689 0 C-N-CA 119.825 -1.179 . . . . 0.0 110.479 -176.373 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -72.49 152.39 97.51 Favored 'Cis proline' 0 C--N 1.333 -0.258 0 CA-C-N 119.474 1.637 . . . . 0.0 112.32 1.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 73.1 mtt180 -105.89 160.77 15.0 Favored 'General case' 0 C--N 1.289 -2.06 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.263 -179.16 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.0 m -69.81 143.32 52.95 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 123.665 0.786 . . . . 0.0 110.953 -177.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 85.2 m -63.3 155.78 27.61 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 176.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.7 m -63.57 106.13 0.9 Allowed 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -179.478 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 101.6 29.61 6.19 Favored Glycine 0 N--CA 1.439 -1.142 0 N-CA-C 110.687 -0.965 . . . . 0.0 110.687 -176.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 23.0 mm-40 -126.7 36.01 4.53 Favored 'General case' 0 CA--C 1.496 -1.098 0 CA-C-O 121.26 0.553 . . . . 0.0 111.506 178.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 76.14 -163.32 53.09 Favored Glycine 0 N--CA 1.42 -2.375 0 C-N-CA 120.469 -0.872 . . . . 0.0 113.138 178.299 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -110.45 145.49 37.55 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 177.444 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 50.3 t -75.69 98.02 3.97 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 176.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.421 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 20.8 t -98.87 126.51 38.3 Favored Pre-proline 0 N--CA 1.427 -1.604 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 -176.725 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 7.8 Cg_exo -72.94 126.45 11.28 Favored 'Trans proline' 0 N--CA 1.45 -1.071 0 C-N-CA 122.714 2.276 . . . . 0.0 112.296 178.468 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 10.6 mp -121.63 119.79 29.02 Favored Pre-proline 0 C--N 1.306 -1.315 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 176.373 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_exo -37.62 -49.69 1.9 Allowed 'Trans proline' 0 CA--C 1.553 1.438 0 C-N-CA 124.634 3.556 . . . . 0.0 116.673 -174.381 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -89.64 -26.34 20.8 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 120.151 -0.619 . . . . 0.0 112.228 -176.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -94.91 -4.88 46.06 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 121.464 0.65 . . . . 0.0 110.793 -174.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 84.53 -77.65 2.09 Favored Glycine 0 N--CA 1.431 -1.699 0 N-CA-C 109.109 -1.597 . . . . 0.0 109.109 -178.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.58 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -168.64 138.2 4.98 Favored Glycine 0 N--CA 1.413 -2.864 0 N-CA-C 107.816 -2.114 . . . . 0.0 107.816 178.258 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.454 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 35.9 m -134.8 146.95 29.83 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 CA-C-O 121.251 0.548 . . . . 0.0 109.796 -178.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.442 ' HB2' ' HA ' ' A' ' 4' ' ' ILE . 81.1 m -72.81 124.69 25.88 Favored 'General case' 0 C--N 1.294 -1.841 0 CA-C-N 115.305 -0.862 . . . . 0.0 109.138 176.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -142.19 133.94 26.98 Favored 'General case' 0 N--CA 1.425 -1.702 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 -176.031 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.7 m . . . . . 0 C--N 1.306 -1.318 0 O-C-N 123.54 0.525 . . . . 0.0 110.72 179.82 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.4 p . . . . . 0 N--CA 1.452 -0.332 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.546 HG23 ' SG ' ' A' ' 33' ' ' CYS . 19.6 m -107.58 162.82 5.72 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.876 0 CA-C-O 121.188 0.518 . . . . 0.0 112.076 -176.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.405 ' O ' ' HB2' ' A' ' 6' ' ' GLN . 16.4 mt -106.98 -177.11 3.27 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.145 -174.528 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 37.7 pt -59.65 139.42 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 N-CA-C 112.483 0.549 . . . . 0.0 112.483 -178.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 83.25 -16.74 27.37 Favored Glycine 0 C--N 1.316 -0.542 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.626 179.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.405 ' HB2' ' O ' ' A' ' 3' ' ' LEU . 78.2 mt-30 -82.02 156.83 24.44 Favored 'General case' 0 N--CA 1.428 -1.53 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 178.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.456 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 43.5 ttp180 -85.94 129.61 34.79 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-N 114.618 -1.173 . . . . 0.0 110.451 -173.185 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 24.6 p -126.35 176.16 7.32 Favored 'General case' 0 C--N 1.284 -2.26 0 CA-C-N 115.296 -0.866 . . . . 0.0 110.138 -177.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -146.76 123.09 10.95 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 105.896 -1.89 . . . . 0.0 105.896 173.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 18.7 m120 -58.44 -45.73 87.96 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.645 -1.162 . . . . 0.0 112.611 -173.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -92.65 -52.89 4.42 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -175.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -85.72 -24.99 26.72 Favored 'General case' 0 C--N 1.315 -0.9 0 C-N-CA 120.1 -0.64 . . . . 0.0 112.563 -173.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 98.18 169.75 32.01 Favored Glycine 0 N--CA 1.43 -1.743 0 C-N-CA 120.135 -1.031 . . . . 0.0 111.291 -177.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -74.57 164.0 89.1 Favored 'Cis proline' 0 C--N 1.332 -0.334 0 C-N-CA 123.342 -1.524 . . . . 0.0 112.351 0.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 77.0 mtt180 -117.7 164.26 15.24 Favored 'General case' 0 C--N 1.292 -1.895 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.076 -178.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 28.0 m -71.16 140.72 50.63 Favored 'General case' 0 C--N 1.289 -2.038 0 C-N-CA 123.829 0.852 . . . . 0.0 110.192 -177.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.429 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 59.0 m -67.26 151.98 46.54 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 176.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.3 t -67.15 103.66 1.26 Allowed 'General case' 0 N--CA 1.439 -1.005 0 C-N-CA 123.424 0.69 . . . . 0.0 109.181 -177.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 122.92 -12.3 8.67 Favored Glycine 0 N--CA 1.437 -1.267 0 N-CA-C 110.429 -1.068 . . . . 0.0 110.429 -177.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.429 ' CG ' ' HB2' ' A' ' 17' ' ' CYS . 84.2 mm-40 -85.78 -45.12 11.91 Favored 'General case' 0 CA--C 1.5 -0.96 0 CA-C-N 115.46 -0.37 . . . . 0.0 110.353 178.661 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 152.71 -161.62 29.61 Favored Glycine 0 N--CA 1.419 -2.45 0 C-N-CA 119.079 -1.534 . . . . 0.0 113.019 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -112.36 147.43 36.4 Favored 'General case' 0 C--N 1.279 -2.475 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 178.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 53.0 t -82.0 105.98 13.55 Favored 'General case' 0 C--N 1.294 -1.83 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -92.53 117.04 67.45 Favored Pre-proline 0 C--N 1.311 -1.078 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 176.184 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -74.36 148.25 38.13 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 122.025 1.817 . . . . 0.0 114.114 -174.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 8.1 mp -126.28 132.39 24.3 Favored Pre-proline 0 C--N 1.308 -1.198 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 176.573 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_exo -39.0 -57.2 1.01 Allowed 'Trans proline' 0 CA--C 1.543 0.933 0 C-N-CA 124.611 3.541 . . . . 0.0 115.299 -175.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -93.43 -46.4 7.35 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-O 121.801 0.81 . . . . 0.0 110.327 -178.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 26.7 mt -77.15 0.52 21.36 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 114.339 -1.3 . . . . 0.0 113.189 -167.439 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 87.03 -65.79 3.65 Favored Glycine 0 CA--C 1.492 -1.345 0 N-CA-C 112.201 -0.36 . . . . 0.0 112.201 175.069 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.456 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . 165.02 162.75 16.77 Favored Glycine 0 N--CA 1.412 -2.944 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.8 m -135.46 147.64 28.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 177.462 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.546 ' SG ' HG23 ' A' ' 2' ' ' VAL . 94.7 m -80.42 131.47 35.6 Favored 'General case' 0 C--N 1.293 -1.856 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.692 177.24 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.61 168.61 26.59 Favored 'General case' 0 N--CA 1.427 -1.596 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 -178.095 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 4.1 p . . . . . 0 C--O 1.259 1.586 0 C-N-CA 123.919 0.888 . . . . 0.0 113.101 -178.925 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 22.3 p . . . . . 0 N--CA 1.447 -0.606 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.563 HG21 ' SG ' ' A' ' 16' ' ' CYS . 23.8 m -94.15 178.42 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.594 -0.276 . . . . 0.0 110.586 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 27.3 mt -117.84 -176.01 2.95 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 112.667 0.617 . . . . 0.0 112.667 -172.669 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.523 HG13 ' OE1' ' A' ' 20' ' ' GLN . 66.4 mt -56.6 135.88 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 123.714 0.806 . . . . 0.0 110.764 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.04 -6.85 73.4 Favored Glycine 0 C--N 1.313 -0.704 0 C-N-CA 121.447 -0.406 . . . . 0.0 112.693 177.29 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -94.14 150.55 20.22 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 178.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.2 tmm_? -86.76 129.7 34.77 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.5 -172.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 18.5 p -128.33 175.45 8.48 Favored 'General case' 0 C--N 1.297 -1.694 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.175 -175.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -152.9 121.51 6.4 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 106.161 -1.792 . . . . 0.0 106.161 174.456 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -72.17 -26.27 62.01 Favored 'General case' 0 C--N 1.294 -1.843 0 CA-C-O 120.832 0.349 . . . . 0.0 111.091 -174.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -78.74 -56.8 4.14 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.788 -176.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 26.9 mmm180 -106.53 -9.61 16.55 Favored 'General case' 0 C--N 1.312 -1.043 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -174.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 90.64 165.51 40.39 Favored Glycine 0 C--N 1.297 -1.622 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -177.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -81.39 170.87 60.26 Favored 'Cis proline' 0 CA--C 1.534 0.486 0 C-N-CA 123.385 -1.506 . . . . 0.0 111.831 0.314 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 78.7 mtm180 -122.76 152.12 40.94 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.14 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.563 ' SG ' HG21 ' A' ' 2' ' ' VAL . 57.9 m -86.01 158.67 19.8 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.068 -176.345 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.457 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 26.4 m -67.28 153.81 42.79 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 178.295 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.7 m -46.86 -45.59 20.41 Favored 'General case' 0 CA--C 1.56 1.334 0 N-CA-C 115.188 1.551 . . . . 0.0 115.188 -172.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -97.0 22.01 43.06 Favored Glycine 0 C--N 1.318 -0.472 0 C-N-CA 120.501 -0.857 . . . . 0.0 112.559 -178.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.523 ' OE1' HG13 ' A' ' 4' ' ' ILE . 85.9 mm-40 -105.28 23.28 13.96 Favored 'General case' 0 C--N 1.311 -1.1 0 O-C-N 122.648 -0.324 . . . . 0.0 111.692 -178.602 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 92.65 -177.42 38.88 Favored Glycine 0 N--CA 1.43 -1.7 0 C-N-CA 120.451 -0.881 . . . . 0.0 112.774 177.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.467 ' O ' ' HA ' ' A' ' 33' ' ' CYS . 35.3 t30 -119.16 143.8 47.03 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 179.135 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 92.2 m -63.38 102.04 0.37 Allowed 'General case' 0 C--N 1.316 -0.872 0 O-C-N 123.871 0.732 . . . . 0.0 110.535 178.103 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.7 m -110.1 137.23 20.49 Favored Pre-proline 0 N--CA 1.421 -1.924 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 177.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -67.91 120.85 7.85 Favored 'Trans proline' 0 N--CA 1.448 -1.184 0 C-N-CA 121.699 1.6 . . . . 0.0 112.14 -178.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 56.5 tp -115.98 104.99 51.91 Favored Pre-proline 0 N--CA 1.42 -1.964 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 176.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -70.78 56.15 1.79 Allowed 'Trans proline' 0 N--CA 1.479 0.653 0 C-N-CA 124.056 3.171 . . . . 0.0 113.219 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -148.06 -63.54 0.26 Allowed 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 125.294 1.438 . . . . 0.0 108.09 179.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -104.03 -19.38 14.22 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.518 -179.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 121.76 -165.01 14.73 Favored Glycine 0 C--N 1.305 -1.167 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -177.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -72.91 125.43 9.82 Favored Glycine 0 CA--C 1.49 -1.481 0 C-N-CA 119.986 -1.102 . . . . 0.0 110.356 177.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 33.2 m -127.62 153.14 36.55 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.327 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -176.733 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.467 ' HA ' ' O ' ' A' ' 22' ' ' ASN . 74.1 m -85.84 116.55 24.16 Favored 'General case' 0 C--N 1.284 -2.246 0 C-N-CA 119.718 -0.793 . . . . 0.0 111.25 178.302 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.54 168.51 22.54 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.256 179.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.1 t . . . . . 0 C--N 1.307 -1.255 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 176.507 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.5 p . . . . . 0 C--O 1.244 0.808 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.406 HG22 ' SG ' ' A' ' 33' ' ' CYS . 27.9 m -116.35 159.44 16.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-O 120.916 0.389 . . . . 0.0 111.243 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 67.8 mt -105.41 -177.83 3.48 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 115.58 -0.737 . . . . 0.0 111.01 -175.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.5 pt -56.05 137.34 17.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 178.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.15 -14.42 60.79 Favored Glycine 0 C--N 1.316 -0.543 0 CA-C-N 115.761 -0.654 . . . . 0.0 113.288 177.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . 0.451 ' O ' ' HA ' ' A' ' 32' ' ' VAL . 78.0 mt-30 -87.73 162.06 17.26 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-O 121.031 0.443 . . . . 0.0 110.794 -178.453 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 37.6 ttt180 -84.88 123.59 30.66 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 114.753 -1.112 . . . . 0.0 109.092 -175.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -134.88 167.6 20.59 Favored 'General case' 0 C--N 1.294 -1.82 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.038 -176.702 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -146.55 130.54 17.27 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 175.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 35.7 m-80 -66.32 -40.33 89.86 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 114.753 -1.112 . . . . 0.0 112.977 -171.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -93.04 -52.01 4.78 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -175.113 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 78.4 mtp180 -84.46 -24.68 29.39 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.29 -173.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 99.58 163.17 29.22 Favored Glycine 0 N--CA 1.429 -1.818 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -175.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -81.15 159.73 82.94 Favored 'Cis proline' 0 N--CA 1.446 -1.311 0 CA-C-N 119.662 1.731 . . . . 0.0 111.296 0.267 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -107.94 149.93 27.72 Favored 'General case' 0 C--N 1.291 -1.972 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.017 -178.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 45.7 m -65.08 142.45 58.38 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.053 -0.976 . . . . 0.0 108.6 178.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 61.2 m -63.84 144.96 56.64 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 176.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.7 p -53.04 86.54 0.0 OUTLIER 'General case' 0 CA--C 1.546 0.818 0 N-CA-C 113.909 1.077 . . . . 0.0 113.909 -176.144 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.6 26.81 1.54 Allowed Glycine 0 N--CA 1.435 -1.392 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.3 -178.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 23.1 mm-40 -115.87 30.19 7.5 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.427 0.632 . . . . 0.0 111.87 179.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.64 -150.5 24.4 Favored Glycine 0 N--CA 1.425 -2.073 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.402 177.164 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.8 p-10 -130.64 159.35 37.46 Favored 'General case' 0 C--N 1.287 -2.127 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 179.064 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 85.5 m -77.5 99.27 5.61 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 123.572 0.545 . . . . 0.0 109.798 175.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 14.6 p -90.22 120.47 69.15 Favored Pre-proline 0 N--CA 1.421 -1.914 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 176.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -74.59 134.73 18.94 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 121.982 1.788 . . . . 0.0 113.222 -176.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.0 mt -135.94 129.92 18.34 Favored Pre-proline 0 C--N 1.301 -1.513 0 CA-C-N 115.046 -0.979 . . . . 0.0 108.573 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.79 54.23 2.01 Favored 'Trans proline' 0 CA--C 1.536 0.581 0 C-N-CA 124.031 3.154 . . . . 0.0 113.898 -174.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -143.06 -66.9 0.37 Allowed 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 178.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.486 HD22 ' H ' ' A' ' 29' ' ' LEU . 1.9 pt? -107.45 0.27 22.73 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.496 -0.774 . . . . 0.0 112.369 -178.458 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 109.94 -86.88 0.45 Allowed Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.393 -0.908 . . . . 0.0 111.39 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.54 148.83 20.19 Favored Glycine 0 CA--C 1.49 -1.518 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.451 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 28.4 m -128.79 145.79 35.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 120.834 0.349 . . . . 0.0 111.439 -178.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.406 ' SG ' HG22 ' A' ' 2' ' ' VAL . 79.7 m -71.72 121.68 19.31 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 175.598 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -142.33 136.49 29.74 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.025 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 58.1 t . . . . . 0 N--CA 1.438 -1.07 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 177.192 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.4 p . . . . . 0 C--O 1.242 0.694 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.436 HG21 ' SG ' ' A' ' 33' ' ' CYS . 26.1 m -108.87 162.68 6.55 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.166 0.508 . . . . 0.0 111.277 -179.038 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 54.3 mt -105.79 -175.28 2.75 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.737 -175.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.5 pt -58.02 129.03 19.48 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 N-CA-C 113.224 0.824 . . . . 0.0 113.224 -178.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.18 -13.92 65.02 Favored Glycine 0 CA--C 1.503 -0.664 0 CA-C-N 115.639 -0.71 . . . . 0.0 112.681 177.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -88.82 159.72 17.59 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 62.1 ttt180 -86.02 131.37 34.28 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.827 -173.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.7 p -126.2 156.67 39.86 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.813 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -137.38 126.57 24.58 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 176.202 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 46.9 m-80 -78.98 -31.62 44.96 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 120.485 -0.486 . . . . 0.0 111.893 -178.09 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -72.67 -52.86 13.55 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-O 121.097 0.475 . . . . 0.0 111.727 -174.7 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.422 ' HA ' ' NE ' ' A' ' 12' ' ' ARG . 5.4 mmp_? -108.06 -17.58 14.0 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 113.398 0.888 . . . . 0.0 113.398 -176.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 91.26 168.28 41.5 Favored Glycine 0 N--CA 1.432 -1.6 0 C-N-CA 119.842 -1.17 . . . . 0.0 110.502 -177.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -79.25 159.9 89.53 Favored 'Cis proline' 0 C--N 1.329 -0.47 0 CA-C-N 119.082 1.441 . . . . 0.0 111.863 -1.143 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 83.0 mtm180 -109.6 177.0 4.87 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 178.514 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.2 m -70.51 144.45 51.35 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 86.3 m -68.17 145.02 54.73 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 173.585 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.5 t -50.93 99.0 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.236 1.015 . . . . 0.0 112.177 -175.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 118.01 -11.33 13.33 Favored Glycine 0 N--CA 1.443 -0.84 0 CA-C-N 115.83 -0.623 . . . . 0.0 112.123 179.3 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.462 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 23.7 mm-40 -86.17 23.55 1.52 Allowed 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 114.674 1.361 . . . . 0.0 114.674 -176.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 101.27 -176.63 26.86 Favored Glycine 0 N--CA 1.427 -1.946 0 C-N-CA 119.439 -1.362 . . . . 0.0 113.934 174.441 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 38.4 m-80 -113.4 150.31 32.88 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 179.407 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 89.1 m -74.52 98.18 3.29 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 123.193 0.308 . . . . 0.0 111.101 179.112 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.9 t -82.42 122.24 78.84 Favored Pre-proline 0 C--N 1.303 -1.42 0 N-CA-C 106.279 -1.749 . . . . 0.0 106.279 175.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -86.4 121.72 1.98 Allowed 'Trans proline' 0 N--CA 1.439 -1.686 0 C-N-CA 122.66 2.24 . . . . 0.0 113.679 -174.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -119.45 148.41 45.56 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 178.011 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_exo -41.19 -69.3 0.08 OUTLIER 'Trans proline' 0 CA--C 1.548 1.198 0 C-N-CA 124.74 3.627 . . . . 0.0 116.037 -175.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 24.6 p90 -93.01 -17.66 23.61 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 112.966 0.728 . . . . 0.0 112.966 -173.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 96.5 mt -86.64 -13.48 45.49 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.495 179.227 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 81.79 -79.46 1.84 Allowed Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.84 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -166.34 136.26 4.07 Favored Glycine 0 N--CA 1.426 -1.992 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 179.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 36.0 m -126.51 143.44 39.99 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 CA-C-O 120.909 0.385 . . . . 0.0 110.821 -179.006 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.462 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 74.8 m -71.42 114.08 9.12 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.792 178.696 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.43 156.41 42.45 Favored 'General case' 0 C--N 1.315 -0.912 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 178.561 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 39.3 t . . . . . 0 C--O 1.255 1.37 0 C-N-CA 123.684 0.794 . . . . 0.0 110.006 -179.315 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.5 p . . . . . 0 C--O 1.24 0.56 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 33.9 m -110.75 164.68 6.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 121.185 0.517 . . . . 0.0 110.866 -178.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 48.4 mt -102.47 -179.22 3.92 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.767 -178.286 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 27.3 pt -59.4 133.19 24.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.126 0.489 . . . . 0.0 112.213 178.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.1 -10.26 75.47 Favored Glycine 0 C--N 1.316 -0.536 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.98 178.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 86.7 mt-30 -94.85 157.53 15.88 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.124 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 2.7 tmm_? -85.96 124.55 32.53 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.367 -173.618 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.403 ' HB2' ' HA ' ' A' ' 15' ' ' ARG . 10.4 p -121.36 165.8 15.01 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.009 179.254 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -125.0 124.93 43.06 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 176.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -73.48 -33.43 64.82 Favored 'General case' 0 C--N 1.305 -1.365 0 N-CA-C 112.751 0.649 . . . . 0.0 112.751 -171.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -91.17 -50.56 5.77 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 120.542 -0.463 . . . . 0.0 111.928 -175.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 58.4 mtp180 -102.18 -8.67 21.14 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -172.177 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.14 168.36 44.57 Favored Glycine 0 C--N 1.31 -0.909 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.491 178.304 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -81.87 166.89 70.91 Favored 'Cis proline' 0 N--CA 1.474 0.327 0 C-N-CA 123.837 -1.318 . . . . 0.0 111.283 -0.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.403 ' HA ' ' HB2' ' A' ' 8' ' ' CYS . 73.4 mtm180 -121.49 -173.79 2.71 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 116.763 -0.199 . . . . 0.0 111.006 178.283 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 33.1 m -60.38 144.46 50.78 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 123.846 0.859 . . . . 0.0 112.142 -178.302 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 74.4 m -71.97 166.23 22.6 Favored 'General case' 0 C--O 1.243 0.731 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 170.541 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.7 t -67.83 109.82 3.55 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.056 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 101.16 26.68 7.71 Favored Glycine 0 N--CA 1.443 -0.886 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 -179.253 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.526 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 86.9 mm-40 -126.06 35.68 4.64 Favored 'General case' 0 C--N 1.318 -0.792 0 O-C-N 122.68 -0.306 . . . . 0.0 111.503 -179.239 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 70.81 -158.59 53.71 Favored Glycine 0 C--O 1.248 0.997 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.407 178.617 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -127.05 158.84 35.91 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 176.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 98.4 m -68.66 104.81 2.08 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 121.168 0.509 . . . . 0.0 110.779 178.616 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 59.9 t -91.83 120.06 68.14 Favored Pre-proline 0 N--CA 1.426 -1.647 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 175.608 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_exo -67.51 136.86 40.95 Favored 'Trans proline' 0 N--CA 1.445 -1.37 0 C-N-CA 122.459 2.106 . . . . 0.0 111.858 -179.461 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 24.0 tp -132.49 117.01 15.3 Favored Pre-proline 0 C--N 1.29 -2.017 0 N-CA-C 105.271 -2.122 . . . . 0.0 105.271 176.224 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -63.42 51.61 0.14 Allowed 'Trans proline' 0 N--CA 1.502 1.982 0 C-N-CA 125.029 3.819 . . . . 0.0 116.575 -170.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -144.34 -64.39 0.36 Allowed 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 177.531 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.465 HD22 ' H ' ' A' ' 29' ' ' LEU . 1.9 pt? -103.7 -3.4 25.11 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.213 -0.903 . . . . 0.0 112.88 -173.148 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 113.94 -103.91 1.39 Allowed Glycine 0 C--N 1.304 -1.216 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -177.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -139.78 152.48 22.63 Favored Glycine 0 N--CA 1.43 -1.724 0 C-N-CA 120.674 -0.774 . . . . 0.0 111.425 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 19.5 m -132.06 139.71 49.63 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.526 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 84.2 m -69.31 128.14 35.53 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.295 179.271 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -164.85 158.36 17.27 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 109.484 -0.562 . . . . 0.0 109.484 -178.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.2 t . . . . . 0 C--O 1.252 1.206 0 O-C-N 124.9 1.375 . . . . 0.0 111.603 177.329 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.6 p . . . . . 0 N--CA 1.456 -0.164 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.472 HG21 ' SG ' ' A' ' 33' ' ' CYS . 15.3 m -105.43 164.59 4.05 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-O 121.094 0.473 . . . . 0.0 111.846 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 21.4 mt -107.39 178.84 4.42 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.244 -173.652 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 40.0 pt -57.85 137.35 20.15 Favored 'Isoleucine or valine' 0 C--O 1.24 0.57 0 CA-C-O 121.571 0.7 . . . . 0.0 112.685 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.13 -23.98 24.18 Favored Glycine 0 C--N 1.306 -1.083 0 CA-C-N 115.645 -0.707 . . . . 0.0 112.795 178.661 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 92.3 mt-30 -82.8 155.79 24.01 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -178.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.9 tmm_? -85.75 127.18 34.47 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -173.512 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 21.8 p -122.52 172.92 8.02 Favored 'General case' 0 C--N 1.288 -2.107 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.376 -177.109 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -153.35 124.02 7.24 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 177.001 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 -72.96 -37.79 66.98 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 112.64 0.607 . . . . 0.0 112.64 -174.475 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -85.6 -47.3 9.98 Favored 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 120.072 -0.651 . . . . 0.0 112.533 -174.656 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 5.1 mmp_? -93.58 -29.21 15.6 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.891 -0.723 . . . . 0.0 112.196 -177.327 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 103.61 162.45 25.14 Favored Glycine 0 N--CA 1.434 -1.471 0 N-CA-C 109.826 -1.31 . . . . 0.0 109.826 -175.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -82.77 157.59 76.47 Favored 'Cis proline' 0 CA--C 1.535 0.536 0 CA-C-N 119.276 1.538 . . . . 0.0 112.432 1.278 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 63.7 mtm180 -107.23 157.04 18.21 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-O 120.853 0.359 . . . . 0.0 110.054 179.7 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 35.6 m -68.51 142.85 55.15 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 124.19 0.996 . . . . 0.0 110.282 -178.654 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . 0.441 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 54.7 m -67.78 154.4 41.61 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 174.032 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.1 p -54.55 -23.05 15.04 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 115.776 1.769 . . . . 0.0 115.776 -171.196 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -115.83 22.84 11.31 Favored Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 177.483 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.441 ' CG ' ' HB2' ' A' ' 17' ' ' CYS . 86.4 mm-40 -115.56 20.9 14.41 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.254 0.55 . . . . 0.0 110.91 -178.236 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 80.16 -151.6 33.46 Favored Glycine 0 N--CA 1.426 -2.002 0 C-N-CA 120.282 -0.961 . . . . 0.0 113.166 176.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -135.88 168.57 19.07 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 77.6 m -74.74 124.72 27.3 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 123.648 0.592 . . . . 0.0 111.234 -179.182 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 22.0 t -106.25 116.52 59.22 Favored Pre-proline 0 C--N 1.291 -1.954 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 173.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -80.72 125.01 5.34 Favored 'Trans proline' 0 N--CA 1.445 -1.371 0 C-N-CA 122.583 2.188 . . . . 0.0 112.953 -175.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 4.1 pp -118.72 153.96 52.52 Favored Pre-proline 0 C--N 1.302 -1.47 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.23 178.742 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_endo -83.54 49.66 2.99 Favored 'Trans proline' 0 C--O 1.236 0.396 0 C-N-CA 123.53 2.82 . . . . 0.0 113.935 -170.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -141.48 -77.59 0.28 Allowed 'General case' 0 C--N 1.314 -0.959 0 CA-C-O 120.878 0.37 . . . . 0.0 110.915 179.29 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.434 ' H ' HD13 ' A' ' 29' ' ' LEU . 0.0 OUTLIER -106.85 0.88 24.31 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -177.11 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 116.98 -138.62 14.44 Favored Glycine 0 N--CA 1.437 -1.266 0 C-N-CA 120.371 -0.919 . . . . 0.0 111.206 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -108.92 149.23 17.0 Favored Glycine 0 N--CA 1.428 -1.841 0 C-N-CA 120.395 -0.907 . . . . 0.0 112.52 -178.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.8 m -124.04 146.75 29.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 177.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.472 ' SG ' HG21 ' A' ' 2' ' ' VAL . 74.4 m -71.1 136.7 48.35 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.828 179.493 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -160.33 146.06 15.16 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.7 t . . . . . 0 C--N 1.307 -1.258 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 -179.063 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.5 p . . . . . 0 N--CA 1.443 -0.778 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.444 HG23 ' SG ' ' A' ' 33' ' ' CYS . 35.7 m -102.26 169.19 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-O 121.146 0.498 . . . . 0.0 111.088 -178.427 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 26.0 mt -109.84 -176.11 2.92 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.399 -0.818 . . . . 0.0 110.542 -175.432 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.507 HG13 ' OE1' ' A' ' 20' ' ' GLN . 61.5 mt -56.37 133.25 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 122.681 0.392 . . . . 0.0 111.029 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.26 -15.03 56.09 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 116.024 -0.534 . . . . 0.0 113.057 177.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -88.42 159.25 18.09 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 -178.662 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.55 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 85.9 mtm180 -86.63 134.53 33.62 Favored 'General case' 0 CA--C 1.496 -1.098 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.916 -175.523 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.413 ' HB3' ' CG2' ' A' ' 2' ' ' VAL . 24.0 p -139.49 171.34 14.4 Favored 'General case' 0 C--N 1.285 -2.205 0 CA-C-N 114.276 -1.329 . . . . 0.0 109.379 -178.148 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -145.51 125.7 13.8 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 174.427 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -65.79 -32.75 74.46 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -177.308 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -91.16 -52.34 4.87 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -172.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 55.3 mtp180 -92.46 -25.91 18.22 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -176.068 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 90.51 167.92 42.07 Favored Glycine 0 N--CA 1.437 -1.288 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -76.78 168.84 76.04 Favored 'Cis proline' 0 N--CA 1.475 0.387 0 CA-C-N 119.669 1.735 . . . . 0.0 110.517 -0.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 5.7 mpt_? -116.09 -179.18 3.59 Favored 'General case' 0 C--N 1.291 -1.943 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.267 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.7 m -70.71 148.59 47.82 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 178.161 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 60.9 m -69.85 142.86 53.01 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 106.04 -1.837 . . . . 0.0 106.04 170.526 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.6 m -62.23 99.23 0.13 Allowed 'General case' 0 C--O 1.243 0.749 0 CA-C-O 121.002 0.429 . . . . 0.0 111.111 -175.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 128.84 -6.59 6.49 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.204 -176.372 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.507 ' OE1' HG13 ' A' ' 4' ' ' ILE . 84.8 mm-40 -98.42 10.87 39.82 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 -178.478 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.4 ' HA2' ' HB ' ' A' ' 35' ' ' VAL . . . 103.73 -172.44 20.97 Favored Glycine 0 N--CA 1.442 -0.963 0 C-N-CA 120.009 -1.091 . . . . 0.0 113.442 176.138 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 -117.02 147.16 42.57 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 -179.301 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 96.1 m -72.67 102.21 3.26 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 123.884 0.74 . . . . 0.0 112.018 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.2 p -87.23 119.85 71.08 Favored Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 171.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -82.97 141.13 10.42 Favored 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 121.987 1.791 . . . . 0.0 114.606 -173.141 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 5.8 mp -122.83 122.97 26.98 Favored Pre-proline 0 C--N 1.3 -1.551 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 177.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_exo -36.34 -54.64 0.88 Allowed 'Trans proline' 0 N--CA 1.485 1.015 0 C-N-CA 124.957 3.772 . . . . 0.0 116.012 -175.398 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -111.05 -15.35 13.74 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 113.75 1.018 . . . . 0.0 113.75 -177.647 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -80.0 -30.13 39.58 Favored 'General case' 0 C--N 1.294 -1.836 0 C-N-CA 120.313 -0.555 . . . . 0.0 112.002 174.521 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 114.73 -99.0 0.9 Allowed Glycine 0 N--CA 1.431 -1.664 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.55 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -171.64 148.62 11.15 Favored Glycine 0 C--N 1.282 -2.471 0 N-CA-C 108.649 -1.78 . . . . 0.0 108.649 178.147 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 31.5 m -130.47 145.91 34.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 CA-C-N 117.928 0.864 . . . . 0.0 111.484 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.444 ' SG ' HG23 ' A' ' 2' ' ' VAL . 71.9 m -76.11 116.74 17.11 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.896 176.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -141.56 149.19 40.48 Favored 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -179.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.4 ' HB ' ' HA2' ' A' ' 21' ' ' GLY . 4.1 p . . . . . 0 C--N 1.3 -1.544 0 CA-C-O 118.74 -0.647 . . . . 0.0 109.485 177.232 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.0 p . . . . . 0 C--O 1.227 -0.118 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.524 HG23 ' SG ' ' A' ' 33' ' ' CYS . 16.5 m -110.13 161.21 8.68 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -177.54 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 36.0 mt -107.41 -178.96 3.78 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.09 -175.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 24.0 pt -61.13 128.81 23.03 Favored 'Isoleucine or valine' 0 C--O 1.238 0.489 0 N-CA-C 113.282 0.845 . . . . 0.0 113.282 -179.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.62 -5.35 73.57 Favored Glycine 0 N--CA 1.443 -0.859 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.767 -179.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 77.5 mt-30 -101.32 156.01 17.7 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 176.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 54.1 mtm180 -86.03 140.75 30.0 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.727 0.775 . . . . 0.0 112.606 -173.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.415 ' SG ' ' N ' ' A' ' 9' ' ' ASP . 1.6 t -133.16 171.68 13.68 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-N 113.68 -1.6 . . . . 0.0 109.321 -175.16 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.415 ' N ' ' SG ' ' A' ' 8' ' ' CYS . 17.1 t70 -161.86 118.73 2.13 Favored 'General case' 0 C--N 1.276 -2.59 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 172.363 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -57.68 -39.57 77.43 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 113.984 1.105 . . . . 0.0 113.984 -175.536 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -91.13 -47.78 7.33 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -175.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 29.1 mmt180 -80.7 -43.0 21.01 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.709 0.766 . . . . 0.0 111.592 -177.012 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 105.46 163.87 23.55 Favored Glycine 0 N--CA 1.425 -2.064 0 N-CA-C 108.337 -1.905 . . . . 0.0 108.337 -172.286 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -79.01 165.85 80.58 Favored 'Cis proline' 0 C--N 1.322 -0.865 0 CA-C-N 119.88 1.84 . . . . 0.0 111.891 -0.002 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 60.5 mtp180 -108.2 153.49 23.11 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 179.412 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 55.9 m -68.01 138.69 56.07 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 55.9 m -65.93 158.28 28.5 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 178.148 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.8 t -60.89 104.43 0.36 Allowed 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 123.194 0.597 . . . . 0.0 110.343 -179.342 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 108.85 17.35 10.4 Favored Glycine 0 N--CA 1.443 -0.897 0 N-CA-C 111.524 -0.631 . . . . 0.0 111.524 -178.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 83.6 mm-40 -111.18 52.19 0.75 Allowed 'General case' 0 C--N 1.307 -1.243 0 O-C-N 122.038 -0.684 . . . . 0.0 111.591 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 71.03 -143.4 36.15 Favored Glycine 0 N--CA 1.434 -1.492 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.376 178.079 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 46.4 m-80 -128.94 146.12 51.04 Favored 'General case' 0 C--N 1.289 -2.05 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 176.194 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 42.9 t -83.11 97.12 8.63 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.01 -1.107 . . . . 0.0 108.01 179.036 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.0 p -94.37 114.99 64.72 Favored Pre-proline 0 N--CA 1.432 -1.341 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.353 -179.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.45 ' HA ' ' CA ' ' A' ' 31' ' ' GLY . 73.9 Cg_endo -76.72 142.15 22.54 Favored 'Trans proline' 0 N--CA 1.449 -1.136 0 C-N-CA 122.557 2.172 . . . . 0.0 113.605 -176.107 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 5.8 mp -116.06 142.4 29.16 Favored Pre-proline 0 N--CA 1.422 -1.867 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 172.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_endo -74.57 53.99 3.3 Favored 'Trans proline' 0 C--N 1.326 -0.65 0 C-N-CA 123.164 2.576 . . . . 0.0 113.464 -177.247 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -139.17 -87.51 0.22 Allowed 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 178.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 4.5 mp -104.66 -28.27 11.33 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-O 121.589 0.709 . . . . 0.0 110.47 -176.181 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 167.41 -152.59 21.32 Favored Glycine 0 N--CA 1.418 -2.543 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -179.22 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.45 ' CA ' ' HA ' ' A' ' 25' ' ' PRO . . . -113.42 -172.75 18.36 Favored Glycine 0 N--CA 1.411 -3.033 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.3 p -138.06 152.59 26.22 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.24 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.061 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.524 ' SG ' HG23 ' A' ' 2' ' ' VAL . 63.7 m -89.12 119.43 29.62 Favored 'General case' 0 C--N 1.275 -2.633 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.297 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.04 139.56 24.83 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -176.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 C--N 1.306 -1.316 0 CA-C-O 118.867 -0.587 . . . . 0.0 109.978 -179.861 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.7 p . . . . . 0 CA--C 1.513 -0.45 0 N-CA-C 109.29 -0.634 . . . . 0.0 109.29 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.409 HG22 ' SG ' ' A' ' 33' ' ' CYS . 33.5 m -103.17 152.53 5.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-O 120.953 0.406 . . . . 0.0 111.076 -177.293 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 52.3 mt -97.68 -174.3 2.86 Favored 'General case' 0 N--CA 1.438 -1.043 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.667 -179.273 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 43.2 pt -59.28 142.06 15.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.059 0.457 . . . . 0.0 111.704 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.59 -26.07 8.67 Favored Glycine 0 C--N 1.311 -0.82 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.26 178.366 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 24.1 mt-30 -79.18 152.92 30.42 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -178.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 10.2 mpt_? -86.76 136.86 32.84 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.883 -175.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.5 p -130.02 168.27 16.98 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.984 -175.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -132.5 123.68 27.06 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.9 m120 -72.73 -26.59 61.63 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -175.685 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -84.17 -56.55 3.6 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-O 121.228 0.537 . . . . 0.0 111.4 -175.112 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 71.9 mtm180 -105.45 -24.14 12.69 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 -170.339 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 95.48 172.48 36.59 Favored Glycine 0 N--CA 1.426 -1.999 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 -172.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -72.21 160.54 93.94 Favored 'Cis proline' 0 C--O 1.235 0.373 0 CA-C-N 119.771 1.785 . . . . 0.0 111.574 -0.218 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 57.8 mtm180 -120.18 176.04 5.65 Favored 'General case' 0 C--N 1.291 -1.959 0 CA-C-N 116.495 -0.321 . . . . 0.0 110.17 179.281 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 20.5 m -68.02 144.45 55.12 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 123.607 0.567 . . . . 0.0 109.494 -178.501 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.9 m -67.9 145.67 54.36 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 105.977 -1.86 . . . . 0.0 105.977 171.333 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 14.6 p -56.43 107.75 0.41 Allowed 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 112.017 0.377 . . . . 0.0 112.017 -177.218 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 115.03 -11.46 20.32 Favored Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.497 -177.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.437 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 86.8 mm-40 -91.98 26.61 2.39 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-O 121.321 0.581 . . . . 0.0 111.45 -178.514 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.84 -168.02 37.17 Favored Glycine 0 N--CA 1.415 -2.73 0 C-N-CA 120.54 -0.838 . . . . 0.0 113.074 176.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 47.4 m-80 -129.9 153.07 48.68 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 -179.121 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 74.3 m -68.32 104.7 1.93 Allowed 'General case' 0 C--N 1.314 -0.946 0 O-C-N 123.895 0.747 . . . . 0.0 112.602 -176.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.53 117.5 61.78 Favored Pre-proline 0 N--CA 1.434 -1.259 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 175.248 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -77.98 122.36 5.76 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 122.125 1.884 . . . . 0.0 112.198 -179.051 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 34.9 tp -129.31 109.92 17.86 Favored Pre-proline 0 N--CA 1.427 -1.607 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 175.351 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -64.29 51.53 0.18 Allowed 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 125.122 3.881 . . . . 0.0 116.476 -172.464 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -139.16 -53.34 0.56 Allowed 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 174.009 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.499 HD22 ' H ' ' A' ' 29' ' ' LEU . 1.9 pt? -107.05 -18.37 13.92 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 114.595 -1.184 . . . . 0.0 111.842 -178.011 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 115.42 -154.97 16.61 Favored Glycine 0 N--CA 1.442 -0.954 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -101.81 123.94 8.05 Favored Glycine 0 CA--C 1.483 -1.965 0 N-CA-C 110.136 -1.186 . . . . 0.0 110.136 178.352 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 33.3 m -120.12 150.41 22.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.047 0 CA-C-O 121.157 0.503 . . . . 0.0 111.601 -174.101 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.437 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 82.0 m -75.13 116.43 15.86 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.152 176.12 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -130.86 136.3 48.51 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 55.2 t . . . . . 0 C--N 1.315 -0.933 0 CA-C-O 118.778 -0.629 . . . . 0.0 109.366 -179.518 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 28.4 p . . . . . 0 CA--C 1.51 -0.572 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.429 HG22 ' SG ' ' A' ' 33' ' ' CYS . 20.0 m -109.19 164.41 5.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.314 -178.333 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 38.8 mt -103.05 -179.83 4.06 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -177.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 34.2 pt -62.64 135.66 26.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.426 0.631 . . . . 0.0 112.683 -178.5 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.08 -12.77 66.68 Favored Glycine 0 C--N 1.314 -0.677 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.985 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -92.23 154.22 18.78 Favored 'General case' 0 N--CA 1.435 -1.211 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.368 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.0 mtm180 -86.16 143.41 28.02 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.545 -174.011 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.466 ' HB2' ' O ' ' A' ' 14' ' ' PRO . 26.4 p -144.46 176.13 9.61 Favored 'General case' 0 C--N 1.278 -2.519 0 CA-C-N 114.519 -1.219 . . . . 0.0 108.362 -177.681 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -130.23 124.14 31.8 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -69.29 -27.69 65.62 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 112.645 0.609 . . . . 0.0 112.645 -177.705 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -91.94 -57.05 2.86 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 111.688 0.255 . . . . 0.0 111.688 -175.683 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -96.75 -18.47 19.6 Favored 'General case' 0 C--N 1.312 -1.051 0 N-CA-C 112.756 0.65 . . . . 0.0 112.756 -172.315 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.02 172.99 47.53 Favored Glycine 0 N--CA 1.437 -1.283 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 -174.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.466 ' O ' ' HB2' ' A' ' 8' ' ' CYS . 80.6 Cg_endo -75.77 173.09 59.83 Favored 'Cis proline' 0 C--O 1.23 0.093 0 CA-C-N 120.013 1.907 . . . . 0.0 111.014 -0.538 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.412 ' HA ' ' HB2' ' A' ' 8' ' ' CYS . 73.2 mtm180 -126.59 -173.91 2.99 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.678 -0.237 . . . . 0.0 110.437 178.492 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.2 m -65.45 146.74 54.5 Favored 'General case' 0 C--N 1.294 -1.826 0 C-N-CA 124.08 0.952 . . . . 0.0 111.591 -179.037 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 62.9 m -66.75 149.65 50.24 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 171.131 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.9 t -62.05 100.48 0.16 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.762 0.315 . . . . 0.0 110.365 -178.075 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 121.35 1.23 11.2 Favored Glycine 0 N--CA 1.444 -0.824 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -177.481 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 27.3 mm-40 -109.76 39.6 2.08 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 120.976 0.417 . . . . 0.0 112.103 179.564 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 74.43 -159.21 52.28 Favored Glycine 0 N--CA 1.423 -2.172 0 C-N-CA 120.308 -0.949 . . . . 0.0 112.628 178.38 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -133.96 148.92 51.22 Favored 'General case' 0 C--N 1.278 -2.5 0 N-CA-C 109.338 -0.615 . . . . 0.0 109.338 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 88.4 m -64.78 112.69 3.36 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 124.112 0.883 . . . . 0.0 111.079 177.677 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.3 p -96.19 124.67 50.81 Favored Pre-proline 0 C--N 1.284 -2.242 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 172.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -78.39 145.86 21.52 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 C-N-CA 121.594 1.529 . . . . 0.0 112.585 -177.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -130.07 146.54 61.89 Favored Pre-proline 0 C--N 1.301 -1.534 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 178.003 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo -41.75 -68.19 0.1 Allowed 'Trans proline' 0 N--CA 1.481 0.791 0 C-N-CA 124.503 3.469 . . . . 0.0 115.111 -177.124 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 33.4 p90 -104.79 -25.22 12.74 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-O 121.074 0.464 . . . . 0.0 112.04 -176.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -66.05 -32.04 73.28 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.441 179.178 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 101.19 -88.12 0.7 Allowed Glycine 0 N--CA 1.429 -1.822 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 178.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -158.82 147.69 15.64 Favored Glycine 0 N--CA 1.427 -1.927 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 179.279 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.7 p -140.41 148.82 21.91 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 CA-C-O 121.197 0.522 . . . . 0.0 110.103 178.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.429 ' SG ' HG22 ' A' ' 2' ' ' VAL . 76.9 m -82.2 132.87 35.24 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.51 179.112 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.93 140.73 17.12 Favored 'General case' 0 N--CA 1.425 -1.678 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -178.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.1 m . . . . . 0 C--N 1.307 -1.282 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 176.125 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.3 p . . . . . 0 N--CA 1.445 -0.684 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 16' ' ' CYS . 30.8 m -96.67 169.2 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 120.936 0.398 . . . . 0.0 111.087 -179.562 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 42.5 mt -114.41 -176.14 2.84 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.788 -176.326 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.3 pp -51.92 145.01 2.56 Favored 'Isoleucine or valine' 0 C--O 1.246 0.917 0 N-CA-C 113.546 0.943 . . . . 0.0 113.546 176.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.32 -15.98 15.36 Favored Glycine 0 C--N 1.32 -0.348 0 CA-C-N 115.728 -0.669 . . . . 0.0 113.632 179.383 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 11.5 mt-30 -85.91 157.96 20.04 Favored 'General case' 0 C--N 1.307 -1.271 0 O-C-N 122.384 -0.48 . . . . 0.0 110.136 177.254 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -86.44 125.05 33.43 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.894 -177.245 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.4 p -119.07 163.48 16.93 Favored 'General case' 0 C--N 1.278 -2.538 0 CA-C-N 114.569 -1.196 . . . . 0.0 110.697 -175.318 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -148.15 126.32 12.17 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 174.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -77.78 -22.13 50.61 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -174.047 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -90.5 -54.81 3.84 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-O 121.255 0.55 . . . . 0.0 111.158 -175.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -100.04 -27.58 13.49 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.271 -172.424 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.0 169.93 27.32 Favored Glycine 0 N--CA 1.432 -1.599 0 N-CA-C 110.141 -1.184 . . . . 0.0 110.141 -174.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -79.85 155.53 88.16 Favored 'Cis proline' 0 N--CA 1.457 -0.655 0 CA-C-N 119.461 1.631 . . . . 0.0 111.704 -0.605 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 66.1 mtt180 -107.45 145.44 33.02 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 -179.358 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 2' ' ' VAL . 81.6 m -74.38 149.92 40.29 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.374 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 64.0 m -58.23 141.18 51.52 Favored 'General case' 0 C--N 1.317 -0.821 0 O-C-N 124.223 0.952 . . . . 0.0 109.693 -176.406 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 13.7 t -68.66 97.68 0.82 Allowed 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 141.01 -19.18 2.71 Favored Glycine 0 N--CA 1.435 -1.428 0 N-CA-C 108.559 -1.817 . . . . 0.0 108.559 -173.662 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 24.9 mm-40 -81.49 -178.98 7.18 Favored 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 123.681 0.792 . . . . 0.0 111.839 177.215 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.54 169.61 19.17 Favored Glycine 0 C--N 1.314 -0.681 0 CA-C-O 121.42 0.456 . . . . 0.0 114.083 -177.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . 0.526 ' O ' ' HA ' ' A' ' 33' ' ' CYS . 9.0 t30 -85.82 139.93 30.87 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 178.72 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 21.4 t -76.25 101.46 5.45 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 -178.276 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.6 t -99.9 113.95 65.41 Favored Pre-proline 0 N--CA 1.426 -1.652 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 -179.302 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.421 ' HA ' ' CA ' ' A' ' 31' ' ' GLY . 3.0 Cg_exo -71.87 121.38 7.56 Favored 'Trans proline' 0 N--CA 1.442 -1.545 0 C-N-CA 122.19 1.927 . . . . 0.0 110.706 179.257 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.1 mt -117.12 122.88 30.67 Favored Pre-proline 0 N--CA 1.425 -1.695 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 178.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -73.65 42.86 0.72 Allowed 'Trans proline' 0 CA--C 1.542 0.878 0 C-N-CA 123.716 2.944 . . . . 0.0 113.102 -176.721 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -135.2 -67.65 0.54 Allowed 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 -179.282 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . 0.467 HD22 ' H ' ' A' ' 29' ' ' LEU . 2.3 pt? -107.14 -5.72 17.8 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.669 -178.559 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 111.71 -172.76 15.12 Favored Glycine 0 N--CA 1.432 -1.595 0 N-CA-C 110.129 -1.188 . . . . 0.0 110.129 -175.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.421 ' CA ' ' HA ' ' A' ' 25' ' ' PRO . . . -90.64 132.78 11.45 Favored Glycine 0 CA--C 1.484 -1.894 0 C-N-CA 120.526 -0.845 . . . . 0.0 111.336 179.381 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.4 m -129.88 147.74 33.23 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.938 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -178.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.526 ' HA ' ' O ' ' A' ' 22' ' ' ASN . 96.4 m -82.25 120.07 24.9 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.132 178.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -119.76 137.71 53.78 Favored 'General case' 0 N--CA 1.427 -1.589 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 178.428 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--N 1.292 -1.898 0 C-N-CA 121.008 -0.277 . . . . 0.0 111.194 -177.472 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 25.8 p . . . . . 0 N--CA 1.446 -0.648 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.464 HG23 ' SG ' ' A' ' 33' ' ' CYS . 18.6 m -108.37 154.91 9.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 CA-C-O 121.134 0.492 . . . . 0.0 111.513 -179.605 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.409 ' HB3' ' OE1' ' A' ' 20' ' ' GLN . 57.7 mt -100.33 -176.96 3.37 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.52 -175.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.9 pt -61.13 130.49 25.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.503 0 CA-C-O 121.477 0.656 . . . . 0.0 112.438 -179.114 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 96.59 -22.64 39.12 Favored Glycine 0 C--N 1.311 -0.821 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.841 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -81.02 154.9 26.64 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 121.067 0.46 . . . . 0.0 109.794 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.1 tmt_? -86.34 138.15 32.04 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.349 -173.679 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 17.5 p -137.07 167.89 20.65 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.917 -177.364 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -141.66 120.49 12.7 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 175.41 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -63.37 -35.18 79.56 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.84 -0.618 . . . . 0.0 112.168 -170.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -92.44 -52.54 4.61 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 113.026 0.75 . . . . 0.0 113.026 -175.469 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.4 mtm180 -87.08 -27.81 22.92 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 121.133 0.492 . . . . 0.0 112.306 -174.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.0 163.42 26.76 Favored Glycine 0 N--CA 1.427 -1.966 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 -175.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -78.44 165.93 81.37 Favored 'Cis proline' 0 C--N 1.332 -0.323 0 C-N-CA 123.378 -1.509 . . . . 0.0 112.375 0.569 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 60.1 mtt180 -115.74 163.09 16.34 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.678 -179.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 58.4 m -70.14 142.33 52.55 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 123.638 0.775 . . . . 0.0 110.514 -177.39 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 81.9 m -67.39 157.48 34.0 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 174.667 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.1 p -57.64 96.6 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.818 0 C-N-CA 124.207 1.003 . . . . 0.0 112.477 -177.467 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 99.09 34.76 5.02 Favored Glycine 0 N--CA 1.433 -1.566 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.293 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.419 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 23.9 mm-40 -122.58 34.57 5.11 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-O 121.547 0.689 . . . . 0.0 111.013 177.184 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 78.47 -166.38 52.34 Favored Glycine 0 N--CA 1.419 -2.457 0 CA-C-N 114.928 -1.033 . . . . 0.0 112.169 178.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 40.4 m-80 -127.95 157.19 41.26 Favored 'General case' 0 C--N 1.29 -2.016 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 -179.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 99.3 m -68.13 97.92 0.74 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 123.819 0.7 . . . . 0.0 111.765 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.82 126.62 72.54 Favored Pre-proline 0 N--CA 1.425 -1.699 0 N-CA-C 106.153 -1.795 . . . . 0.0 106.153 174.082 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -70.3 129.99 17.94 Favored 'Trans proline' 0 N--CA 1.446 -1.288 0 C-N-CA 121.558 1.506 . . . . 0.0 114.283 -174.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -121.42 143.24 37.19 Favored Pre-proline 0 C--N 1.309 -1.187 0 CA-C-N 114.932 -1.031 . . . . 0.0 108.747 178.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_exo -44.26 -63.7 0.31 Allowed 'Trans proline' 0 CA--C 1.546 1.094 0 C-N-CA 123.731 2.954 . . . . 0.0 115.298 -176.744 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -89.65 -25.42 21.27 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 112.599 0.592 . . . . 0.0 112.599 -173.518 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -88.81 -17.97 28.66 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-O 121.362 0.601 . . . . 0.0 111.093 -175.434 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 88.89 -63.59 3.49 Favored Glycine 0 N--CA 1.429 -1.832 0 N-CA-C 109.389 -1.485 . . . . 0.0 109.389 -177.038 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -165.13 148.18 13.68 Favored Glycine 0 N--CA 1.419 -2.441 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 178.021 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.0 m -131.79 150.97 34.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 176.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.464 ' SG ' HG23 ' A' ' 2' ' ' VAL . 71.7 m -76.32 117.24 17.79 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -142.65 145.47 33.49 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 120.726 -0.389 . . . . 0.0 110.786 -179.733 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.6 m . . . . . 0 C--N 1.308 -1.22 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.603 176.963 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 23.4 p . . . . . 0 C--O 1.233 0.217 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.41 HG23 ' SG ' ' A' ' 33' ' ' CYS . 28.8 m -110.54 154.44 12.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-O 120.606 0.241 . . . . 0.0 111.367 -178.583 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 35.5 mt -99.69 -176.36 3.24 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.297 -177.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.423 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 33.8 pt -58.14 134.6 22.84 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.73 0 CA-C-O 121.477 0.656 . . . . 0.0 112.489 179.027 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.73 -18.72 55.98 Favored Glycine 0 C--N 1.311 -0.828 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.296 178.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 23.7 mt-30 -89.66 152.33 21.42 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -179.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.434 ' HA ' ' HA ' ' A' ' 32' ' ' VAL . 16.4 ptp180 -86.61 148.71 25.36 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.07 0.462 . . . . 0.0 111.106 -175.317 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.2 p -138.56 158.24 44.62 Favored 'General case' 0 C--N 1.298 -1.652 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.611 -174.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -129.06 124.03 33.8 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 176.152 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -79.17 -27.11 42.64 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 120.955 0.407 . . . . 0.0 111.626 -173.107 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -91.1 -42.08 10.68 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 115.723 -0.671 . . . . 0.0 112.154 -173.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 83.7 mtm180 -112.54 -13.3 13.35 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 -175.597 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 89.35 165.74 41.33 Favored Glycine 0 N--CA 1.44 -1.094 0 C-N-CA 120.055 -1.069 . . . . 0.0 110.805 -177.408 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -79.85 158.73 88.28 Favored 'Cis proline' 0 N--CA 1.463 -0.284 0 CA-C-N 119.227 1.513 . . . . 0.0 111.195 -0.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 80.9 mtm180 -113.49 172.67 6.83 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 121.03 -0.268 . . . . 0.0 110.502 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.7 m -68.01 141.0 56.37 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 123.634 0.583 . . . . 0.0 109.834 -179.228 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 55.8 m -67.33 140.86 57.29 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 172.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 5.9 p -58.4 94.77 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.73 0 CA-C-O 121.663 0.744 . . . . 0.0 112.794 -177.383 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 132.38 -5.32 5.26 Favored Glycine 0 N--CA 1.438 -1.179 0 CA-C-N 114.853 -1.067 . . . . 0.0 110.644 -176.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . 0.43 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 86.0 mm-40 -101.58 30.09 4.49 Favored 'General case' 0 C--N 1.323 -0.561 0 C-N-CA 123.348 0.659 . . . . 0.0 112.456 -177.483 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 84.44 -171.6 47.89 Favored Glycine 0 N--CA 1.436 -1.352 0 C-N-CA 120.103 -1.046 . . . . 0.0 113.9 175.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -113.44 162.59 15.94 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.747 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 98.8 m -76.87 97.23 4.51 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-O 121.553 0.692 . . . . 0.0 109.689 177.253 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.5 t -93.43 127.91 44.55 Favored Pre-proline 0 N--CA 1.416 -2.14 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 -179.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -85.0 121.01 2.34 Favored 'Trans proline' 0 N--CA 1.427 -2.421 0 C-N-CA 121.953 1.769 . . . . 0.0 112.018 -178.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 10.3 mp -110.39 124.52 33.08 Favored Pre-proline 0 C--N 1.29 -2.018 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 177.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -53.24 -17.38 8.46 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 C-N-CA 124.448 3.432 . . . . 0.0 115.564 -173.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -110.55 -22.74 11.49 Favored 'General case' 0 C--N 1.309 -1.164 0 C-N-CA 120.858 -0.337 . . . . 0.0 111.388 -179.167 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 6.1 mp -106.55 -16.89 14.41 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 112.177 0.436 . . . . 0.0 112.177 -173.76 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.94 -104.91 2.98 Favored Glycine 0 N--CA 1.426 -2.006 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 -176.449 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -147.35 127.9 2.79 Favored Glycine 0 C--N 1.295 -1.744 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 176.465 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.434 ' HA ' ' HA ' ' A' ' 7' ' ' ARG . 34.5 m -131.83 154.19 39.88 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 C-N-CA 122.926 0.49 . . . . 0.0 110.187 -175.809 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' CYS . . . . . 0.43 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 74.4 m -74.53 119.69 19.06 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.705 178.033 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -146.53 148.75 32.5 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.752 0.311 . . . . 0.0 110.551 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 17.9 m . . . . . 0 C--N 1.306 -1.291 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.007 176.663 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.5 p . . . . . 0 N--CA 1.452 -0.334 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.544 HG23 ' SG ' ' A' ' 33' ' ' CYS . 21.2 m -106.84 167.4 3.45 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-O 121.184 0.516 . . . . 0.0 111.291 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.415 ' HA ' ' HG3' ' A' ' 20' ' ' GLN . 25.3 mt -107.41 175.97 5.31 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.174 -172.509 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 27.9 pt -61.07 134.99 26.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.438 0 CA-C-O 121.415 0.626 . . . . 0.0 112.394 -178.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.65 -13.3 60.97 Favored Glycine 0 C--N 1.312 -0.78 0 CA-C-N 115.486 -0.779 . . . . 0.0 112.622 -179.214 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -90.4 151.18 21.54 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 106.892 -1.522 . . . . 0.0 106.892 176.617 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 34.3 ptt180 -85.9 146.24 26.8 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.949 -0.7 . . . . 0.0 111.064 -173.156 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.4 p -139.09 176.91 8.29 Favored 'General case' 0 C--N 1.282 -2.331 0 CA-C-N 115.164 -0.926 . . . . 0.0 109.224 -174.81 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -152.11 117.31 5.24 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 174.281 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -57.08 -38.99 74.1 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 113.629 0.974 . . . . 0.0 113.629 -173.784 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -91.86 -47.58 7.25 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 113.628 0.973 . . . . 0.0 113.628 -175.241 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.0 mtm180 -89.48 -29.88 18.67 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -173.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.55 160.31 25.94 Favored Glycine 0 N--CA 1.435 -1.389 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -174.786 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -79.65 167.45 75.47 Favored 'Cis proline' 0 C--O 1.218 -0.475 0 CA-C-N 119.542 1.671 . . . . 0.0 111.987 1.309 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 88.0 mtm180 -122.01 156.25 33.87 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 33.6 m -70.2 149.25 47.7 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 124.825 1.25 . . . . 0.0 111.319 -175.658 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 85.4 m -68.43 143.74 54.95 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 175.229 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 11.4 t -54.3 -26.45 29.41 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 125.25 1.42 . . . . 0.0 113.039 -172.211 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -108.08 16.53 35.8 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.188 178.138 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.415 ' HG3' ' HA ' ' A' ' 3' ' ' LEU . 18.3 mm-40 -97.74 -68.1 0.82 Allowed 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -179.368 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -175.85 -179.18 46.2 Favored Glycine 0 CA--C 1.481 -2.089 0 C-N-CA 120.261 -0.971 . . . . 0.0 110.703 -176.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 52.4 t30 -93.29 139.6 30.46 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 177.416 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 49.9 t -79.47 98.13 6.68 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.075 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.62 120.09 69.53 Favored Pre-proline 0 C--N 1.302 -1.47 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -67.18 141.7 58.19 Favored 'Trans proline' 0 N--CA 1.449 -1.114 0 C-N-CA 122.431 2.087 . . . . 0.0 113.106 -176.269 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.4 mt -119.36 144.19 35.95 Favored Pre-proline 0 C--N 1.302 -1.5 0 CA-C-N 114.743 -1.117 . . . . 0.0 109.078 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_exo -40.26 -57.31 1.23 Allowed 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 124.731 3.621 . . . . 0.0 114.806 -176.553 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 30.4 p90 -119.18 -24.18 6.54 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -177.666 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 78.3 mt -79.9 0.49 31.02 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 179.04 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 87.57 -59.22 4.37 Favored Glycine 0 CA--C 1.499 -0.939 0 C-N-CA 121.149 -0.548 . . . . 0.0 111.871 177.246 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 171.64 170.79 36.07 Favored Glycine 0 N--CA 1.418 -2.512 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 9.2 p -147.3 146.15 18.59 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.986 0 CA-C-O 121.503 0.668 . . . . 0.0 109.992 177.282 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.544 ' SG ' HG23 ' A' ' 2' ' ' VAL . 74.1 m -80.06 118.4 21.75 Favored 'General case' 0 C--N 1.285 -2.223 0 CA-C-N 114.713 -1.13 . . . . 0.0 109.923 179.639 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -143.87 153.66 42.57 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 -177.179 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 52.4 t . . . . . 0 C--N 1.306 -1.32 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -179.109 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.3 p . . . . . 0 C--O 1.24 0.57 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.582 HG23 ' SG ' ' A' ' 33' ' ' CYS . 30.2 m -112.06 158.28 12.55 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-O 120.655 0.264 . . . . 0.0 111.504 -178.567 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 38.2 mt -99.57 -178.56 3.92 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.482 -176.554 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.435 ' HA ' ' HB2' ' A' ' 33' ' ' CYS . 34.0 pt -58.64 140.37 17.04 Favored 'Isoleucine or valine' 0 C--O 1.241 0.651 0 N-CA-C 113.023 0.749 . . . . 0.0 113.023 -179.394 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.8 -14.34 48.48 Favored Glycine 0 C--N 1.311 -0.86 0 CA-C-N 115.708 -0.678 . . . . 0.0 113.183 178.577 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 27.2 mt-30 -86.15 156.53 20.31 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 108.056 -1.091 . . . . 0.0 108.056 178.668 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 47.1 ttp180 -86.01 132.22 34.11 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 123.623 0.577 . . . . 0.0 109.962 -176.203 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.2 p -128.71 175.11 8.85 Favored 'General case' 0 C--N 1.278 -2.543 0 CA-C-N 115.069 -0.969 . . . . 0.0 109.197 -177.478 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -149.82 125.68 10.5 Favored 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 174.709 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ASN . . . . . 0.403 ' OD1' ' HB3' ' A' ' 23' ' ' CYS . 43.6 m-80 -76.64 -23.11 53.31 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 120.531 0.205 . . . . 0.0 111.526 -175.84 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -84.87 -57.56 3.06 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.903 -175.031 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 63.2 mtt180 -103.07 -21.85 13.86 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 113.107 0.78 . . . . 0.0 113.107 -175.356 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 103.86 168.55 25.25 Favored Glycine 0 N--CA 1.433 -1.543 0 C-N-CA 120.121 -1.038 . . . . 0.0 110.609 -177.393 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -80.1 159.17 87.18 Favored 'Cis proline' 0 CA--C 1.535 0.549 0 CA-C-N 119.085 1.442 . . . . 0.0 112.065 0.217 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 -104.55 169.91 8.19 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 177.83 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.6 m -80.52 147.16 30.96 Favored 'General case' 0 C--N 1.297 -1.688 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.419 -176.191 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 39.5 m -72.77 153.28 41.19 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 175.807 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.1 t -67.77 120.12 13.59 Favored 'General case' 0 N--CA 1.435 -1.214 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 103.54 0.1 46.4 Favored Glycine 0 N--CA 1.437 -1.264 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -175.658 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 86.0 mm-40 -111.86 38.01 2.78 Favored 'General case' 0 C--N 1.31 -1.132 0 CA-C-O 121.496 0.665 . . . . 0.0 110.366 179.064 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 78.14 -156.58 43.77 Favored Glycine 0 N--CA 1.418 -2.554 0 CA-C-N 115.057 -0.974 . . . . 0.0 112.962 177.271 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 79.6 m-20 -123.74 153.75 40.47 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 106.123 -1.806 . . . . 0.0 106.123 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' CYS . . . . . 0.403 ' HB3' ' OD1' ' A' ' 10' ' ' ASN . 51.6 t -84.52 98.46 10.14 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.656 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.411 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 22.9 t -97.34 118.05 64.9 Favored Pre-proline 0 C--N 1.303 -1.456 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 -178.026 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 4.0 Cg_exo -70.76 129.84 17.16 Favored 'Trans proline' 0 N--CA 1.451 -0.99 0 C-N-CA 122.611 2.207 . . . . 0.0 110.113 177.887 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 85.2 mt -129.3 150.6 75.96 Favored Pre-proline 0 C--N 1.309 -1.154 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.951 -175.525 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -42.49 -67.37 0.12 Allowed 'Trans proline' 0 CA--C 1.545 1.044 0 C-N-CA 124.792 3.661 . . . . 0.0 115.679 -177.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 26.5 p90 -97.8 -23.58 15.82 Favored 'General case' 0 C--N 1.314 -0.975 0 N-CA-C 113.325 0.861 . . . . 0.0 113.325 -174.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 97.4 mt -83.13 -12.11 57.32 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.557 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 84.06 -65.65 4.06 Favored Glycine 0 CA--C 1.501 -0.813 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -178.23 134.79 2.48 Favored Glycine 0 CA--C 1.47 -2.773 0 N-CA-C 108.569 -1.812 . . . . 0.0 108.569 177.36 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.5 m -136.02 153.68 32.45 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.224 0 CA-C-O 121.505 0.669 . . . . 0.0 110.998 -178.517 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.582 ' SG ' HG23 ' A' ' 2' ' ' VAL . 84.1 m -79.15 117.27 20.02 Favored 'General case' 0 C--N 1.291 -1.957 0 CA-C-N 114.503 -1.226 . . . . 0.0 108.833 175.613 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -135.07 130.41 35.53 Favored 'General case' 0 N--CA 1.431 -1.399 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -177.314 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 N--CA 1.432 -1.338 0 O-C-N 123.306 0.378 . . . . 0.0 110.63 178.847 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 22.2 p . . . . . 0 N--CA 1.446 -0.673 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.572 HG23 ' SG ' ' A' ' 33' ' ' CYS . 15.7 m -101.29 163.22 3.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-O 121.17 0.51 . . . . 0.0 111.511 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 23.9 mt -107.88 179.99 4.06 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.454 -0.793 . . . . 0.0 111.108 -172.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 24.3 pt -55.11 134.34 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.42 -17.85 41.12 Favored Glycine 0 C--O 1.242 0.614 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.937 177.757 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.7 mt-30 -81.54 159.72 24.06 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.133 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.458 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 40.5 ttp180 -85.78 129.0 34.95 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.269 -173.802 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 30.3 p -128.17 172.43 11.01 Favored 'General case' 0 C--N 1.291 -1.949 0 CA-C-O 121.294 0.569 . . . . 0.0 110.677 -177.22 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -147.12 118.97 8.09 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 175.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -58.22 -42.03 85.4 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 124.192 0.997 . . . . 0.0 113.113 -173.241 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -91.93 -56.63 3.01 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -175.412 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -83.15 -31.0 27.42 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-O 121.133 0.492 . . . . 0.0 112.024 -171.046 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 104.85 165.0 24.16 Favored Glycine 0 N--CA 1.427 -1.906 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 -176.331 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -76.25 156.76 98.41 Favored 'Cis proline' 0 C--N 1.329 -0.468 0 C-N-CA 123.382 -1.507 . . . . 0.0 112.122 0.488 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 82.1 mtt180 -108.03 156.35 19.35 Favored 'General case' 0 C--N 1.289 -2.04 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.56 -179.346 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 58.8 m -76.23 144.03 40.65 Favored 'General case' 0 C--N 1.29 -1.99 0 C-N-CA 124.06 0.944 . . . . 0.0 110.79 -176.865 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.441 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 59.2 m -67.42 161.51 25.12 Favored 'General case' 0 C--O 1.243 0.743 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.543 177.617 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 37.6 t -46.96 -56.21 6.77 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.065 0.946 . . . . 0.0 113.414 -174.094 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -95.19 27.22 15.79 Favored Glycine 0 C--N 1.314 -0.672 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.825 -176.26 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.441 ' CG ' ' HB2' ' A' ' 17' ' ' CYS . 84.9 mm-40 -110.84 29.69 7.53 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-O 121.337 0.589 . . . . 0.0 110.707 -178.556 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.414 ' CA ' ' HB ' ' A' ' 35' ' ' VAL . . . 85.51 -140.5 18.2 Favored Glycine 0 N--CA 1.43 -1.712 0 C-N-CA 120.365 -0.921 . . . . 0.0 112.874 177.528 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -133.8 155.87 49.04 Favored 'General case' 0 C--N 1.287 -2.142 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 176.294 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 52.5 t -83.06 100.83 10.74 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.244 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.409 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 7.4 p -98.0 120.07 60.78 Favored Pre-proline 0 N--CA 1.419 -2.021 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.62 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 10.1 Cg_exo -69.42 139.9 42.57 Favored 'Trans proline' 0 N--CA 1.45 -1.034 0 C-N-CA 122.076 1.851 . . . . 0.0 112.62 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 11.0 mp -119.49 134.92 23.81 Favored Pre-proline 0 C--N 1.304 -1.41 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.468 179.733 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_exo -39.93 -54.18 2.16 Favored 'Trans proline' 0 C--N 1.356 0.965 0 C-N-CA 124.58 3.52 . . . . 0.0 115.483 -175.464 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 75.5 m-85 -99.43 -40.88 7.66 Favored 'General case' 0 CA--C 1.504 -0.799 0 CA-C-O 121.079 0.466 . . . . 0.0 111.038 -178.152 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 14.0 mt -75.65 -14.58 60.37 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.872 -0.604 . . . . 0.0 112.594 -170.009 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.73 -64.53 0.75 Allowed Glycine 0 CA--C 1.486 -1.765 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 -179.619 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.458 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . 174.33 156.35 13.65 Favored Glycine 0 N--CA 1.425 -2.083 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 178.013 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.4 m -139.06 152.76 24.17 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-O 121.248 0.547 . . . . 0.0 109.925 177.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.572 ' SG ' HG23 ' A' ' 2' ' ' VAL . 60.4 m -82.55 125.01 30.65 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 115.426 -0.807 . . . . 0.0 108.964 176.751 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -146.82 135.74 22.34 Favored 'General case' 0 N--CA 1.439 -0.998 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.267 -176.782 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.414 ' HB ' ' CA ' ' A' ' 21' ' ' GLY . 7.7 p . . . . . 0 C--N 1.301 -1.542 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 178.49 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 25.8 p . . . . . 0 C--O 1.24 0.59 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.497 HG23 ' SG ' ' A' ' 33' ' ' CYS . 30.1 m -103.84 168.68 2.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 120.902 0.382 . . . . 0.0 110.878 -179.508 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.401 ' HB2' ' OE1' ' A' ' 6' ' ' GLN . 24.8 mt -109.12 -179.48 3.86 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.771 -0.649 . . . . 0.0 109.695 -175.784 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.7 pt -57.68 134.02 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-O 121.643 0.735 . . . . 0.0 112.87 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 95.71 -23.99 31.58 Favored Glycine 0 N--CA 1.442 -0.945 0 CA-C-N 115.175 -0.92 . . . . 0.0 112.303 178.539 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.401 ' OE1' ' HB2' ' A' ' 3' ' ' LEU . 36.2 mt-30 -83.09 152.65 25.24 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 16.5 ptm180 -87.0 145.39 26.52 Favored 'General case' 0 C--N 1.297 -1.694 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.309 -176.402 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.441 ' HB2' ' O ' ' A' ' 14' ' ' PRO . 15.7 p -144.3 176.26 9.48 Favored 'General case' 0 C--N 1.285 -2.21 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.983 -174.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -145.0 116.78 8.2 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 177.64 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -62.32 -32.67 73.46 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 112.968 0.729 . . . . 0.0 112.968 -178.459 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -82.63 -56.59 3.77 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 121.186 0.517 . . . . 0.0 111.523 -172.597 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 77.5 mtm180 -96.95 -20.23 18.24 Favored 'General case' 0 C--N 1.295 -1.778 0 CA-C-N 115.614 -0.721 . . . . 0.0 112.788 -172.172 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 94.36 162.55 35.34 Favored Glycine 0 N--CA 1.43 -1.738 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -177.046 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.441 ' O ' ' HB2' ' A' ' 8' ' ' CYS . 97.9 Cg_endo -85.26 167.53 53.0 Favored 'Cis proline' 0 C--N 1.326 -0.649 0 CA-C-N 119.272 1.536 . . . . 0.0 110.979 0.254 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -115.94 178.33 4.35 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 175.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 32.7 m -68.12 146.12 53.74 Favored 'General case' 0 C--N 1.293 -1.881 0 C-N-CA 123.277 0.631 . . . . 0.0 110.884 178.731 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 71.3 m -70.89 154.9 41.42 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 171.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.7 t -60.68 113.31 2.4 Favored 'General case' 0 N--CA 1.436 -1.128 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 106.48 0.2 37.36 Favored Glycine 0 N--CA 1.441 -0.982 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.555 -178.657 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 86.3 mm-40 -107.93 33.86 3.87 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.168 0.509 . . . . 0.0 110.93 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 80.7 -140.35 21.67 Favored Glycine 0 N--CA 1.428 -1.867 0 C-N-CA 120.131 -1.033 . . . . 0.0 113.241 177.539 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 52.9 t30 -151.32 159.92 44.06 Favored 'General case' 0 C--N 1.288 -2.097 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 92.3 m -72.08 97.76 1.97 Allowed 'General case' 0 C--N 1.308 -1.199 0 O-C-N 123.884 0.74 . . . . 0.0 109.192 176.361 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.3 t -96.52 126.9 41.76 Favored Pre-proline 0 N--CA 1.42 -1.946 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 179.223 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_exo -58.84 127.0 22.79 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 122.764 2.309 . . . . 0.0 112.627 -177.659 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.441 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 47.5 tp -118.02 131.91 23.95 Favored Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 179.384 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 6.9 Cg_exo -74.38 45.6 1.24 Allowed 'Trans proline' 0 N--CA 1.482 0.809 0 C-N-CA 123.636 2.891 . . . . 0.0 113.17 -176.61 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -148.98 -69.63 0.21 Allowed 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 124.143 0.977 . . . . 0.0 109.3 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 25.6 mt -95.66 1.53 53.6 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 114.285 -1.325 . . . . 0.0 111.516 -170.837 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.63 -77.14 0.63 Allowed Glycine 0 N--CA 1.435 -1.404 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.539 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -146.45 139.2 7.9 Favored Glycine 0 C--N 1.29 -2.015 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.051 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.8 m -134.38 157.09 41.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 178.693 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.497 ' SG ' HG23 ' A' ' 2' ' ' VAL . 81.4 m -73.78 124.54 26.26 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.103 179.622 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -144.5 143.24 30.75 Favored 'General case' 0 N--CA 1.425 -1.69 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.2 m . . . . . 0 C--N 1.301 -1.512 0 O-C-N 123.789 0.68 . . . . 0.0 111.124 178.767 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 19.9 p . . . . . 0 C--O 1.241 0.647 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.603 HG23 ' SG ' ' A' ' 33' ' ' CYS . 15.1 m -109.72 157.53 10.15 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.656 0 CA-C-O 121.131 0.491 . . . . 0.0 111.458 176.333 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 18.4 mt -111.98 179.34 4.03 Favored 'General case' 0 N--CA 1.432 -1.357 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.069 -172.747 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 23.7 pt -54.1 133.46 17.11 Favored 'Isoleucine or valine' 0 C--O 1.239 0.545 0 CA-C-O 121.76 0.791 . . . . 0.0 112.88 -179.513 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.57 -9.08 72.4 Favored Glycine 0 C--N 1.309 -0.954 0 CA-C-N 115.375 -0.83 . . . . 0.0 113.04 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 75.7 mt-30 -94.47 156.47 16.45 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 176.741 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.403 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 18.1 ptp180 -85.81 145.72 27.09 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-O 121.139 0.495 . . . . 0.0 111.504 -174.156 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.447 ' SG ' ' HA ' ' A' ' 15' ' ' ARG . 3.8 t -137.21 159.72 41.09 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.819 -1.082 . . . . 0.0 112.324 -172.791 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -150.86 117.54 5.79 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 113.277 -1.783 . . . . 0.0 107.062 176.137 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 48.2 m-80 -63.72 -43.04 97.71 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 113.671 0.989 . . . . 0.0 113.671 -173.278 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 17.4 m-20 -92.46 -35.88 13.4 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 113.678 0.992 . . . . 0.0 113.678 -174.474 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 54.8 mtm180 -100.99 -14.86 17.68 Favored 'General case' 0 C--N 1.309 -1.176 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -174.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.77 155.98 29.55 Favored Glycine 0 N--CA 1.442 -0.932 0 N-CA-C 111.081 -0.807 . . . . 0.0 111.081 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -84.91 159.33 66.08 Favored 'Cis proline' 0 CA--C 1.535 0.546 0 CA-C-N 119.206 1.503 . . . . 0.0 111.883 0.397 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.447 ' HA ' ' SG ' ' A' ' 8' ' ' CYS . 39.7 mtm180 -112.21 155.27 24.26 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-O 120.89 0.376 . . . . 0.0 110.083 -178.776 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.445 ' HA ' ' O ' ' A' ' 2' ' ' VAL . 36.8 m -78.02 142.01 38.52 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 123.882 0.873 . . . . 0.0 110.533 -176.918 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 m -67.05 153.37 43.82 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 119.144 -1.022 . . . . 0.0 111.312 172.006 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 12.3 p -48.74 -46.65 41.29 Favored 'General case' 0 C--O 1.241 0.622 0 N-CA-C 114.229 1.196 . . . . 0.0 114.229 -173.189 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -90.63 11.79 70.56 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.448 -0.882 . . . . 0.0 112.703 -179.236 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 78.7 mm-40 -105.28 37.19 2.25 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.276 0.56 . . . . 0.0 111.716 -178.001 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.48 -158.92 30.32 Favored Glycine 0 N--CA 1.423 -2.205 0 C-N-CA 120.091 -1.052 . . . . 0.0 112.32 177.02 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 -122.18 149.44 43.63 Favored 'General case' 0 C--N 1.282 -2.35 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 49.1 t -84.02 97.33 9.23 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.002 -1.111 . . . . 0.0 108.002 179.218 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.6 p -104.82 124.88 35.37 Favored Pre-proline 0 C--N 1.305 -1.34 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.52 -177.885 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -67.07 141.74 58.93 Favored 'Trans proline' 0 C--O 1.243 0.762 0 C-N-CA 122.645 2.23 . . . . 0.0 112.951 -176.7 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 87.9 mt -122.21 148.63 52.57 Favored Pre-proline 0 C--N 1.309 -1.181 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.601 -178.558 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo -49.29 -64.22 0.24 Allowed 'Trans proline' 0 CA--C 1.545 1.072 0 C-N-CA 123.715 2.943 . . . . 0.0 114.394 -178.198 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -97.16 -40.36 8.84 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.947 0.403 . . . . 0.0 110.987 -174.5 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 9.2 mp -78.98 0.74 26.38 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 113.737 1.014 . . . . 0.0 113.737 -174.681 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 86.28 -65.33 3.86 Favored Glycine 0 CA--C 1.501 -0.803 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.081 176.699 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.403 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -176.35 160.43 28.11 Favored Glycine 0 CA--C 1.477 -2.323 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 8.8 p -142.76 157.63 18.39 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 CA-C-N 117.73 0.765 . . . . 0.0 109.922 -178.265 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.603 ' SG ' HG23 ' A' ' 2' ' ' VAL . 59.9 m -88.0 108.73 19.36 Favored 'General case' 0 C--N 1.278 -2.514 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 174.547 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -149.88 163.84 36.97 Favored 'General case' 0 N--CA 1.435 -1.182 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 -175.28 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.9 p . . . . . 0 C--N 1.293 -1.852 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.653 178.786 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.4 p . . . . . 0 C--O 1.243 0.722 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 19.0 m -109.11 168.61 3.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 120.813 0.34 . . . . 0.0 111.147 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 29.3 mt -108.02 -176.24 3.0 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.327 -175.549 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 21.9 pt -56.78 138.83 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 N-CA-C 112.695 0.628 . . . . 0.0 112.695 179.755 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.29 -20.11 19.12 Favored Glycine 0 CA--C 1.506 -0.476 0 CA-C-N 115.707 -0.678 . . . . 0.0 112.694 178.682 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -80.5 153.73 27.98 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-O 121.252 0.549 . . . . 0.0 109.892 -179.259 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 4.2 tmt_? -86.31 130.14 34.61 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 114.657 -1.156 . . . . 0.0 109.038 -173.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.4 ' HB2' ' O ' ' A' ' 14' ' ' PRO . 27.8 p -130.29 170.67 13.82 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.242 -176.745 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -147.42 124.59 11.47 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 177.182 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 14.6 m120 -71.56 -35.88 70.75 Favored 'General case' 0 C--N 1.298 -1.662 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.424 -175.238 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -76.3 -56.86 4.25 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.637 -0.71 . . . . 0.0 112.146 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 74.1 mtm180 -93.8 -21.3 19.38 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 115.872 -0.604 . . . . 0.0 112.511 -173.48 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 94.74 163.45 35.24 Favored Glycine 0 N--CA 1.427 -1.947 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -175.769 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.4 ' O ' ' HB2' ' A' ' 8' ' ' CYS . 89.7 Cg_endo -89.86 165.68 34.52 Favored 'Cis proline' 0 N--CA 1.451 -0.998 0 C-N-CA 123.353 -1.52 . . . . 0.0 110.76 -1.184 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 69.8 mtm180 -106.86 179.43 4.27 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 176.139 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 26.4 m -73.42 140.75 46.76 Favored 'General case' 0 C--N 1.293 -1.856 0 C-N-CA 122.914 0.486 . . . . 0.0 109.963 -179.085 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 60.9 m -67.83 155.03 40.25 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 173.25 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 29.1 t -60.98 113.5 2.57 Favored 'General case' 0 C--O 1.246 0.899 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 -178.504 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 102.36 14.39 28.21 Favored Glycine 0 N--CA 1.435 -1.389 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.657 -178.472 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.45 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 83.9 mm-40 -116.8 28.85 8.28 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 -178.421 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.33 -163.11 35.54 Favored Glycine 0 N--CA 1.433 -1.553 0 C-N-CA 119.689 -1.243 . . . . 0.0 111.756 178.529 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 52.8 m-80 -130.43 152.05 50.25 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 107.756 -1.202 . . . . 0.0 107.756 179.166 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 63.1 m -66.95 98.1 0.53 Allowed 'General case' 0 N--CA 1.439 -1.007 0 O-C-N 124.04 0.837 . . . . 0.0 110.713 176.809 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.4 m -92.99 111.81 53.19 Favored Pre-proline 0 N--CA 1.411 -2.378 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 175.449 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.37 141.4 31.78 Favored 'Trans proline' 0 N--CA 1.44 -1.634 0 C-N-CA 122.069 1.846 . . . . 0.0 112.977 -173.93 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 91.8 mt -137.3 117.34 10.47 Favored Pre-proline 0 C--N 1.292 -1.928 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -72.15 51.03 1.63 Allowed 'Trans proline' 0 N--CA 1.485 0.984 0 C-N-CA 124.393 3.395 . . . . 0.0 113.969 -171.794 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 70.8 m-85 -143.83 -60.51 0.4 Allowed 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.638 ' H ' HD23 ' A' ' 29' ' ' LEU . 2.1 pt? -106.95 0.22 23.6 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.922 -178.208 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 109.46 -76.76 0.22 Allowed Glycine 0 C--N 1.306 -1.123 0 C-N-CA 120.399 -0.905 . . . . 0.0 111.755 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 177.27 159.56 22.63 Favored Glycine 0 N--CA 1.425 -2.057 0 N-CA-C 109.984 -1.247 . . . . 0.0 109.984 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.2 m -133.9 157.14 41.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-O 120.927 0.394 . . . . 0.0 110.697 -179.118 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.45 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 86.3 m -83.67 108.63 16.87 Favored 'General case' 0 C--N 1.296 -1.74 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.77 176.519 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -141.45 155.38 45.86 Favored 'General case' 0 N--CA 1.429 -1.518 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 -178.662 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 49.0 t . . . . . 0 C--N 1.3 -1.572 0 N-CA-C 108.293 -1.002 . . . . 0.0 108.293 177.326 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 29.6 p . . . . . 0 CA--C 1.519 -0.246 0 N-CA-C 110.078 -0.341 . . . . 0.0 110.078 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.425 HG23 ' SG ' ' A' ' 33' ' ' CYS . 16.6 m -107.95 168.37 3.42 Favored 'Isoleucine or valine' 0 C--O 1.243 0.743 0 CA-C-O 121.113 0.482 . . . . 0.0 110.946 178.467 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 29.2 mt -108.2 178.54 4.47 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.185 -173.805 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.506 ' HA ' ' HB2' ' A' ' 33' ' ' CYS . 26.9 pt -59.49 136.27 23.25 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.131 177.073 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.99 -13.45 59.4 Favored Glycine 0 C--N 1.311 -0.856 0 CA-C-N 115.843 -0.617 . . . . 0.0 112.596 178.812 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.455 ' O ' ' HA ' ' A' ' 32' ' ' VAL . 89.9 mt-30 -92.09 159.7 15.56 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 179.582 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.597 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 41.9 ttm180 -85.34 124.61 32.15 Favored 'General case' 0 C--N 1.317 -0.839 0 O-C-N 123.729 0.643 . . . . 0.0 110.805 -175.266 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 23.6 p -123.34 176.26 6.23 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.795 -177.285 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -145.81 125.63 13.49 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 174.451 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 47.3 m-80 -71.78 -30.0 65.08 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 113.339 0.866 . . . . 0.0 113.339 -175.673 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -91.37 -47.1 7.66 Favored 'General case' 0 C--N 1.295 -1.761 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 -172.549 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 51.0 mtp180 -106.1 -23.1 12.7 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 112.593 0.59 . . . . 0.0 112.593 -176.065 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 98.96 169.7 30.94 Favored Glycine 0 N--CA 1.431 -1.689 0 C-N-CA 119.825 -1.179 . . . . 0.0 110.479 -176.373 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -72.49 152.39 97.51 Favored 'Cis proline' 0 C--N 1.333 -0.258 0 CA-C-N 119.474 1.637 . . . . 0.0 112.32 1.515 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 73.1 mtt180 -105.89 160.77 15.0 Favored 'General case' 0 C--N 1.289 -2.06 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.263 -179.16 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.0 m -69.81 143.32 52.95 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 123.665 0.786 . . . . 0.0 110.953 -177.438 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 85.2 m -63.3 155.78 27.61 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 176.869 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.7 m -63.57 106.13 0.9 Allowed 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -179.478 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 101.6 29.61 6.19 Favored Glycine 0 N--CA 1.439 -1.142 0 N-CA-C 110.687 -0.965 . . . . 0.0 110.687 -176.846 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.405 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 23.0 mm-40 -126.7 36.01 4.53 Favored 'General case' 0 CA--C 1.496 -1.098 0 CA-C-O 121.26 0.553 . . . . 0.0 111.506 178.698 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 76.14 -163.32 53.09 Favored Glycine 0 N--CA 1.42 -2.375 0 C-N-CA 120.469 -0.872 . . . . 0.0 113.138 178.299 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -110.45 145.49 37.55 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 177.444 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 50.3 t -75.69 98.02 3.97 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 176.539 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.441 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 20.8 t -98.87 126.51 38.3 Favored Pre-proline 0 N--CA 1.427 -1.604 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 -176.725 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 7.8 Cg_exo -72.94 126.45 11.28 Favored 'Trans proline' 0 N--CA 1.45 -1.071 0 C-N-CA 122.714 2.276 . . . . 0.0 112.296 178.468 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.487 HD13 HG22 ' A' ' 32' ' ' VAL . 10.6 mp -121.63 119.79 29.02 Favored Pre-proline 0 C--N 1.306 -1.315 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 176.373 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_exo -37.62 -49.69 1.9 Allowed 'Trans proline' 0 CA--C 1.553 1.438 0 C-N-CA 124.634 3.556 . . . . 0.0 116.673 -174.381 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -89.64 -26.34 20.8 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 120.151 -0.619 . . . . 0.0 112.228 -176.142 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -94.91 -4.88 46.06 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 121.464 0.65 . . . . 0.0 110.793 -174.705 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 84.53 -77.65 2.09 Favored Glycine 0 N--CA 1.431 -1.699 0 N-CA-C 109.109 -1.597 . . . . 0.0 109.109 -178.21 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -168.64 138.2 4.98 Favored Glycine 0 N--CA 1.413 -2.864 0 N-CA-C 107.816 -2.114 . . . . 0.0 107.816 178.258 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.487 HG22 HD13 ' A' ' 26' ' ' LEU . 35.9 m -134.8 146.95 29.83 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 CA-C-O 121.251 0.548 . . . . 0.0 109.796 -178.509 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.506 ' HB2' ' HA ' ' A' ' 4' ' ' ILE . 81.1 m -72.81 124.69 25.88 Favored 'General case' 0 C--N 1.294 -1.841 0 CA-C-N 115.305 -0.862 . . . . 0.0 109.138 176.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -142.19 133.94 26.98 Favored 'General case' 0 N--CA 1.425 -1.702 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 -176.031 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.7 m . . . . . 0 C--N 1.306 -1.318 0 O-C-N 123.54 0.525 . . . . 0.0 110.72 179.82 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.4 p . . . . . 0 N--CA 1.452 -0.332 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.554 HG23 ' SG ' ' A' ' 33' ' ' CYS . 19.6 m -107.58 162.82 5.72 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.876 0 CA-C-O 121.188 0.518 . . . . 0.0 112.076 -176.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.402 ' O ' ' HB2' ' A' ' 6' ' ' GLN . 16.4 mt -106.98 -177.11 3.27 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.145 -174.528 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 37.7 pt -59.65 139.42 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 N-CA-C 112.483 0.549 . . . . 0.0 112.483 -178.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 83.25 -16.74 27.37 Favored Glycine 0 C--N 1.316 -0.542 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.626 179.599 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.402 ' HB2' ' O ' ' A' ' 3' ' ' LEU . 78.2 mt-30 -82.02 156.83 24.44 Favored 'General case' 0 N--CA 1.428 -1.53 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 178.802 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.479 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 43.5 ttp180 -85.94 129.61 34.79 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-N 114.618 -1.173 . . . . 0.0 110.451 -173.185 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 24.6 p -126.35 176.16 7.32 Favored 'General case' 0 C--N 1.284 -2.26 0 CA-C-N 115.296 -0.866 . . . . 0.0 110.138 -177.54 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -146.76 123.09 10.95 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 105.896 -1.89 . . . . 0.0 105.896 173.592 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 18.7 m120 -58.44 -45.73 87.96 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.645 -1.162 . . . . 0.0 112.611 -173.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -92.65 -52.89 4.42 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -175.469 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -85.72 -24.99 26.72 Favored 'General case' 0 C--N 1.315 -0.9 0 C-N-CA 120.1 -0.64 . . . . 0.0 112.563 -173.507 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 98.18 169.75 32.01 Favored Glycine 0 N--CA 1.43 -1.743 0 C-N-CA 120.135 -1.031 . . . . 0.0 111.291 -177.957 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -74.57 164.0 89.1 Favored 'Cis proline' 0 C--N 1.332 -0.334 0 C-N-CA 123.342 -1.524 . . . . 0.0 112.351 0.433 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 77.0 mtt180 -117.7 164.26 15.24 Favored 'General case' 0 C--N 1.292 -1.895 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.076 -178.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.417 ' HA ' ' O ' ' A' ' 2' ' ' VAL . 28.0 m -71.16 140.72 50.63 Favored 'General case' 0 C--N 1.289 -2.038 0 C-N-CA 123.829 0.852 . . . . 0.0 110.192 -177.348 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.429 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 59.0 m -67.26 151.98 46.54 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 176.817 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.3 t -67.15 103.66 1.26 Allowed 'General case' 0 N--CA 1.439 -1.005 0 C-N-CA 123.424 0.69 . . . . 0.0 109.181 -177.768 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 122.92 -12.3 8.67 Favored Glycine 0 N--CA 1.437 -1.267 0 N-CA-C 110.429 -1.068 . . . . 0.0 110.429 -177.384 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.429 ' CG ' ' HB2' ' A' ' 17' ' ' CYS . 84.2 mm-40 -85.78 -45.12 11.91 Favored 'General case' 0 CA--C 1.5 -0.96 0 CA-C-N 115.46 -0.37 . . . . 0.0 110.353 178.661 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 152.71 -161.62 29.61 Favored Glycine 0 N--CA 1.419 -2.45 0 C-N-CA 119.079 -1.534 . . . . 0.0 113.019 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -112.36 147.43 36.4 Favored 'General case' 0 C--N 1.279 -2.475 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 178.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 53.0 t -82.0 105.98 13.55 Favored 'General case' 0 C--N 1.294 -1.83 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.129 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -92.53 117.04 67.45 Favored Pre-proline 0 C--N 1.311 -1.078 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 176.184 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -74.36 148.25 38.13 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 122.025 1.817 . . . . 0.0 114.114 -174.774 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 8.1 mp -126.28 132.39 24.3 Favored Pre-proline 0 C--N 1.308 -1.198 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 176.573 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_exo -39.0 -57.2 1.01 Allowed 'Trans proline' 0 CA--C 1.543 0.933 0 C-N-CA 124.611 3.541 . . . . 0.0 115.299 -175.875 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -93.43 -46.4 7.35 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-O 121.801 0.81 . . . . 0.0 110.327 -178.697 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 26.7 mt -77.15 0.52 21.36 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 114.339 -1.3 . . . . 0.0 113.189 -167.439 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 87.03 -65.79 3.65 Favored Glycine 0 CA--C 1.492 -1.345 0 N-CA-C 112.201 -0.36 . . . . 0.0 112.201 175.069 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.479 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . 165.02 162.75 16.77 Favored Glycine 0 N--CA 1.412 -2.944 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.8 m -135.46 147.64 28.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 177.462 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.554 ' SG ' HG23 ' A' ' 2' ' ' VAL . 94.7 m -80.42 131.47 35.6 Favored 'General case' 0 C--N 1.293 -1.856 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.692 177.24 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.61 168.61 26.59 Favored 'General case' 0 N--CA 1.427 -1.596 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 -178.095 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 4.1 p . . . . . 0 C--O 1.259 1.586 0 C-N-CA 123.919 0.888 . . . . 0.0 113.101 -178.925 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 22.3 p . . . . . 0 N--CA 1.447 -0.606 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.569 HG23 ' SG ' ' A' ' 16' ' ' CYS . 23.8 m -94.15 178.42 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.594 -0.276 . . . . 0.0 110.586 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 27.3 mt -117.84 -176.01 2.95 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 112.667 0.617 . . . . 0.0 112.667 -172.669 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.532 HG13 ' OE1' ' A' ' 20' ' ' GLN . 66.4 mt -56.6 135.88 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 123.714 0.806 . . . . 0.0 110.764 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.04 -6.85 73.4 Favored Glycine 0 C--N 1.313 -0.704 0 C-N-CA 121.447 -0.406 . . . . 0.0 112.693 177.29 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -94.14 150.55 20.22 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 178.038 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.2 tmm_? -86.76 129.7 34.77 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.5 -172.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 18.5 p -128.33 175.45 8.48 Favored 'General case' 0 C--N 1.297 -1.694 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.175 -175.766 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -152.9 121.51 6.4 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 106.161 -1.792 . . . . 0.0 106.161 174.456 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -72.17 -26.27 62.01 Favored 'General case' 0 C--N 1.294 -1.843 0 CA-C-O 120.832 0.349 . . . . 0.0 111.091 -174.848 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -78.74 -56.8 4.14 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.788 -176.724 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 26.9 mmm180 -106.53 -9.61 16.55 Favored 'General case' 0 C--N 1.312 -1.043 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -174.216 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 90.64 165.51 40.39 Favored Glycine 0 C--N 1.297 -1.622 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -177.422 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -81.39 170.87 60.26 Favored 'Cis proline' 0 CA--C 1.534 0.486 0 C-N-CA 123.385 -1.506 . . . . 0.0 111.831 0.314 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 78.7 mtm180 -122.76 152.12 40.94 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.14 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.569 ' SG ' HG23 ' A' ' 2' ' ' VAL . 57.9 m -86.01 158.67 19.8 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.068 -176.345 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.445 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 26.4 m -67.28 153.81 42.79 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 178.295 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.7 m -46.86 -45.59 20.41 Favored 'General case' 0 CA--C 1.56 1.334 0 N-CA-C 115.188 1.551 . . . . 0.0 115.188 -172.356 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -97.0 22.01 43.06 Favored Glycine 0 C--N 1.318 -0.472 0 C-N-CA 120.501 -0.857 . . . . 0.0 112.559 -178.582 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.532 ' OE1' HG13 ' A' ' 4' ' ' ILE . 85.9 mm-40 -105.28 23.28 13.96 Favored 'General case' 0 C--N 1.311 -1.1 0 O-C-N 122.648 -0.324 . . . . 0.0 111.692 -178.602 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 92.65 -177.42 38.88 Favored Glycine 0 N--CA 1.43 -1.7 0 C-N-CA 120.451 -0.881 . . . . 0.0 112.774 177.154 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 33' ' ' CYS . 35.3 t30 -119.16 143.8 47.03 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 179.135 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 92.2 m -63.38 102.04 0.37 Allowed 'General case' 0 C--N 1.316 -0.872 0 O-C-N 123.871 0.732 . . . . 0.0 110.535 178.103 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.7 m -110.1 137.23 20.49 Favored Pre-proline 0 N--CA 1.421 -1.924 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 177.607 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -67.91 120.85 7.85 Favored 'Trans proline' 0 N--CA 1.448 -1.184 0 C-N-CA 121.699 1.6 . . . . 0.0 112.14 -178.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.41 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 56.5 tp -115.98 104.99 51.91 Favored Pre-proline 0 N--CA 1.42 -1.964 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 176.131 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 18.3 Cg_exo -70.78 56.15 1.79 Allowed 'Trans proline' 0 N--CA 1.479 0.653 0 C-N-CA 124.056 3.171 . . . . 0.0 113.219 -175.53 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -148.06 -63.54 0.26 Allowed 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 125.294 1.438 . . . . 0.0 108.09 179.389 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -104.03 -19.38 14.22 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.518 -179.069 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 121.76 -165.01 14.73 Favored Glycine 0 C--N 1.305 -1.167 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -177.469 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -72.91 125.43 9.82 Favored Glycine 0 CA--C 1.49 -1.481 0 C-N-CA 119.986 -1.102 . . . . 0.0 110.356 177.884 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 33.2 m -127.62 153.14 36.55 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.327 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -176.733 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.478 ' HA ' ' O ' ' A' ' 22' ' ' ASN . 74.1 m -85.84 116.55 24.16 Favored 'General case' 0 C--N 1.284 -2.246 0 C-N-CA 119.718 -0.793 . . . . 0.0 111.25 178.302 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.54 168.51 22.54 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.256 179.738 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.1 t . . . . . 0 C--N 1.307 -1.255 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 176.507 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.5 p . . . . . 0 C--O 1.244 0.808 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.405 HG23 ' SG ' ' A' ' 33' ' ' CYS . 27.9 m -116.35 159.44 16.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-O 120.916 0.389 . . . . 0.0 111.243 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 67.8 mt -105.41 -177.83 3.48 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 115.58 -0.737 . . . . 0.0 111.01 -175.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.5 pt -56.05 137.34 17.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 178.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.15 -14.42 60.79 Favored Glycine 0 C--N 1.316 -0.543 0 CA-C-N 115.761 -0.654 . . . . 0.0 113.288 177.648 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.438 ' O ' ' HA ' ' A' ' 32' ' ' VAL . 78.0 mt-30 -87.73 162.06 17.26 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-O 121.031 0.443 . . . . 0.0 110.794 -178.453 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.406 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 37.6 ttt180 -84.88 123.59 30.66 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 114.753 -1.112 . . . . 0.0 109.092 -175.603 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -134.88 167.6 20.59 Favored 'General case' 0 C--N 1.294 -1.82 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.038 -176.702 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -146.55 130.54 17.27 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 175.66 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 35.7 m-80 -66.32 -40.33 89.86 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 114.753 -1.112 . . . . 0.0 112.977 -171.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -93.04 -52.01 4.78 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -175.113 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 78.4 mtp180 -84.46 -24.68 29.39 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.29 -173.028 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 99.58 163.17 29.22 Favored Glycine 0 N--CA 1.429 -1.818 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -175.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -81.15 159.73 82.94 Favored 'Cis proline' 0 N--CA 1.446 -1.311 0 CA-C-N 119.662 1.731 . . . . 0.0 111.296 0.267 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -107.94 149.93 27.72 Favored 'General case' 0 C--N 1.291 -1.972 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.017 -178.516 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 45.7 m -65.08 142.45 58.38 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.053 -0.976 . . . . 0.0 108.6 178.853 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 61.2 m -63.84 144.96 56.64 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 176.621 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.7 p -53.04 86.54 0.0 OUTLIER 'General case' 0 CA--C 1.546 0.818 0 N-CA-C 113.909 1.077 . . . . 0.0 113.909 -176.144 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.6 26.81 1.54 Allowed Glycine 0 N--CA 1.435 -1.392 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.3 -178.372 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 23.1 mm-40 -115.87 30.19 7.5 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.427 0.632 . . . . 0.0 111.87 179.133 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.64 -150.5 24.4 Favored Glycine 0 N--CA 1.425 -2.073 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.402 177.164 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.8 p-10 -130.64 159.35 37.46 Favored 'General case' 0 C--N 1.287 -2.127 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 179.064 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 85.5 m -77.5 99.27 5.61 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 123.572 0.545 . . . . 0.0 109.798 175.694 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 14.6 p -90.22 120.47 69.15 Favored Pre-proline 0 N--CA 1.421 -1.914 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 176.479 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -74.59 134.73 18.94 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 121.982 1.788 . . . . 0.0 113.222 -176.584 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.0 mt -135.94 129.92 18.34 Favored Pre-proline 0 C--N 1.301 -1.513 0 CA-C-N 115.046 -0.979 . . . . 0.0 108.573 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.79 54.23 2.01 Favored 'Trans proline' 0 CA--C 1.536 0.581 0 C-N-CA 124.031 3.154 . . . . 0.0 113.898 -174.236 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -143.06 -66.9 0.37 Allowed 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 178.784 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.618 ' H ' HD23 ' A' ' 29' ' ' LEU . 1.9 pt? -107.45 0.27 22.73 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.496 -0.774 . . . . 0.0 112.369 -178.458 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 109.94 -86.88 0.45 Allowed Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.393 -0.908 . . . . 0.0 111.39 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.406 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -152.54 148.83 20.19 Favored Glycine 0 CA--C 1.49 -1.518 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.438 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 28.4 m -128.79 145.79 35.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 120.834 0.349 . . . . 0.0 111.439 -178.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.405 ' SG ' HG23 ' A' ' 2' ' ' VAL . 79.7 m -71.72 121.68 19.31 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 175.598 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -142.33 136.49 29.74 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.025 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 58.1 t . . . . . 0 N--CA 1.438 -1.07 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 177.192 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.4 p . . . . . 0 C--O 1.242 0.694 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.443 HG23 ' SG ' ' A' ' 33' ' ' CYS . 26.1 m -108.87 162.68 6.55 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.166 0.508 . . . . 0.0 111.277 -179.038 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 54.3 mt -105.79 -175.28 2.75 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.737 -175.878 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.5 pt -58.02 129.03 19.48 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 N-CA-C 113.224 0.824 . . . . 0.0 113.224 -178.864 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.18 -13.92 65.02 Favored Glycine 0 CA--C 1.503 -0.664 0 CA-C-N 115.639 -0.71 . . . . 0.0 112.681 177.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.42 ' HB2' ' HB ' ' A' ' 2' ' ' VAL . 87.5 mt-30 -88.82 159.72 17.59 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.408 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 62.1 ttt180 -86.02 131.37 34.28 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.827 -173.874 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.7 p -126.2 156.67 39.86 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.813 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -137.38 126.57 24.58 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 176.202 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 46.9 m-80 -78.98 -31.62 44.96 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 120.485 -0.486 . . . . 0.0 111.893 -178.09 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -72.67 -52.86 13.55 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-O 121.097 0.475 . . . . 0.0 111.727 -174.7 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.423 ' HA ' ' NE ' ' A' ' 12' ' ' ARG . 5.4 mmp_? -108.06 -17.58 14.0 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 113.398 0.888 . . . . 0.0 113.398 -176.953 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 91.26 168.28 41.5 Favored Glycine 0 N--CA 1.432 -1.6 0 C-N-CA 119.842 -1.17 . . . . 0.0 110.502 -177.612 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -79.25 159.9 89.53 Favored 'Cis proline' 0 C--N 1.329 -0.47 0 CA-C-N 119.082 1.441 . . . . 0.0 111.863 -1.143 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 83.0 mtm180 -109.6 177.0 4.87 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 178.514 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.2 m -70.51 144.45 51.35 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.424 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 86.3 m -68.17 145.02 54.73 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 173.585 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.5 t -50.93 99.0 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.236 1.015 . . . . 0.0 112.177 -175.724 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 118.01 -11.33 13.33 Favored Glycine 0 N--CA 1.443 -0.84 0 CA-C-N 115.83 -0.623 . . . . 0.0 112.123 179.3 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.476 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 23.7 mm-40 -86.17 23.55 1.52 Allowed 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 114.674 1.361 . . . . 0.0 114.674 -176.872 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 101.27 -176.63 26.86 Favored Glycine 0 N--CA 1.427 -1.946 0 C-N-CA 119.439 -1.362 . . . . 0.0 113.934 174.441 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 38.4 m-80 -113.4 150.31 32.88 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 179.407 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 89.1 m -74.52 98.18 3.29 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 123.193 0.308 . . . . 0.0 111.101 179.112 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.9 t -82.42 122.24 78.84 Favored Pre-proline 0 C--N 1.303 -1.42 0 N-CA-C 106.279 -1.749 . . . . 0.0 106.279 175.417 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -86.4 121.72 1.98 Allowed 'Trans proline' 0 N--CA 1.439 -1.686 0 C-N-CA 122.66 2.24 . . . . 0.0 113.679 -174.637 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -119.45 148.41 45.56 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 178.011 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_exo -41.19 -69.3 0.08 OUTLIER 'Trans proline' 0 CA--C 1.548 1.198 0 C-N-CA 124.74 3.627 . . . . 0.0 116.037 -175.874 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 24.6 p90 -93.01 -17.66 23.61 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 112.966 0.728 . . . . 0.0 112.966 -173.474 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 96.5 mt -86.64 -13.48 45.49 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.495 179.227 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 81.79 -79.46 1.84 Allowed Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.84 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.408 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -166.34 136.26 4.07 Favored Glycine 0 N--CA 1.426 -1.992 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 179.471 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 36.0 m -126.51 143.44 39.99 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 CA-C-O 120.909 0.385 . . . . 0.0 110.821 -179.006 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.476 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 74.8 m -71.42 114.08 9.12 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.792 178.696 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.43 156.41 42.45 Favored 'General case' 0 C--N 1.315 -0.912 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 178.561 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 39.3 t . . . . . 0 C--O 1.255 1.37 0 C-N-CA 123.684 0.794 . . . . 0.0 110.006 -179.315 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.5 p . . . . . 0 C--O 1.24 0.56 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.435 ' HB ' ' HB2' ' A' ' 6' ' ' GLN . 33.9 m -110.75 164.68 6.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 121.185 0.517 . . . . 0.0 110.866 -178.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 48.4 mt -102.47 -179.22 3.92 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.767 -178.286 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 27.3 pt -59.4 133.19 24.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.126 0.489 . . . . 0.0 112.213 178.446 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.1 -10.26 75.47 Favored Glycine 0 C--N 1.316 -0.536 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.98 178.535 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.435 ' HB2' ' HB ' ' A' ' 2' ' ' VAL . 86.7 mt-30 -94.85 157.53 15.88 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.124 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 2.7 tmm_? -85.96 124.55 32.53 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.367 -173.618 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.46 ' HB2' ' HA ' ' A' ' 15' ' ' ARG . 10.4 p -121.36 165.8 15.01 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.009 179.254 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -125.0 124.93 43.06 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 176.296 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -73.48 -33.43 64.82 Favored 'General case' 0 C--N 1.305 -1.365 0 N-CA-C 112.751 0.649 . . . . 0.0 112.751 -171.562 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -91.17 -50.56 5.77 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 120.542 -0.463 . . . . 0.0 111.928 -175.384 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 58.4 mtp180 -102.18 -8.67 21.14 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -172.177 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.14 168.36 44.57 Favored Glycine 0 C--N 1.31 -0.909 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.491 178.304 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -81.87 166.89 70.91 Favored 'Cis proline' 0 N--CA 1.474 0.327 0 C-N-CA 123.837 -1.318 . . . . 0.0 111.283 -0.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.46 ' HA ' ' HB2' ' A' ' 8' ' ' CYS . 73.4 mtm180 -121.49 -173.79 2.71 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 116.763 -0.199 . . . . 0.0 111.006 178.283 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 33.1 m -60.38 144.46 50.78 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 123.846 0.859 . . . . 0.0 112.142 -178.302 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 74.4 m -71.97 166.23 22.6 Favored 'General case' 0 C--O 1.243 0.731 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 170.541 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.7 t -67.83 109.82 3.55 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.056 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 101.16 26.68 7.71 Favored Glycine 0 N--CA 1.443 -0.886 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 -179.253 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.537 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 86.9 mm-40 -126.06 35.68 4.64 Favored 'General case' 0 C--N 1.318 -0.792 0 O-C-N 122.68 -0.306 . . . . 0.0 111.503 -179.239 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 70.81 -158.59 53.71 Favored Glycine 0 C--O 1.248 0.997 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.407 178.617 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -127.05 158.84 35.91 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 176.887 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 98.4 m -68.66 104.81 2.08 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 121.168 0.509 . . . . 0.0 110.779 178.616 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 59.9 t -91.83 120.06 68.14 Favored Pre-proline 0 N--CA 1.426 -1.647 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 175.608 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_exo -67.51 136.86 40.95 Favored 'Trans proline' 0 N--CA 1.445 -1.37 0 C-N-CA 122.459 2.106 . . . . 0.0 111.858 -179.461 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 24.0 tp -132.49 117.01 15.3 Favored Pre-proline 0 C--N 1.29 -2.017 0 N-CA-C 105.271 -2.122 . . . . 0.0 105.271 176.224 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -63.42 51.61 0.14 Allowed 'Trans proline' 0 N--CA 1.502 1.982 0 C-N-CA 125.029 3.819 . . . . 0.0 116.575 -170.726 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -144.34 -64.39 0.36 Allowed 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 177.531 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.641 ' H ' HD23 ' A' ' 29' ' ' LEU . 1.9 pt? -103.7 -3.4 25.11 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.213 -0.903 . . . . 0.0 112.88 -173.148 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 113.94 -103.91 1.39 Allowed Glycine 0 C--N 1.304 -1.216 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -177.659 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -139.78 152.48 22.63 Favored Glycine 0 N--CA 1.43 -1.724 0 C-N-CA 120.674 -0.774 . . . . 0.0 111.425 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 19.5 m -132.06 139.71 49.63 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.537 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 84.2 m -69.31 128.14 35.53 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.295 179.271 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -164.85 158.36 17.27 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 109.484 -0.562 . . . . 0.0 109.484 -178.894 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.2 t . . . . . 0 C--O 1.252 1.206 0 O-C-N 124.9 1.375 . . . . 0.0 111.603 177.329 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.6 p . . . . . 0 N--CA 1.456 -0.164 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.48 HG23 ' SG ' ' A' ' 33' ' ' CYS . 15.3 m -105.43 164.59 4.05 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-O 121.094 0.473 . . . . 0.0 111.846 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 21.4 mt -107.39 178.84 4.42 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.244 -173.652 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 40.0 pt -57.85 137.35 20.15 Favored 'Isoleucine or valine' 0 C--O 1.24 0.57 0 CA-C-O 121.571 0.7 . . . . 0.0 112.685 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.13 -23.98 24.18 Favored Glycine 0 C--N 1.306 -1.083 0 CA-C-N 115.645 -0.707 . . . . 0.0 112.795 178.661 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 92.3 mt-30 -82.8 155.79 24.01 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -178.316 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.9 tmm_? -85.75 127.18 34.47 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -173.512 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 21.8 p -122.52 172.92 8.02 Favored 'General case' 0 C--N 1.288 -2.107 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.376 -177.109 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -153.35 124.02 7.24 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 177.001 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 -72.96 -37.79 66.98 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 112.64 0.607 . . . . 0.0 112.64 -174.475 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -85.6 -47.3 9.98 Favored 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 120.072 -0.651 . . . . 0.0 112.533 -174.656 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 5.1 mmp_? -93.58 -29.21 15.6 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.891 -0.723 . . . . 0.0 112.196 -177.327 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 103.61 162.45 25.14 Favored Glycine 0 N--CA 1.434 -1.471 0 N-CA-C 109.826 -1.31 . . . . 0.0 109.826 -175.91 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -82.77 157.59 76.47 Favored 'Cis proline' 0 CA--C 1.535 0.536 0 CA-C-N 119.276 1.538 . . . . 0.0 112.432 1.278 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 63.7 mtm180 -107.23 157.04 18.21 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-O 120.853 0.359 . . . . 0.0 110.054 179.7 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 35.6 m -68.51 142.85 55.15 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 124.19 0.996 . . . . 0.0 110.282 -178.654 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.446 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 54.7 m -67.78 154.4 41.61 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 174.032 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.1 p -54.55 -23.05 15.04 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 115.776 1.769 . . . . 0.0 115.776 -171.196 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -115.83 22.84 11.31 Favored Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 177.483 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.446 ' CG ' ' HB2' ' A' ' 17' ' ' CYS . 86.4 mm-40 -115.56 20.9 14.41 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.254 0.55 . . . . 0.0 110.91 -178.236 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 80.16 -151.6 33.46 Favored Glycine 0 N--CA 1.426 -2.002 0 C-N-CA 120.282 -0.961 . . . . 0.0 113.166 176.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -135.88 168.57 19.07 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 77.6 m -74.74 124.72 27.3 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 123.648 0.592 . . . . 0.0 111.234 -179.182 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 22.0 t -106.25 116.52 59.22 Favored Pre-proline 0 C--N 1.291 -1.954 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 173.083 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.427 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 56.4 Cg_endo -80.72 125.01 5.34 Favored 'Trans proline' 0 N--CA 1.445 -1.371 0 C-N-CA 122.583 2.188 . . . . 0.0 112.953 -175.702 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.405 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 4.1 pp -118.72 153.96 52.52 Favored Pre-proline 0 C--N 1.302 -1.47 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.23 178.742 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 5.4 Cg_endo -83.54 49.66 2.99 Favored 'Trans proline' 0 C--O 1.236 0.396 0 C-N-CA 123.53 2.82 . . . . 0.0 113.935 -170.912 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -141.48 -77.59 0.28 Allowed 'General case' 0 C--N 1.314 -0.959 0 CA-C-O 120.878 0.37 . . . . 0.0 110.915 179.29 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.468 ' H ' HD13 ' A' ' 29' ' ' LEU . 0.0 OUTLIER -106.85 0.88 24.31 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -177.11 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 116.98 -138.62 14.44 Favored Glycine 0 N--CA 1.437 -1.266 0 C-N-CA 120.371 -0.919 . . . . 0.0 111.206 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.427 ' HA2' ' HA ' ' A' ' 25' ' ' PRO . . . -108.92 149.23 17.0 Favored Glycine 0 N--CA 1.428 -1.841 0 C-N-CA 120.395 -0.907 . . . . 0.0 112.52 -178.849 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.8 m -124.04 146.75 29.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 177.471 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.48 ' SG ' HG23 ' A' ' 2' ' ' VAL . 74.4 m -71.1 136.7 48.35 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.828 179.493 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -160.33 146.06 15.16 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.867 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.7 t . . . . . 0 C--N 1.307 -1.258 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 -179.063 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.5 p . . . . . 0 N--CA 1.443 -0.778 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.451 HG23 ' SG ' ' A' ' 33' ' ' CYS . 35.7 m -102.26 169.19 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-O 121.146 0.498 . . . . 0.0 111.088 -178.427 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 26.0 mt -109.84 -176.11 2.92 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.399 -0.818 . . . . 0.0 110.542 -175.432 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.514 HG13 ' OE1' ' A' ' 20' ' ' GLN . 61.5 mt -56.37 133.25 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 122.681 0.392 . . . . 0.0 111.029 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.26 -15.03 56.09 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 116.024 -0.534 . . . . 0.0 113.057 177.761 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -88.42 159.25 18.09 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 -178.662 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.551 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 85.9 mtm180 -86.63 134.53 33.62 Favored 'General case' 0 CA--C 1.496 -1.098 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.916 -175.523 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.427 ' HB3' ' CG2' ' A' ' 2' ' ' VAL . 24.0 p -139.49 171.34 14.4 Favored 'General case' 0 C--N 1.285 -2.205 0 CA-C-N 114.276 -1.329 . . . . 0.0 109.379 -178.148 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -145.51 125.7 13.8 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 174.427 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 84.7 m-20 -65.79 -32.75 74.46 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -177.308 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -91.16 -52.34 4.87 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -172.558 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 55.3 mtp180 -92.46 -25.91 18.22 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -176.068 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 90.51 167.92 42.07 Favored Glycine 0 N--CA 1.437 -1.288 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -76.78 168.84 76.04 Favored 'Cis proline' 0 N--CA 1.475 0.387 0 CA-C-N 119.669 1.735 . . . . 0.0 110.517 -0.584 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 5.7 mpt_? -116.09 -179.18 3.59 Favored 'General case' 0 C--N 1.291 -1.943 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.267 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.7 m -70.71 148.59 47.82 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 178.161 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 60.9 m -69.85 142.86 53.01 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 106.04 -1.837 . . . . 0.0 106.04 170.526 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.6 m -62.23 99.23 0.13 Allowed 'General case' 0 C--O 1.243 0.749 0 CA-C-O 121.002 0.429 . . . . 0.0 111.111 -175.832 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 128.84 -6.59 6.49 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.204 -176.372 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.514 ' OE1' HG13 ' A' ' 4' ' ' ILE . 84.8 mm-40 -98.42 10.87 39.82 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 -178.478 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.452 ' HA2' ' HB ' ' A' ' 35' ' ' VAL . . . 103.73 -172.44 20.97 Favored Glycine 0 N--CA 1.442 -0.963 0 C-N-CA 120.009 -1.091 . . . . 0.0 113.442 176.138 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 -117.02 147.16 42.57 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 -179.301 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 96.1 m -72.67 102.21 3.26 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 123.884 0.74 . . . . 0.0 112.018 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.2 p -87.23 119.85 71.08 Favored Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 171.299 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -82.97 141.13 10.42 Favored 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 121.987 1.791 . . . . 0.0 114.606 -173.141 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 5.8 mp -122.83 122.97 26.98 Favored Pre-proline 0 C--N 1.3 -1.551 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 177.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_exo -36.34 -54.64 0.88 Allowed 'Trans proline' 0 N--CA 1.485 1.015 0 C-N-CA 124.957 3.772 . . . . 0.0 116.012 -175.398 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -111.05 -15.35 13.74 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 113.75 1.018 . . . . 0.0 113.75 -177.647 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -80.0 -30.13 39.58 Favored 'General case' 0 C--N 1.294 -1.836 0 C-N-CA 120.313 -0.555 . . . . 0.0 112.002 174.521 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 114.73 -99.0 0.9 Allowed Glycine 0 N--CA 1.431 -1.664 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.551 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -171.64 148.62 11.15 Favored Glycine 0 C--N 1.282 -2.471 0 N-CA-C 108.649 -1.78 . . . . 0.0 108.649 178.147 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 31.5 m -130.47 145.91 34.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 CA-C-N 117.928 0.864 . . . . 0.0 111.484 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.451 ' SG ' HG23 ' A' ' 2' ' ' VAL . 71.9 m -76.11 116.74 17.11 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.896 176.904 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -141.56 149.19 40.48 Favored 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -179.783 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.452 ' HB ' ' HA2' ' A' ' 21' ' ' GLY . 4.1 p . . . . . 0 C--N 1.3 -1.544 0 CA-C-O 118.74 -0.647 . . . . 0.0 109.485 177.232 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.0 p . . . . . 0 C--O 1.227 -0.118 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.532 HG23 ' SG ' ' A' ' 33' ' ' CYS . 16.5 m -110.13 161.21 8.68 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -177.54 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 36.0 mt -107.41 -178.96 3.78 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.09 -175.841 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 24.0 pt -61.13 128.81 23.03 Favored 'Isoleucine or valine' 0 C--O 1.238 0.489 0 N-CA-C 113.282 0.845 . . . . 0.0 113.282 -179.337 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.62 -5.35 73.57 Favored Glycine 0 N--CA 1.443 -0.859 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.767 -179.103 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 77.5 mt-30 -101.32 156.01 17.7 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 176.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.401 ' NH1' HD22 ' A' ' 29' ' ' LEU . 54.1 mtm180 -86.03 140.75 30.0 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.727 0.775 . . . . 0.0 112.606 -173.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.415 ' SG ' ' N ' ' A' ' 9' ' ' ASP . 1.6 t -133.16 171.68 13.68 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-N 113.68 -1.6 . . . . 0.0 109.321 -175.16 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.415 ' N ' ' SG ' ' A' ' 8' ' ' CYS . 17.1 t70 -161.86 118.73 2.13 Favored 'General case' 0 C--N 1.276 -2.59 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 172.363 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -57.68 -39.57 77.43 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 113.984 1.105 . . . . 0.0 113.984 -175.536 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -91.13 -47.78 7.33 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -175.856 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 29.1 mmt180 -80.7 -43.0 21.01 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.709 0.766 . . . . 0.0 111.592 -177.012 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 105.46 163.87 23.55 Favored Glycine 0 N--CA 1.425 -2.064 0 N-CA-C 108.337 -1.905 . . . . 0.0 108.337 -172.286 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -79.01 165.85 80.58 Favored 'Cis proline' 0 C--N 1.322 -0.865 0 CA-C-N 119.88 1.84 . . . . 0.0 111.891 -0.002 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 60.5 mtp180 -108.2 153.49 23.11 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 179.412 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 55.9 m -68.01 138.69 56.07 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.548 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 55.9 m -65.93 158.28 28.5 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 178.148 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.8 t -60.89 104.43 0.36 Allowed 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 123.194 0.597 . . . . 0.0 110.343 -179.342 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 108.85 17.35 10.4 Favored Glycine 0 N--CA 1.443 -0.897 0 N-CA-C 111.524 -0.631 . . . . 0.0 111.524 -178.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 83.6 mm-40 -111.18 52.19 0.75 Allowed 'General case' 0 C--N 1.307 -1.243 0 O-C-N 122.038 -0.684 . . . . 0.0 111.591 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 71.03 -143.4 36.15 Favored Glycine 0 N--CA 1.434 -1.492 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.376 178.079 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 46.4 m-80 -128.94 146.12 51.04 Favored 'General case' 0 C--N 1.289 -2.05 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 176.194 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 42.9 t -83.11 97.12 8.63 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.01 -1.107 . . . . 0.0 108.01 179.036 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.0 p -94.37 114.99 64.72 Favored Pre-proline 0 N--CA 1.432 -1.341 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.353 -179.426 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.485 ' HA ' ' CA ' ' A' ' 31' ' ' GLY . 73.9 Cg_endo -76.72 142.15 22.54 Favored 'Trans proline' 0 N--CA 1.449 -1.136 0 C-N-CA 122.557 2.172 . . . . 0.0 113.605 -176.107 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 5.8 mp -116.06 142.4 29.16 Favored Pre-proline 0 N--CA 1.422 -1.867 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 172.704 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_endo -74.57 53.99 3.3 Favored 'Trans proline' 0 C--N 1.326 -0.65 0 C-N-CA 123.164 2.576 . . . . 0.0 113.464 -177.247 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.46 ' HB3' HD12 ' A' ' 29' ' ' LEU . 70.2 m-85 -139.17 -87.51 0.22 Allowed 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 178.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.46 HD12 ' HB3' ' A' ' 28' ' ' PHE . 4.5 mp -104.66 -28.27 11.33 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-O 121.589 0.709 . . . . 0.0 110.47 -176.181 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 167.41 -152.59 21.32 Favored Glycine 0 N--CA 1.418 -2.543 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -179.22 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.485 ' CA ' ' HA ' ' A' ' 25' ' ' PRO . . . -113.42 -172.75 18.36 Favored Glycine 0 N--CA 1.411 -3.033 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.3 p -138.06 152.59 26.22 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.24 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.061 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.532 ' SG ' HG23 ' A' ' 2' ' ' VAL . 63.7 m -89.12 119.43 29.62 Favored 'General case' 0 C--N 1.275 -2.633 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.297 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.04 139.56 24.83 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -176.746 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 C--N 1.306 -1.316 0 CA-C-O 118.867 -0.587 . . . . 0.0 109.978 -179.861 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.7 p . . . . . 0 CA--C 1.513 -0.45 0 N-CA-C 109.29 -0.634 . . . . 0.0 109.29 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.458 ' HB ' ' HB2' ' A' ' 6' ' ' GLN . 33.5 m -103.17 152.53 5.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-O 120.953 0.406 . . . . 0.0 111.076 -177.293 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 52.3 mt -97.68 -174.3 2.86 Favored 'General case' 0 N--CA 1.438 -1.043 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.667 -179.273 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 43.2 pt -59.28 142.06 15.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.059 0.457 . . . . 0.0 111.704 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.59 -26.07 8.67 Favored Glycine 0 C--N 1.311 -0.82 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.26 178.366 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.458 ' HB2' ' HB ' ' A' ' 2' ' ' VAL . 24.1 mt-30 -79.18 152.92 30.42 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -178.552 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 10.2 mpt_? -86.76 136.86 32.84 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.883 -175.799 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.5 p -130.02 168.27 16.98 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.984 -175.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -132.5 123.68 27.06 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.708 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.9 m120 -72.73 -26.59 61.63 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -175.685 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -84.17 -56.55 3.6 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-O 121.228 0.537 . . . . 0.0 111.4 -175.112 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 71.9 mtm180 -105.45 -24.14 12.69 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 -170.339 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 95.48 172.48 36.59 Favored Glycine 0 N--CA 1.426 -1.999 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 -172.744 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -72.21 160.54 93.94 Favored 'Cis proline' 0 C--O 1.235 0.373 0 CA-C-N 119.771 1.785 . . . . 0.0 111.574 -0.218 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 57.8 mtm180 -120.18 176.04 5.65 Favored 'General case' 0 C--N 1.291 -1.959 0 CA-C-N 116.495 -0.321 . . . . 0.0 110.17 179.281 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 20.5 m -68.02 144.45 55.12 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 123.607 0.567 . . . . 0.0 109.494 -178.501 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' CYS . . . . . 0.405 ' HB2' ' HG3' ' A' ' 20' ' ' GLN . 52.9 m -67.9 145.67 54.36 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 105.977 -1.86 . . . . 0.0 105.977 171.333 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 14.6 p -56.43 107.75 0.41 Allowed 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 112.017 0.377 . . . . 0.0 112.017 -177.218 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 115.03 -11.46 20.32 Favored Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.497 -177.789 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.452 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 86.8 mm-40 -91.98 26.61 2.39 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-O 121.321 0.581 . . . . 0.0 111.45 -178.514 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.84 -168.02 37.17 Favored Glycine 0 N--CA 1.415 -2.73 0 C-N-CA 120.54 -0.838 . . . . 0.0 113.074 176.41 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 47.4 m-80 -129.9 153.07 48.68 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 -179.121 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 74.3 m -68.32 104.7 1.93 Allowed 'General case' 0 C--N 1.314 -0.946 0 O-C-N 123.895 0.747 . . . . 0.0 112.602 -176.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.53 117.5 61.78 Favored Pre-proline 0 N--CA 1.434 -1.259 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 175.248 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.443 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 6.1 Cg_exo -77.98 122.36 5.76 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 122.125 1.884 . . . . 0.0 112.198 -179.051 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.423 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 34.9 tp -129.31 109.92 17.86 Favored Pre-proline 0 N--CA 1.427 -1.607 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 175.351 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 35.5 Cg_exo -64.29 51.53 0.18 Allowed 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 125.122 3.881 . . . . 0.0 116.476 -172.464 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -139.16 -53.34 0.56 Allowed 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 174.009 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.669 ' H ' HD23 ' A' ' 29' ' ' LEU . 1.9 pt? -107.05 -18.37 13.92 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 114.595 -1.184 . . . . 0.0 111.842 -178.011 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 115.42 -154.97 16.61 Favored Glycine 0 N--CA 1.442 -0.954 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.443 ' HA2' ' HA ' ' A' ' 25' ' ' PRO . . . -101.81 123.94 8.05 Favored Glycine 0 CA--C 1.483 -1.965 0 N-CA-C 110.136 -1.186 . . . . 0.0 110.136 178.352 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 33.3 m -120.12 150.41 22.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.047 0 CA-C-O 121.157 0.503 . . . . 0.0 111.601 -174.101 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.452 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 82.0 m -75.13 116.43 15.86 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.152 176.12 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -130.86 136.3 48.51 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.56 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 55.2 t . . . . . 0 C--N 1.315 -0.933 0 CA-C-O 118.778 -0.629 . . . . 0.0 109.366 -179.518 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 28.4 p . . . . . 0 CA--C 1.51 -0.572 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.428 HG23 ' SG ' ' A' ' 33' ' ' CYS . 20.0 m -109.19 164.41 5.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.314 -178.333 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 38.8 mt -103.05 -179.83 4.06 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -177.774 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 34.2 pt -62.64 135.66 26.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.426 0.631 . . . . 0.0 112.683 -178.5 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.08 -12.77 66.68 Favored Glycine 0 C--N 1.314 -0.677 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.985 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -92.23 154.22 18.78 Favored 'General case' 0 N--CA 1.435 -1.211 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.368 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.0 mtm180 -86.16 143.41 28.02 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.545 -174.011 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.477 ' HB2' ' O ' ' A' ' 14' ' ' PRO . 26.4 p -144.46 176.13 9.61 Favored 'General case' 0 C--N 1.278 -2.519 0 CA-C-N 114.519 -1.219 . . . . 0.0 108.362 -177.681 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -130.23 124.14 31.8 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -69.29 -27.69 65.62 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 112.645 0.609 . . . . 0.0 112.645 -177.705 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -91.94 -57.05 2.86 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 111.688 0.255 . . . . 0.0 111.688 -175.683 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -96.75 -18.47 19.6 Favored 'General case' 0 C--N 1.312 -1.051 0 N-CA-C 112.756 0.65 . . . . 0.0 112.756 -172.315 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.02 172.99 47.53 Favored Glycine 0 N--CA 1.437 -1.283 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 -174.575 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.477 ' O ' ' HB2' ' A' ' 8' ' ' CYS . 80.6 Cg_endo -75.77 173.09 59.83 Favored 'Cis proline' 0 C--O 1.23 0.093 0 CA-C-N 120.013 1.907 . . . . 0.0 111.014 -0.538 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.453 ' HA ' ' HB2' ' A' ' 8' ' ' CYS . 73.2 mtm180 -126.59 -173.91 2.99 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.678 -0.237 . . . . 0.0 110.437 178.492 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.2 m -65.45 146.74 54.5 Favored 'General case' 0 C--N 1.294 -1.826 0 C-N-CA 124.08 0.952 . . . . 0.0 111.591 -179.037 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 62.9 m -66.75 149.65 50.24 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 171.131 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.9 t -62.05 100.48 0.16 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.762 0.315 . . . . 0.0 110.365 -178.075 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 121.35 1.23 11.2 Favored Glycine 0 N--CA 1.444 -0.824 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -177.481 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 27.3 mm-40 -109.76 39.6 2.08 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 120.976 0.417 . . . . 0.0 112.103 179.564 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 74.43 -159.21 52.28 Favored Glycine 0 N--CA 1.423 -2.172 0 C-N-CA 120.308 -0.949 . . . . 0.0 112.628 178.38 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -133.96 148.92 51.22 Favored 'General case' 0 C--N 1.278 -2.5 0 N-CA-C 109.338 -0.615 . . . . 0.0 109.338 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 88.4 m -64.78 112.69 3.36 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 124.112 0.883 . . . . 0.0 111.079 177.677 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.3 p -96.19 124.67 50.81 Favored Pre-proline 0 C--N 1.284 -2.242 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 172.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -78.39 145.86 21.52 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 C-N-CA 121.594 1.529 . . . . 0.0 112.585 -177.475 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.452 ' HB2' ' HB3' ' A' ' 29' ' ' LEU . 3.8 mm? -130.07 146.54 61.89 Favored Pre-proline 0 C--N 1.301 -1.534 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 178.003 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo -41.75 -68.19 0.1 Allowed 'Trans proline' 0 N--CA 1.481 0.791 0 C-N-CA 124.503 3.469 . . . . 0.0 115.111 -177.124 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 33.4 p90 -104.79 -25.22 12.74 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-O 121.074 0.464 . . . . 0.0 112.04 -176.819 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.452 ' HB3' ' HB2' ' A' ' 26' ' ' LEU . 3.2 tm? -66.05 -32.04 73.28 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.441 179.178 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 101.19 -88.12 0.7 Allowed Glycine 0 N--CA 1.429 -1.822 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 178.578 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -158.82 147.69 15.64 Favored Glycine 0 N--CA 1.427 -1.927 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 179.279 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.7 p -140.41 148.82 21.91 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 CA-C-O 121.197 0.522 . . . . 0.0 110.103 178.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.428 ' SG ' HG23 ' A' ' 2' ' ' VAL . 76.9 m -82.2 132.87 35.24 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.51 179.112 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.93 140.73 17.12 Favored 'General case' 0 N--CA 1.425 -1.678 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -178.82 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.1 m . . . . . 0 C--N 1.307 -1.282 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 176.125 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.3 p . . . . . 0 N--CA 1.445 -0.684 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' A' ' 16' ' ' CYS . 30.8 m -96.67 169.2 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 120.936 0.398 . . . . 0.0 111.087 -179.562 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 42.5 mt -114.41 -176.14 2.84 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.788 -176.326 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.3 pp -51.92 145.01 2.56 Favored 'Isoleucine or valine' 0 C--O 1.246 0.917 0 N-CA-C 113.546 0.943 . . . . 0.0 113.546 176.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.32 -15.98 15.36 Favored Glycine 0 C--N 1.32 -0.348 0 CA-C-N 115.728 -0.669 . . . . 0.0 113.632 179.383 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 -85.91 157.96 20.04 Favored 'General case' 0 C--N 1.307 -1.271 0 O-C-N 122.384 -0.48 . . . . 0.0 110.136 177.254 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -86.44 125.05 33.43 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.894 -177.245 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.4 p -119.07 163.48 16.93 Favored 'General case' 0 C--N 1.278 -2.538 0 CA-C-N 114.569 -1.196 . . . . 0.0 110.697 -175.318 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -148.15 126.32 12.17 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 174.844 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -77.78 -22.13 50.61 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -174.047 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -90.5 -54.81 3.84 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-O 121.255 0.55 . . . . 0.0 111.158 -175.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -100.04 -27.58 13.49 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.271 -172.424 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.0 169.93 27.32 Favored Glycine 0 N--CA 1.432 -1.599 0 N-CA-C 110.141 -1.184 . . . . 0.0 110.141 -174.872 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -79.85 155.53 88.16 Favored 'Cis proline' 0 N--CA 1.457 -0.655 0 CA-C-N 119.461 1.631 . . . . 0.0 111.704 -0.605 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 66.1 mtt180 -107.45 145.44 33.02 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 -179.358 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.491 ' HA ' ' O ' ' A' ' 2' ' ' VAL . 81.6 m -74.38 149.92 40.29 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.374 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 64.0 m -58.23 141.18 51.52 Favored 'General case' 0 C--N 1.317 -0.821 0 O-C-N 124.223 0.952 . . . . 0.0 109.693 -176.406 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 13.7 t -68.66 97.68 0.82 Allowed 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 141.01 -19.18 2.71 Favored Glycine 0 N--CA 1.435 -1.428 0 N-CA-C 108.559 -1.817 . . . . 0.0 108.559 -173.662 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 24.9 mm-40 -81.49 -178.98 7.18 Favored 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 123.681 0.792 . . . . 0.0 111.839 177.215 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.54 169.61 19.17 Favored Glycine 0 C--N 1.314 -0.681 0 CA-C-O 121.42 0.456 . . . . 0.0 114.083 -177.888 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ASN . . . . . 0.531 ' O ' ' HA ' ' A' ' 33' ' ' CYS . 27.2 t-20 -85.82 139.93 30.87 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 178.72 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 21.4 t -76.25 101.46 5.45 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 -178.276 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.6 t -99.9 113.95 65.41 Favored Pre-proline 0 N--CA 1.426 -1.652 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 -179.302 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.444 ' HA ' ' CA ' ' A' ' 31' ' ' GLY . 3.0 Cg_exo -71.87 121.38 7.56 Favored 'Trans proline' 0 N--CA 1.442 -1.545 0 C-N-CA 122.19 1.927 . . . . 0.0 110.706 179.257 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.1 mt -117.12 122.88 30.67 Favored Pre-proline 0 N--CA 1.425 -1.695 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 178.699 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -73.65 42.86 0.72 Allowed 'Trans proline' 0 CA--C 1.542 0.878 0 C-N-CA 123.716 2.944 . . . . 0.0 113.102 -176.721 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -135.2 -67.65 0.54 Allowed 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 -179.282 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.621 ' H ' HD23 ' A' ' 29' ' ' LEU . 2.3 pt? -107.14 -5.72 17.8 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.669 -178.559 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 111.71 -172.76 15.12 Favored Glycine 0 N--CA 1.432 -1.595 0 N-CA-C 110.129 -1.188 . . . . 0.0 110.129 -175.905 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.444 ' CA ' ' HA ' ' A' ' 25' ' ' PRO . . . -90.64 132.78 11.45 Favored Glycine 0 CA--C 1.484 -1.894 0 C-N-CA 120.526 -0.845 . . . . 0.0 111.336 179.381 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.4 m -129.88 147.74 33.23 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.938 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -178.239 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.531 ' HA ' ' O ' ' A' ' 22' ' ' ASN . 96.4 m -82.25 120.07 24.9 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.132 178.887 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -119.76 137.71 53.78 Favored 'General case' 0 N--CA 1.427 -1.589 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 178.428 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--N 1.292 -1.898 0 C-N-CA 121.008 -0.277 . . . . 0.0 111.194 -177.472 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 25.8 p . . . . . 0 N--CA 1.446 -0.648 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.471 HG23 ' SG ' ' A' ' 33' ' ' CYS . 18.6 m -108.37 154.91 9.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 CA-C-O 121.134 0.492 . . . . 0.0 111.513 -179.605 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 57.7 mt -100.33 -176.96 3.37 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.52 -175.844 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.9 pt -61.13 130.49 25.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.503 0 CA-C-O 121.477 0.656 . . . . 0.0 112.438 -179.114 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 96.59 -22.64 39.12 Favored Glycine 0 C--N 1.311 -0.821 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.841 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -81.02 154.9 26.64 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 121.067 0.46 . . . . 0.0 109.794 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.1 tmt_? -86.34 138.15 32.04 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.349 -173.679 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 17.5 p -137.07 167.89 20.65 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.917 -177.364 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -141.66 120.49 12.7 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 175.41 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -63.37 -35.18 79.56 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.84 -0.618 . . . . 0.0 112.168 -170.849 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -92.44 -52.54 4.61 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 113.026 0.75 . . . . 0.0 113.026 -175.469 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.4 mtm180 -87.08 -27.81 22.92 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 121.133 0.492 . . . . 0.0 112.306 -174.319 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.0 163.42 26.76 Favored Glycine 0 N--CA 1.427 -1.966 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 -175.946 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -78.44 165.93 81.37 Favored 'Cis proline' 0 C--N 1.332 -0.323 0 C-N-CA 123.378 -1.509 . . . . 0.0 112.375 0.569 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 60.1 mtt180 -115.74 163.09 16.34 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.678 -179.358 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 58.4 m -70.14 142.33 52.55 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 123.638 0.775 . . . . 0.0 110.514 -177.39 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 81.9 m -67.39 157.48 34.0 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 174.667 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.1 p -57.64 96.6 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.818 0 C-N-CA 124.207 1.003 . . . . 0.0 112.477 -177.467 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 99.09 34.76 5.02 Favored Glycine 0 N--CA 1.433 -1.566 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.293 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.435 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 23.9 mm-40 -122.58 34.57 5.11 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-O 121.547 0.689 . . . . 0.0 111.013 177.184 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 78.47 -166.38 52.34 Favored Glycine 0 N--CA 1.419 -2.457 0 CA-C-N 114.928 -1.033 . . . . 0.0 112.169 178.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 40.4 m-80 -127.95 157.19 41.26 Favored 'General case' 0 C--N 1.29 -2.016 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 -179.83 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 99.3 m -68.13 97.92 0.74 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 123.819 0.7 . . . . 0.0 111.765 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.82 126.62 72.54 Favored Pre-proline 0 N--CA 1.425 -1.699 0 N-CA-C 106.153 -1.795 . . . . 0.0 106.153 174.082 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.41 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 48.2 Cg_endo -70.3 129.99 17.94 Favored 'Trans proline' 0 N--CA 1.446 -1.288 0 C-N-CA 121.558 1.506 . . . . 0.0 114.283 -174.891 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.41 HD23 HG22 ' A' ' 32' ' ' VAL . 4.6 mm? -121.42 143.24 37.19 Favored Pre-proline 0 C--N 1.309 -1.187 0 CA-C-N 114.932 -1.031 . . . . 0.0 108.747 178.941 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_exo -44.26 -63.7 0.31 Allowed 'Trans proline' 0 CA--C 1.546 1.094 0 C-N-CA 123.731 2.954 . . . . 0.0 115.298 -176.744 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -89.65 -25.42 21.27 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 112.599 0.592 . . . . 0.0 112.599 -173.518 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -88.81 -17.97 28.66 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-O 121.362 0.601 . . . . 0.0 111.093 -175.434 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 88.89 -63.59 3.49 Favored Glycine 0 N--CA 1.429 -1.832 0 N-CA-C 109.389 -1.485 . . . . 0.0 109.389 -177.038 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.41 ' HA2' ' HA ' ' A' ' 25' ' ' PRO . . . -165.13 148.18 13.68 Favored Glycine 0 N--CA 1.419 -2.441 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.41 HG22 HD23 ' A' ' 26' ' ' LEU . 14.0 m -131.79 150.97 34.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 176.778 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.471 ' SG ' HG23 ' A' ' 2' ' ' VAL . 71.7 m -76.32 117.24 17.79 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -142.65 145.47 33.49 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 120.726 -0.389 . . . . 0.0 110.786 -179.733 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.6 m . . . . . 0 C--N 1.308 -1.22 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.603 176.963 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 23.4 p . . . . . 0 C--O 1.233 0.217 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.417 HG23 ' SG ' ' A' ' 33' ' ' CYS . 28.8 m -110.54 154.44 12.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-O 120.606 0.241 . . . . 0.0 111.367 -178.583 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 35.5 mt -99.69 -176.36 3.24 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.297 -177.477 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.408 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 33.8 pt -58.14 134.6 22.84 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.73 0 CA-C-O 121.477 0.656 . . . . 0.0 112.489 179.027 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.73 -18.72 55.98 Favored Glycine 0 C--N 1.311 -0.828 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.296 178.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' GLN . . . . . 0.414 ' HB2' ' HB ' ' A' ' 2' ' ' VAL . 23.7 mt-30 -89.66 152.33 21.42 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -179.556 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.462 ' HA ' ' HA ' ' A' ' 32' ' ' VAL . 16.4 ptp180 -86.61 148.71 25.36 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.07 0.462 . . . . 0.0 111.106 -175.317 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.2 p -138.56 158.24 44.62 Favored 'General case' 0 C--N 1.298 -1.652 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.611 -174.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -129.06 124.03 33.8 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 176.152 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -79.17 -27.11 42.64 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 120.955 0.407 . . . . 0.0 111.626 -173.107 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -91.1 -42.08 10.68 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 115.723 -0.671 . . . . 0.0 112.154 -173.417 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 83.7 mtm180 -112.54 -13.3 13.35 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 -175.597 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 89.35 165.74 41.33 Favored Glycine 0 N--CA 1.44 -1.094 0 C-N-CA 120.055 -1.069 . . . . 0.0 110.805 -177.408 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -79.85 158.73 88.28 Favored 'Cis proline' 0 N--CA 1.463 -0.284 0 CA-C-N 119.227 1.513 . . . . 0.0 111.195 -0.812 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 80.9 mtm180 -113.49 172.67 6.83 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 121.03 -0.268 . . . . 0.0 110.502 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.7 m -68.01 141.0 56.37 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 123.634 0.583 . . . . 0.0 109.834 -179.228 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 55.8 m -67.33 140.86 57.29 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 172.855 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 5.9 p -58.4 94.77 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.73 0 CA-C-O 121.663 0.744 . . . . 0.0 112.794 -177.383 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 132.38 -5.32 5.26 Favored Glycine 0 N--CA 1.438 -1.179 0 CA-C-N 114.853 -1.067 . . . . 0.0 110.644 -176.895 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLN . . . . . 0.448 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 86.0 mm-40 -101.58 30.09 4.49 Favored 'General case' 0 C--N 1.323 -0.561 0 C-N-CA 123.348 0.659 . . . . 0.0 112.456 -177.483 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 84.44 -171.6 47.89 Favored Glycine 0 N--CA 1.436 -1.352 0 C-N-CA 120.103 -1.046 . . . . 0.0 113.9 175.803 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 -113.44 162.59 15.94 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.747 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 98.8 m -76.87 97.23 4.51 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-O 121.553 0.692 . . . . 0.0 109.689 177.253 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.4 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 43.5 t -93.43 127.91 44.55 Favored Pre-proline 0 N--CA 1.416 -2.14 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 -179.045 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 57.5 Cg_endo -85.0 121.01 2.34 Favored 'Trans proline' 0 N--CA 1.427 -2.421 0 C-N-CA 121.953 1.769 . . . . 0.0 112.018 -178.532 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.42 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 10.3 mp -110.39 124.52 33.08 Favored Pre-proline 0 C--N 1.29 -2.018 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 177.463 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 78.2 Cg_exo -53.24 -17.38 8.46 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 C-N-CA 124.448 3.432 . . . . 0.0 115.564 -173.725 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.411 ' HB2' HD12 ' A' ' 29' ' ' LEU . 73.6 m-85 -110.55 -22.74 11.49 Favored 'General case' 0 C--N 1.309 -1.164 0 C-N-CA 120.858 -0.337 . . . . 0.0 111.388 -179.167 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' LEU . . . . . 0.411 HD12 ' HB2' ' A' ' 28' ' ' PHE . 6.1 mp -106.55 -16.89 14.41 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 112.177 0.436 . . . . 0.0 112.177 -173.76 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.94 -104.91 2.98 Favored Glycine 0 N--CA 1.426 -2.006 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 -176.449 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -147.35 127.9 2.79 Favored Glycine 0 C--N 1.295 -1.744 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 176.465 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.462 ' HA ' ' HA ' ' A' ' 7' ' ' ARG . 34.5 m -131.83 154.19 39.88 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 C-N-CA 122.926 0.49 . . . . 0.0 110.187 -175.809 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' CYS . . . . . 0.448 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 74.4 m -74.53 119.69 19.06 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.705 178.033 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -146.53 148.75 32.5 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.752 0.311 . . . . 0.0 110.551 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 17.9 m . . . . . 0 C--N 1.306 -1.291 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.007 176.663 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.5 p . . . . . 0 N--CA 1.452 -0.334 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.544 HG23 ' SG ' ' A' ' 33' ' ' CYS . 21.2 m -106.84 167.4 3.45 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-O 121.184 0.516 . . . . 0.0 111.291 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.415 ' HA ' ' HG3' ' A' ' 20' ' ' GLN . 25.3 mt -107.41 175.97 5.31 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.174 -172.509 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 27.9 pt -61.07 134.99 26.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.438 0 CA-C-O 121.415 0.626 . . . . 0.0 112.394 -178.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.65 -13.3 60.97 Favored Glycine 0 C--N 1.312 -0.78 0 CA-C-N 115.486 -0.779 . . . . 0.0 112.622 -179.214 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -90.4 151.18 21.54 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 106.892 -1.522 . . . . 0.0 106.892 176.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 34.3 ptt180 -85.9 146.24 26.8 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.949 -0.7 . . . . 0.0 111.064 -173.156 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.4 p -139.09 176.91 8.29 Favored 'General case' 0 C--N 1.282 -2.331 0 CA-C-N 115.164 -0.926 . . . . 0.0 109.224 -174.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -152.11 117.31 5.24 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 174.281 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -57.08 -38.99 74.1 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 113.629 0.974 . . . . 0.0 113.629 -173.784 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -91.86 -47.58 7.25 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 113.628 0.973 . . . . 0.0 113.628 -175.241 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.0 mtm180 -89.48 -29.88 18.67 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -173.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.55 160.31 25.94 Favored Glycine 0 N--CA 1.435 -1.389 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -174.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -79.65 167.45 75.47 Favored 'Cis proline' 0 C--O 1.218 -0.475 0 CA-C-N 119.542 1.671 . . . . 0.0 111.987 1.309 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 88.0 mtm180 -122.01 156.25 33.87 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 33.6 m -70.2 149.25 47.7 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 124.825 1.25 . . . . 0.0 111.319 -175.658 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 85.4 m -68.43 143.74 54.95 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 175.229 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 11.4 t -54.3 -26.45 29.41 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 125.25 1.42 . . . . 0.0 113.039 -172.211 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -108.08 16.53 35.8 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.188 178.138 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.415 ' HG3' ' HA ' ' A' ' 3' ' ' LEU . 18.3 mm-40 -97.74 -68.1 0.82 Allowed 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -179.368 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -175.85 -179.18 46.2 Favored Glycine 0 CA--C 1.481 -2.089 0 C-N-CA 120.261 -0.971 . . . . 0.0 110.703 -176.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 52.4 t30 -93.29 139.6 30.46 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 177.416 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 49.9 t -79.47 98.13 6.68 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.075 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.62 120.09 69.53 Favored Pre-proline 0 C--N 1.302 -1.47 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -67.18 141.7 58.19 Favored 'Trans proline' 0 N--CA 1.449 -1.114 0 C-N-CA 122.431 2.087 . . . . 0.0 113.106 -176.269 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.4 mt -119.36 144.19 35.95 Favored Pre-proline 0 C--N 1.302 -1.5 0 CA-C-N 114.743 -1.117 . . . . 0.0 109.078 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_exo -40.26 -57.31 1.23 Allowed 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 124.731 3.621 . . . . 0.0 114.806 -176.553 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 30.4 p90 -119.18 -24.18 6.54 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -177.666 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 78.3 mt -79.9 0.49 31.02 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 179.04 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 87.57 -59.22 4.37 Favored Glycine 0 CA--C 1.499 -0.939 0 C-N-CA 121.149 -0.548 . . . . 0.0 111.871 177.246 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 171.64 170.79 36.07 Favored Glycine 0 N--CA 1.418 -2.512 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 9.2 p -147.3 146.15 18.59 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.986 0 CA-C-O 121.503 0.668 . . . . 0.0 109.992 177.282 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.544 ' SG ' HG23 ' A' ' 2' ' ' VAL . 74.1 m -80.06 118.4 21.75 Favored 'General case' 0 C--N 1.285 -2.223 0 CA-C-N 114.713 -1.13 . . . . 0.0 109.923 179.639 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -143.87 153.66 42.57 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 -177.179 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 52.4 t . . . . . 0 C--N 1.306 -1.32 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -179.109 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.3 p . . . . . 0 C--O 1.24 0.57 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.582 HG23 ' SG ' ' A' ' 33' ' ' CYS . 30.2 m -112.06 158.28 12.55 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-O 120.655 0.264 . . . . 0.0 111.504 -178.567 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 38.2 mt -99.57 -178.56 3.92 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.482 -176.554 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.435 ' HA ' ' HB2' ' A' ' 33' ' ' CYS . 34.0 pt -58.64 140.37 17.04 Favored 'Isoleucine or valine' 0 C--O 1.241 0.651 0 N-CA-C 113.023 0.749 . . . . 0.0 113.023 -179.394 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.8 -14.34 48.48 Favored Glycine 0 C--N 1.311 -0.86 0 CA-C-N 115.708 -0.678 . . . . 0.0 113.183 178.577 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 27.2 mt-30 -86.15 156.53 20.31 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 108.056 -1.091 . . . . 0.0 108.056 178.668 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 47.1 ttp180 -86.01 132.22 34.11 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 123.623 0.577 . . . . 0.0 109.962 -176.203 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.2 p -128.71 175.11 8.85 Favored 'General case' 0 C--N 1.278 -2.543 0 CA-C-N 115.069 -0.969 . . . . 0.0 109.197 -177.478 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -149.82 125.68 10.5 Favored 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 174.709 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.403 ' OD1' ' HB3' ' A' ' 23' ' ' CYS . 43.6 m-80 -76.64 -23.11 53.31 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 120.531 0.205 . . . . 0.0 111.526 -175.84 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -84.87 -57.56 3.06 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.903 -175.031 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 63.2 mtt180 -103.07 -21.85 13.86 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 113.107 0.78 . . . . 0.0 113.107 -175.356 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 103.86 168.55 25.25 Favored Glycine 0 N--CA 1.433 -1.543 0 C-N-CA 120.121 -1.038 . . . . 0.0 110.609 -177.393 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -80.1 159.17 87.18 Favored 'Cis proline' 0 CA--C 1.535 0.549 0 CA-C-N 119.085 1.442 . . . . 0.0 112.065 0.217 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 -104.55 169.91 8.19 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 177.83 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.6 m -80.52 147.16 30.96 Favored 'General case' 0 C--N 1.297 -1.688 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.419 -176.191 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 39.5 m -72.77 153.28 41.19 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 175.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.1 t -67.77 120.12 13.59 Favored 'General case' 0 N--CA 1.435 -1.214 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 103.54 0.1 46.4 Favored Glycine 0 N--CA 1.437 -1.264 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -175.658 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 86.0 mm-40 -111.86 38.01 2.78 Favored 'General case' 0 C--N 1.31 -1.132 0 CA-C-O 121.496 0.665 . . . . 0.0 110.366 179.064 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 78.14 -156.58 43.77 Favored Glycine 0 N--CA 1.418 -2.554 0 CA-C-N 115.057 -0.974 . . . . 0.0 112.962 177.271 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 79.6 m-20 -123.74 153.75 40.47 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 106.123 -1.806 . . . . 0.0 106.123 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' CYS . . . . . 0.403 ' HB3' ' OD1' ' A' ' 10' ' ' ASN . 51.6 t -84.52 98.46 10.14 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.656 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.411 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 22.9 t -97.34 118.05 64.9 Favored Pre-proline 0 C--N 1.303 -1.456 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 -178.026 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 4.0 Cg_exo -70.76 129.84 17.16 Favored 'Trans proline' 0 N--CA 1.451 -0.99 0 C-N-CA 122.611 2.207 . . . . 0.0 110.113 177.887 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 85.2 mt -129.3 150.6 75.96 Favored Pre-proline 0 C--N 1.309 -1.154 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.951 -175.525 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -42.49 -67.37 0.12 Allowed 'Trans proline' 0 CA--C 1.545 1.044 0 C-N-CA 124.792 3.661 . . . . 0.0 115.679 -177.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 26.5 p90 -97.8 -23.58 15.82 Favored 'General case' 0 C--N 1.314 -0.975 0 N-CA-C 113.325 0.861 . . . . 0.0 113.325 -174.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 97.4 mt -83.13 -12.11 57.32 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.557 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 84.06 -65.65 4.06 Favored Glycine 0 CA--C 1.501 -0.813 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -178.23 134.79 2.48 Favored Glycine 0 CA--C 1.47 -2.773 0 N-CA-C 108.569 -1.812 . . . . 0.0 108.569 177.36 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.5 m -136.02 153.68 32.45 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.224 0 CA-C-O 121.505 0.669 . . . . 0.0 110.998 -178.517 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.582 ' SG ' HG23 ' A' ' 2' ' ' VAL . 84.1 m -79.15 117.27 20.02 Favored 'General case' 0 C--N 1.291 -1.957 0 CA-C-N 114.503 -1.226 . . . . 0.0 108.833 175.613 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -135.07 130.41 35.53 Favored 'General case' 0 N--CA 1.431 -1.399 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -177.314 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 N--CA 1.432 -1.338 0 O-C-N 123.306 0.378 . . . . 0.0 110.63 178.847 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 22.2 p . . . . . 0 N--CA 1.446 -0.673 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.572 HG23 ' SG ' ' A' ' 33' ' ' CYS . 15.7 m -101.29 163.22 3.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-O 121.17 0.51 . . . . 0.0 111.511 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 23.9 mt -107.88 179.99 4.06 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.454 -0.793 . . . . 0.0 111.108 -172.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 24.3 pt -55.11 134.34 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.42 -17.85 41.12 Favored Glycine 0 C--O 1.242 0.614 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.937 177.757 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.7 mt-30 -81.54 159.72 24.06 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.133 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.458 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 40.5 ttp180 -85.78 129.0 34.95 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.269 -173.802 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 30.3 p -128.17 172.43 11.01 Favored 'General case' 0 C--N 1.291 -1.949 0 CA-C-O 121.294 0.569 . . . . 0.0 110.677 -177.22 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -147.12 118.97 8.09 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 175.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -58.22 -42.03 85.4 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 124.192 0.997 . . . . 0.0 113.113 -173.241 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -91.93 -56.63 3.01 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -175.412 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -83.15 -31.0 27.42 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-O 121.133 0.492 . . . . 0.0 112.024 -171.046 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 104.85 165.0 24.16 Favored Glycine 0 N--CA 1.427 -1.906 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 -176.331 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -76.25 156.76 98.41 Favored 'Cis proline' 0 C--N 1.329 -0.468 0 C-N-CA 123.382 -1.507 . . . . 0.0 112.122 0.488 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 82.1 mtt180 -108.03 156.35 19.35 Favored 'General case' 0 C--N 1.289 -2.04 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.56 -179.346 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 58.8 m -76.23 144.03 40.65 Favored 'General case' 0 C--N 1.29 -1.99 0 C-N-CA 124.06 0.944 . . . . 0.0 110.79 -176.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.441 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 59.2 m -67.42 161.51 25.12 Favored 'General case' 0 C--O 1.243 0.743 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.543 177.617 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 37.6 t -46.96 -56.21 6.77 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.065 0.946 . . . . 0.0 113.414 -174.094 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -95.19 27.22 15.79 Favored Glycine 0 C--N 1.314 -0.672 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.825 -176.26 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.441 ' CG ' ' HB2' ' A' ' 17' ' ' CYS . 84.9 mm-40 -110.84 29.69 7.53 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-O 121.337 0.589 . . . . 0.0 110.707 -178.556 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.414 ' CA ' ' HB ' ' A' ' 35' ' ' VAL . . . 85.51 -140.5 18.2 Favored Glycine 0 N--CA 1.43 -1.712 0 C-N-CA 120.365 -0.921 . . . . 0.0 112.874 177.528 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -133.8 155.87 49.04 Favored 'General case' 0 C--N 1.287 -2.142 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 176.294 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 52.5 t -83.06 100.83 10.74 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.244 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.409 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 7.4 p -98.0 120.07 60.78 Favored Pre-proline 0 N--CA 1.419 -2.021 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.62 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 10.1 Cg_exo -69.42 139.9 42.57 Favored 'Trans proline' 0 N--CA 1.45 -1.034 0 C-N-CA 122.076 1.851 . . . . 0.0 112.62 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 11.0 mp -119.49 134.92 23.81 Favored Pre-proline 0 C--N 1.304 -1.41 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.468 179.733 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_exo -39.93 -54.18 2.16 Favored 'Trans proline' 0 C--N 1.356 0.965 0 C-N-CA 124.58 3.52 . . . . 0.0 115.483 -175.464 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 75.5 m-85 -99.43 -40.88 7.66 Favored 'General case' 0 CA--C 1.504 -0.799 0 CA-C-O 121.079 0.466 . . . . 0.0 111.038 -178.152 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 14.0 mt -75.65 -14.58 60.37 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.872 -0.604 . . . . 0.0 112.594 -170.009 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.73 -64.53 0.75 Allowed Glycine 0 CA--C 1.486 -1.765 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 -179.619 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.458 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . 174.33 156.35 13.65 Favored Glycine 0 N--CA 1.425 -2.083 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 178.013 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.4 m -139.06 152.76 24.17 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-O 121.248 0.547 . . . . 0.0 109.925 177.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.572 ' SG ' HG23 ' A' ' 2' ' ' VAL . 60.4 m -82.55 125.01 30.65 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 115.426 -0.807 . . . . 0.0 108.964 176.751 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -146.82 135.74 22.34 Favored 'General case' 0 N--CA 1.439 -0.998 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.267 -176.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.414 ' HB ' ' CA ' ' A' ' 21' ' ' GLY . 7.7 p . . . . . 0 C--N 1.301 -1.542 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 178.49 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 25.8 p . . . . . 0 C--O 1.24 0.59 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.497 HG23 ' SG ' ' A' ' 33' ' ' CYS . 30.1 m -103.84 168.68 2.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 120.902 0.382 . . . . 0.0 110.878 -179.508 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.401 ' HB2' ' OE1' ' A' ' 6' ' ' GLN . 24.8 mt -109.12 -179.48 3.86 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.771 -0.649 . . . . 0.0 109.695 -175.784 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.7 pt -57.68 134.02 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-O 121.643 0.735 . . . . 0.0 112.87 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 95.71 -23.99 31.58 Favored Glycine 0 N--CA 1.442 -0.945 0 CA-C-N 115.175 -0.92 . . . . 0.0 112.303 178.539 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.401 ' OE1' ' HB2' ' A' ' 3' ' ' LEU . 36.2 mt-30 -83.09 152.65 25.24 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 16.5 ptm180 -87.0 145.39 26.52 Favored 'General case' 0 C--N 1.297 -1.694 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.309 -176.402 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.441 ' HB2' ' O ' ' A' ' 14' ' ' PRO . 15.7 p -144.3 176.26 9.48 Favored 'General case' 0 C--N 1.285 -2.21 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.983 -174.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -145.0 116.78 8.2 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 177.64 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -62.32 -32.67 73.46 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 112.968 0.729 . . . . 0.0 112.968 -178.459 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -82.63 -56.59 3.77 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 121.186 0.517 . . . . 0.0 111.523 -172.597 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 77.5 mtm180 -96.95 -20.23 18.24 Favored 'General case' 0 C--N 1.295 -1.778 0 CA-C-N 115.614 -0.721 . . . . 0.0 112.788 -172.172 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 94.36 162.55 35.34 Favored Glycine 0 N--CA 1.43 -1.738 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -177.046 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.441 ' O ' ' HB2' ' A' ' 8' ' ' CYS . 97.9 Cg_endo -85.26 167.53 53.0 Favored 'Cis proline' 0 C--N 1.326 -0.649 0 CA-C-N 119.272 1.536 . . . . 0.0 110.979 0.254 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -115.94 178.33 4.35 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 175.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 32.7 m -68.12 146.12 53.74 Favored 'General case' 0 C--N 1.293 -1.881 0 C-N-CA 123.277 0.631 . . . . 0.0 110.884 178.731 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 71.3 m -70.89 154.9 41.42 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 171.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.7 t -60.68 113.31 2.4 Favored 'General case' 0 N--CA 1.436 -1.128 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 106.48 0.2 37.36 Favored Glycine 0 N--CA 1.441 -0.982 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.555 -178.657 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 86.3 mm-40 -107.93 33.86 3.87 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.168 0.509 . . . . 0.0 110.93 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 80.7 -140.35 21.67 Favored Glycine 0 N--CA 1.428 -1.867 0 C-N-CA 120.131 -1.033 . . . . 0.0 113.241 177.539 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 52.9 t30 -151.32 159.92 44.06 Favored 'General case' 0 C--N 1.288 -2.097 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 92.3 m -72.08 97.76 1.97 Allowed 'General case' 0 C--N 1.308 -1.199 0 O-C-N 123.884 0.74 . . . . 0.0 109.192 176.361 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.3 t -96.52 126.9 41.76 Favored Pre-proline 0 N--CA 1.42 -1.946 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 179.223 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_exo -58.84 127.0 22.79 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 122.764 2.309 . . . . 0.0 112.627 -177.659 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.441 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 47.5 tp -118.02 131.91 23.95 Favored Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 179.384 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 6.9 Cg_exo -74.38 45.6 1.24 Allowed 'Trans proline' 0 N--CA 1.482 0.809 0 C-N-CA 123.636 2.891 . . . . 0.0 113.17 -176.61 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -148.98 -69.63 0.21 Allowed 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 124.143 0.977 . . . . 0.0 109.3 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 25.6 mt -95.66 1.53 53.6 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 114.285 -1.325 . . . . 0.0 111.516 -170.837 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.63 -77.14 0.63 Allowed Glycine 0 N--CA 1.435 -1.404 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.539 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -146.45 139.2 7.9 Favored Glycine 0 C--N 1.29 -2.015 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.051 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.8 m -134.38 157.09 41.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 178.693 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.497 ' SG ' HG23 ' A' ' 2' ' ' VAL . 81.4 m -73.78 124.54 26.26 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.103 179.622 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -144.5 143.24 30.75 Favored 'General case' 0 N--CA 1.425 -1.69 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.2 m . . . . . 0 C--N 1.301 -1.512 0 O-C-N 123.789 0.68 . . . . 0.0 111.124 178.767 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 19.9 p . . . . . 0 C--O 1.241 0.647 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.603 HG23 ' SG ' ' A' ' 33' ' ' CYS . 15.1 m -109.72 157.53 10.15 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.656 0 CA-C-O 121.131 0.491 . . . . 0.0 111.458 176.333 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 18.4 mt -111.98 179.34 4.03 Favored 'General case' 0 N--CA 1.432 -1.357 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.069 -172.747 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 23.7 pt -54.1 133.46 17.11 Favored 'Isoleucine or valine' 0 C--O 1.239 0.545 0 CA-C-O 121.76 0.791 . . . . 0.0 112.88 -179.513 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.57 -9.08 72.4 Favored Glycine 0 C--N 1.309 -0.954 0 CA-C-N 115.375 -0.83 . . . . 0.0 113.04 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 75.7 mt-30 -94.47 156.47 16.45 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 176.741 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.403 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 18.1 ptp180 -85.81 145.72 27.09 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-O 121.139 0.495 . . . . 0.0 111.504 -174.156 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.447 ' SG ' ' HA ' ' A' ' 15' ' ' ARG . 3.8 t -137.21 159.72 41.09 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.819 -1.082 . . . . 0.0 112.324 -172.791 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -150.86 117.54 5.79 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 113.277 -1.783 . . . . 0.0 107.062 176.137 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 48.2 m-80 -63.72 -43.04 97.71 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 113.671 0.989 . . . . 0.0 113.671 -173.278 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 17.4 m-20 -92.46 -35.88 13.4 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 113.678 0.992 . . . . 0.0 113.678 -174.474 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 54.8 mtm180 -100.99 -14.86 17.68 Favored 'General case' 0 C--N 1.309 -1.176 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -174.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.77 155.98 29.55 Favored Glycine 0 N--CA 1.442 -0.932 0 N-CA-C 111.081 -0.807 . . . . 0.0 111.081 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -84.91 159.33 66.08 Favored 'Cis proline' 0 CA--C 1.535 0.546 0 CA-C-N 119.206 1.503 . . . . 0.0 111.883 0.397 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.447 ' HA ' ' SG ' ' A' ' 8' ' ' CYS . 39.7 mtm180 -112.21 155.27 24.26 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-O 120.89 0.376 . . . . 0.0 110.083 -178.776 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.445 ' HA ' ' O ' ' A' ' 2' ' ' VAL . 36.8 m -78.02 142.01 38.52 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 123.882 0.873 . . . . 0.0 110.533 -176.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 m -67.05 153.37 43.82 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 119.144 -1.022 . . . . 0.0 111.312 172.006 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 12.3 p -48.74 -46.65 41.29 Favored 'General case' 0 C--O 1.241 0.622 0 N-CA-C 114.229 1.196 . . . . 0.0 114.229 -173.189 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -90.63 11.79 70.56 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.448 -0.882 . . . . 0.0 112.703 -179.236 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 78.7 mm-40 -105.28 37.19 2.25 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.276 0.56 . . . . 0.0 111.716 -178.001 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.48 -158.92 30.32 Favored Glycine 0 N--CA 1.423 -2.205 0 C-N-CA 120.091 -1.052 . . . . 0.0 112.32 177.02 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 -122.18 149.44 43.63 Favored 'General case' 0 C--N 1.282 -2.35 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 49.1 t -84.02 97.33 9.23 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.002 -1.111 . . . . 0.0 108.002 179.218 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.6 p -104.82 124.88 35.37 Favored Pre-proline 0 C--N 1.305 -1.34 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.52 -177.885 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -67.07 141.74 58.93 Favored 'Trans proline' 0 C--O 1.243 0.762 0 C-N-CA 122.645 2.23 . . . . 0.0 112.951 -176.7 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 87.9 mt -122.21 148.63 52.57 Favored Pre-proline 0 C--N 1.309 -1.181 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.601 -178.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo -49.29 -64.22 0.24 Allowed 'Trans proline' 0 CA--C 1.545 1.072 0 C-N-CA 123.715 2.943 . . . . 0.0 114.394 -178.198 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -97.16 -40.36 8.84 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.947 0.403 . . . . 0.0 110.987 -174.5 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 9.2 mp -78.98 0.74 26.38 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 113.737 1.014 . . . . 0.0 113.737 -174.681 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 86.28 -65.33 3.86 Favored Glycine 0 CA--C 1.501 -0.803 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.081 176.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.403 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -176.35 160.43 28.11 Favored Glycine 0 CA--C 1.477 -2.323 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 8.8 p -142.76 157.63 18.39 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 CA-C-N 117.73 0.765 . . . . 0.0 109.922 -178.265 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.603 ' SG ' HG23 ' A' ' 2' ' ' VAL . 59.9 m -88.0 108.73 19.36 Favored 'General case' 0 C--N 1.278 -2.514 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 174.547 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -149.88 163.84 36.97 Favored 'General case' 0 N--CA 1.435 -1.182 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 -175.28 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.9 p . . . . . 0 C--N 1.293 -1.852 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.653 178.786 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.4 p . . . . . 0 C--O 1.243 0.722 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 19.0 m -109.11 168.61 3.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 120.813 0.34 . . . . 0.0 111.147 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 29.3 mt -108.02 -176.24 3.0 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.327 -175.549 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 21.9 pt -56.78 138.83 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 N-CA-C 112.695 0.628 . . . . 0.0 112.695 179.755 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.29 -20.11 19.12 Favored Glycine 0 CA--C 1.506 -0.476 0 CA-C-N 115.707 -0.678 . . . . 0.0 112.694 178.682 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -80.5 153.73 27.98 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-O 121.252 0.549 . . . . 0.0 109.892 -179.259 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 4.2 tmt_? -86.31 130.14 34.61 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 114.657 -1.156 . . . . 0.0 109.038 -173.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.4 ' HB2' ' O ' ' A' ' 14' ' ' PRO . 27.8 p -130.29 170.67 13.82 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.242 -176.745 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -147.42 124.59 11.47 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 177.182 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 14.6 m120 -71.56 -35.88 70.75 Favored 'General case' 0 C--N 1.298 -1.662 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.424 -175.238 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -76.3 -56.86 4.25 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.637 -0.71 . . . . 0.0 112.146 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 74.1 mtm180 -93.8 -21.3 19.38 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 115.872 -0.604 . . . . 0.0 112.511 -173.48 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 94.74 163.45 35.24 Favored Glycine 0 N--CA 1.427 -1.947 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -175.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.4 ' O ' ' HB2' ' A' ' 8' ' ' CYS . 89.7 Cg_endo -89.86 165.68 34.52 Favored 'Cis proline' 0 N--CA 1.451 -0.998 0 C-N-CA 123.353 -1.52 . . . . 0.0 110.76 -1.184 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 69.8 mtm180 -106.86 179.43 4.27 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 176.139 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 26.4 m -73.42 140.75 46.76 Favored 'General case' 0 C--N 1.293 -1.856 0 C-N-CA 122.914 0.486 . . . . 0.0 109.963 -179.085 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 60.9 m -67.83 155.03 40.25 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 173.25 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 29.1 t -60.98 113.5 2.57 Favored 'General case' 0 C--O 1.246 0.899 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 -178.504 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 102.36 14.39 28.21 Favored Glycine 0 N--CA 1.435 -1.389 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.657 -178.472 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.45 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 83.9 mm-40 -116.8 28.85 8.28 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 -178.421 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.33 -163.11 35.54 Favored Glycine 0 N--CA 1.433 -1.553 0 C-N-CA 119.689 -1.243 . . . . 0.0 111.756 178.529 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 52.8 m-80 -130.43 152.05 50.25 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 107.756 -1.202 . . . . 0.0 107.756 179.166 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 63.1 m -66.95 98.1 0.53 Allowed 'General case' 0 N--CA 1.439 -1.007 0 O-C-N 124.04 0.837 . . . . 0.0 110.713 176.809 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.4 m -92.99 111.81 53.19 Favored Pre-proline 0 N--CA 1.411 -2.378 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 175.449 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.37 141.4 31.78 Favored 'Trans proline' 0 N--CA 1.44 -1.634 0 C-N-CA 122.069 1.846 . . . . 0.0 112.977 -173.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 91.8 mt -137.3 117.34 10.47 Favored Pre-proline 0 C--N 1.292 -1.928 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -72.15 51.03 1.63 Allowed 'Trans proline' 0 N--CA 1.485 0.984 0 C-N-CA 124.393 3.395 . . . . 0.0 113.969 -171.794 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 70.8 m-85 -143.83 -60.51 0.4 Allowed 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.638 ' H ' HD23 ' A' ' 29' ' ' LEU . 2.1 pt? -106.95 0.22 23.6 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.922 -178.208 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 109.46 -76.76 0.22 Allowed Glycine 0 C--N 1.306 -1.123 0 C-N-CA 120.399 -0.905 . . . . 0.0 111.755 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 177.27 159.56 22.63 Favored Glycine 0 N--CA 1.425 -2.057 0 N-CA-C 109.984 -1.247 . . . . 0.0 109.984 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.2 m -133.9 157.14 41.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-O 120.927 0.394 . . . . 0.0 110.697 -179.118 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.45 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 86.3 m -83.67 108.63 16.87 Favored 'General case' 0 C--N 1.296 -1.74 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.77 176.519 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -141.45 155.38 45.86 Favored 'General case' 0 N--CA 1.429 -1.518 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 -178.662 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 49.0 t . . . . . 0 C--N 1.3 -1.572 0 N-CA-C 108.293 -1.002 . . . . 0.0 108.293 177.326 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 29.6 p . . . . . 0 CA--C 1.519 -0.246 0 N-CA-C 110.078 -0.341 . . . . 0.0 110.078 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.425 HG23 ' SG ' ' A' ' 33' ' ' CYS . 16.6 m -107.95 168.37 3.42 Favored 'Isoleucine or valine' 0 C--O 1.243 0.743 0 CA-C-O 121.113 0.482 . . . . 0.0 110.946 178.467 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 29.2 mt -108.2 178.54 4.47 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.185 -173.805 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.506 ' HA ' ' HB2' ' A' ' 33' ' ' CYS . 26.9 pt -59.49 136.27 23.25 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.131 177.073 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.99 -13.45 59.4 Favored Glycine 0 C--N 1.311 -0.856 0 CA-C-N 115.843 -0.617 . . . . 0.0 112.596 178.812 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.455 ' O ' ' HA ' ' A' ' 32' ' ' VAL . 89.9 mt-30 -92.09 159.7 15.56 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 179.582 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.597 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 41.9 ttm180 -85.34 124.61 32.15 Favored 'General case' 0 C--N 1.317 -0.839 0 O-C-N 123.729 0.643 . . . . 0.0 110.805 -175.266 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 23.6 p -123.34 176.26 6.23 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.795 -177.285 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -145.81 125.63 13.49 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 174.451 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 47.3 m-80 -71.78 -30.0 65.08 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 113.339 0.866 . . . . 0.0 113.339 -175.673 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -91.37 -47.1 7.66 Favored 'General case' 0 C--N 1.295 -1.761 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 -172.549 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 51.0 mtp180 -106.1 -23.1 12.7 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 112.593 0.59 . . . . 0.0 112.593 -176.065 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 98.96 169.7 30.94 Favored Glycine 0 N--CA 1.431 -1.689 0 C-N-CA 119.825 -1.179 . . . . 0.0 110.479 -176.373 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -72.49 152.39 97.51 Favored 'Cis proline' 0 C--N 1.333 -0.258 0 CA-C-N 119.474 1.637 . . . . 0.0 112.32 1.515 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 73.1 mtt180 -105.89 160.77 15.0 Favored 'General case' 0 C--N 1.289 -2.06 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.263 -179.16 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.0 m -69.81 143.32 52.95 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 123.665 0.786 . . . . 0.0 110.953 -177.438 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 85.2 m -63.3 155.78 27.61 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 176.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.7 m -63.57 106.13 0.9 Allowed 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -179.478 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 101.6 29.61 6.19 Favored Glycine 0 N--CA 1.439 -1.142 0 N-CA-C 110.687 -0.965 . . . . 0.0 110.687 -176.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.405 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 23.0 mm-40 -126.7 36.01 4.53 Favored 'General case' 0 CA--C 1.496 -1.098 0 CA-C-O 121.26 0.553 . . . . 0.0 111.506 178.698 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 76.14 -163.32 53.09 Favored Glycine 0 N--CA 1.42 -2.375 0 C-N-CA 120.469 -0.872 . . . . 0.0 113.138 178.299 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -110.45 145.49 37.55 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 177.444 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 50.3 t -75.69 98.02 3.97 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 176.539 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.441 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 20.8 t -98.87 126.51 38.3 Favored Pre-proline 0 N--CA 1.427 -1.604 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 -176.725 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 7.8 Cg_exo -72.94 126.45 11.28 Favored 'Trans proline' 0 N--CA 1.45 -1.071 0 C-N-CA 122.714 2.276 . . . . 0.0 112.296 178.468 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.487 HD13 HG22 ' A' ' 32' ' ' VAL . 10.6 mp -121.63 119.79 29.02 Favored Pre-proline 0 C--N 1.306 -1.315 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 176.373 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_exo -37.62 -49.69 1.9 Allowed 'Trans proline' 0 CA--C 1.553 1.438 0 C-N-CA 124.634 3.556 . . . . 0.0 116.673 -174.381 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -89.64 -26.34 20.8 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 120.151 -0.619 . . . . 0.0 112.228 -176.142 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -94.91 -4.88 46.06 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 121.464 0.65 . . . . 0.0 110.793 -174.705 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 84.53 -77.65 2.09 Favored Glycine 0 N--CA 1.431 -1.699 0 N-CA-C 109.109 -1.597 . . . . 0.0 109.109 -178.21 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -168.64 138.2 4.98 Favored Glycine 0 N--CA 1.413 -2.864 0 N-CA-C 107.816 -2.114 . . . . 0.0 107.816 178.258 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.487 HG22 HD13 ' A' ' 26' ' ' LEU . 35.9 m -134.8 146.95 29.83 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 CA-C-O 121.251 0.548 . . . . 0.0 109.796 -178.509 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.506 ' HB2' ' HA ' ' A' ' 4' ' ' ILE . 81.1 m -72.81 124.69 25.88 Favored 'General case' 0 C--N 1.294 -1.841 0 CA-C-N 115.305 -0.862 . . . . 0.0 109.138 176.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -142.19 133.94 26.98 Favored 'General case' 0 N--CA 1.425 -1.702 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 -176.031 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.7 m . . . . . 0 C--N 1.306 -1.318 0 O-C-N 123.54 0.525 . . . . 0.0 110.72 179.82 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.4 p . . . . . 0 N--CA 1.452 -0.332 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.554 HG23 ' SG ' ' A' ' 33' ' ' CYS . 19.6 m -107.58 162.82 5.72 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.876 0 CA-C-O 121.188 0.518 . . . . 0.0 112.076 -176.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.402 ' O ' ' HB2' ' A' ' 6' ' ' GLN . 16.4 mt -106.98 -177.11 3.27 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.145 -174.528 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 37.7 pt -59.65 139.42 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 N-CA-C 112.483 0.549 . . . . 0.0 112.483 -178.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 83.25 -16.74 27.37 Favored Glycine 0 C--N 1.316 -0.542 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.626 179.599 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.402 ' HB2' ' O ' ' A' ' 3' ' ' LEU . 78.2 mt-30 -82.02 156.83 24.44 Favored 'General case' 0 N--CA 1.428 -1.53 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 178.802 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.479 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 43.5 ttp180 -85.94 129.61 34.79 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-N 114.618 -1.173 . . . . 0.0 110.451 -173.185 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 24.6 p -126.35 176.16 7.32 Favored 'General case' 0 C--N 1.284 -2.26 0 CA-C-N 115.296 -0.866 . . . . 0.0 110.138 -177.54 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -146.76 123.09 10.95 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 105.896 -1.89 . . . . 0.0 105.896 173.592 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 18.7 m120 -58.44 -45.73 87.96 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.645 -1.162 . . . . 0.0 112.611 -173.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -92.65 -52.89 4.42 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -175.469 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -85.72 -24.99 26.72 Favored 'General case' 0 C--N 1.315 -0.9 0 C-N-CA 120.1 -0.64 . . . . 0.0 112.563 -173.507 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 98.18 169.75 32.01 Favored Glycine 0 N--CA 1.43 -1.743 0 C-N-CA 120.135 -1.031 . . . . 0.0 111.291 -177.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -74.57 164.0 89.1 Favored 'Cis proline' 0 C--N 1.332 -0.334 0 C-N-CA 123.342 -1.524 . . . . 0.0 112.351 0.433 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 77.0 mtt180 -117.7 164.26 15.24 Favored 'General case' 0 C--N 1.292 -1.895 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.076 -178.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.417 ' HA ' ' O ' ' A' ' 2' ' ' VAL . 28.0 m -71.16 140.72 50.63 Favored 'General case' 0 C--N 1.289 -2.038 0 C-N-CA 123.829 0.852 . . . . 0.0 110.192 -177.348 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.429 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 59.0 m -67.26 151.98 46.54 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 176.817 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.3 t -67.15 103.66 1.26 Allowed 'General case' 0 N--CA 1.439 -1.005 0 C-N-CA 123.424 0.69 . . . . 0.0 109.181 -177.768 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 122.92 -12.3 8.67 Favored Glycine 0 N--CA 1.437 -1.267 0 N-CA-C 110.429 -1.068 . . . . 0.0 110.429 -177.384 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.429 ' CG ' ' HB2' ' A' ' 17' ' ' CYS . 84.2 mm-40 -85.78 -45.12 11.91 Favored 'General case' 0 CA--C 1.5 -0.96 0 CA-C-N 115.46 -0.37 . . . . 0.0 110.353 178.661 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 152.71 -161.62 29.61 Favored Glycine 0 N--CA 1.419 -2.45 0 C-N-CA 119.079 -1.534 . . . . 0.0 113.019 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -112.36 147.43 36.4 Favored 'General case' 0 C--N 1.279 -2.475 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 178.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 53.0 t -82.0 105.98 13.55 Favored 'General case' 0 C--N 1.294 -1.83 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.129 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -92.53 117.04 67.45 Favored Pre-proline 0 C--N 1.311 -1.078 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 176.184 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -74.36 148.25 38.13 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 122.025 1.817 . . . . 0.0 114.114 -174.774 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 8.1 mp -126.28 132.39 24.3 Favored Pre-proline 0 C--N 1.308 -1.198 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 176.573 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_exo -39.0 -57.2 1.01 Allowed 'Trans proline' 0 CA--C 1.543 0.933 0 C-N-CA 124.611 3.541 . . . . 0.0 115.299 -175.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -93.43 -46.4 7.35 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-O 121.801 0.81 . . . . 0.0 110.327 -178.697 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 26.7 mt -77.15 0.52 21.36 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 114.339 -1.3 . . . . 0.0 113.189 -167.439 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 87.03 -65.79 3.65 Favored Glycine 0 CA--C 1.492 -1.345 0 N-CA-C 112.201 -0.36 . . . . 0.0 112.201 175.069 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.479 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . 165.02 162.75 16.77 Favored Glycine 0 N--CA 1.412 -2.944 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.8 m -135.46 147.64 28.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 177.462 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.554 ' SG ' HG23 ' A' ' 2' ' ' VAL . 94.7 m -80.42 131.47 35.6 Favored 'General case' 0 C--N 1.293 -1.856 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.692 177.24 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.61 168.61 26.59 Favored 'General case' 0 N--CA 1.427 -1.596 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 -178.095 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 4.1 p . . . . . 0 C--O 1.259 1.586 0 C-N-CA 123.919 0.888 . . . . 0.0 113.101 -178.925 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 22.3 p . . . . . 0 N--CA 1.447 -0.606 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.569 HG23 ' SG ' ' A' ' 16' ' ' CYS . 23.8 m -94.15 178.42 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.594 -0.276 . . . . 0.0 110.586 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 27.3 mt -117.84 -176.01 2.95 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 112.667 0.617 . . . . 0.0 112.667 -172.669 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.532 HG13 ' OE1' ' A' ' 20' ' ' GLN . 66.4 mt -56.6 135.88 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 123.714 0.806 . . . . 0.0 110.764 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.04 -6.85 73.4 Favored Glycine 0 C--N 1.313 -0.704 0 C-N-CA 121.447 -0.406 . . . . 0.0 112.693 177.29 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -94.14 150.55 20.22 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 178.038 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.2 tmm_? -86.76 129.7 34.77 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.5 -172.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 18.5 p -128.33 175.45 8.48 Favored 'General case' 0 C--N 1.297 -1.694 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.175 -175.766 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -152.9 121.51 6.4 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 106.161 -1.792 . . . . 0.0 106.161 174.456 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -72.17 -26.27 62.01 Favored 'General case' 0 C--N 1.294 -1.843 0 CA-C-O 120.832 0.349 . . . . 0.0 111.091 -174.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -78.74 -56.8 4.14 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.788 -176.724 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 26.9 mmm180 -106.53 -9.61 16.55 Favored 'General case' 0 C--N 1.312 -1.043 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -174.216 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 90.64 165.51 40.39 Favored Glycine 0 C--N 1.297 -1.622 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -177.422 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -81.39 170.87 60.26 Favored 'Cis proline' 0 CA--C 1.534 0.486 0 C-N-CA 123.385 -1.506 . . . . 0.0 111.831 0.314 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 78.7 mtm180 -122.76 152.12 40.94 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.14 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.569 ' SG ' HG23 ' A' ' 2' ' ' VAL . 57.9 m -86.01 158.67 19.8 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.068 -176.345 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.445 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 26.4 m -67.28 153.81 42.79 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 178.295 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.7 m -46.86 -45.59 20.41 Favored 'General case' 0 CA--C 1.56 1.334 0 N-CA-C 115.188 1.551 . . . . 0.0 115.188 -172.356 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -97.0 22.01 43.06 Favored Glycine 0 C--N 1.318 -0.472 0 C-N-CA 120.501 -0.857 . . . . 0.0 112.559 -178.582 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.532 ' OE1' HG13 ' A' ' 4' ' ' ILE . 85.9 mm-40 -105.28 23.28 13.96 Favored 'General case' 0 C--N 1.311 -1.1 0 O-C-N 122.648 -0.324 . . . . 0.0 111.692 -178.602 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 92.65 -177.42 38.88 Favored Glycine 0 N--CA 1.43 -1.7 0 C-N-CA 120.451 -0.881 . . . . 0.0 112.774 177.154 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 33' ' ' CYS . 35.3 t30 -119.16 143.8 47.03 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 179.135 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 92.2 m -63.38 102.04 0.37 Allowed 'General case' 0 C--N 1.316 -0.872 0 O-C-N 123.871 0.732 . . . . 0.0 110.535 178.103 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.7 m -110.1 137.23 20.49 Favored Pre-proline 0 N--CA 1.421 -1.924 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 177.607 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -67.91 120.85 7.85 Favored 'Trans proline' 0 N--CA 1.448 -1.184 0 C-N-CA 121.699 1.6 . . . . 0.0 112.14 -178.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.41 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 56.5 tp -115.98 104.99 51.91 Favored Pre-proline 0 N--CA 1.42 -1.964 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 176.131 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 18.3 Cg_exo -70.78 56.15 1.79 Allowed 'Trans proline' 0 N--CA 1.479 0.653 0 C-N-CA 124.056 3.171 . . . . 0.0 113.219 -175.53 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -148.06 -63.54 0.26 Allowed 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 125.294 1.438 . . . . 0.0 108.09 179.389 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -104.03 -19.38 14.22 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.518 -179.069 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 121.76 -165.01 14.73 Favored Glycine 0 C--N 1.305 -1.167 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -177.469 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -72.91 125.43 9.82 Favored Glycine 0 CA--C 1.49 -1.481 0 C-N-CA 119.986 -1.102 . . . . 0.0 110.356 177.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 33.2 m -127.62 153.14 36.55 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.327 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -176.733 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.478 ' HA ' ' O ' ' A' ' 22' ' ' ASN . 74.1 m -85.84 116.55 24.16 Favored 'General case' 0 C--N 1.284 -2.246 0 C-N-CA 119.718 -0.793 . . . . 0.0 111.25 178.302 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.54 168.51 22.54 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.256 179.738 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.1 t . . . . . 0 C--N 1.307 -1.255 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 176.507 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.5 p . . . . . 0 C--O 1.244 0.808 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.405 HG23 ' SG ' ' A' ' 33' ' ' CYS . 27.9 m -116.35 159.44 16.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-O 120.916 0.389 . . . . 0.0 111.243 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 67.8 mt -105.41 -177.83 3.48 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 115.58 -0.737 . . . . 0.0 111.01 -175.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.5 pt -56.05 137.34 17.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 178.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.15 -14.42 60.79 Favored Glycine 0 C--N 1.316 -0.543 0 CA-C-N 115.761 -0.654 . . . . 0.0 113.288 177.648 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.438 ' O ' ' HA ' ' A' ' 32' ' ' VAL . 78.0 mt-30 -87.73 162.06 17.26 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-O 121.031 0.443 . . . . 0.0 110.794 -178.453 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.406 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 37.6 ttt180 -84.88 123.59 30.66 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 114.753 -1.112 . . . . 0.0 109.092 -175.603 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -134.88 167.6 20.59 Favored 'General case' 0 C--N 1.294 -1.82 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.038 -176.702 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -146.55 130.54 17.27 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 175.66 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 35.7 m-80 -66.32 -40.33 89.86 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 114.753 -1.112 . . . . 0.0 112.977 -171.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -93.04 -52.01 4.78 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -175.113 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 78.4 mtp180 -84.46 -24.68 29.39 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.29 -173.028 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 99.58 163.17 29.22 Favored Glycine 0 N--CA 1.429 -1.818 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -175.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -81.15 159.73 82.94 Favored 'Cis proline' 0 N--CA 1.446 -1.311 0 CA-C-N 119.662 1.731 . . . . 0.0 111.296 0.267 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -107.94 149.93 27.72 Favored 'General case' 0 C--N 1.291 -1.972 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.017 -178.516 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 45.7 m -65.08 142.45 58.38 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.053 -0.976 . . . . 0.0 108.6 178.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 61.2 m -63.84 144.96 56.64 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 176.621 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.7 p -53.04 86.54 0.0 OUTLIER 'General case' 0 CA--C 1.546 0.818 0 N-CA-C 113.909 1.077 . . . . 0.0 113.909 -176.144 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.6 26.81 1.54 Allowed Glycine 0 N--CA 1.435 -1.392 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.3 -178.372 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 23.1 mm-40 -115.87 30.19 7.5 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.427 0.632 . . . . 0.0 111.87 179.133 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.64 -150.5 24.4 Favored Glycine 0 N--CA 1.425 -2.073 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.402 177.164 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.8 p-10 -130.64 159.35 37.46 Favored 'General case' 0 C--N 1.287 -2.127 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 179.064 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 85.5 m -77.5 99.27 5.61 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 123.572 0.545 . . . . 0.0 109.798 175.694 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 14.6 p -90.22 120.47 69.15 Favored Pre-proline 0 N--CA 1.421 -1.914 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 176.479 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -74.59 134.73 18.94 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 121.982 1.788 . . . . 0.0 113.222 -176.584 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.0 mt -135.94 129.92 18.34 Favored Pre-proline 0 C--N 1.301 -1.513 0 CA-C-N 115.046 -0.979 . . . . 0.0 108.573 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.79 54.23 2.01 Favored 'Trans proline' 0 CA--C 1.536 0.581 0 C-N-CA 124.031 3.154 . . . . 0.0 113.898 -174.236 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -143.06 -66.9 0.37 Allowed 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 178.784 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.618 ' H ' HD23 ' A' ' 29' ' ' LEU . 1.9 pt? -107.45 0.27 22.73 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.496 -0.774 . . . . 0.0 112.369 -178.458 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 109.94 -86.88 0.45 Allowed Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.393 -0.908 . . . . 0.0 111.39 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.406 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -152.54 148.83 20.19 Favored Glycine 0 CA--C 1.49 -1.518 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.438 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 28.4 m -128.79 145.79 35.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 120.834 0.349 . . . . 0.0 111.439 -178.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.405 ' SG ' HG23 ' A' ' 2' ' ' VAL . 79.7 m -71.72 121.68 19.31 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 175.598 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -142.33 136.49 29.74 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.025 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 58.1 t . . . . . 0 N--CA 1.438 -1.07 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 177.192 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.4 p . . . . . 0 C--O 1.242 0.694 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.443 HG23 ' SG ' ' A' ' 33' ' ' CYS . 26.1 m -108.87 162.68 6.55 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.166 0.508 . . . . 0.0 111.277 -179.038 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 54.3 mt -105.79 -175.28 2.75 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.737 -175.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.5 pt -58.02 129.03 19.48 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 N-CA-C 113.224 0.824 . . . . 0.0 113.224 -178.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.18 -13.92 65.02 Favored Glycine 0 CA--C 1.503 -0.664 0 CA-C-N 115.639 -0.71 . . . . 0.0 112.681 177.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.42 ' HB2' ' HB ' ' A' ' 2' ' ' VAL . 87.5 mt-30 -88.82 159.72 17.59 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.408 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 62.1 ttt180 -86.02 131.37 34.28 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.827 -173.874 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.7 p -126.2 156.67 39.86 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.813 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -137.38 126.57 24.58 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 176.202 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 46.9 m-80 -78.98 -31.62 44.96 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 120.485 -0.486 . . . . 0.0 111.893 -178.09 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -72.67 -52.86 13.55 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-O 121.097 0.475 . . . . 0.0 111.727 -174.7 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.423 ' HA ' ' NE ' ' A' ' 12' ' ' ARG . 5.4 mmp_? -108.06 -17.58 14.0 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 113.398 0.888 . . . . 0.0 113.398 -176.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 91.26 168.28 41.5 Favored Glycine 0 N--CA 1.432 -1.6 0 C-N-CA 119.842 -1.17 . . . . 0.0 110.502 -177.612 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -79.25 159.9 89.53 Favored 'Cis proline' 0 C--N 1.329 -0.47 0 CA-C-N 119.082 1.441 . . . . 0.0 111.863 -1.143 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 83.0 mtm180 -109.6 177.0 4.87 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 178.514 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.2 m -70.51 144.45 51.35 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.424 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 86.3 m -68.17 145.02 54.73 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 173.585 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.5 t -50.93 99.0 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.236 1.015 . . . . 0.0 112.177 -175.724 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 118.01 -11.33 13.33 Favored Glycine 0 N--CA 1.443 -0.84 0 CA-C-N 115.83 -0.623 . . . . 0.0 112.123 179.3 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.476 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 23.7 mm-40 -86.17 23.55 1.52 Allowed 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 114.674 1.361 . . . . 0.0 114.674 -176.872 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 101.27 -176.63 26.86 Favored Glycine 0 N--CA 1.427 -1.946 0 C-N-CA 119.439 -1.362 . . . . 0.0 113.934 174.441 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 38.4 m-80 -113.4 150.31 32.88 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 179.407 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 89.1 m -74.52 98.18 3.29 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 123.193 0.308 . . . . 0.0 111.101 179.112 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.9 t -82.42 122.24 78.84 Favored Pre-proline 0 C--N 1.303 -1.42 0 N-CA-C 106.279 -1.749 . . . . 0.0 106.279 175.417 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -86.4 121.72 1.98 Allowed 'Trans proline' 0 N--CA 1.439 -1.686 0 C-N-CA 122.66 2.24 . . . . 0.0 113.679 -174.637 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -119.45 148.41 45.56 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 178.011 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_exo -41.19 -69.3 0.08 OUTLIER 'Trans proline' 0 CA--C 1.548 1.198 0 C-N-CA 124.74 3.627 . . . . 0.0 116.037 -175.874 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 24.6 p90 -93.01 -17.66 23.61 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 112.966 0.728 . . . . 0.0 112.966 -173.474 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 96.5 mt -86.64 -13.48 45.49 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.495 179.227 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 81.79 -79.46 1.84 Allowed Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.84 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.408 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -166.34 136.26 4.07 Favored Glycine 0 N--CA 1.426 -1.992 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 179.471 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 36.0 m -126.51 143.44 39.99 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 CA-C-O 120.909 0.385 . . . . 0.0 110.821 -179.006 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.476 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 74.8 m -71.42 114.08 9.12 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.792 178.696 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.43 156.41 42.45 Favored 'General case' 0 C--N 1.315 -0.912 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 178.561 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 39.3 t . . . . . 0 C--O 1.255 1.37 0 C-N-CA 123.684 0.794 . . . . 0.0 110.006 -179.315 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.5 p . . . . . 0 C--O 1.24 0.56 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.435 ' HB ' ' HB2' ' A' ' 6' ' ' GLN . 33.9 m -110.75 164.68 6.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 121.185 0.517 . . . . 0.0 110.866 -178.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 48.4 mt -102.47 -179.22 3.92 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.767 -178.286 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 27.3 pt -59.4 133.19 24.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.126 0.489 . . . . 0.0 112.213 178.446 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.1 -10.26 75.47 Favored Glycine 0 C--N 1.316 -0.536 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.98 178.535 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.435 ' HB2' ' HB ' ' A' ' 2' ' ' VAL . 86.7 mt-30 -94.85 157.53 15.88 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.124 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 2.7 tmm_? -85.96 124.55 32.53 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.367 -173.618 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.46 ' HB2' ' HA ' ' A' ' 15' ' ' ARG . 10.4 p -121.36 165.8 15.01 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.009 179.254 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -125.0 124.93 43.06 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 176.296 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -73.48 -33.43 64.82 Favored 'General case' 0 C--N 1.305 -1.365 0 N-CA-C 112.751 0.649 . . . . 0.0 112.751 -171.562 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -91.17 -50.56 5.77 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 120.542 -0.463 . . . . 0.0 111.928 -175.384 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 58.4 mtp180 -102.18 -8.67 21.14 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -172.177 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.14 168.36 44.57 Favored Glycine 0 C--N 1.31 -0.909 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.491 178.304 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -81.87 166.89 70.91 Favored 'Cis proline' 0 N--CA 1.474 0.327 0 C-N-CA 123.837 -1.318 . . . . 0.0 111.283 -0.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.46 ' HA ' ' HB2' ' A' ' 8' ' ' CYS . 73.4 mtm180 -121.49 -173.79 2.71 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 116.763 -0.199 . . . . 0.0 111.006 178.283 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 33.1 m -60.38 144.46 50.78 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 123.846 0.859 . . . . 0.0 112.142 -178.302 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 74.4 m -71.97 166.23 22.6 Favored 'General case' 0 C--O 1.243 0.731 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 170.541 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.7 t -67.83 109.82 3.55 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.056 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 101.16 26.68 7.71 Favored Glycine 0 N--CA 1.443 -0.886 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 -179.253 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.537 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 86.9 mm-40 -126.06 35.68 4.64 Favored 'General case' 0 C--N 1.318 -0.792 0 O-C-N 122.68 -0.306 . . . . 0.0 111.503 -179.239 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 70.81 -158.59 53.71 Favored Glycine 0 C--O 1.248 0.997 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.407 178.617 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -127.05 158.84 35.91 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 176.887 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 98.4 m -68.66 104.81 2.08 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 121.168 0.509 . . . . 0.0 110.779 178.616 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 59.9 t -91.83 120.06 68.14 Favored Pre-proline 0 N--CA 1.426 -1.647 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 175.608 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_exo -67.51 136.86 40.95 Favored 'Trans proline' 0 N--CA 1.445 -1.37 0 C-N-CA 122.459 2.106 . . . . 0.0 111.858 -179.461 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 24.0 tp -132.49 117.01 15.3 Favored Pre-proline 0 C--N 1.29 -2.017 0 N-CA-C 105.271 -2.122 . . . . 0.0 105.271 176.224 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -63.42 51.61 0.14 Allowed 'Trans proline' 0 N--CA 1.502 1.982 0 C-N-CA 125.029 3.819 . . . . 0.0 116.575 -170.726 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -144.34 -64.39 0.36 Allowed 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 177.531 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.641 ' H ' HD23 ' A' ' 29' ' ' LEU . 1.9 pt? -103.7 -3.4 25.11 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.213 -0.903 . . . . 0.0 112.88 -173.148 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 113.94 -103.91 1.39 Allowed Glycine 0 C--N 1.304 -1.216 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -177.659 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -139.78 152.48 22.63 Favored Glycine 0 N--CA 1.43 -1.724 0 C-N-CA 120.674 -0.774 . . . . 0.0 111.425 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 19.5 m -132.06 139.71 49.63 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.537 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 84.2 m -69.31 128.14 35.53 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.295 179.271 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -164.85 158.36 17.27 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 109.484 -0.562 . . . . 0.0 109.484 -178.894 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.2 t . . . . . 0 C--O 1.252 1.206 0 O-C-N 124.9 1.375 . . . . 0.0 111.603 177.329 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.6 p . . . . . 0 N--CA 1.456 -0.164 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.48 HG23 ' SG ' ' A' ' 33' ' ' CYS . 15.3 m -105.43 164.59 4.05 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-O 121.094 0.473 . . . . 0.0 111.846 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 21.4 mt -107.39 178.84 4.42 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.244 -173.652 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 40.0 pt -57.85 137.35 20.15 Favored 'Isoleucine or valine' 0 C--O 1.24 0.57 0 CA-C-O 121.571 0.7 . . . . 0.0 112.685 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.13 -23.98 24.18 Favored Glycine 0 C--N 1.306 -1.083 0 CA-C-N 115.645 -0.707 . . . . 0.0 112.795 178.661 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 92.3 mt-30 -82.8 155.79 24.01 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -178.316 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.9 tmm_? -85.75 127.18 34.47 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -173.512 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 21.8 p -122.52 172.92 8.02 Favored 'General case' 0 C--N 1.288 -2.107 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.376 -177.109 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -153.35 124.02 7.24 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 177.001 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 -72.96 -37.79 66.98 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 112.64 0.607 . . . . 0.0 112.64 -174.475 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -85.6 -47.3 9.98 Favored 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 120.072 -0.651 . . . . 0.0 112.533 -174.656 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 5.1 mmp_? -93.58 -29.21 15.6 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.891 -0.723 . . . . 0.0 112.196 -177.327 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 103.61 162.45 25.14 Favored Glycine 0 N--CA 1.434 -1.471 0 N-CA-C 109.826 -1.31 . . . . 0.0 109.826 -175.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -82.77 157.59 76.47 Favored 'Cis proline' 0 CA--C 1.535 0.536 0 CA-C-N 119.276 1.538 . . . . 0.0 112.432 1.278 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 63.7 mtm180 -107.23 157.04 18.21 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-O 120.853 0.359 . . . . 0.0 110.054 179.7 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 35.6 m -68.51 142.85 55.15 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 124.19 0.996 . . . . 0.0 110.282 -178.654 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.446 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 54.7 m -67.78 154.4 41.61 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 174.032 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.1 p -54.55 -23.05 15.04 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 115.776 1.769 . . . . 0.0 115.776 -171.196 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -115.83 22.84 11.31 Favored Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 177.483 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.446 ' CG ' ' HB2' ' A' ' 17' ' ' CYS . 86.4 mm-40 -115.56 20.9 14.41 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.254 0.55 . . . . 0.0 110.91 -178.236 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 80.16 -151.6 33.46 Favored Glycine 0 N--CA 1.426 -2.002 0 C-N-CA 120.282 -0.961 . . . . 0.0 113.166 176.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -135.88 168.57 19.07 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 77.6 m -74.74 124.72 27.3 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 123.648 0.592 . . . . 0.0 111.234 -179.182 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 22.0 t -106.25 116.52 59.22 Favored Pre-proline 0 C--N 1.291 -1.954 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 173.083 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.427 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 56.4 Cg_endo -80.72 125.01 5.34 Favored 'Trans proline' 0 N--CA 1.445 -1.371 0 C-N-CA 122.583 2.188 . . . . 0.0 112.953 -175.702 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.405 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 4.1 pp -118.72 153.96 52.52 Favored Pre-proline 0 C--N 1.302 -1.47 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.23 178.742 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 5.4 Cg_endo -83.54 49.66 2.99 Favored 'Trans proline' 0 C--O 1.236 0.396 0 C-N-CA 123.53 2.82 . . . . 0.0 113.935 -170.912 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -141.48 -77.59 0.28 Allowed 'General case' 0 C--N 1.314 -0.959 0 CA-C-O 120.878 0.37 . . . . 0.0 110.915 179.29 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.468 ' H ' HD13 ' A' ' 29' ' ' LEU . 0.0 OUTLIER -106.85 0.88 24.31 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -177.11 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 116.98 -138.62 14.44 Favored Glycine 0 N--CA 1.437 -1.266 0 C-N-CA 120.371 -0.919 . . . . 0.0 111.206 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.427 ' HA2' ' HA ' ' A' ' 25' ' ' PRO . . . -108.92 149.23 17.0 Favored Glycine 0 N--CA 1.428 -1.841 0 C-N-CA 120.395 -0.907 . . . . 0.0 112.52 -178.849 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.8 m -124.04 146.75 29.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 177.471 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.48 ' SG ' HG23 ' A' ' 2' ' ' VAL . 74.4 m -71.1 136.7 48.35 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.828 179.493 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -160.33 146.06 15.16 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.867 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.7 t . . . . . 0 C--N 1.307 -1.258 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 -179.063 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.5 p . . . . . 0 N--CA 1.443 -0.778 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.451 HG23 ' SG ' ' A' ' 33' ' ' CYS . 35.7 m -102.26 169.19 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-O 121.146 0.498 . . . . 0.0 111.088 -178.427 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 26.0 mt -109.84 -176.11 2.92 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.399 -0.818 . . . . 0.0 110.542 -175.432 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.514 HG13 ' OE1' ' A' ' 20' ' ' GLN . 61.5 mt -56.37 133.25 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 122.681 0.392 . . . . 0.0 111.029 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.26 -15.03 56.09 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 116.024 -0.534 . . . . 0.0 113.057 177.761 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -88.42 159.25 18.09 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 -178.662 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.551 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 85.9 mtm180 -86.63 134.53 33.62 Favored 'General case' 0 CA--C 1.496 -1.098 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.916 -175.523 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.427 ' HB3' ' CG2' ' A' ' 2' ' ' VAL . 24.0 p -139.49 171.34 14.4 Favored 'General case' 0 C--N 1.285 -2.205 0 CA-C-N 114.276 -1.329 . . . . 0.0 109.379 -178.148 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -145.51 125.7 13.8 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 174.427 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 84.7 m-20 -65.79 -32.75 74.46 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -177.308 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -91.16 -52.34 4.87 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -172.558 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 55.3 mtp180 -92.46 -25.91 18.22 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -176.068 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 90.51 167.92 42.07 Favored Glycine 0 N--CA 1.437 -1.288 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -76.78 168.84 76.04 Favored 'Cis proline' 0 N--CA 1.475 0.387 0 CA-C-N 119.669 1.735 . . . . 0.0 110.517 -0.584 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 5.7 mpt_? -116.09 -179.18 3.59 Favored 'General case' 0 C--N 1.291 -1.943 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.267 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.7 m -70.71 148.59 47.82 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 178.161 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 60.9 m -69.85 142.86 53.01 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 106.04 -1.837 . . . . 0.0 106.04 170.526 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.6 m -62.23 99.23 0.13 Allowed 'General case' 0 C--O 1.243 0.749 0 CA-C-O 121.002 0.429 . . . . 0.0 111.111 -175.832 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 128.84 -6.59 6.49 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.204 -176.372 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.514 ' OE1' HG13 ' A' ' 4' ' ' ILE . 84.8 mm-40 -98.42 10.87 39.82 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 -178.478 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.452 ' HA2' ' HB ' ' A' ' 35' ' ' VAL . . . 103.73 -172.44 20.97 Favored Glycine 0 N--CA 1.442 -0.963 0 C-N-CA 120.009 -1.091 . . . . 0.0 113.442 176.138 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 -117.02 147.16 42.57 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 -179.301 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 96.1 m -72.67 102.21 3.26 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 123.884 0.74 . . . . 0.0 112.018 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.2 p -87.23 119.85 71.08 Favored Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 171.299 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -82.97 141.13 10.42 Favored 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 121.987 1.791 . . . . 0.0 114.606 -173.141 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 5.8 mp -122.83 122.97 26.98 Favored Pre-proline 0 C--N 1.3 -1.551 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 177.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_exo -36.34 -54.64 0.88 Allowed 'Trans proline' 0 N--CA 1.485 1.015 0 C-N-CA 124.957 3.772 . . . . 0.0 116.012 -175.398 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -111.05 -15.35 13.74 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 113.75 1.018 . . . . 0.0 113.75 -177.647 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -80.0 -30.13 39.58 Favored 'General case' 0 C--N 1.294 -1.836 0 C-N-CA 120.313 -0.555 . . . . 0.0 112.002 174.521 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 114.73 -99.0 0.9 Allowed Glycine 0 N--CA 1.431 -1.664 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.551 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -171.64 148.62 11.15 Favored Glycine 0 C--N 1.282 -2.471 0 N-CA-C 108.649 -1.78 . . . . 0.0 108.649 178.147 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 31.5 m -130.47 145.91 34.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 CA-C-N 117.928 0.864 . . . . 0.0 111.484 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.451 ' SG ' HG23 ' A' ' 2' ' ' VAL . 71.9 m -76.11 116.74 17.11 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.896 176.904 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -141.56 149.19 40.48 Favored 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -179.783 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.452 ' HB ' ' HA2' ' A' ' 21' ' ' GLY . 4.1 p . . . . . 0 C--N 1.3 -1.544 0 CA-C-O 118.74 -0.647 . . . . 0.0 109.485 177.232 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.0 p . . . . . 0 C--O 1.227 -0.118 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.532 HG23 ' SG ' ' A' ' 33' ' ' CYS . 16.5 m -110.13 161.21 8.68 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -177.54 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 36.0 mt -107.41 -178.96 3.78 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.09 -175.841 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 24.0 pt -61.13 128.81 23.03 Favored 'Isoleucine or valine' 0 C--O 1.238 0.489 0 N-CA-C 113.282 0.845 . . . . 0.0 113.282 -179.337 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.62 -5.35 73.57 Favored Glycine 0 N--CA 1.443 -0.859 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.767 -179.103 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 77.5 mt-30 -101.32 156.01 17.7 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 176.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.401 ' NH1' HD22 ' A' ' 29' ' ' LEU . 54.1 mtm180 -86.03 140.75 30.0 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.727 0.775 . . . . 0.0 112.606 -173.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.415 ' SG ' ' N ' ' A' ' 9' ' ' ASP . 1.6 t -133.16 171.68 13.68 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-N 113.68 -1.6 . . . . 0.0 109.321 -175.16 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.415 ' N ' ' SG ' ' A' ' 8' ' ' CYS . 17.1 t70 -161.86 118.73 2.13 Favored 'General case' 0 C--N 1.276 -2.59 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 172.363 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -57.68 -39.57 77.43 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 113.984 1.105 . . . . 0.0 113.984 -175.536 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -91.13 -47.78 7.33 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -175.856 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 29.1 mmt180 -80.7 -43.0 21.01 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.709 0.766 . . . . 0.0 111.592 -177.012 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 105.46 163.87 23.55 Favored Glycine 0 N--CA 1.425 -2.064 0 N-CA-C 108.337 -1.905 . . . . 0.0 108.337 -172.286 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -79.01 165.85 80.58 Favored 'Cis proline' 0 C--N 1.322 -0.865 0 CA-C-N 119.88 1.84 . . . . 0.0 111.891 -0.002 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 60.5 mtp180 -108.2 153.49 23.11 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 179.412 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 55.9 m -68.01 138.69 56.07 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.548 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 55.9 m -65.93 158.28 28.5 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 178.148 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.8 t -60.89 104.43 0.36 Allowed 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 123.194 0.597 . . . . 0.0 110.343 -179.342 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 108.85 17.35 10.4 Favored Glycine 0 N--CA 1.443 -0.897 0 N-CA-C 111.524 -0.631 . . . . 0.0 111.524 -178.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 83.6 mm-40 -111.18 52.19 0.75 Allowed 'General case' 0 C--N 1.307 -1.243 0 O-C-N 122.038 -0.684 . . . . 0.0 111.591 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 71.03 -143.4 36.15 Favored Glycine 0 N--CA 1.434 -1.492 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.376 178.079 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 46.4 m-80 -128.94 146.12 51.04 Favored 'General case' 0 C--N 1.289 -2.05 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 176.194 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 42.9 t -83.11 97.12 8.63 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.01 -1.107 . . . . 0.0 108.01 179.036 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.0 p -94.37 114.99 64.72 Favored Pre-proline 0 N--CA 1.432 -1.341 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.353 -179.426 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.485 ' HA ' ' CA ' ' A' ' 31' ' ' GLY . 73.9 Cg_endo -76.72 142.15 22.54 Favored 'Trans proline' 0 N--CA 1.449 -1.136 0 C-N-CA 122.557 2.172 . . . . 0.0 113.605 -176.107 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 5.8 mp -116.06 142.4 29.16 Favored Pre-proline 0 N--CA 1.422 -1.867 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 172.704 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_endo -74.57 53.99 3.3 Favored 'Trans proline' 0 C--N 1.326 -0.65 0 C-N-CA 123.164 2.576 . . . . 0.0 113.464 -177.247 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.46 ' HB3' HD12 ' A' ' 29' ' ' LEU . 70.2 m-85 -139.17 -87.51 0.22 Allowed 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 178.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.46 HD12 ' HB3' ' A' ' 28' ' ' PHE . 4.5 mp -104.66 -28.27 11.33 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-O 121.589 0.709 . . . . 0.0 110.47 -176.181 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 167.41 -152.59 21.32 Favored Glycine 0 N--CA 1.418 -2.543 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -179.22 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.485 ' CA ' ' HA ' ' A' ' 25' ' ' PRO . . . -113.42 -172.75 18.36 Favored Glycine 0 N--CA 1.411 -3.033 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.3 p -138.06 152.59 26.22 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.24 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.061 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.532 ' SG ' HG23 ' A' ' 2' ' ' VAL . 63.7 m -89.12 119.43 29.62 Favored 'General case' 0 C--N 1.275 -2.633 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.297 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.04 139.56 24.83 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -176.746 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 C--N 1.306 -1.316 0 CA-C-O 118.867 -0.587 . . . . 0.0 109.978 -179.861 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.7 p . . . . . 0 CA--C 1.513 -0.45 0 N-CA-C 109.29 -0.634 . . . . 0.0 109.29 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.458 ' HB ' ' HB2' ' A' ' 6' ' ' GLN . 33.5 m -103.17 152.53 5.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-O 120.953 0.406 . . . . 0.0 111.076 -177.293 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 52.3 mt -97.68 -174.3 2.86 Favored 'General case' 0 N--CA 1.438 -1.043 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.667 -179.273 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 43.2 pt -59.28 142.06 15.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.059 0.457 . . . . 0.0 111.704 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.59 -26.07 8.67 Favored Glycine 0 C--N 1.311 -0.82 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.26 178.366 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.458 ' HB2' ' HB ' ' A' ' 2' ' ' VAL . 24.1 mt-30 -79.18 152.92 30.42 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -178.552 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 10.2 mpt_? -86.76 136.86 32.84 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.883 -175.799 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.5 p -130.02 168.27 16.98 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.984 -175.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -132.5 123.68 27.06 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.708 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.9 m120 -72.73 -26.59 61.63 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -175.685 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -84.17 -56.55 3.6 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-O 121.228 0.537 . . . . 0.0 111.4 -175.112 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 71.9 mtm180 -105.45 -24.14 12.69 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 -170.339 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 95.48 172.48 36.59 Favored Glycine 0 N--CA 1.426 -1.999 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 -172.744 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -72.21 160.54 93.94 Favored 'Cis proline' 0 C--O 1.235 0.373 0 CA-C-N 119.771 1.785 . . . . 0.0 111.574 -0.218 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 57.8 mtm180 -120.18 176.04 5.65 Favored 'General case' 0 C--N 1.291 -1.959 0 CA-C-N 116.495 -0.321 . . . . 0.0 110.17 179.281 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 20.5 m -68.02 144.45 55.12 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 123.607 0.567 . . . . 0.0 109.494 -178.501 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' CYS . . . . . 0.405 ' HB2' ' HG3' ' A' ' 20' ' ' GLN . 52.9 m -67.9 145.67 54.36 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 105.977 -1.86 . . . . 0.0 105.977 171.333 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 14.6 p -56.43 107.75 0.41 Allowed 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 112.017 0.377 . . . . 0.0 112.017 -177.218 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 115.03 -11.46 20.32 Favored Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.497 -177.789 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.452 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 86.8 mm-40 -91.98 26.61 2.39 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-O 121.321 0.581 . . . . 0.0 111.45 -178.514 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.84 -168.02 37.17 Favored Glycine 0 N--CA 1.415 -2.73 0 C-N-CA 120.54 -0.838 . . . . 0.0 113.074 176.41 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 47.4 m-80 -129.9 153.07 48.68 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 -179.121 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 74.3 m -68.32 104.7 1.93 Allowed 'General case' 0 C--N 1.314 -0.946 0 O-C-N 123.895 0.747 . . . . 0.0 112.602 -176.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.53 117.5 61.78 Favored Pre-proline 0 N--CA 1.434 -1.259 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 175.248 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.443 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 6.1 Cg_exo -77.98 122.36 5.76 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 122.125 1.884 . . . . 0.0 112.198 -179.051 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.423 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 34.9 tp -129.31 109.92 17.86 Favored Pre-proline 0 N--CA 1.427 -1.607 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 175.351 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 35.5 Cg_exo -64.29 51.53 0.18 Allowed 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 125.122 3.881 . . . . 0.0 116.476 -172.464 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -139.16 -53.34 0.56 Allowed 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 174.009 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.669 ' H ' HD23 ' A' ' 29' ' ' LEU . 1.9 pt? -107.05 -18.37 13.92 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 114.595 -1.184 . . . . 0.0 111.842 -178.011 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 115.42 -154.97 16.61 Favored Glycine 0 N--CA 1.442 -0.954 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.443 ' HA2' ' HA ' ' A' ' 25' ' ' PRO . . . -101.81 123.94 8.05 Favored Glycine 0 CA--C 1.483 -1.965 0 N-CA-C 110.136 -1.186 . . . . 0.0 110.136 178.352 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 33.3 m -120.12 150.41 22.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.047 0 CA-C-O 121.157 0.503 . . . . 0.0 111.601 -174.101 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.452 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 82.0 m -75.13 116.43 15.86 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.152 176.12 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -130.86 136.3 48.51 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.56 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 55.2 t . . . . . 0 C--N 1.315 -0.933 0 CA-C-O 118.778 -0.629 . . . . 0.0 109.366 -179.518 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 28.4 p . . . . . 0 CA--C 1.51 -0.572 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.428 HG23 ' SG ' ' A' ' 33' ' ' CYS . 20.0 m -109.19 164.41 5.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.314 -178.333 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 38.8 mt -103.05 -179.83 4.06 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -177.774 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 34.2 pt -62.64 135.66 26.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.426 0.631 . . . . 0.0 112.683 -178.5 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.08 -12.77 66.68 Favored Glycine 0 C--N 1.314 -0.677 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.985 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -92.23 154.22 18.78 Favored 'General case' 0 N--CA 1.435 -1.211 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.368 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.0 mtm180 -86.16 143.41 28.02 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.545 -174.011 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.477 ' HB2' ' O ' ' A' ' 14' ' ' PRO . 26.4 p -144.46 176.13 9.61 Favored 'General case' 0 C--N 1.278 -2.519 0 CA-C-N 114.519 -1.219 . . . . 0.0 108.362 -177.681 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -130.23 124.14 31.8 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -69.29 -27.69 65.62 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 112.645 0.609 . . . . 0.0 112.645 -177.705 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -91.94 -57.05 2.86 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 111.688 0.255 . . . . 0.0 111.688 -175.683 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -96.75 -18.47 19.6 Favored 'General case' 0 C--N 1.312 -1.051 0 N-CA-C 112.756 0.65 . . . . 0.0 112.756 -172.315 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.02 172.99 47.53 Favored Glycine 0 N--CA 1.437 -1.283 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 -174.575 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.477 ' O ' ' HB2' ' A' ' 8' ' ' CYS . 80.6 Cg_endo -75.77 173.09 59.83 Favored 'Cis proline' 0 C--O 1.23 0.093 0 CA-C-N 120.013 1.907 . . . . 0.0 111.014 -0.538 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.453 ' HA ' ' HB2' ' A' ' 8' ' ' CYS . 73.2 mtm180 -126.59 -173.91 2.99 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.678 -0.237 . . . . 0.0 110.437 178.492 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.2 m -65.45 146.74 54.5 Favored 'General case' 0 C--N 1.294 -1.826 0 C-N-CA 124.08 0.952 . . . . 0.0 111.591 -179.037 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 62.9 m -66.75 149.65 50.24 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 171.131 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.9 t -62.05 100.48 0.16 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.762 0.315 . . . . 0.0 110.365 -178.075 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 121.35 1.23 11.2 Favored Glycine 0 N--CA 1.444 -0.824 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -177.481 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 27.3 mm-40 -109.76 39.6 2.08 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 120.976 0.417 . . . . 0.0 112.103 179.564 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 74.43 -159.21 52.28 Favored Glycine 0 N--CA 1.423 -2.172 0 C-N-CA 120.308 -0.949 . . . . 0.0 112.628 178.38 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -133.96 148.92 51.22 Favored 'General case' 0 C--N 1.278 -2.5 0 N-CA-C 109.338 -0.615 . . . . 0.0 109.338 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 88.4 m -64.78 112.69 3.36 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 124.112 0.883 . . . . 0.0 111.079 177.677 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.3 p -96.19 124.67 50.81 Favored Pre-proline 0 C--N 1.284 -2.242 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 172.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -78.39 145.86 21.52 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 C-N-CA 121.594 1.529 . . . . 0.0 112.585 -177.475 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.452 ' HB2' ' HB3' ' A' ' 29' ' ' LEU . 3.8 mm? -130.07 146.54 61.89 Favored Pre-proline 0 C--N 1.301 -1.534 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 178.003 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo -41.75 -68.19 0.1 Allowed 'Trans proline' 0 N--CA 1.481 0.791 0 C-N-CA 124.503 3.469 . . . . 0.0 115.111 -177.124 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 33.4 p90 -104.79 -25.22 12.74 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-O 121.074 0.464 . . . . 0.0 112.04 -176.819 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.452 ' HB3' ' HB2' ' A' ' 26' ' ' LEU . 3.2 tm? -66.05 -32.04 73.28 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.441 179.178 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 101.19 -88.12 0.7 Allowed Glycine 0 N--CA 1.429 -1.822 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 178.578 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -158.82 147.69 15.64 Favored Glycine 0 N--CA 1.427 -1.927 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 179.279 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.7 p -140.41 148.82 21.91 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 CA-C-O 121.197 0.522 . . . . 0.0 110.103 178.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.428 ' SG ' HG23 ' A' ' 2' ' ' VAL . 76.9 m -82.2 132.87 35.24 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.51 179.112 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.93 140.73 17.12 Favored 'General case' 0 N--CA 1.425 -1.678 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -178.82 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.1 m . . . . . 0 C--N 1.307 -1.282 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 176.125 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.3 p . . . . . 0 N--CA 1.445 -0.684 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' A' ' 16' ' ' CYS . 30.8 m -96.67 169.2 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 120.936 0.398 . . . . 0.0 111.087 -179.562 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 42.5 mt -114.41 -176.14 2.84 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.788 -176.326 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.3 pp -51.92 145.01 2.56 Favored 'Isoleucine or valine' 0 C--O 1.246 0.917 0 N-CA-C 113.546 0.943 . . . . 0.0 113.546 176.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.32 -15.98 15.36 Favored Glycine 0 C--N 1.32 -0.348 0 CA-C-N 115.728 -0.669 . . . . 0.0 113.632 179.383 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 -85.91 157.96 20.04 Favored 'General case' 0 C--N 1.307 -1.271 0 O-C-N 122.384 -0.48 . . . . 0.0 110.136 177.254 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -86.44 125.05 33.43 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.894 -177.245 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.4 p -119.07 163.48 16.93 Favored 'General case' 0 C--N 1.278 -2.538 0 CA-C-N 114.569 -1.196 . . . . 0.0 110.697 -175.318 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -148.15 126.32 12.17 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 174.844 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -77.78 -22.13 50.61 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -174.047 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -90.5 -54.81 3.84 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-O 121.255 0.55 . . . . 0.0 111.158 -175.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -100.04 -27.58 13.49 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.271 -172.424 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.0 169.93 27.32 Favored Glycine 0 N--CA 1.432 -1.599 0 N-CA-C 110.141 -1.184 . . . . 0.0 110.141 -174.872 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -79.85 155.53 88.16 Favored 'Cis proline' 0 N--CA 1.457 -0.655 0 CA-C-N 119.461 1.631 . . . . 0.0 111.704 -0.605 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 66.1 mtt180 -107.45 145.44 33.02 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 -179.358 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.491 ' HA ' ' O ' ' A' ' 2' ' ' VAL . 81.6 m -74.38 149.92 40.29 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.374 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 64.0 m -58.23 141.18 51.52 Favored 'General case' 0 C--N 1.317 -0.821 0 O-C-N 124.223 0.952 . . . . 0.0 109.693 -176.406 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 13.7 t -68.66 97.68 0.82 Allowed 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 141.01 -19.18 2.71 Favored Glycine 0 N--CA 1.435 -1.428 0 N-CA-C 108.559 -1.817 . . . . 0.0 108.559 -173.662 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 24.9 mm-40 -81.49 -178.98 7.18 Favored 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 123.681 0.792 . . . . 0.0 111.839 177.215 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.54 169.61 19.17 Favored Glycine 0 C--N 1.314 -0.681 0 CA-C-O 121.42 0.456 . . . . 0.0 114.083 -177.888 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ASN . . . . . 0.531 ' O ' ' HA ' ' A' ' 33' ' ' CYS . 27.2 t-20 -85.82 139.93 30.87 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 178.72 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 21.4 t -76.25 101.46 5.45 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 -178.276 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.6 t -99.9 113.95 65.41 Favored Pre-proline 0 N--CA 1.426 -1.652 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 -179.302 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.444 ' HA ' ' CA ' ' A' ' 31' ' ' GLY . 3.0 Cg_exo -71.87 121.38 7.56 Favored 'Trans proline' 0 N--CA 1.442 -1.545 0 C-N-CA 122.19 1.927 . . . . 0.0 110.706 179.257 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.1 mt -117.12 122.88 30.67 Favored Pre-proline 0 N--CA 1.425 -1.695 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 178.699 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -73.65 42.86 0.72 Allowed 'Trans proline' 0 CA--C 1.542 0.878 0 C-N-CA 123.716 2.944 . . . . 0.0 113.102 -176.721 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -135.2 -67.65 0.54 Allowed 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 -179.282 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.621 ' H ' HD23 ' A' ' 29' ' ' LEU . 2.3 pt? -107.14 -5.72 17.8 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.669 -178.559 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 111.71 -172.76 15.12 Favored Glycine 0 N--CA 1.432 -1.595 0 N-CA-C 110.129 -1.188 . . . . 0.0 110.129 -175.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.444 ' CA ' ' HA ' ' A' ' 25' ' ' PRO . . . -90.64 132.78 11.45 Favored Glycine 0 CA--C 1.484 -1.894 0 C-N-CA 120.526 -0.845 . . . . 0.0 111.336 179.381 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.4 m -129.88 147.74 33.23 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.938 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -178.239 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.531 ' HA ' ' O ' ' A' ' 22' ' ' ASN . 96.4 m -82.25 120.07 24.9 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.132 178.887 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -119.76 137.71 53.78 Favored 'General case' 0 N--CA 1.427 -1.589 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 178.428 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--N 1.292 -1.898 0 C-N-CA 121.008 -0.277 . . . . 0.0 111.194 -177.472 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 25.8 p . . . . . 0 N--CA 1.446 -0.648 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.471 HG23 ' SG ' ' A' ' 33' ' ' CYS . 18.6 m -108.37 154.91 9.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 CA-C-O 121.134 0.492 . . . . 0.0 111.513 -179.605 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 57.7 mt -100.33 -176.96 3.37 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.52 -175.844 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.9 pt -61.13 130.49 25.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.503 0 CA-C-O 121.477 0.656 . . . . 0.0 112.438 -179.114 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 96.59 -22.64 39.12 Favored Glycine 0 C--N 1.311 -0.821 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.841 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -81.02 154.9 26.64 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 121.067 0.46 . . . . 0.0 109.794 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.1 tmt_? -86.34 138.15 32.04 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.349 -173.679 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 17.5 p -137.07 167.89 20.65 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.917 -177.364 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -141.66 120.49 12.7 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 175.41 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -63.37 -35.18 79.56 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.84 -0.618 . . . . 0.0 112.168 -170.849 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -92.44 -52.54 4.61 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 113.026 0.75 . . . . 0.0 113.026 -175.469 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.4 mtm180 -87.08 -27.81 22.92 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 121.133 0.492 . . . . 0.0 112.306 -174.319 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.0 163.42 26.76 Favored Glycine 0 N--CA 1.427 -1.966 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 -175.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -78.44 165.93 81.37 Favored 'Cis proline' 0 C--N 1.332 -0.323 0 C-N-CA 123.378 -1.509 . . . . 0.0 112.375 0.569 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 60.1 mtt180 -115.74 163.09 16.34 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.678 -179.358 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 58.4 m -70.14 142.33 52.55 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 123.638 0.775 . . . . 0.0 110.514 -177.39 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 81.9 m -67.39 157.48 34.0 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 174.667 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.1 p -57.64 96.6 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.818 0 C-N-CA 124.207 1.003 . . . . 0.0 112.477 -177.467 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 99.09 34.76 5.02 Favored Glycine 0 N--CA 1.433 -1.566 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.293 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.435 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 23.9 mm-40 -122.58 34.57 5.11 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-O 121.547 0.689 . . . . 0.0 111.013 177.184 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 78.47 -166.38 52.34 Favored Glycine 0 N--CA 1.419 -2.457 0 CA-C-N 114.928 -1.033 . . . . 0.0 112.169 178.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 40.4 m-80 -127.95 157.19 41.26 Favored 'General case' 0 C--N 1.29 -2.016 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 -179.83 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 99.3 m -68.13 97.92 0.74 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 123.819 0.7 . . . . 0.0 111.765 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.82 126.62 72.54 Favored Pre-proline 0 N--CA 1.425 -1.699 0 N-CA-C 106.153 -1.795 . . . . 0.0 106.153 174.082 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.41 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 48.2 Cg_endo -70.3 129.99 17.94 Favored 'Trans proline' 0 N--CA 1.446 -1.288 0 C-N-CA 121.558 1.506 . . . . 0.0 114.283 -174.891 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.41 HD23 HG22 ' A' ' 32' ' ' VAL . 4.6 mm? -121.42 143.24 37.19 Favored Pre-proline 0 C--N 1.309 -1.187 0 CA-C-N 114.932 -1.031 . . . . 0.0 108.747 178.941 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_exo -44.26 -63.7 0.31 Allowed 'Trans proline' 0 CA--C 1.546 1.094 0 C-N-CA 123.731 2.954 . . . . 0.0 115.298 -176.744 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -89.65 -25.42 21.27 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 112.599 0.592 . . . . 0.0 112.599 -173.518 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -88.81 -17.97 28.66 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-O 121.362 0.601 . . . . 0.0 111.093 -175.434 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 88.89 -63.59 3.49 Favored Glycine 0 N--CA 1.429 -1.832 0 N-CA-C 109.389 -1.485 . . . . 0.0 109.389 -177.038 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.41 ' HA2' ' HA ' ' A' ' 25' ' ' PRO . . . -165.13 148.18 13.68 Favored Glycine 0 N--CA 1.419 -2.441 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.41 HG22 HD23 ' A' ' 26' ' ' LEU . 14.0 m -131.79 150.97 34.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 176.778 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.471 ' SG ' HG23 ' A' ' 2' ' ' VAL . 71.7 m -76.32 117.24 17.79 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -142.65 145.47 33.49 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 120.726 -0.389 . . . . 0.0 110.786 -179.733 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.6 m . . . . . 0 C--N 1.308 -1.22 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.603 176.963 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 23.4 p . . . . . 0 C--O 1.233 0.217 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.417 HG23 ' SG ' ' A' ' 33' ' ' CYS . 28.8 m -110.54 154.44 12.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-O 120.606 0.241 . . . . 0.0 111.367 -178.583 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 35.5 mt -99.69 -176.36 3.24 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.297 -177.477 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.408 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 33.8 pt -58.14 134.6 22.84 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.73 0 CA-C-O 121.477 0.656 . . . . 0.0 112.489 179.027 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.73 -18.72 55.98 Favored Glycine 0 C--N 1.311 -0.828 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.296 178.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLN . . . . . 0.414 ' HB2' ' HB ' ' A' ' 2' ' ' VAL . 23.7 mt-30 -89.66 152.33 21.42 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -179.556 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.462 ' HA ' ' HA ' ' A' ' 32' ' ' VAL . 16.4 ptp180 -86.61 148.71 25.36 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.07 0.462 . . . . 0.0 111.106 -175.317 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.2 p -138.56 158.24 44.62 Favored 'General case' 0 C--N 1.298 -1.652 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.611 -174.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -129.06 124.03 33.8 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 176.152 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -79.17 -27.11 42.64 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 120.955 0.407 . . . . 0.0 111.626 -173.107 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -91.1 -42.08 10.68 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 115.723 -0.671 . . . . 0.0 112.154 -173.417 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 83.7 mtm180 -112.54 -13.3 13.35 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 -175.597 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 89.35 165.74 41.33 Favored Glycine 0 N--CA 1.44 -1.094 0 C-N-CA 120.055 -1.069 . . . . 0.0 110.805 -177.408 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -79.85 158.73 88.28 Favored 'Cis proline' 0 N--CA 1.463 -0.284 0 CA-C-N 119.227 1.513 . . . . 0.0 111.195 -0.812 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 80.9 mtm180 -113.49 172.67 6.83 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 121.03 -0.268 . . . . 0.0 110.502 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.7 m -68.01 141.0 56.37 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 123.634 0.583 . . . . 0.0 109.834 -179.228 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 55.8 m -67.33 140.86 57.29 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 172.855 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 5.9 p -58.4 94.77 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.73 0 CA-C-O 121.663 0.744 . . . . 0.0 112.794 -177.383 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 132.38 -5.32 5.26 Favored Glycine 0 N--CA 1.438 -1.179 0 CA-C-N 114.853 -1.067 . . . . 0.0 110.644 -176.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLN . . . . . 0.448 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 86.0 mm-40 -101.58 30.09 4.49 Favored 'General case' 0 C--N 1.323 -0.561 0 C-N-CA 123.348 0.659 . . . . 0.0 112.456 -177.483 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 84.44 -171.6 47.89 Favored Glycine 0 N--CA 1.436 -1.352 0 C-N-CA 120.103 -1.046 . . . . 0.0 113.9 175.803 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 -113.44 162.59 15.94 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.747 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 98.8 m -76.87 97.23 4.51 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-O 121.553 0.692 . . . . 0.0 109.689 177.253 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.4 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 43.5 t -93.43 127.91 44.55 Favored Pre-proline 0 N--CA 1.416 -2.14 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 -179.045 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 57.5 Cg_endo -85.0 121.01 2.34 Favored 'Trans proline' 0 N--CA 1.427 -2.421 0 C-N-CA 121.953 1.769 . . . . 0.0 112.018 -178.532 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.42 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 10.3 mp -110.39 124.52 33.08 Favored Pre-proline 0 C--N 1.29 -2.018 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 177.463 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 78.2 Cg_exo -53.24 -17.38 8.46 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 C-N-CA 124.448 3.432 . . . . 0.0 115.564 -173.725 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.411 ' HB2' HD12 ' A' ' 29' ' ' LEU . 73.6 m-85 -110.55 -22.74 11.49 Favored 'General case' 0 C--N 1.309 -1.164 0 C-N-CA 120.858 -0.337 . . . . 0.0 111.388 -179.167 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' LEU . . . . . 0.411 HD12 ' HB2' ' A' ' 28' ' ' PHE . 6.1 mp -106.55 -16.89 14.41 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 112.177 0.436 . . . . 0.0 112.177 -173.76 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.94 -104.91 2.98 Favored Glycine 0 N--CA 1.426 -2.006 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 -176.449 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -147.35 127.9 2.79 Favored Glycine 0 C--N 1.295 -1.744 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 176.465 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.462 ' HA ' ' HA ' ' A' ' 7' ' ' ARG . 34.5 m -131.83 154.19 39.88 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 C-N-CA 122.926 0.49 . . . . 0.0 110.187 -175.809 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' CYS . . . . . 0.448 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 74.4 m -74.53 119.69 19.06 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.705 178.033 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -146.53 148.75 32.5 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.752 0.311 . . . . 0.0 110.551 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 17.9 m . . . . . 0 C--N 1.306 -1.291 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.007 176.663 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.5 p . . . . . 0 N--CA 1.452 -0.334 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.544 HG23 ' SG ' ' A' ' 33' ' ' CYS . 21.2 m -106.84 167.4 3.45 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-O 121.184 0.516 . . . . 0.0 111.291 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.415 ' HA ' ' HG3' ' A' ' 20' ' ' GLN . 25.3 mt -107.41 175.97 5.31 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.174 -172.509 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 27.9 pt -61.07 134.99 26.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.438 0 CA-C-O 121.415 0.626 . . . . 0.0 112.394 -178.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.65 -13.3 60.97 Favored Glycine 0 C--N 1.312 -0.78 0 CA-C-N 115.486 -0.779 . . . . 0.0 112.622 -179.214 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -90.4 151.18 21.54 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 106.892 -1.522 . . . . 0.0 106.892 176.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 34.3 ptt180 -85.9 146.24 26.8 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.949 -0.7 . . . . 0.0 111.064 -173.156 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.4 p -139.09 176.91 8.29 Favored 'General case' 0 C--N 1.282 -2.331 0 CA-C-N 115.164 -0.926 . . . . 0.0 109.224 -174.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -152.11 117.31 5.24 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 174.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -57.08 -38.99 74.1 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 113.629 0.974 . . . . 0.0 113.629 -173.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -91.86 -47.58 7.25 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 113.628 0.973 . . . . 0.0 113.628 -175.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.0 mtm180 -89.48 -29.88 18.67 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -173.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.55 160.31 25.94 Favored Glycine 0 N--CA 1.435 -1.389 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -174.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -79.65 167.45 75.47 Favored 'Cis proline' 0 C--O 1.218 -0.475 0 CA-C-N 119.542 1.671 . . . . 0.0 111.987 1.309 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 88.0 mtm180 -122.01 156.25 33.87 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 33.6 m -70.2 149.25 47.7 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 124.825 1.25 . . . . 0.0 111.319 -175.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 85.4 m -68.43 143.74 54.95 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 175.229 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 11.4 t -54.3 -26.45 29.41 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 125.25 1.42 . . . . 0.0 113.039 -172.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -108.08 16.53 35.8 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.188 178.138 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.415 ' HG3' ' HA ' ' A' ' 3' ' ' LEU . 18.3 mm-40 -97.74 -68.1 0.82 Allowed 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -179.368 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -175.85 -179.18 46.2 Favored Glycine 0 CA--C 1.481 -2.089 0 C-N-CA 120.261 -0.971 . . . . 0.0 110.703 -176.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 52.4 t30 -93.29 139.6 30.46 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 177.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 49.9 t -79.47 98.13 6.68 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.075 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.62 120.09 69.53 Favored Pre-proline 0 C--N 1.302 -1.47 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -67.18 141.7 58.19 Favored 'Trans proline' 0 N--CA 1.449 -1.114 0 C-N-CA 122.431 2.087 . . . . 0.0 113.106 -176.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.4 mt -119.36 144.19 35.95 Favored Pre-proline 0 C--N 1.302 -1.5 0 CA-C-N 114.743 -1.117 . . . . 0.0 109.078 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_exo -40.26 -57.31 1.23 Allowed 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 124.731 3.621 . . . . 0.0 114.806 -176.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 30.4 p90 -119.18 -24.18 6.54 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -177.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 78.3 mt -79.9 0.49 31.02 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 179.04 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 87.57 -59.22 4.37 Favored Glycine 0 CA--C 1.499 -0.939 0 C-N-CA 121.149 -0.548 . . . . 0.0 111.871 177.246 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 171.64 170.79 36.07 Favored Glycine 0 N--CA 1.418 -2.512 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 9.2 p -147.3 146.15 18.59 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.986 0 CA-C-O 121.503 0.668 . . . . 0.0 109.992 177.282 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.544 ' SG ' HG23 ' A' ' 2' ' ' VAL . 74.1 m -80.06 118.4 21.75 Favored 'General case' 0 C--N 1.285 -2.223 0 CA-C-N 114.713 -1.13 . . . . 0.0 109.923 179.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -143.87 153.66 42.57 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 -177.179 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 52.4 t . . . . . 0 C--N 1.306 -1.32 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -179.109 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.3 p . . . . . 0 C--O 1.24 0.57 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.582 HG23 ' SG ' ' A' ' 33' ' ' CYS . 30.2 m -112.06 158.28 12.55 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-O 120.655 0.264 . . . . 0.0 111.504 -178.567 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 38.2 mt -99.57 -178.56 3.92 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.482 -176.554 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.435 ' HA ' ' HB2' ' A' ' 33' ' ' CYS . 34.0 pt -58.64 140.37 17.04 Favored 'Isoleucine or valine' 0 C--O 1.241 0.651 0 N-CA-C 113.023 0.749 . . . . 0.0 113.023 -179.394 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.8 -14.34 48.48 Favored Glycine 0 C--N 1.311 -0.86 0 CA-C-N 115.708 -0.678 . . . . 0.0 113.183 178.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 27.2 mt-30 -86.15 156.53 20.31 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 108.056 -1.091 . . . . 0.0 108.056 178.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 47.1 ttp180 -86.01 132.22 34.11 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 123.623 0.577 . . . . 0.0 109.962 -176.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.2 p -128.71 175.11 8.85 Favored 'General case' 0 C--N 1.278 -2.543 0 CA-C-N 115.069 -0.969 . . . . 0.0 109.197 -177.478 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -149.82 125.68 10.5 Favored 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 174.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . 0.403 ' OD1' ' HB3' ' A' ' 23' ' ' CYS . 43.6 m-80 -76.64 -23.11 53.31 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 120.531 0.205 . . . . 0.0 111.526 -175.84 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -84.87 -57.56 3.06 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.903 -175.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 63.2 mtt180 -103.07 -21.85 13.86 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 113.107 0.78 . . . . 0.0 113.107 -175.356 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 103.86 168.55 25.25 Favored Glycine 0 N--CA 1.433 -1.543 0 C-N-CA 120.121 -1.038 . . . . 0.0 110.609 -177.393 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -80.1 159.17 87.18 Favored 'Cis proline' 0 CA--C 1.535 0.549 0 CA-C-N 119.085 1.442 . . . . 0.0 112.065 0.217 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 -104.55 169.91 8.19 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 177.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.6 m -80.52 147.16 30.96 Favored 'General case' 0 C--N 1.297 -1.688 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.419 -176.191 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 39.5 m -72.77 153.28 41.19 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 175.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.1 t -67.77 120.12 13.59 Favored 'General case' 0 N--CA 1.435 -1.214 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 103.54 0.1 46.4 Favored Glycine 0 N--CA 1.437 -1.264 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -175.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 86.0 mm-40 -111.86 38.01 2.78 Favored 'General case' 0 C--N 1.31 -1.132 0 CA-C-O 121.496 0.665 . . . . 0.0 110.366 179.064 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 78.14 -156.58 43.77 Favored Glycine 0 N--CA 1.418 -2.554 0 CA-C-N 115.057 -0.974 . . . . 0.0 112.962 177.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 79.6 m-20 -123.74 153.75 40.47 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 106.123 -1.806 . . . . 0.0 106.123 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . 0.403 ' HB3' ' OD1' ' A' ' 10' ' ' ASN . 51.6 t -84.52 98.46 10.14 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.656 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.411 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 22.9 t -97.34 118.05 64.9 Favored Pre-proline 0 C--N 1.303 -1.456 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 -178.026 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 4.0 Cg_exo -70.76 129.84 17.16 Favored 'Trans proline' 0 N--CA 1.451 -0.99 0 C-N-CA 122.611 2.207 . . . . 0.0 110.113 177.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 85.2 mt -129.3 150.6 75.96 Favored Pre-proline 0 C--N 1.309 -1.154 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.951 -175.525 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -42.49 -67.37 0.12 Allowed 'Trans proline' 0 CA--C 1.545 1.044 0 C-N-CA 124.792 3.661 . . . . 0.0 115.679 -177.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 26.5 p90 -97.8 -23.58 15.82 Favored 'General case' 0 C--N 1.314 -0.975 0 N-CA-C 113.325 0.861 . . . . 0.0 113.325 -174.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 97.4 mt -83.13 -12.11 57.32 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.557 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 84.06 -65.65 4.06 Favored Glycine 0 CA--C 1.501 -0.813 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -178.23 134.79 2.48 Favored Glycine 0 CA--C 1.47 -2.773 0 N-CA-C 108.569 -1.812 . . . . 0.0 108.569 177.36 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.5 m -136.02 153.68 32.45 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.224 0 CA-C-O 121.505 0.669 . . . . 0.0 110.998 -178.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.582 ' SG ' HG23 ' A' ' 2' ' ' VAL . 84.1 m -79.15 117.27 20.02 Favored 'General case' 0 C--N 1.291 -1.957 0 CA-C-N 114.503 -1.226 . . . . 0.0 108.833 175.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -135.07 130.41 35.53 Favored 'General case' 0 N--CA 1.431 -1.399 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -177.314 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 N--CA 1.432 -1.338 0 O-C-N 123.306 0.378 . . . . 0.0 110.63 178.847 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 22.2 p . . . . . 0 N--CA 1.446 -0.673 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.572 HG23 ' SG ' ' A' ' 33' ' ' CYS . 15.7 m -101.29 163.22 3.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-O 121.17 0.51 . . . . 0.0 111.511 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 23.9 mt -107.88 179.99 4.06 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.454 -0.793 . . . . 0.0 111.108 -172.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 24.3 pt -55.11 134.34 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.42 -17.85 41.12 Favored Glycine 0 C--O 1.242 0.614 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.937 177.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.7 mt-30 -81.54 159.72 24.06 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.133 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.458 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 40.5 ttp180 -85.78 129.0 34.95 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.269 -173.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 30.3 p -128.17 172.43 11.01 Favored 'General case' 0 C--N 1.291 -1.949 0 CA-C-O 121.294 0.569 . . . . 0.0 110.677 -177.22 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -147.12 118.97 8.09 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 175.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -58.22 -42.03 85.4 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 124.192 0.997 . . . . 0.0 113.113 -173.241 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -91.93 -56.63 3.01 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -175.412 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -83.15 -31.0 27.42 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-O 121.133 0.492 . . . . 0.0 112.024 -171.046 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 104.85 165.0 24.16 Favored Glycine 0 N--CA 1.427 -1.906 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 -176.331 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -76.25 156.76 98.41 Favored 'Cis proline' 0 C--N 1.329 -0.468 0 C-N-CA 123.382 -1.507 . . . . 0.0 112.122 0.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 82.1 mtt180 -108.03 156.35 19.35 Favored 'General case' 0 C--N 1.289 -2.04 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.56 -179.346 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 58.8 m -76.23 144.03 40.65 Favored 'General case' 0 C--N 1.29 -1.99 0 C-N-CA 124.06 0.944 . . . . 0.0 110.79 -176.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.441 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 59.2 m -67.42 161.51 25.12 Favored 'General case' 0 C--O 1.243 0.743 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.543 177.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 37.6 t -46.96 -56.21 6.77 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.065 0.946 . . . . 0.0 113.414 -174.094 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -95.19 27.22 15.79 Favored Glycine 0 C--N 1.314 -0.672 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.825 -176.26 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.441 ' CG ' ' HB2' ' A' ' 17' ' ' CYS . 84.9 mm-40 -110.84 29.69 7.53 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-O 121.337 0.589 . . . . 0.0 110.707 -178.556 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.414 ' CA ' ' HB ' ' A' ' 35' ' ' VAL . . . 85.51 -140.5 18.2 Favored Glycine 0 N--CA 1.43 -1.712 0 C-N-CA 120.365 -0.921 . . . . 0.0 112.874 177.528 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -133.8 155.87 49.04 Favored 'General case' 0 C--N 1.287 -2.142 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 176.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 52.5 t -83.06 100.83 10.74 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.409 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 7.4 p -98.0 120.07 60.78 Favored Pre-proline 0 N--CA 1.419 -2.021 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.62 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 10.1 Cg_exo -69.42 139.9 42.57 Favored 'Trans proline' 0 N--CA 1.45 -1.034 0 C-N-CA 122.076 1.851 . . . . 0.0 112.62 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 11.0 mp -119.49 134.92 23.81 Favored Pre-proline 0 C--N 1.304 -1.41 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.468 179.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_exo -39.93 -54.18 2.16 Favored 'Trans proline' 0 C--N 1.356 0.965 0 C-N-CA 124.58 3.52 . . . . 0.0 115.483 -175.464 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 75.5 m-85 -99.43 -40.88 7.66 Favored 'General case' 0 CA--C 1.504 -0.799 0 CA-C-O 121.079 0.466 . . . . 0.0 111.038 -178.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 14.0 mt -75.65 -14.58 60.37 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.872 -0.604 . . . . 0.0 112.594 -170.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.73 -64.53 0.75 Allowed Glycine 0 CA--C 1.486 -1.765 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 -179.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.458 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . 174.33 156.35 13.65 Favored Glycine 0 N--CA 1.425 -2.083 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 178.013 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.4 m -139.06 152.76 24.17 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-O 121.248 0.547 . . . . 0.0 109.925 177.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.572 ' SG ' HG23 ' A' ' 2' ' ' VAL . 60.4 m -82.55 125.01 30.65 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 115.426 -0.807 . . . . 0.0 108.964 176.751 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -146.82 135.74 22.34 Favored 'General case' 0 N--CA 1.439 -0.998 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.267 -176.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.414 ' HB ' ' CA ' ' A' ' 21' ' ' GLY . 7.7 p . . . . . 0 C--N 1.301 -1.542 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 178.49 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 25.8 p . . . . . 0 C--O 1.24 0.59 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.497 HG23 ' SG ' ' A' ' 33' ' ' CYS . 30.1 m -103.84 168.68 2.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 120.902 0.382 . . . . 0.0 110.878 -179.508 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.401 ' HB2' ' OE1' ' A' ' 6' ' ' GLN . 24.8 mt -109.12 -179.48 3.86 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.771 -0.649 . . . . 0.0 109.695 -175.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.7 pt -57.68 134.02 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-O 121.643 0.735 . . . . 0.0 112.87 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 95.71 -23.99 31.58 Favored Glycine 0 N--CA 1.442 -0.945 0 CA-C-N 115.175 -0.92 . . . . 0.0 112.303 178.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.401 ' OE1' ' HB2' ' A' ' 3' ' ' LEU . 36.2 mt-30 -83.09 152.65 25.24 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 16.5 ptm180 -87.0 145.39 26.52 Favored 'General case' 0 C--N 1.297 -1.694 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.309 -176.402 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.441 ' HB2' ' O ' ' A' ' 14' ' ' PRO . 15.7 p -144.3 176.26 9.48 Favored 'General case' 0 C--N 1.285 -2.21 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.983 -174.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -145.0 116.78 8.2 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 177.64 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -62.32 -32.67 73.46 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 112.968 0.729 . . . . 0.0 112.968 -178.459 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -82.63 -56.59 3.77 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 121.186 0.517 . . . . 0.0 111.523 -172.597 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 77.5 mtm180 -96.95 -20.23 18.24 Favored 'General case' 0 C--N 1.295 -1.778 0 CA-C-N 115.614 -0.721 . . . . 0.0 112.788 -172.172 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 94.36 162.55 35.34 Favored Glycine 0 N--CA 1.43 -1.738 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -177.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.441 ' O ' ' HB2' ' A' ' 8' ' ' CYS . 97.9 Cg_endo -85.26 167.53 53.0 Favored 'Cis proline' 0 C--N 1.326 -0.649 0 CA-C-N 119.272 1.536 . . . . 0.0 110.979 0.254 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -115.94 178.33 4.35 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 175.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 32.7 m -68.12 146.12 53.74 Favored 'General case' 0 C--N 1.293 -1.881 0 C-N-CA 123.277 0.631 . . . . 0.0 110.884 178.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 71.3 m -70.89 154.9 41.42 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 171.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.7 t -60.68 113.31 2.4 Favored 'General case' 0 N--CA 1.436 -1.128 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 106.48 0.2 37.36 Favored Glycine 0 N--CA 1.441 -0.982 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.555 -178.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 86.3 mm-40 -107.93 33.86 3.87 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.168 0.509 . . . . 0.0 110.93 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 80.7 -140.35 21.67 Favored Glycine 0 N--CA 1.428 -1.867 0 C-N-CA 120.131 -1.033 . . . . 0.0 113.241 177.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 52.9 t30 -151.32 159.92 44.06 Favored 'General case' 0 C--N 1.288 -2.097 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 92.3 m -72.08 97.76 1.97 Allowed 'General case' 0 C--N 1.308 -1.199 0 O-C-N 123.884 0.74 . . . . 0.0 109.192 176.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.3 t -96.52 126.9 41.76 Favored Pre-proline 0 N--CA 1.42 -1.946 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 179.223 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_exo -58.84 127.0 22.79 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 122.764 2.309 . . . . 0.0 112.627 -177.659 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.441 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 47.5 tp -118.02 131.91 23.95 Favored Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 179.384 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 6.9 Cg_exo -74.38 45.6 1.24 Allowed 'Trans proline' 0 N--CA 1.482 0.809 0 C-N-CA 123.636 2.891 . . . . 0.0 113.17 -176.61 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -148.98 -69.63 0.21 Allowed 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 124.143 0.977 . . . . 0.0 109.3 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 25.6 mt -95.66 1.53 53.6 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 114.285 -1.325 . . . . 0.0 111.516 -170.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.63 -77.14 0.63 Allowed Glycine 0 N--CA 1.435 -1.404 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -146.45 139.2 7.9 Favored Glycine 0 C--N 1.29 -2.015 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.051 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.8 m -134.38 157.09 41.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 178.693 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.497 ' SG ' HG23 ' A' ' 2' ' ' VAL . 81.4 m -73.78 124.54 26.26 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.103 179.622 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -144.5 143.24 30.75 Favored 'General case' 0 N--CA 1.425 -1.69 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.2 m . . . . . 0 C--N 1.301 -1.512 0 O-C-N 123.789 0.68 . . . . 0.0 111.124 178.767 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 19.9 p . . . . . 0 C--O 1.241 0.647 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.603 HG23 ' SG ' ' A' ' 33' ' ' CYS . 15.1 m -109.72 157.53 10.15 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.656 0 CA-C-O 121.131 0.491 . . . . 0.0 111.458 176.333 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 18.4 mt -111.98 179.34 4.03 Favored 'General case' 0 N--CA 1.432 -1.357 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.069 -172.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 23.7 pt -54.1 133.46 17.11 Favored 'Isoleucine or valine' 0 C--O 1.239 0.545 0 CA-C-O 121.76 0.791 . . . . 0.0 112.88 -179.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.57 -9.08 72.4 Favored Glycine 0 C--N 1.309 -0.954 0 CA-C-N 115.375 -0.83 . . . . 0.0 113.04 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 75.7 mt-30 -94.47 156.47 16.45 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 176.741 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.403 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 18.1 ptp180 -85.81 145.72 27.09 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-O 121.139 0.495 . . . . 0.0 111.504 -174.156 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.447 ' SG ' ' HA ' ' A' ' 15' ' ' ARG . 3.8 t -137.21 159.72 41.09 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.819 -1.082 . . . . 0.0 112.324 -172.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -150.86 117.54 5.79 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 113.277 -1.783 . . . . 0.0 107.062 176.137 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 48.2 m-80 -63.72 -43.04 97.71 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 113.671 0.989 . . . . 0.0 113.671 -173.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 17.4 m-20 -92.46 -35.88 13.4 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 113.678 0.992 . . . . 0.0 113.678 -174.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 54.8 mtm180 -100.99 -14.86 17.68 Favored 'General case' 0 C--N 1.309 -1.176 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -174.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.77 155.98 29.55 Favored Glycine 0 N--CA 1.442 -0.932 0 N-CA-C 111.081 -0.807 . . . . 0.0 111.081 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -84.91 159.33 66.08 Favored 'Cis proline' 0 CA--C 1.535 0.546 0 CA-C-N 119.206 1.503 . . . . 0.0 111.883 0.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.447 ' HA ' ' SG ' ' A' ' 8' ' ' CYS . 39.7 mtm180 -112.21 155.27 24.26 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-O 120.89 0.376 . . . . 0.0 110.083 -178.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.445 ' HA ' ' O ' ' A' ' 2' ' ' VAL . 36.8 m -78.02 142.01 38.52 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 123.882 0.873 . . . . 0.0 110.533 -176.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 m -67.05 153.37 43.82 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 119.144 -1.022 . . . . 0.0 111.312 172.006 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 12.3 p -48.74 -46.65 41.29 Favored 'General case' 0 C--O 1.241 0.622 0 N-CA-C 114.229 1.196 . . . . 0.0 114.229 -173.189 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -90.63 11.79 70.56 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.448 -0.882 . . . . 0.0 112.703 -179.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 78.7 mm-40 -105.28 37.19 2.25 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.276 0.56 . . . . 0.0 111.716 -178.001 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.48 -158.92 30.32 Favored Glycine 0 N--CA 1.423 -2.205 0 C-N-CA 120.091 -1.052 . . . . 0.0 112.32 177.02 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 -122.18 149.44 43.63 Favored 'General case' 0 C--N 1.282 -2.35 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 49.1 t -84.02 97.33 9.23 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.002 -1.111 . . . . 0.0 108.002 179.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.6 p -104.82 124.88 35.37 Favored Pre-proline 0 C--N 1.305 -1.34 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.52 -177.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -67.07 141.74 58.93 Favored 'Trans proline' 0 C--O 1.243 0.762 0 C-N-CA 122.645 2.23 . . . . 0.0 112.951 -176.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 87.9 mt -122.21 148.63 52.57 Favored Pre-proline 0 C--N 1.309 -1.181 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.601 -178.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo -49.29 -64.22 0.24 Allowed 'Trans proline' 0 CA--C 1.545 1.072 0 C-N-CA 123.715 2.943 . . . . 0.0 114.394 -178.198 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -97.16 -40.36 8.84 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.947 0.403 . . . . 0.0 110.987 -174.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 9.2 mp -78.98 0.74 26.38 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 113.737 1.014 . . . . 0.0 113.737 -174.681 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 86.28 -65.33 3.86 Favored Glycine 0 CA--C 1.501 -0.803 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.081 176.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.403 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -176.35 160.43 28.11 Favored Glycine 0 CA--C 1.477 -2.323 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 8.8 p -142.76 157.63 18.39 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 CA-C-N 117.73 0.765 . . . . 0.0 109.922 -178.265 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.603 ' SG ' HG23 ' A' ' 2' ' ' VAL . 59.9 m -88.0 108.73 19.36 Favored 'General case' 0 C--N 1.278 -2.514 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 174.547 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -149.88 163.84 36.97 Favored 'General case' 0 N--CA 1.435 -1.182 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 -175.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.9 p . . . . . 0 C--N 1.293 -1.852 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.653 178.786 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.4 p . . . . . 0 C--O 1.243 0.722 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 19.0 m -109.11 168.61 3.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 120.813 0.34 . . . . 0.0 111.147 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 29.3 mt -108.02 -176.24 3.0 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.327 -175.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 21.9 pt -56.78 138.83 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 N-CA-C 112.695 0.628 . . . . 0.0 112.695 179.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.29 -20.11 19.12 Favored Glycine 0 CA--C 1.506 -0.476 0 CA-C-N 115.707 -0.678 . . . . 0.0 112.694 178.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -80.5 153.73 27.98 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-O 121.252 0.549 . . . . 0.0 109.892 -179.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 4.2 tmt_? -86.31 130.14 34.61 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 114.657 -1.156 . . . . 0.0 109.038 -173.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.4 ' HB2' ' O ' ' A' ' 14' ' ' PRO . 27.8 p -130.29 170.67 13.82 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.242 -176.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -147.42 124.59 11.47 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 177.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 14.6 m120 -71.56 -35.88 70.75 Favored 'General case' 0 C--N 1.298 -1.662 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.424 -175.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -76.3 -56.86 4.25 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.637 -0.71 . . . . 0.0 112.146 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 74.1 mtm180 -93.8 -21.3 19.38 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 115.872 -0.604 . . . . 0.0 112.511 -173.48 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 94.74 163.45 35.24 Favored Glycine 0 N--CA 1.427 -1.947 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -175.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.4 ' O ' ' HB2' ' A' ' 8' ' ' CYS . 89.7 Cg_endo -89.86 165.68 34.52 Favored 'Cis proline' 0 N--CA 1.451 -0.998 0 C-N-CA 123.353 -1.52 . . . . 0.0 110.76 -1.184 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 69.8 mtm180 -106.86 179.43 4.27 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 176.139 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 26.4 m -73.42 140.75 46.76 Favored 'General case' 0 C--N 1.293 -1.856 0 C-N-CA 122.914 0.486 . . . . 0.0 109.963 -179.085 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 60.9 m -67.83 155.03 40.25 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 173.25 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 29.1 t -60.98 113.5 2.57 Favored 'General case' 0 C--O 1.246 0.899 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 -178.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 102.36 14.39 28.21 Favored Glycine 0 N--CA 1.435 -1.389 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.657 -178.472 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.45 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 83.9 mm-40 -116.8 28.85 8.28 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 -178.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.33 -163.11 35.54 Favored Glycine 0 N--CA 1.433 -1.553 0 C-N-CA 119.689 -1.243 . . . . 0.0 111.756 178.529 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 52.8 m-80 -130.43 152.05 50.25 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 107.756 -1.202 . . . . 0.0 107.756 179.166 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 63.1 m -66.95 98.1 0.53 Allowed 'General case' 0 N--CA 1.439 -1.007 0 O-C-N 124.04 0.837 . . . . 0.0 110.713 176.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.4 m -92.99 111.81 53.19 Favored Pre-proline 0 N--CA 1.411 -2.378 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 175.449 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.37 141.4 31.78 Favored 'Trans proline' 0 N--CA 1.44 -1.634 0 C-N-CA 122.069 1.846 . . . . 0.0 112.977 -173.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 91.8 mt -137.3 117.34 10.47 Favored Pre-proline 0 C--N 1.292 -1.928 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -72.15 51.03 1.63 Allowed 'Trans proline' 0 N--CA 1.485 0.984 0 C-N-CA 124.393 3.395 . . . . 0.0 113.969 -171.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 70.8 m-85 -143.83 -60.51 0.4 Allowed 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.638 ' H ' HD23 ' A' ' 29' ' ' LEU . 2.1 pt? -106.95 0.22 23.6 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.922 -178.208 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 109.46 -76.76 0.22 Allowed Glycine 0 C--N 1.306 -1.123 0 C-N-CA 120.399 -0.905 . . . . 0.0 111.755 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 177.27 159.56 22.63 Favored Glycine 0 N--CA 1.425 -2.057 0 N-CA-C 109.984 -1.247 . . . . 0.0 109.984 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.2 m -133.9 157.14 41.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-O 120.927 0.394 . . . . 0.0 110.697 -179.118 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.45 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 86.3 m -83.67 108.63 16.87 Favored 'General case' 0 C--N 1.296 -1.74 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.77 176.519 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -141.45 155.38 45.86 Favored 'General case' 0 N--CA 1.429 -1.518 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 -178.662 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 49.0 t . . . . . 0 C--N 1.3 -1.572 0 N-CA-C 108.293 -1.002 . . . . 0.0 108.293 177.326 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 29.6 p . . . . . 0 CA--C 1.519 -0.246 0 N-CA-C 110.078 -0.341 . . . . 0.0 110.078 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.425 HG23 ' SG ' ' A' ' 33' ' ' CYS . 16.6 m -107.95 168.37 3.42 Favored 'Isoleucine or valine' 0 C--O 1.243 0.743 0 CA-C-O 121.113 0.482 . . . . 0.0 110.946 178.467 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 29.2 mt -108.2 178.54 4.47 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.185 -173.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.506 ' HA ' ' HB2' ' A' ' 33' ' ' CYS . 26.9 pt -59.49 136.27 23.25 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.131 177.073 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.99 -13.45 59.4 Favored Glycine 0 C--N 1.311 -0.856 0 CA-C-N 115.843 -0.617 . . . . 0.0 112.596 178.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.455 ' O ' ' HA ' ' A' ' 32' ' ' VAL . 89.9 mt-30 -92.09 159.7 15.56 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 179.582 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.597 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 41.9 ttm180 -85.34 124.61 32.15 Favored 'General case' 0 C--N 1.317 -0.839 0 O-C-N 123.729 0.643 . . . . 0.0 110.805 -175.266 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 23.6 p -123.34 176.26 6.23 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.795 -177.285 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -145.81 125.63 13.49 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 174.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 47.3 m-80 -71.78 -30.0 65.08 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 113.339 0.866 . . . . 0.0 113.339 -175.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -91.37 -47.1 7.66 Favored 'General case' 0 C--N 1.295 -1.761 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 -172.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 51.0 mtp180 -106.1 -23.1 12.7 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 112.593 0.59 . . . . 0.0 112.593 -176.065 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 98.96 169.7 30.94 Favored Glycine 0 N--CA 1.431 -1.689 0 C-N-CA 119.825 -1.179 . . . . 0.0 110.479 -176.373 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -72.49 152.39 97.51 Favored 'Cis proline' 0 C--N 1.333 -0.258 0 CA-C-N 119.474 1.637 . . . . 0.0 112.32 1.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 73.1 mtt180 -105.89 160.77 15.0 Favored 'General case' 0 C--N 1.289 -2.06 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.263 -179.16 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.0 m -69.81 143.32 52.95 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 123.665 0.786 . . . . 0.0 110.953 -177.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 85.2 m -63.3 155.78 27.61 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 176.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.7 m -63.57 106.13 0.9 Allowed 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -179.478 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 101.6 29.61 6.19 Favored Glycine 0 N--CA 1.439 -1.142 0 N-CA-C 110.687 -0.965 . . . . 0.0 110.687 -176.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.405 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 23.0 mm-40 -126.7 36.01 4.53 Favored 'General case' 0 CA--C 1.496 -1.098 0 CA-C-O 121.26 0.553 . . . . 0.0 111.506 178.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 76.14 -163.32 53.09 Favored Glycine 0 N--CA 1.42 -2.375 0 C-N-CA 120.469 -0.872 . . . . 0.0 113.138 178.299 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -110.45 145.49 37.55 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 177.444 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 50.3 t -75.69 98.02 3.97 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 176.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.441 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 20.8 t -98.87 126.51 38.3 Favored Pre-proline 0 N--CA 1.427 -1.604 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 -176.725 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 7.8 Cg_exo -72.94 126.45 11.28 Favored 'Trans proline' 0 N--CA 1.45 -1.071 0 C-N-CA 122.714 2.276 . . . . 0.0 112.296 178.468 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.487 HD13 HG22 ' A' ' 32' ' ' VAL . 10.6 mp -121.63 119.79 29.02 Favored Pre-proline 0 C--N 1.306 -1.315 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 176.373 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_exo -37.62 -49.69 1.9 Allowed 'Trans proline' 0 CA--C 1.553 1.438 0 C-N-CA 124.634 3.556 . . . . 0.0 116.673 -174.381 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -89.64 -26.34 20.8 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 120.151 -0.619 . . . . 0.0 112.228 -176.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -94.91 -4.88 46.06 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 121.464 0.65 . . . . 0.0 110.793 -174.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 84.53 -77.65 2.09 Favored Glycine 0 N--CA 1.431 -1.699 0 N-CA-C 109.109 -1.597 . . . . 0.0 109.109 -178.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -168.64 138.2 4.98 Favored Glycine 0 N--CA 1.413 -2.864 0 N-CA-C 107.816 -2.114 . . . . 0.0 107.816 178.258 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.487 HG22 HD13 ' A' ' 26' ' ' LEU . 35.9 m -134.8 146.95 29.83 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 CA-C-O 121.251 0.548 . . . . 0.0 109.796 -178.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.506 ' HB2' ' HA ' ' A' ' 4' ' ' ILE . 81.1 m -72.81 124.69 25.88 Favored 'General case' 0 C--N 1.294 -1.841 0 CA-C-N 115.305 -0.862 . . . . 0.0 109.138 176.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -142.19 133.94 26.98 Favored 'General case' 0 N--CA 1.425 -1.702 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 -176.031 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.7 m . . . . . 0 C--N 1.306 -1.318 0 O-C-N 123.54 0.525 . . . . 0.0 110.72 179.82 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.4 p . . . . . 0 N--CA 1.452 -0.332 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.554 HG23 ' SG ' ' A' ' 33' ' ' CYS . 19.6 m -107.58 162.82 5.72 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.876 0 CA-C-O 121.188 0.518 . . . . 0.0 112.076 -176.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.402 ' O ' ' HB2' ' A' ' 6' ' ' GLN . 16.4 mt -106.98 -177.11 3.27 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.145 -174.528 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 37.7 pt -59.65 139.42 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 N-CA-C 112.483 0.549 . . . . 0.0 112.483 -178.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 83.25 -16.74 27.37 Favored Glycine 0 C--N 1.316 -0.542 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.626 179.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.402 ' HB2' ' O ' ' A' ' 3' ' ' LEU . 78.2 mt-30 -82.02 156.83 24.44 Favored 'General case' 0 N--CA 1.428 -1.53 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 178.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.479 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 43.5 ttp180 -85.94 129.61 34.79 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-N 114.618 -1.173 . . . . 0.0 110.451 -173.185 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 24.6 p -126.35 176.16 7.32 Favored 'General case' 0 C--N 1.284 -2.26 0 CA-C-N 115.296 -0.866 . . . . 0.0 110.138 -177.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -146.76 123.09 10.95 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 105.896 -1.89 . . . . 0.0 105.896 173.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 18.7 m120 -58.44 -45.73 87.96 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.645 -1.162 . . . . 0.0 112.611 -173.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -92.65 -52.89 4.42 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -175.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -85.72 -24.99 26.72 Favored 'General case' 0 C--N 1.315 -0.9 0 C-N-CA 120.1 -0.64 . . . . 0.0 112.563 -173.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 98.18 169.75 32.01 Favored Glycine 0 N--CA 1.43 -1.743 0 C-N-CA 120.135 -1.031 . . . . 0.0 111.291 -177.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -74.57 164.0 89.1 Favored 'Cis proline' 0 C--N 1.332 -0.334 0 C-N-CA 123.342 -1.524 . . . . 0.0 112.351 0.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 77.0 mtt180 -117.7 164.26 15.24 Favored 'General case' 0 C--N 1.292 -1.895 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.076 -178.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.417 ' HA ' ' O ' ' A' ' 2' ' ' VAL . 28.0 m -71.16 140.72 50.63 Favored 'General case' 0 C--N 1.289 -2.038 0 C-N-CA 123.829 0.852 . . . . 0.0 110.192 -177.348 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.429 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 59.0 m -67.26 151.98 46.54 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 176.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.3 t -67.15 103.66 1.26 Allowed 'General case' 0 N--CA 1.439 -1.005 0 C-N-CA 123.424 0.69 . . . . 0.0 109.181 -177.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 122.92 -12.3 8.67 Favored Glycine 0 N--CA 1.437 -1.267 0 N-CA-C 110.429 -1.068 . . . . 0.0 110.429 -177.384 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.429 ' CG ' ' HB2' ' A' ' 17' ' ' CYS . 84.2 mm-40 -85.78 -45.12 11.91 Favored 'General case' 0 CA--C 1.5 -0.96 0 CA-C-N 115.46 -0.37 . . . . 0.0 110.353 178.661 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 152.71 -161.62 29.61 Favored Glycine 0 N--CA 1.419 -2.45 0 C-N-CA 119.079 -1.534 . . . . 0.0 113.019 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -112.36 147.43 36.4 Favored 'General case' 0 C--N 1.279 -2.475 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 178.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 53.0 t -82.0 105.98 13.55 Favored 'General case' 0 C--N 1.294 -1.83 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.129 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -92.53 117.04 67.45 Favored Pre-proline 0 C--N 1.311 -1.078 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 176.184 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -74.36 148.25 38.13 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 122.025 1.817 . . . . 0.0 114.114 -174.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 8.1 mp -126.28 132.39 24.3 Favored Pre-proline 0 C--N 1.308 -1.198 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 176.573 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_exo -39.0 -57.2 1.01 Allowed 'Trans proline' 0 CA--C 1.543 0.933 0 C-N-CA 124.611 3.541 . . . . 0.0 115.299 -175.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -93.43 -46.4 7.35 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-O 121.801 0.81 . . . . 0.0 110.327 -178.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 26.7 mt -77.15 0.52 21.36 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 114.339 -1.3 . . . . 0.0 113.189 -167.439 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 87.03 -65.79 3.65 Favored Glycine 0 CA--C 1.492 -1.345 0 N-CA-C 112.201 -0.36 . . . . 0.0 112.201 175.069 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.479 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . 165.02 162.75 16.77 Favored Glycine 0 N--CA 1.412 -2.944 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.8 m -135.46 147.64 28.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 177.462 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.554 ' SG ' HG23 ' A' ' 2' ' ' VAL . 94.7 m -80.42 131.47 35.6 Favored 'General case' 0 C--N 1.293 -1.856 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.692 177.24 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.61 168.61 26.59 Favored 'General case' 0 N--CA 1.427 -1.596 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 -178.095 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 4.1 p . . . . . 0 C--O 1.259 1.586 0 C-N-CA 123.919 0.888 . . . . 0.0 113.101 -178.925 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 22.3 p . . . . . 0 N--CA 1.447 -0.606 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.569 HG23 ' SG ' ' A' ' 16' ' ' CYS . 23.8 m -94.15 178.42 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.594 -0.276 . . . . 0.0 110.586 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 27.3 mt -117.84 -176.01 2.95 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 112.667 0.617 . . . . 0.0 112.667 -172.669 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.532 HG13 ' OE1' ' A' ' 20' ' ' GLN . 66.4 mt -56.6 135.88 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 123.714 0.806 . . . . 0.0 110.764 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.04 -6.85 73.4 Favored Glycine 0 C--N 1.313 -0.704 0 C-N-CA 121.447 -0.406 . . . . 0.0 112.693 177.29 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -94.14 150.55 20.22 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 178.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.2 tmm_? -86.76 129.7 34.77 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.5 -172.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 18.5 p -128.33 175.45 8.48 Favored 'General case' 0 C--N 1.297 -1.694 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.175 -175.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -152.9 121.51 6.4 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 106.161 -1.792 . . . . 0.0 106.161 174.456 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -72.17 -26.27 62.01 Favored 'General case' 0 C--N 1.294 -1.843 0 CA-C-O 120.832 0.349 . . . . 0.0 111.091 -174.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -78.74 -56.8 4.14 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.788 -176.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 26.9 mmm180 -106.53 -9.61 16.55 Favored 'General case' 0 C--N 1.312 -1.043 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -174.216 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 90.64 165.51 40.39 Favored Glycine 0 C--N 1.297 -1.622 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -177.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -81.39 170.87 60.26 Favored 'Cis proline' 0 CA--C 1.534 0.486 0 C-N-CA 123.385 -1.506 . . . . 0.0 111.831 0.314 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 78.7 mtm180 -122.76 152.12 40.94 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.14 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.569 ' SG ' HG23 ' A' ' 2' ' ' VAL . 57.9 m -86.01 158.67 19.8 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.068 -176.345 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.445 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 26.4 m -67.28 153.81 42.79 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 178.295 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.7 m -46.86 -45.59 20.41 Favored 'General case' 0 CA--C 1.56 1.334 0 N-CA-C 115.188 1.551 . . . . 0.0 115.188 -172.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -97.0 22.01 43.06 Favored Glycine 0 C--N 1.318 -0.472 0 C-N-CA 120.501 -0.857 . . . . 0.0 112.559 -178.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.532 ' OE1' HG13 ' A' ' 4' ' ' ILE . 85.9 mm-40 -105.28 23.28 13.96 Favored 'General case' 0 C--N 1.311 -1.1 0 O-C-N 122.648 -0.324 . . . . 0.0 111.692 -178.602 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 92.65 -177.42 38.88 Favored Glycine 0 N--CA 1.43 -1.7 0 C-N-CA 120.451 -0.881 . . . . 0.0 112.774 177.154 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 33' ' ' CYS . 35.3 t30 -119.16 143.8 47.03 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 179.135 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 92.2 m -63.38 102.04 0.37 Allowed 'General case' 0 C--N 1.316 -0.872 0 O-C-N 123.871 0.732 . . . . 0.0 110.535 178.103 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.7 m -110.1 137.23 20.49 Favored Pre-proline 0 N--CA 1.421 -1.924 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 177.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -67.91 120.85 7.85 Favored 'Trans proline' 0 N--CA 1.448 -1.184 0 C-N-CA 121.699 1.6 . . . . 0.0 112.14 -178.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.41 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 56.5 tp -115.98 104.99 51.91 Favored Pre-proline 0 N--CA 1.42 -1.964 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 176.131 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 18.3 Cg_exo -70.78 56.15 1.79 Allowed 'Trans proline' 0 N--CA 1.479 0.653 0 C-N-CA 124.056 3.171 . . . . 0.0 113.219 -175.53 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -148.06 -63.54 0.26 Allowed 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 125.294 1.438 . . . . 0.0 108.09 179.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -104.03 -19.38 14.22 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.518 -179.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 121.76 -165.01 14.73 Favored Glycine 0 C--N 1.305 -1.167 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -177.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -72.91 125.43 9.82 Favored Glycine 0 CA--C 1.49 -1.481 0 C-N-CA 119.986 -1.102 . . . . 0.0 110.356 177.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 33.2 m -127.62 153.14 36.55 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.327 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -176.733 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.478 ' HA ' ' O ' ' A' ' 22' ' ' ASN . 74.1 m -85.84 116.55 24.16 Favored 'General case' 0 C--N 1.284 -2.246 0 C-N-CA 119.718 -0.793 . . . . 0.0 111.25 178.302 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.54 168.51 22.54 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.256 179.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.1 t . . . . . 0 C--N 1.307 -1.255 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 176.507 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.5 p . . . . . 0 C--O 1.244 0.808 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.405 HG23 ' SG ' ' A' ' 33' ' ' CYS . 27.9 m -116.35 159.44 16.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-O 120.916 0.389 . . . . 0.0 111.243 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 67.8 mt -105.41 -177.83 3.48 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 115.58 -0.737 . . . . 0.0 111.01 -175.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.5 pt -56.05 137.34 17.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 178.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.15 -14.42 60.79 Favored Glycine 0 C--N 1.316 -0.543 0 CA-C-N 115.761 -0.654 . . . . 0.0 113.288 177.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.438 ' O ' ' HA ' ' A' ' 32' ' ' VAL . 78.0 mt-30 -87.73 162.06 17.26 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-O 121.031 0.443 . . . . 0.0 110.794 -178.453 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.406 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 37.6 ttt180 -84.88 123.59 30.66 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 114.753 -1.112 . . . . 0.0 109.092 -175.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -134.88 167.6 20.59 Favored 'General case' 0 C--N 1.294 -1.82 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.038 -176.702 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -146.55 130.54 17.27 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 175.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 35.7 m-80 -66.32 -40.33 89.86 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 114.753 -1.112 . . . . 0.0 112.977 -171.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -93.04 -52.01 4.78 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -175.113 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 78.4 mtp180 -84.46 -24.68 29.39 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.29 -173.028 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 99.58 163.17 29.22 Favored Glycine 0 N--CA 1.429 -1.818 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -175.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -81.15 159.73 82.94 Favored 'Cis proline' 0 N--CA 1.446 -1.311 0 CA-C-N 119.662 1.731 . . . . 0.0 111.296 0.267 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -107.94 149.93 27.72 Favored 'General case' 0 C--N 1.291 -1.972 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.017 -178.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 45.7 m -65.08 142.45 58.38 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.053 -0.976 . . . . 0.0 108.6 178.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 61.2 m -63.84 144.96 56.64 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 176.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.7 p -53.04 86.54 0.0 OUTLIER 'General case' 0 CA--C 1.546 0.818 0 N-CA-C 113.909 1.077 . . . . 0.0 113.909 -176.144 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.6 26.81 1.54 Allowed Glycine 0 N--CA 1.435 -1.392 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.3 -178.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 23.1 mm-40 -115.87 30.19 7.5 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.427 0.632 . . . . 0.0 111.87 179.133 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.64 -150.5 24.4 Favored Glycine 0 N--CA 1.425 -2.073 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.402 177.164 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.8 p-10 -130.64 159.35 37.46 Favored 'General case' 0 C--N 1.287 -2.127 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 179.064 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 85.5 m -77.5 99.27 5.61 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 123.572 0.545 . . . . 0.0 109.798 175.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 14.6 p -90.22 120.47 69.15 Favored Pre-proline 0 N--CA 1.421 -1.914 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 176.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -74.59 134.73 18.94 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 121.982 1.788 . . . . 0.0 113.222 -176.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.0 mt -135.94 129.92 18.34 Favored Pre-proline 0 C--N 1.301 -1.513 0 CA-C-N 115.046 -0.979 . . . . 0.0 108.573 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.79 54.23 2.01 Favored 'Trans proline' 0 CA--C 1.536 0.581 0 C-N-CA 124.031 3.154 . . . . 0.0 113.898 -174.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -143.06 -66.9 0.37 Allowed 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 178.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.618 ' H ' HD23 ' A' ' 29' ' ' LEU . 1.9 pt? -107.45 0.27 22.73 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.496 -0.774 . . . . 0.0 112.369 -178.458 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 109.94 -86.88 0.45 Allowed Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.393 -0.908 . . . . 0.0 111.39 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.406 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -152.54 148.83 20.19 Favored Glycine 0 CA--C 1.49 -1.518 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.438 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 28.4 m -128.79 145.79 35.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 120.834 0.349 . . . . 0.0 111.439 -178.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.405 ' SG ' HG23 ' A' ' 2' ' ' VAL . 79.7 m -71.72 121.68 19.31 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 175.598 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -142.33 136.49 29.74 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.025 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 58.1 t . . . . . 0 N--CA 1.438 -1.07 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 177.192 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.4 p . . . . . 0 C--O 1.242 0.694 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.443 HG23 ' SG ' ' A' ' 33' ' ' CYS . 26.1 m -108.87 162.68 6.55 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.166 0.508 . . . . 0.0 111.277 -179.038 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 54.3 mt -105.79 -175.28 2.75 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.737 -175.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.5 pt -58.02 129.03 19.48 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 N-CA-C 113.224 0.824 . . . . 0.0 113.224 -178.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.18 -13.92 65.02 Favored Glycine 0 CA--C 1.503 -0.664 0 CA-C-N 115.639 -0.71 . . . . 0.0 112.681 177.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.42 ' HB2' ' HB ' ' A' ' 2' ' ' VAL . 87.5 mt-30 -88.82 159.72 17.59 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.408 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 62.1 ttt180 -86.02 131.37 34.28 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.827 -173.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.7 p -126.2 156.67 39.86 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.813 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -137.38 126.57 24.58 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 176.202 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 46.9 m-80 -78.98 -31.62 44.96 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 120.485 -0.486 . . . . 0.0 111.893 -178.09 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -72.67 -52.86 13.55 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-O 121.097 0.475 . . . . 0.0 111.727 -174.7 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.423 ' HA ' ' NE ' ' A' ' 12' ' ' ARG . 5.4 mmp_? -108.06 -17.58 14.0 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 113.398 0.888 . . . . 0.0 113.398 -176.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 91.26 168.28 41.5 Favored Glycine 0 N--CA 1.432 -1.6 0 C-N-CA 119.842 -1.17 . . . . 0.0 110.502 -177.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -79.25 159.9 89.53 Favored 'Cis proline' 0 C--N 1.329 -0.47 0 CA-C-N 119.082 1.441 . . . . 0.0 111.863 -1.143 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 83.0 mtm180 -109.6 177.0 4.87 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 178.514 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.2 m -70.51 144.45 51.35 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 86.3 m -68.17 145.02 54.73 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 173.585 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.5 t -50.93 99.0 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.236 1.015 . . . . 0.0 112.177 -175.724 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 118.01 -11.33 13.33 Favored Glycine 0 N--CA 1.443 -0.84 0 CA-C-N 115.83 -0.623 . . . . 0.0 112.123 179.3 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.476 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 23.7 mm-40 -86.17 23.55 1.52 Allowed 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 114.674 1.361 . . . . 0.0 114.674 -176.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 101.27 -176.63 26.86 Favored Glycine 0 N--CA 1.427 -1.946 0 C-N-CA 119.439 -1.362 . . . . 0.0 113.934 174.441 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 38.4 m-80 -113.4 150.31 32.88 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 179.407 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 89.1 m -74.52 98.18 3.29 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 123.193 0.308 . . . . 0.0 111.101 179.112 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.9 t -82.42 122.24 78.84 Favored Pre-proline 0 C--N 1.303 -1.42 0 N-CA-C 106.279 -1.749 . . . . 0.0 106.279 175.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -86.4 121.72 1.98 Allowed 'Trans proline' 0 N--CA 1.439 -1.686 0 C-N-CA 122.66 2.24 . . . . 0.0 113.679 -174.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -119.45 148.41 45.56 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 178.011 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_exo -41.19 -69.3 0.08 OUTLIER 'Trans proline' 0 CA--C 1.548 1.198 0 C-N-CA 124.74 3.627 . . . . 0.0 116.037 -175.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 24.6 p90 -93.01 -17.66 23.61 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 112.966 0.728 . . . . 0.0 112.966 -173.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 96.5 mt -86.64 -13.48 45.49 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.495 179.227 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 81.79 -79.46 1.84 Allowed Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.84 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.408 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -166.34 136.26 4.07 Favored Glycine 0 N--CA 1.426 -1.992 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 179.471 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 36.0 m -126.51 143.44 39.99 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 CA-C-O 120.909 0.385 . . . . 0.0 110.821 -179.006 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.476 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 74.8 m -71.42 114.08 9.12 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.792 178.696 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.43 156.41 42.45 Favored 'General case' 0 C--N 1.315 -0.912 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 178.561 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 39.3 t . . . . . 0 C--O 1.255 1.37 0 C-N-CA 123.684 0.794 . . . . 0.0 110.006 -179.315 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.5 p . . . . . 0 C--O 1.24 0.56 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.435 ' HB ' ' HB2' ' A' ' 6' ' ' GLN . 33.9 m -110.75 164.68 6.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 121.185 0.517 . . . . 0.0 110.866 -178.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 48.4 mt -102.47 -179.22 3.92 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.767 -178.286 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 27.3 pt -59.4 133.19 24.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.126 0.489 . . . . 0.0 112.213 178.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.1 -10.26 75.47 Favored Glycine 0 C--N 1.316 -0.536 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.98 178.535 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.435 ' HB2' ' HB ' ' A' ' 2' ' ' VAL . 86.7 mt-30 -94.85 157.53 15.88 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.124 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 2.7 tmm_? -85.96 124.55 32.53 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.367 -173.618 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.46 ' HB2' ' HA ' ' A' ' 15' ' ' ARG . 10.4 p -121.36 165.8 15.01 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.009 179.254 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -125.0 124.93 43.06 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 176.296 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -73.48 -33.43 64.82 Favored 'General case' 0 C--N 1.305 -1.365 0 N-CA-C 112.751 0.649 . . . . 0.0 112.751 -171.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -91.17 -50.56 5.77 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 120.542 -0.463 . . . . 0.0 111.928 -175.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 58.4 mtp180 -102.18 -8.67 21.14 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -172.177 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.14 168.36 44.57 Favored Glycine 0 C--N 1.31 -0.909 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.491 178.304 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -81.87 166.89 70.91 Favored 'Cis proline' 0 N--CA 1.474 0.327 0 C-N-CA 123.837 -1.318 . . . . 0.0 111.283 -0.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.46 ' HA ' ' HB2' ' A' ' 8' ' ' CYS . 73.4 mtm180 -121.49 -173.79 2.71 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 116.763 -0.199 . . . . 0.0 111.006 178.283 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 33.1 m -60.38 144.46 50.78 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 123.846 0.859 . . . . 0.0 112.142 -178.302 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 74.4 m -71.97 166.23 22.6 Favored 'General case' 0 C--O 1.243 0.731 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 170.541 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.7 t -67.83 109.82 3.55 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.056 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 101.16 26.68 7.71 Favored Glycine 0 N--CA 1.443 -0.886 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 -179.253 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.537 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 86.9 mm-40 -126.06 35.68 4.64 Favored 'General case' 0 C--N 1.318 -0.792 0 O-C-N 122.68 -0.306 . . . . 0.0 111.503 -179.239 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 70.81 -158.59 53.71 Favored Glycine 0 C--O 1.248 0.997 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.407 178.617 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -127.05 158.84 35.91 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 176.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 98.4 m -68.66 104.81 2.08 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 121.168 0.509 . . . . 0.0 110.779 178.616 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 59.9 t -91.83 120.06 68.14 Favored Pre-proline 0 N--CA 1.426 -1.647 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 175.608 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_exo -67.51 136.86 40.95 Favored 'Trans proline' 0 N--CA 1.445 -1.37 0 C-N-CA 122.459 2.106 . . . . 0.0 111.858 -179.461 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 24.0 tp -132.49 117.01 15.3 Favored Pre-proline 0 C--N 1.29 -2.017 0 N-CA-C 105.271 -2.122 . . . . 0.0 105.271 176.224 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -63.42 51.61 0.14 Allowed 'Trans proline' 0 N--CA 1.502 1.982 0 C-N-CA 125.029 3.819 . . . . 0.0 116.575 -170.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -144.34 -64.39 0.36 Allowed 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 177.531 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.641 ' H ' HD23 ' A' ' 29' ' ' LEU . 1.9 pt? -103.7 -3.4 25.11 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.213 -0.903 . . . . 0.0 112.88 -173.148 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 113.94 -103.91 1.39 Allowed Glycine 0 C--N 1.304 -1.216 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -177.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -139.78 152.48 22.63 Favored Glycine 0 N--CA 1.43 -1.724 0 C-N-CA 120.674 -0.774 . . . . 0.0 111.425 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 19.5 m -132.06 139.71 49.63 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.537 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 84.2 m -69.31 128.14 35.53 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.295 179.271 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -164.85 158.36 17.27 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 109.484 -0.562 . . . . 0.0 109.484 -178.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.2 t . . . . . 0 C--O 1.252 1.206 0 O-C-N 124.9 1.375 . . . . 0.0 111.603 177.329 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.6 p . . . . . 0 N--CA 1.456 -0.164 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.48 HG23 ' SG ' ' A' ' 33' ' ' CYS . 15.3 m -105.43 164.59 4.05 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-O 121.094 0.473 . . . . 0.0 111.846 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 21.4 mt -107.39 178.84 4.42 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.244 -173.652 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 40.0 pt -57.85 137.35 20.15 Favored 'Isoleucine or valine' 0 C--O 1.24 0.57 0 CA-C-O 121.571 0.7 . . . . 0.0 112.685 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.13 -23.98 24.18 Favored Glycine 0 C--N 1.306 -1.083 0 CA-C-N 115.645 -0.707 . . . . 0.0 112.795 178.661 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 92.3 mt-30 -82.8 155.79 24.01 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -178.316 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.9 tmm_? -85.75 127.18 34.47 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -173.512 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 21.8 p -122.52 172.92 8.02 Favored 'General case' 0 C--N 1.288 -2.107 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.376 -177.109 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -153.35 124.02 7.24 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 177.001 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 -72.96 -37.79 66.98 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 112.64 0.607 . . . . 0.0 112.64 -174.475 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -85.6 -47.3 9.98 Favored 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 120.072 -0.651 . . . . 0.0 112.533 -174.656 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 5.1 mmp_? -93.58 -29.21 15.6 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.891 -0.723 . . . . 0.0 112.196 -177.327 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 103.61 162.45 25.14 Favored Glycine 0 N--CA 1.434 -1.471 0 N-CA-C 109.826 -1.31 . . . . 0.0 109.826 -175.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -82.77 157.59 76.47 Favored 'Cis proline' 0 CA--C 1.535 0.536 0 CA-C-N 119.276 1.538 . . . . 0.0 112.432 1.278 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 63.7 mtm180 -107.23 157.04 18.21 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-O 120.853 0.359 . . . . 0.0 110.054 179.7 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 35.6 m -68.51 142.85 55.15 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 124.19 0.996 . . . . 0.0 110.282 -178.654 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.446 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 54.7 m -67.78 154.4 41.61 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 174.032 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.1 p -54.55 -23.05 15.04 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 115.776 1.769 . . . . 0.0 115.776 -171.196 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -115.83 22.84 11.31 Favored Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 177.483 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.446 ' CG ' ' HB2' ' A' ' 17' ' ' CYS . 86.4 mm-40 -115.56 20.9 14.41 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.254 0.55 . . . . 0.0 110.91 -178.236 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 80.16 -151.6 33.46 Favored Glycine 0 N--CA 1.426 -2.002 0 C-N-CA 120.282 -0.961 . . . . 0.0 113.166 176.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -135.88 168.57 19.07 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 77.6 m -74.74 124.72 27.3 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 123.648 0.592 . . . . 0.0 111.234 -179.182 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 22.0 t -106.25 116.52 59.22 Favored Pre-proline 0 C--N 1.291 -1.954 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 173.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.427 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 56.4 Cg_endo -80.72 125.01 5.34 Favored 'Trans proline' 0 N--CA 1.445 -1.371 0 C-N-CA 122.583 2.188 . . . . 0.0 112.953 -175.702 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.405 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 4.1 pp -118.72 153.96 52.52 Favored Pre-proline 0 C--N 1.302 -1.47 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.23 178.742 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 5.4 Cg_endo -83.54 49.66 2.99 Favored 'Trans proline' 0 C--O 1.236 0.396 0 C-N-CA 123.53 2.82 . . . . 0.0 113.935 -170.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -141.48 -77.59 0.28 Allowed 'General case' 0 C--N 1.314 -0.959 0 CA-C-O 120.878 0.37 . . . . 0.0 110.915 179.29 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.468 ' H ' HD13 ' A' ' 29' ' ' LEU . 0.0 OUTLIER -106.85 0.88 24.31 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -177.11 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 116.98 -138.62 14.44 Favored Glycine 0 N--CA 1.437 -1.266 0 C-N-CA 120.371 -0.919 . . . . 0.0 111.206 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.427 ' HA2' ' HA ' ' A' ' 25' ' ' PRO . . . -108.92 149.23 17.0 Favored Glycine 0 N--CA 1.428 -1.841 0 C-N-CA 120.395 -0.907 . . . . 0.0 112.52 -178.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.8 m -124.04 146.75 29.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 177.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.48 ' SG ' HG23 ' A' ' 2' ' ' VAL . 74.4 m -71.1 136.7 48.35 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.828 179.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -160.33 146.06 15.16 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.7 t . . . . . 0 C--N 1.307 -1.258 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 -179.063 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.5 p . . . . . 0 N--CA 1.443 -0.778 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.451 HG23 ' SG ' ' A' ' 33' ' ' CYS . 35.7 m -102.26 169.19 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-O 121.146 0.498 . . . . 0.0 111.088 -178.427 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 26.0 mt -109.84 -176.11 2.92 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.399 -0.818 . . . . 0.0 110.542 -175.432 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.514 HG13 ' OE1' ' A' ' 20' ' ' GLN . 61.5 mt -56.37 133.25 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 122.681 0.392 . . . . 0.0 111.029 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.26 -15.03 56.09 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 116.024 -0.534 . . . . 0.0 113.057 177.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -88.42 159.25 18.09 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 -178.662 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.551 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 85.9 mtm180 -86.63 134.53 33.62 Favored 'General case' 0 CA--C 1.496 -1.098 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.916 -175.523 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.427 ' HB3' ' CG2' ' A' ' 2' ' ' VAL . 24.0 p -139.49 171.34 14.4 Favored 'General case' 0 C--N 1.285 -2.205 0 CA-C-N 114.276 -1.329 . . . . 0.0 109.379 -178.148 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -145.51 125.7 13.8 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 174.427 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -65.79 -32.75 74.46 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -177.308 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -91.16 -52.34 4.87 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -172.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 55.3 mtp180 -92.46 -25.91 18.22 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -176.068 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 90.51 167.92 42.07 Favored Glycine 0 N--CA 1.437 -1.288 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -76.78 168.84 76.04 Favored 'Cis proline' 0 N--CA 1.475 0.387 0 CA-C-N 119.669 1.735 . . . . 0.0 110.517 -0.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 5.7 mpt_? -116.09 -179.18 3.59 Favored 'General case' 0 C--N 1.291 -1.943 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.267 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.7 m -70.71 148.59 47.82 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 178.161 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 60.9 m -69.85 142.86 53.01 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 106.04 -1.837 . . . . 0.0 106.04 170.526 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.6 m -62.23 99.23 0.13 Allowed 'General case' 0 C--O 1.243 0.749 0 CA-C-O 121.002 0.429 . . . . 0.0 111.111 -175.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 128.84 -6.59 6.49 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.204 -176.372 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.514 ' OE1' HG13 ' A' ' 4' ' ' ILE . 84.8 mm-40 -98.42 10.87 39.82 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 -178.478 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.452 ' HA2' ' HB ' ' A' ' 35' ' ' VAL . . . 103.73 -172.44 20.97 Favored Glycine 0 N--CA 1.442 -0.963 0 C-N-CA 120.009 -1.091 . . . . 0.0 113.442 176.138 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 -117.02 147.16 42.57 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 -179.301 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 96.1 m -72.67 102.21 3.26 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 123.884 0.74 . . . . 0.0 112.018 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.2 p -87.23 119.85 71.08 Favored Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 171.299 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -82.97 141.13 10.42 Favored 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 121.987 1.791 . . . . 0.0 114.606 -173.141 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 5.8 mp -122.83 122.97 26.98 Favored Pre-proline 0 C--N 1.3 -1.551 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 177.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_exo -36.34 -54.64 0.88 Allowed 'Trans proline' 0 N--CA 1.485 1.015 0 C-N-CA 124.957 3.772 . . . . 0.0 116.012 -175.398 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -111.05 -15.35 13.74 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 113.75 1.018 . . . . 0.0 113.75 -177.647 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -80.0 -30.13 39.58 Favored 'General case' 0 C--N 1.294 -1.836 0 C-N-CA 120.313 -0.555 . . . . 0.0 112.002 174.521 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 114.73 -99.0 0.9 Allowed Glycine 0 N--CA 1.431 -1.664 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.551 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -171.64 148.62 11.15 Favored Glycine 0 C--N 1.282 -2.471 0 N-CA-C 108.649 -1.78 . . . . 0.0 108.649 178.147 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 31.5 m -130.47 145.91 34.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 CA-C-N 117.928 0.864 . . . . 0.0 111.484 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.451 ' SG ' HG23 ' A' ' 2' ' ' VAL . 71.9 m -76.11 116.74 17.11 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.896 176.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -141.56 149.19 40.48 Favored 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -179.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.452 ' HB ' ' HA2' ' A' ' 21' ' ' GLY . 4.1 p . . . . . 0 C--N 1.3 -1.544 0 CA-C-O 118.74 -0.647 . . . . 0.0 109.485 177.232 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.0 p . . . . . 0 C--O 1.227 -0.118 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.532 HG23 ' SG ' ' A' ' 33' ' ' CYS . 16.5 m -110.13 161.21 8.68 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -177.54 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 36.0 mt -107.41 -178.96 3.78 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.09 -175.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 24.0 pt -61.13 128.81 23.03 Favored 'Isoleucine or valine' 0 C--O 1.238 0.489 0 N-CA-C 113.282 0.845 . . . . 0.0 113.282 -179.337 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.62 -5.35 73.57 Favored Glycine 0 N--CA 1.443 -0.859 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.767 -179.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 77.5 mt-30 -101.32 156.01 17.7 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 176.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.401 ' NH1' HD22 ' A' ' 29' ' ' LEU . 54.1 mtm180 -86.03 140.75 30.0 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.727 0.775 . . . . 0.0 112.606 -173.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.415 ' SG ' ' N ' ' A' ' 9' ' ' ASP . 1.6 t -133.16 171.68 13.68 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-N 113.68 -1.6 . . . . 0.0 109.321 -175.16 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.415 ' N ' ' SG ' ' A' ' 8' ' ' CYS . 17.1 t70 -161.86 118.73 2.13 Favored 'General case' 0 C--N 1.276 -2.59 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 172.363 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -57.68 -39.57 77.43 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 113.984 1.105 . . . . 0.0 113.984 -175.536 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -91.13 -47.78 7.33 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -175.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 29.1 mmt180 -80.7 -43.0 21.01 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.709 0.766 . . . . 0.0 111.592 -177.012 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 105.46 163.87 23.55 Favored Glycine 0 N--CA 1.425 -2.064 0 N-CA-C 108.337 -1.905 . . . . 0.0 108.337 -172.286 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -79.01 165.85 80.58 Favored 'Cis proline' 0 C--N 1.322 -0.865 0 CA-C-N 119.88 1.84 . . . . 0.0 111.891 -0.002 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 60.5 mtp180 -108.2 153.49 23.11 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 179.412 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 55.9 m -68.01 138.69 56.07 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 55.9 m -65.93 158.28 28.5 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 178.148 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.8 t -60.89 104.43 0.36 Allowed 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 123.194 0.597 . . . . 0.0 110.343 -179.342 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 108.85 17.35 10.4 Favored Glycine 0 N--CA 1.443 -0.897 0 N-CA-C 111.524 -0.631 . . . . 0.0 111.524 -178.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 83.6 mm-40 -111.18 52.19 0.75 Allowed 'General case' 0 C--N 1.307 -1.243 0 O-C-N 122.038 -0.684 . . . . 0.0 111.591 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 71.03 -143.4 36.15 Favored Glycine 0 N--CA 1.434 -1.492 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.376 178.079 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 46.4 m-80 -128.94 146.12 51.04 Favored 'General case' 0 C--N 1.289 -2.05 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 176.194 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 42.9 t -83.11 97.12 8.63 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.01 -1.107 . . . . 0.0 108.01 179.036 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.0 p -94.37 114.99 64.72 Favored Pre-proline 0 N--CA 1.432 -1.341 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.353 -179.426 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.485 ' HA ' ' CA ' ' A' ' 31' ' ' GLY . 73.9 Cg_endo -76.72 142.15 22.54 Favored 'Trans proline' 0 N--CA 1.449 -1.136 0 C-N-CA 122.557 2.172 . . . . 0.0 113.605 -176.107 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 5.8 mp -116.06 142.4 29.16 Favored Pre-proline 0 N--CA 1.422 -1.867 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 172.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_endo -74.57 53.99 3.3 Favored 'Trans proline' 0 C--N 1.326 -0.65 0 C-N-CA 123.164 2.576 . . . . 0.0 113.464 -177.247 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.46 ' HB3' HD12 ' A' ' 29' ' ' LEU . 70.2 m-85 -139.17 -87.51 0.22 Allowed 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 178.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.46 HD12 ' HB3' ' A' ' 28' ' ' PHE . 4.5 mp -104.66 -28.27 11.33 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-O 121.589 0.709 . . . . 0.0 110.47 -176.181 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 167.41 -152.59 21.32 Favored Glycine 0 N--CA 1.418 -2.543 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -179.22 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.485 ' CA ' ' HA ' ' A' ' 25' ' ' PRO . . . -113.42 -172.75 18.36 Favored Glycine 0 N--CA 1.411 -3.033 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.3 p -138.06 152.59 26.22 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.24 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.061 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.532 ' SG ' HG23 ' A' ' 2' ' ' VAL . 63.7 m -89.12 119.43 29.62 Favored 'General case' 0 C--N 1.275 -2.633 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.297 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.04 139.56 24.83 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -176.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 C--N 1.306 -1.316 0 CA-C-O 118.867 -0.587 . . . . 0.0 109.978 -179.861 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.7 p . . . . . 0 CA--C 1.513 -0.45 0 N-CA-C 109.29 -0.634 . . . . 0.0 109.29 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.458 ' HB ' ' HB2' ' A' ' 6' ' ' GLN . 33.5 m -103.17 152.53 5.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-O 120.953 0.406 . . . . 0.0 111.076 -177.293 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 52.3 mt -97.68 -174.3 2.86 Favored 'General case' 0 N--CA 1.438 -1.043 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.667 -179.273 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 43.2 pt -59.28 142.06 15.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.059 0.457 . . . . 0.0 111.704 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.59 -26.07 8.67 Favored Glycine 0 C--N 1.311 -0.82 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.26 178.366 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.458 ' HB2' ' HB ' ' A' ' 2' ' ' VAL . 24.1 mt-30 -79.18 152.92 30.42 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -178.552 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 10.2 mpt_? -86.76 136.86 32.84 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.883 -175.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.5 p -130.02 168.27 16.98 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.984 -175.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -132.5 123.68 27.06 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.9 m120 -72.73 -26.59 61.63 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -175.685 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -84.17 -56.55 3.6 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-O 121.228 0.537 . . . . 0.0 111.4 -175.112 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 71.9 mtm180 -105.45 -24.14 12.69 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 -170.339 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 95.48 172.48 36.59 Favored Glycine 0 N--CA 1.426 -1.999 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 -172.744 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -72.21 160.54 93.94 Favored 'Cis proline' 0 C--O 1.235 0.373 0 CA-C-N 119.771 1.785 . . . . 0.0 111.574 -0.218 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 57.8 mtm180 -120.18 176.04 5.65 Favored 'General case' 0 C--N 1.291 -1.959 0 CA-C-N 116.495 -0.321 . . . . 0.0 110.17 179.281 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 20.5 m -68.02 144.45 55.12 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 123.607 0.567 . . . . 0.0 109.494 -178.501 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . 0.405 ' HB2' ' HG3' ' A' ' 20' ' ' GLN . 52.9 m -67.9 145.67 54.36 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 105.977 -1.86 . . . . 0.0 105.977 171.333 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 14.6 p -56.43 107.75 0.41 Allowed 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 112.017 0.377 . . . . 0.0 112.017 -177.218 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 115.03 -11.46 20.32 Favored Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.497 -177.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.452 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 86.8 mm-40 -91.98 26.61 2.39 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-O 121.321 0.581 . . . . 0.0 111.45 -178.514 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.84 -168.02 37.17 Favored Glycine 0 N--CA 1.415 -2.73 0 C-N-CA 120.54 -0.838 . . . . 0.0 113.074 176.41 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 47.4 m-80 -129.9 153.07 48.68 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 -179.121 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 74.3 m -68.32 104.7 1.93 Allowed 'General case' 0 C--N 1.314 -0.946 0 O-C-N 123.895 0.747 . . . . 0.0 112.602 -176.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.53 117.5 61.78 Favored Pre-proline 0 N--CA 1.434 -1.259 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 175.248 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.443 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 6.1 Cg_exo -77.98 122.36 5.76 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 122.125 1.884 . . . . 0.0 112.198 -179.051 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.423 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 34.9 tp -129.31 109.92 17.86 Favored Pre-proline 0 N--CA 1.427 -1.607 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 175.351 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 35.5 Cg_exo -64.29 51.53 0.18 Allowed 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 125.122 3.881 . . . . 0.0 116.476 -172.464 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -139.16 -53.34 0.56 Allowed 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 174.009 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.669 ' H ' HD23 ' A' ' 29' ' ' LEU . 1.9 pt? -107.05 -18.37 13.92 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 114.595 -1.184 . . . . 0.0 111.842 -178.011 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 115.42 -154.97 16.61 Favored Glycine 0 N--CA 1.442 -0.954 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.443 ' HA2' ' HA ' ' A' ' 25' ' ' PRO . . . -101.81 123.94 8.05 Favored Glycine 0 CA--C 1.483 -1.965 0 N-CA-C 110.136 -1.186 . . . . 0.0 110.136 178.352 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 33.3 m -120.12 150.41 22.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.047 0 CA-C-O 121.157 0.503 . . . . 0.0 111.601 -174.101 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.452 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 82.0 m -75.13 116.43 15.86 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.152 176.12 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -130.86 136.3 48.51 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.56 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 55.2 t . . . . . 0 C--N 1.315 -0.933 0 CA-C-O 118.778 -0.629 . . . . 0.0 109.366 -179.518 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 28.4 p . . . . . 0 CA--C 1.51 -0.572 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.428 HG23 ' SG ' ' A' ' 33' ' ' CYS . 20.0 m -109.19 164.41 5.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.314 -178.333 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 38.8 mt -103.05 -179.83 4.06 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -177.774 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 34.2 pt -62.64 135.66 26.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.426 0.631 . . . . 0.0 112.683 -178.5 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.08 -12.77 66.68 Favored Glycine 0 C--N 1.314 -0.677 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.985 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -92.23 154.22 18.78 Favored 'General case' 0 N--CA 1.435 -1.211 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.368 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.0 mtm180 -86.16 143.41 28.02 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.545 -174.011 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.477 ' HB2' ' O ' ' A' ' 14' ' ' PRO . 26.4 p -144.46 176.13 9.61 Favored 'General case' 0 C--N 1.278 -2.519 0 CA-C-N 114.519 -1.219 . . . . 0.0 108.362 -177.681 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -130.23 124.14 31.8 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -69.29 -27.69 65.62 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 112.645 0.609 . . . . 0.0 112.645 -177.705 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -91.94 -57.05 2.86 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 111.688 0.255 . . . . 0.0 111.688 -175.683 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -96.75 -18.47 19.6 Favored 'General case' 0 C--N 1.312 -1.051 0 N-CA-C 112.756 0.65 . . . . 0.0 112.756 -172.315 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.02 172.99 47.53 Favored Glycine 0 N--CA 1.437 -1.283 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 -174.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.477 ' O ' ' HB2' ' A' ' 8' ' ' CYS . 80.6 Cg_endo -75.77 173.09 59.83 Favored 'Cis proline' 0 C--O 1.23 0.093 0 CA-C-N 120.013 1.907 . . . . 0.0 111.014 -0.538 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.453 ' HA ' ' HB2' ' A' ' 8' ' ' CYS . 73.2 mtm180 -126.59 -173.91 2.99 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.678 -0.237 . . . . 0.0 110.437 178.492 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.2 m -65.45 146.74 54.5 Favored 'General case' 0 C--N 1.294 -1.826 0 C-N-CA 124.08 0.952 . . . . 0.0 111.591 -179.037 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 62.9 m -66.75 149.65 50.24 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 171.131 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.9 t -62.05 100.48 0.16 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.762 0.315 . . . . 0.0 110.365 -178.075 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 121.35 1.23 11.2 Favored Glycine 0 N--CA 1.444 -0.824 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -177.481 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 27.3 mm-40 -109.76 39.6 2.08 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 120.976 0.417 . . . . 0.0 112.103 179.564 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 74.43 -159.21 52.28 Favored Glycine 0 N--CA 1.423 -2.172 0 C-N-CA 120.308 -0.949 . . . . 0.0 112.628 178.38 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -133.96 148.92 51.22 Favored 'General case' 0 C--N 1.278 -2.5 0 N-CA-C 109.338 -0.615 . . . . 0.0 109.338 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 88.4 m -64.78 112.69 3.36 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 124.112 0.883 . . . . 0.0 111.079 177.677 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.3 p -96.19 124.67 50.81 Favored Pre-proline 0 C--N 1.284 -2.242 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 172.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -78.39 145.86 21.52 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 C-N-CA 121.594 1.529 . . . . 0.0 112.585 -177.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.452 ' HB2' ' HB3' ' A' ' 29' ' ' LEU . 3.8 mm? -130.07 146.54 61.89 Favored Pre-proline 0 C--N 1.301 -1.534 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 178.003 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo -41.75 -68.19 0.1 Allowed 'Trans proline' 0 N--CA 1.481 0.791 0 C-N-CA 124.503 3.469 . . . . 0.0 115.111 -177.124 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 33.4 p90 -104.79 -25.22 12.74 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-O 121.074 0.464 . . . . 0.0 112.04 -176.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.452 ' HB3' ' HB2' ' A' ' 26' ' ' LEU . 3.2 tm? -66.05 -32.04 73.28 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.441 179.178 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 101.19 -88.12 0.7 Allowed Glycine 0 N--CA 1.429 -1.822 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 178.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -158.82 147.69 15.64 Favored Glycine 0 N--CA 1.427 -1.927 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 179.279 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.7 p -140.41 148.82 21.91 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 CA-C-O 121.197 0.522 . . . . 0.0 110.103 178.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.428 ' SG ' HG23 ' A' ' 2' ' ' VAL . 76.9 m -82.2 132.87 35.24 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.51 179.112 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.93 140.73 17.12 Favored 'General case' 0 N--CA 1.425 -1.678 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -178.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.1 m . . . . . 0 C--N 1.307 -1.282 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 176.125 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.3 p . . . . . 0 N--CA 1.445 -0.684 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' A' ' 16' ' ' CYS . 30.8 m -96.67 169.2 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 120.936 0.398 . . . . 0.0 111.087 -179.562 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.473 ' HB2' HE22 ' A' ' 6' ' ' GLN . 42.5 mt -114.41 -176.14 2.84 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.788 -176.326 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.3 pp -51.92 145.01 2.56 Favored 'Isoleucine or valine' 0 C--O 1.246 0.917 0 N-CA-C 113.546 0.943 . . . . 0.0 113.546 176.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.32 -15.98 15.36 Favored Glycine 0 C--N 1.32 -0.348 0 CA-C-N 115.728 -0.669 . . . . 0.0 113.632 179.383 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.473 HE22 ' HB2' ' A' ' 3' ' ' LEU . 11.5 mt-30 -85.91 157.96 20.04 Favored 'General case' 0 C--N 1.307 -1.271 0 O-C-N 122.384 -0.48 . . . . 0.0 110.136 177.254 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -86.44 125.05 33.43 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.894 -177.245 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.4 p -119.07 163.48 16.93 Favored 'General case' 0 C--N 1.278 -2.538 0 CA-C-N 114.569 -1.196 . . . . 0.0 110.697 -175.318 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -148.15 126.32 12.17 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 174.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -77.78 -22.13 50.61 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -174.047 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -90.5 -54.81 3.84 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-O 121.255 0.55 . . . . 0.0 111.158 -175.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -100.04 -27.58 13.49 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.271 -172.424 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.0 169.93 27.32 Favored Glycine 0 N--CA 1.432 -1.599 0 N-CA-C 110.141 -1.184 . . . . 0.0 110.141 -174.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -79.85 155.53 88.16 Favored 'Cis proline' 0 N--CA 1.457 -0.655 0 CA-C-N 119.461 1.631 . . . . 0.0 111.704 -0.605 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 66.1 mtt180 -107.45 145.44 33.02 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 -179.358 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.491 ' HA ' ' O ' ' A' ' 2' ' ' VAL . 81.6 m -74.38 149.92 40.29 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.374 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 64.0 m -58.23 141.18 51.52 Favored 'General case' 0 C--N 1.317 -0.821 0 O-C-N 124.223 0.952 . . . . 0.0 109.693 -176.406 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 13.7 t -68.66 97.68 0.82 Allowed 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 141.01 -19.18 2.71 Favored Glycine 0 N--CA 1.435 -1.428 0 N-CA-C 108.559 -1.817 . . . . 0.0 108.559 -173.662 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 24.9 mm-40 -81.49 -178.98 7.18 Favored 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 123.681 0.792 . . . . 0.0 111.839 177.215 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.54 169.61 19.17 Favored Glycine 0 C--N 1.314 -0.681 0 CA-C-O 121.42 0.456 . . . . 0.0 114.083 -177.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . 0.531 ' O ' ' HA ' ' A' ' 33' ' ' CYS . 9.0 t30 -85.82 139.93 30.87 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 178.72 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 21.4 t -76.25 101.46 5.45 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 -178.276 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.6 t -99.9 113.95 65.41 Favored Pre-proline 0 N--CA 1.426 -1.652 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 -179.302 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.444 ' HA ' ' CA ' ' A' ' 31' ' ' GLY . 3.0 Cg_exo -71.87 121.38 7.56 Favored 'Trans proline' 0 N--CA 1.442 -1.545 0 C-N-CA 122.19 1.927 . . . . 0.0 110.706 179.257 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.1 mt -117.12 122.88 30.67 Favored Pre-proline 0 N--CA 1.425 -1.695 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 178.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -73.65 42.86 0.72 Allowed 'Trans proline' 0 CA--C 1.542 0.878 0 C-N-CA 123.716 2.944 . . . . 0.0 113.102 -176.721 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -135.2 -67.65 0.54 Allowed 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 -179.282 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.621 ' H ' HD23 ' A' ' 29' ' ' LEU . 2.3 pt? -107.14 -5.72 17.8 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.669 -178.559 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 111.71 -172.76 15.12 Favored Glycine 0 N--CA 1.432 -1.595 0 N-CA-C 110.129 -1.188 . . . . 0.0 110.129 -175.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.444 ' CA ' ' HA ' ' A' ' 25' ' ' PRO . . . -90.64 132.78 11.45 Favored Glycine 0 CA--C 1.484 -1.894 0 C-N-CA 120.526 -0.845 . . . . 0.0 111.336 179.381 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.4 m -129.88 147.74 33.23 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.938 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -178.239 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.531 ' HA ' ' O ' ' A' ' 22' ' ' ASN . 96.4 m -82.25 120.07 24.9 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.132 178.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -119.76 137.71 53.78 Favored 'General case' 0 N--CA 1.427 -1.589 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 178.428 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--N 1.292 -1.898 0 C-N-CA 121.008 -0.277 . . . . 0.0 111.194 -177.472 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 25.8 p . . . . . 0 N--CA 1.446 -0.648 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.471 HG23 ' SG ' ' A' ' 33' ' ' CYS . 18.6 m -108.37 154.91 9.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 CA-C-O 121.134 0.492 . . . . 0.0 111.513 -179.605 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 57.7 mt -100.33 -176.96 3.37 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.52 -175.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.9 pt -61.13 130.49 25.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.503 0 CA-C-O 121.477 0.656 . . . . 0.0 112.438 -179.114 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 96.59 -22.64 39.12 Favored Glycine 0 C--N 1.311 -0.821 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.841 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -81.02 154.9 26.64 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 121.067 0.46 . . . . 0.0 109.794 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.1 tmt_? -86.34 138.15 32.04 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.349 -173.679 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 17.5 p -137.07 167.89 20.65 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.917 -177.364 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -141.66 120.49 12.7 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 175.41 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -63.37 -35.18 79.56 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.84 -0.618 . . . . 0.0 112.168 -170.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -92.44 -52.54 4.61 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 113.026 0.75 . . . . 0.0 113.026 -175.469 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.4 mtm180 -87.08 -27.81 22.92 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 121.133 0.492 . . . . 0.0 112.306 -174.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.0 163.42 26.76 Favored Glycine 0 N--CA 1.427 -1.966 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 -175.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -78.44 165.93 81.37 Favored 'Cis proline' 0 C--N 1.332 -0.323 0 C-N-CA 123.378 -1.509 . . . . 0.0 112.375 0.569 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 60.1 mtt180 -115.74 163.09 16.34 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.678 -179.358 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 58.4 m -70.14 142.33 52.55 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 123.638 0.775 . . . . 0.0 110.514 -177.39 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 81.9 m -67.39 157.48 34.0 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 174.667 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.1 p -57.64 96.6 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.818 0 C-N-CA 124.207 1.003 . . . . 0.0 112.477 -177.467 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 99.09 34.76 5.02 Favored Glycine 0 N--CA 1.433 -1.566 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.293 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.435 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 23.9 mm-40 -122.58 34.57 5.11 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-O 121.547 0.689 . . . . 0.0 111.013 177.184 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 78.47 -166.38 52.34 Favored Glycine 0 N--CA 1.419 -2.457 0 CA-C-N 114.928 -1.033 . . . . 0.0 112.169 178.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 40.4 m-80 -127.95 157.19 41.26 Favored 'General case' 0 C--N 1.29 -2.016 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 -179.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 99.3 m -68.13 97.92 0.74 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 123.819 0.7 . . . . 0.0 111.765 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.82 126.62 72.54 Favored Pre-proline 0 N--CA 1.425 -1.699 0 N-CA-C 106.153 -1.795 . . . . 0.0 106.153 174.082 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.41 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 48.2 Cg_endo -70.3 129.99 17.94 Favored 'Trans proline' 0 N--CA 1.446 -1.288 0 C-N-CA 121.558 1.506 . . . . 0.0 114.283 -174.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.41 HD23 HG22 ' A' ' 32' ' ' VAL . 4.6 mm? -121.42 143.24 37.19 Favored Pre-proline 0 C--N 1.309 -1.187 0 CA-C-N 114.932 -1.031 . . . . 0.0 108.747 178.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_exo -44.26 -63.7 0.31 Allowed 'Trans proline' 0 CA--C 1.546 1.094 0 C-N-CA 123.731 2.954 . . . . 0.0 115.298 -176.744 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -89.65 -25.42 21.27 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 112.599 0.592 . . . . 0.0 112.599 -173.518 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -88.81 -17.97 28.66 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-O 121.362 0.601 . . . . 0.0 111.093 -175.434 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 88.89 -63.59 3.49 Favored Glycine 0 N--CA 1.429 -1.832 0 N-CA-C 109.389 -1.485 . . . . 0.0 109.389 -177.038 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.41 ' HA2' ' HA ' ' A' ' 25' ' ' PRO . . . -165.13 148.18 13.68 Favored Glycine 0 N--CA 1.419 -2.441 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.41 HG22 HD23 ' A' ' 26' ' ' LEU . 14.0 m -131.79 150.97 34.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 176.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.471 ' SG ' HG23 ' A' ' 2' ' ' VAL . 71.7 m -76.32 117.24 17.79 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -142.65 145.47 33.49 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 120.726 -0.389 . . . . 0.0 110.786 -179.733 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.6 m . . . . . 0 C--N 1.308 -1.22 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.603 176.963 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 23.4 p . . . . . 0 C--O 1.233 0.217 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.417 HG23 ' SG ' ' A' ' 33' ' ' CYS . 28.8 m -110.54 154.44 12.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-O 120.606 0.241 . . . . 0.0 111.367 -178.583 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 35.5 mt -99.69 -176.36 3.24 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.297 -177.477 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.408 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 33.8 pt -58.14 134.6 22.84 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.73 0 CA-C-O 121.477 0.656 . . . . 0.0 112.489 179.027 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.73 -18.72 55.98 Favored Glycine 0 C--N 1.311 -0.828 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.296 178.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' GLN . . . . . 0.414 ' HB2' ' HB ' ' A' ' 2' ' ' VAL . 23.7 mt-30 -89.66 152.33 21.42 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -179.556 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.462 ' HA ' ' HA ' ' A' ' 32' ' ' VAL . 16.4 ptp180 -86.61 148.71 25.36 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.07 0.462 . . . . 0.0 111.106 -175.317 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.2 p -138.56 158.24 44.62 Favored 'General case' 0 C--N 1.298 -1.652 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.611 -174.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -129.06 124.03 33.8 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 176.152 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -79.17 -27.11 42.64 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 120.955 0.407 . . . . 0.0 111.626 -173.107 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -91.1 -42.08 10.68 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 115.723 -0.671 . . . . 0.0 112.154 -173.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 83.7 mtm180 -112.54 -13.3 13.35 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 -175.597 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 89.35 165.74 41.33 Favored Glycine 0 N--CA 1.44 -1.094 0 C-N-CA 120.055 -1.069 . . . . 0.0 110.805 -177.408 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -79.85 158.73 88.28 Favored 'Cis proline' 0 N--CA 1.463 -0.284 0 CA-C-N 119.227 1.513 . . . . 0.0 111.195 -0.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 80.9 mtm180 -113.49 172.67 6.83 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 121.03 -0.268 . . . . 0.0 110.502 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.7 m -68.01 141.0 56.37 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 123.634 0.583 . . . . 0.0 109.834 -179.228 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 55.8 m -67.33 140.86 57.29 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 172.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 5.9 p -58.4 94.77 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.73 0 CA-C-O 121.663 0.744 . . . . 0.0 112.794 -177.383 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 132.38 -5.32 5.26 Favored Glycine 0 N--CA 1.438 -1.179 0 CA-C-N 114.853 -1.067 . . . . 0.0 110.644 -176.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . 0.448 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 86.0 mm-40 -101.58 30.09 4.49 Favored 'General case' 0 C--N 1.323 -0.561 0 C-N-CA 123.348 0.659 . . . . 0.0 112.456 -177.483 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 84.44 -171.6 47.89 Favored Glycine 0 N--CA 1.436 -1.352 0 C-N-CA 120.103 -1.046 . . . . 0.0 113.9 175.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -113.44 162.59 15.94 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.747 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 98.8 m -76.87 97.23 4.51 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-O 121.553 0.692 . . . . 0.0 109.689 177.253 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.4 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 43.5 t -93.43 127.91 44.55 Favored Pre-proline 0 N--CA 1.416 -2.14 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 -179.045 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 57.5 Cg_endo -85.0 121.01 2.34 Favored 'Trans proline' 0 N--CA 1.427 -2.421 0 C-N-CA 121.953 1.769 . . . . 0.0 112.018 -178.532 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.42 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 10.3 mp -110.39 124.52 33.08 Favored Pre-proline 0 C--N 1.29 -2.018 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 177.463 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 78.2 Cg_exo -53.24 -17.38 8.46 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 C-N-CA 124.448 3.432 . . . . 0.0 115.564 -173.725 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.411 ' HB2' HD12 ' A' ' 29' ' ' LEU . 73.6 m-85 -110.55 -22.74 11.49 Favored 'General case' 0 C--N 1.309 -1.164 0 C-N-CA 120.858 -0.337 . . . . 0.0 111.388 -179.167 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' LEU . . . . . 0.411 HD12 ' HB2' ' A' ' 28' ' ' PHE . 6.1 mp -106.55 -16.89 14.41 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 112.177 0.436 . . . . 0.0 112.177 -173.76 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.94 -104.91 2.98 Favored Glycine 0 N--CA 1.426 -2.006 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 -176.449 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -147.35 127.9 2.79 Favored Glycine 0 C--N 1.295 -1.744 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 176.465 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.462 ' HA ' ' HA ' ' A' ' 7' ' ' ARG . 34.5 m -131.83 154.19 39.88 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 C-N-CA 122.926 0.49 . . . . 0.0 110.187 -175.809 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' CYS . . . . . 0.448 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 74.4 m -74.53 119.69 19.06 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.705 178.033 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -146.53 148.75 32.5 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.752 0.311 . . . . 0.0 110.551 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 17.9 m . . . . . 0 C--N 1.306 -1.291 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.007 176.663 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.5 p . . . . . 0 N--CA 1.452 -0.334 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.544 HG23 ' SG ' ' A' ' 33' ' ' CYS . 21.2 m -106.84 167.4 3.45 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-O 121.184 0.516 . . . . 0.0 111.291 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.415 ' HA ' ' HG3' ' A' ' 20' ' ' GLN . 25.3 mt -107.41 175.97 5.31 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.174 -172.509 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 27.9 pt -61.07 134.99 26.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.438 0 CA-C-O 121.415 0.626 . . . . 0.0 112.394 -178.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.65 -13.3 60.97 Favored Glycine 0 C--N 1.312 -0.78 0 CA-C-N 115.486 -0.779 . . . . 0.0 112.622 -179.214 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -90.4 151.18 21.54 Favored 'General case' 0 C--N 1.315 -0.905 0 N-CA-C 106.892 -1.522 . . . . 0.0 106.892 176.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 34.3 ptt180 -85.9 146.24 26.8 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.949 -0.7 . . . . 0.0 111.064 -173.156 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.4 p -139.09 176.91 8.29 Favored 'General case' 0 C--N 1.282 -2.331 0 CA-C-N 115.164 -0.926 . . . . 0.0 109.224 -174.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -152.11 117.31 5.24 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 174.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -57.08 -38.99 74.1 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 113.629 0.974 . . . . 0.0 113.629 -173.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -91.86 -47.58 7.25 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 113.628 0.973 . . . . 0.0 113.628 -175.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.0 mtm180 -89.48 -29.88 18.67 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -173.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.55 160.31 25.94 Favored Glycine 0 N--CA 1.435 -1.389 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -174.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -79.65 167.45 75.47 Favored 'Cis proline' 0 C--O 1.218 -0.475 0 CA-C-N 119.542 1.671 . . . . 0.0 111.987 1.309 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 88.0 mtm180 -122.01 156.25 33.87 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 33.6 m -70.2 149.25 47.7 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 124.825 1.25 . . . . 0.0 111.319 -175.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 85.4 m -68.43 143.74 54.95 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 175.229 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 11.4 t -54.3 -26.45 29.41 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 125.25 1.42 . . . . 0.0 113.039 -172.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -108.08 16.53 35.8 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.188 178.138 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.415 ' HG3' ' HA ' ' A' ' 3' ' ' LEU . 18.3 mm-40 -97.74 -68.1 0.82 Allowed 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -179.368 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -175.85 -179.18 46.2 Favored Glycine 0 CA--C 1.481 -2.089 0 C-N-CA 120.261 -0.971 . . . . 0.0 110.703 -176.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 52.4 t30 -93.29 139.6 30.46 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 177.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 49.9 t -79.47 98.13 6.68 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.075 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.62 120.09 69.53 Favored Pre-proline 0 C--N 1.302 -1.47 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -179.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -67.18 141.7 58.19 Favored 'Trans proline' 0 N--CA 1.449 -1.114 0 C-N-CA 122.431 2.087 . . . . 0.0 113.106 -176.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 95.4 mt -119.36 144.19 35.95 Favored Pre-proline 0 C--N 1.302 -1.5 0 CA-C-N 114.743 -1.117 . . . . 0.0 109.078 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_exo -40.26 -57.31 1.23 Allowed 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 124.731 3.621 . . . . 0.0 114.806 -176.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 30.4 p90 -119.18 -24.18 6.54 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -177.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 78.3 mt -79.9 0.49 31.02 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 179.04 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 87.57 -59.22 4.37 Favored Glycine 0 CA--C 1.499 -0.939 0 C-N-CA 121.149 -0.548 . . . . 0.0 111.871 177.246 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 171.64 170.79 36.07 Favored Glycine 0 N--CA 1.418 -2.512 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 9.2 p -147.3 146.15 18.59 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.986 0 CA-C-O 121.503 0.668 . . . . 0.0 109.992 177.282 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.544 ' SG ' HG23 ' A' ' 2' ' ' VAL . 74.1 m -80.06 118.4 21.75 Favored 'General case' 0 C--N 1.285 -2.223 0 CA-C-N 114.713 -1.13 . . . . 0.0 109.923 179.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -143.87 153.66 42.57 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 -177.179 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 52.4 t . . . . . 0 C--N 1.306 -1.32 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 -179.109 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.3 p . . . . . 0 C--O 1.24 0.57 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.582 HG23 ' SG ' ' A' ' 33' ' ' CYS . 30.2 m -112.06 158.28 12.55 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-O 120.655 0.264 . . . . 0.0 111.504 -178.567 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 38.2 mt -99.57 -178.56 3.92 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.482 -176.554 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.435 ' HA ' ' HB2' ' A' ' 33' ' ' CYS . 34.0 pt -58.64 140.37 17.04 Favored 'Isoleucine or valine' 0 C--O 1.241 0.651 0 N-CA-C 113.023 0.749 . . . . 0.0 113.023 -179.394 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.8 -14.34 48.48 Favored Glycine 0 C--N 1.311 -0.86 0 CA-C-N 115.708 -0.678 . . . . 0.0 113.183 178.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 27.2 mt-30 -86.15 156.53 20.31 Favored 'General case' 0 C--N 1.309 -1.179 0 N-CA-C 108.056 -1.091 . . . . 0.0 108.056 178.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 47.1 ttp180 -86.01 132.22 34.11 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 123.623 0.577 . . . . 0.0 109.962 -176.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.2 p -128.71 175.11 8.85 Favored 'General case' 0 C--N 1.278 -2.543 0 CA-C-N 115.069 -0.969 . . . . 0.0 109.197 -177.478 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -149.82 125.68 10.5 Favored 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 174.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.403 ' OD1' ' HB3' ' A' ' 23' ' ' CYS . 43.6 m-80 -76.64 -23.11 53.31 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 120.531 0.205 . . . . 0.0 111.526 -175.84 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -84.87 -57.56 3.06 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.903 -175.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 63.2 mtt180 -103.07 -21.85 13.86 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 113.107 0.78 . . . . 0.0 113.107 -175.356 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 103.86 168.55 25.25 Favored Glycine 0 N--CA 1.433 -1.543 0 C-N-CA 120.121 -1.038 . . . . 0.0 110.609 -177.393 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -80.1 159.17 87.18 Favored 'Cis proline' 0 CA--C 1.535 0.549 0 CA-C-N 119.085 1.442 . . . . 0.0 112.065 0.217 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 -104.55 169.91 8.19 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 177.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.6 m -80.52 147.16 30.96 Favored 'General case' 0 C--N 1.297 -1.688 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.419 -176.191 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 39.5 m -72.77 153.28 41.19 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 175.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.1 t -67.77 120.12 13.59 Favored 'General case' 0 N--CA 1.435 -1.214 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 103.54 0.1 46.4 Favored Glycine 0 N--CA 1.437 -1.264 0 N-CA-C 110.271 -1.131 . . . . 0.0 110.271 -175.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 86.0 mm-40 -111.86 38.01 2.78 Favored 'General case' 0 C--N 1.31 -1.132 0 CA-C-O 121.496 0.665 . . . . 0.0 110.366 179.064 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 78.14 -156.58 43.77 Favored Glycine 0 N--CA 1.418 -2.554 0 CA-C-N 115.057 -0.974 . . . . 0.0 112.962 177.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 79.6 m-20 -123.74 153.75 40.47 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 106.123 -1.806 . . . . 0.0 106.123 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . 0.403 ' HB3' ' OD1' ' A' ' 10' ' ' ASN . 51.6 t -84.52 98.46 10.14 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.656 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.411 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 22.9 t -97.34 118.05 64.9 Favored Pre-proline 0 C--N 1.303 -1.456 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 -178.026 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 4.0 Cg_exo -70.76 129.84 17.16 Favored 'Trans proline' 0 N--CA 1.451 -0.99 0 C-N-CA 122.611 2.207 . . . . 0.0 110.113 177.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 85.2 mt -129.3 150.6 75.96 Favored Pre-proline 0 C--N 1.309 -1.154 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.951 -175.525 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -42.49 -67.37 0.12 Allowed 'Trans proline' 0 CA--C 1.545 1.044 0 C-N-CA 124.792 3.661 . . . . 0.0 115.679 -177.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 26.5 p90 -97.8 -23.58 15.82 Favored 'General case' 0 C--N 1.314 -0.975 0 N-CA-C 113.325 0.861 . . . . 0.0 113.325 -174.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 97.4 mt -83.13 -12.11 57.32 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.557 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 84.06 -65.65 4.06 Favored Glycine 0 CA--C 1.501 -0.813 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -178.23 134.79 2.48 Favored Glycine 0 CA--C 1.47 -2.773 0 N-CA-C 108.569 -1.812 . . . . 0.0 108.569 177.36 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.5 m -136.02 153.68 32.45 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.224 0 CA-C-O 121.505 0.669 . . . . 0.0 110.998 -178.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.582 ' SG ' HG23 ' A' ' 2' ' ' VAL . 84.1 m -79.15 117.27 20.02 Favored 'General case' 0 C--N 1.291 -1.957 0 CA-C-N 114.503 -1.226 . . . . 0.0 108.833 175.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -135.07 130.41 35.53 Favored 'General case' 0 N--CA 1.431 -1.399 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -177.314 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 N--CA 1.432 -1.338 0 O-C-N 123.306 0.378 . . . . 0.0 110.63 178.847 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 22.2 p . . . . . 0 N--CA 1.446 -0.673 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.572 HG23 ' SG ' ' A' ' 33' ' ' CYS . 15.7 m -101.29 163.22 3.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-O 121.17 0.51 . . . . 0.0 111.511 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 23.9 mt -107.88 179.99 4.06 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-N 115.454 -0.793 . . . . 0.0 111.108 -172.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 24.3 pt -55.11 134.34 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 N-CA-C 112.95 0.722 . . . . 0.0 112.95 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.42 -17.85 41.12 Favored Glycine 0 C--O 1.242 0.614 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.937 177.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.7 mt-30 -81.54 159.72 24.06 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.133 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.458 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 40.5 ttp180 -85.78 129.0 34.95 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.269 -173.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 30.3 p -128.17 172.43 11.01 Favored 'General case' 0 C--N 1.291 -1.949 0 CA-C-O 121.294 0.569 . . . . 0.0 110.677 -177.22 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -147.12 118.97 8.09 Favored 'General case' 0 C--N 1.308 -1.199 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 175.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.3 m120 -58.22 -42.03 85.4 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 124.192 0.997 . . . . 0.0 113.113 -173.241 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -91.93 -56.63 3.01 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -175.412 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -83.15 -31.0 27.42 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-O 121.133 0.492 . . . . 0.0 112.024 -171.046 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 104.85 165.0 24.16 Favored Glycine 0 N--CA 1.427 -1.906 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 -176.331 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -76.25 156.76 98.41 Favored 'Cis proline' 0 C--N 1.329 -0.468 0 C-N-CA 123.382 -1.507 . . . . 0.0 112.122 0.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 82.1 mtt180 -108.03 156.35 19.35 Favored 'General case' 0 C--N 1.289 -2.04 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.56 -179.346 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 58.8 m -76.23 144.03 40.65 Favored 'General case' 0 C--N 1.29 -1.99 0 C-N-CA 124.06 0.944 . . . . 0.0 110.79 -176.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.441 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 59.2 m -67.42 161.51 25.12 Favored 'General case' 0 C--O 1.243 0.743 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.543 177.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 37.6 t -46.96 -56.21 6.77 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 124.065 0.946 . . . . 0.0 113.414 -174.094 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -95.19 27.22 15.79 Favored Glycine 0 C--N 1.314 -0.672 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.825 -176.26 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.441 ' CG ' ' HB2' ' A' ' 17' ' ' CYS . 84.9 mm-40 -110.84 29.69 7.53 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-O 121.337 0.589 . . . . 0.0 110.707 -178.556 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.414 ' CA ' ' HB ' ' A' ' 35' ' ' VAL . . . 85.51 -140.5 18.2 Favored Glycine 0 N--CA 1.43 -1.712 0 C-N-CA 120.365 -0.921 . . . . 0.0 112.874 177.528 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -133.8 155.87 49.04 Favored 'General case' 0 C--N 1.287 -2.142 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 176.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 52.5 t -83.06 100.83 10.74 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.409 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 7.4 p -98.0 120.07 60.78 Favored Pre-proline 0 N--CA 1.419 -2.021 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.62 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 10.1 Cg_exo -69.42 139.9 42.57 Favored 'Trans proline' 0 N--CA 1.45 -1.034 0 C-N-CA 122.076 1.851 . . . . 0.0 112.62 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 11.0 mp -119.49 134.92 23.81 Favored Pre-proline 0 C--N 1.304 -1.41 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.468 179.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_exo -39.93 -54.18 2.16 Favored 'Trans proline' 0 C--N 1.356 0.965 0 C-N-CA 124.58 3.52 . . . . 0.0 115.483 -175.464 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 75.5 m-85 -99.43 -40.88 7.66 Favored 'General case' 0 CA--C 1.504 -0.799 0 CA-C-O 121.079 0.466 . . . . 0.0 111.038 -178.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 14.0 mt -75.65 -14.58 60.37 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.872 -0.604 . . . . 0.0 112.594 -170.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.73 -64.53 0.75 Allowed Glycine 0 CA--C 1.486 -1.765 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 -179.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.458 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . 174.33 156.35 13.65 Favored Glycine 0 N--CA 1.425 -2.083 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 178.013 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 35.4 m -139.06 152.76 24.17 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 CA-C-O 121.248 0.547 . . . . 0.0 109.925 177.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.572 ' SG ' HG23 ' A' ' 2' ' ' VAL . 60.4 m -82.55 125.01 30.65 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-N 115.426 -0.807 . . . . 0.0 108.964 176.751 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -146.82 135.74 22.34 Favored 'General case' 0 N--CA 1.439 -0.998 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.267 -176.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.414 ' HB ' ' CA ' ' A' ' 21' ' ' GLY . 7.7 p . . . . . 0 C--N 1.301 -1.542 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 178.49 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 25.8 p . . . . . 0 C--O 1.24 0.59 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.497 HG23 ' SG ' ' A' ' 33' ' ' CYS . 30.1 m -103.84 168.68 2.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 120.902 0.382 . . . . 0.0 110.878 -179.508 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.401 ' HB2' ' OE1' ' A' ' 6' ' ' GLN . 24.8 mt -109.12 -179.48 3.86 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.771 -0.649 . . . . 0.0 109.695 -175.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.7 pt -57.68 134.02 22.33 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-O 121.643 0.735 . . . . 0.0 112.87 -179.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 95.71 -23.99 31.58 Favored Glycine 0 N--CA 1.442 -0.945 0 CA-C-N 115.175 -0.92 . . . . 0.0 112.303 178.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.401 ' OE1' ' HB2' ' A' ' 3' ' ' LEU . 36.2 mt-30 -83.09 152.65 25.24 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 16.5 ptm180 -87.0 145.39 26.52 Favored 'General case' 0 C--N 1.297 -1.694 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.309 -176.402 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.441 ' HB2' ' O ' ' A' ' 14' ' ' PRO . 15.7 p -144.3 176.26 9.48 Favored 'General case' 0 C--N 1.285 -2.21 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.983 -174.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -145.0 116.78 8.2 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 177.64 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 82.0 m-20 -62.32 -32.67 73.46 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 112.968 0.729 . . . . 0.0 112.968 -178.459 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -82.63 -56.59 3.77 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 121.186 0.517 . . . . 0.0 111.523 -172.597 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 77.5 mtm180 -96.95 -20.23 18.24 Favored 'General case' 0 C--N 1.295 -1.778 0 CA-C-N 115.614 -0.721 . . . . 0.0 112.788 -172.172 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 94.36 162.55 35.34 Favored Glycine 0 N--CA 1.43 -1.738 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -177.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.441 ' O ' ' HB2' ' A' ' 8' ' ' CYS . 97.9 Cg_endo -85.26 167.53 53.0 Favored 'Cis proline' 0 C--N 1.326 -0.649 0 CA-C-N 119.272 1.536 . . . . 0.0 110.979 0.254 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -115.94 178.33 4.35 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 175.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 32.7 m -68.12 146.12 53.74 Favored 'General case' 0 C--N 1.293 -1.881 0 C-N-CA 123.277 0.631 . . . . 0.0 110.884 178.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 71.3 m -70.89 154.9 41.42 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 171.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.7 t -60.68 113.31 2.4 Favored 'General case' 0 N--CA 1.436 -1.128 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 106.48 0.2 37.36 Favored Glycine 0 N--CA 1.441 -0.982 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.555 -178.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 86.3 mm-40 -107.93 33.86 3.87 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.168 0.509 . . . . 0.0 110.93 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 80.7 -140.35 21.67 Favored Glycine 0 N--CA 1.428 -1.867 0 C-N-CA 120.131 -1.033 . . . . 0.0 113.241 177.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 52.9 t30 -151.32 159.92 44.06 Favored 'General case' 0 C--N 1.288 -2.097 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 92.3 m -72.08 97.76 1.97 Allowed 'General case' 0 C--N 1.308 -1.199 0 O-C-N 123.884 0.74 . . . . 0.0 109.192 176.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.3 t -96.52 126.9 41.76 Favored Pre-proline 0 N--CA 1.42 -1.946 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 179.223 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_exo -58.84 127.0 22.79 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 122.764 2.309 . . . . 0.0 112.627 -177.659 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.441 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 47.5 tp -118.02 131.91 23.95 Favored Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 179.384 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 6.9 Cg_exo -74.38 45.6 1.24 Allowed 'Trans proline' 0 N--CA 1.482 0.809 0 C-N-CA 123.636 2.891 . . . . 0.0 113.17 -176.61 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -148.98 -69.63 0.21 Allowed 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 124.143 0.977 . . . . 0.0 109.3 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 25.6 mt -95.66 1.53 53.6 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 114.285 -1.325 . . . . 0.0 111.516 -170.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 97.63 -77.14 0.63 Allowed Glycine 0 N--CA 1.435 -1.404 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -179.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -146.45 139.2 7.9 Favored Glycine 0 C--N 1.29 -2.015 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.051 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.8 m -134.38 157.09 41.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 178.693 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.497 ' SG ' HG23 ' A' ' 2' ' ' VAL . 81.4 m -73.78 124.54 26.26 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.103 179.622 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -144.5 143.24 30.75 Favored 'General case' 0 N--CA 1.425 -1.69 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.2 m . . . . . 0 C--N 1.301 -1.512 0 O-C-N 123.789 0.68 . . . . 0.0 111.124 178.767 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 19.9 p . . . . . 0 C--O 1.241 0.647 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.603 HG23 ' SG ' ' A' ' 33' ' ' CYS . 15.1 m -109.72 157.53 10.15 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.656 0 CA-C-O 121.131 0.491 . . . . 0.0 111.458 176.333 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 18.4 mt -111.98 179.34 4.03 Favored 'General case' 0 N--CA 1.432 -1.357 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.069 -172.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 23.7 pt -54.1 133.46 17.11 Favored 'Isoleucine or valine' 0 C--O 1.239 0.545 0 CA-C-O 121.76 0.791 . . . . 0.0 112.88 -179.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.57 -9.08 72.4 Favored Glycine 0 C--N 1.309 -0.954 0 CA-C-N 115.375 -0.83 . . . . 0.0 113.04 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 75.7 mt-30 -94.47 156.47 16.45 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 176.741 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.403 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 18.1 ptp180 -85.81 145.72 27.09 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-O 121.139 0.495 . . . . 0.0 111.504 -174.156 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.447 ' SG ' ' HA ' ' A' ' 15' ' ' ARG . 3.8 t -137.21 159.72 41.09 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.819 -1.082 . . . . 0.0 112.324 -172.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -150.86 117.54 5.79 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 113.277 -1.783 . . . . 0.0 107.062 176.137 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 48.2 m-80 -63.72 -43.04 97.71 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 113.671 0.989 . . . . 0.0 113.671 -173.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 17.4 m-20 -92.46 -35.88 13.4 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 113.678 0.992 . . . . 0.0 113.678 -174.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 54.8 mtm180 -100.99 -14.86 17.68 Favored 'General case' 0 C--N 1.309 -1.176 0 N-CA-C 113.122 0.786 . . . . 0.0 113.122 -174.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.77 155.98 29.55 Favored Glycine 0 N--CA 1.442 -0.932 0 N-CA-C 111.081 -0.807 . . . . 0.0 111.081 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -84.91 159.33 66.08 Favored 'Cis proline' 0 CA--C 1.535 0.546 0 CA-C-N 119.206 1.503 . . . . 0.0 111.883 0.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.447 ' HA ' ' SG ' ' A' ' 8' ' ' CYS . 39.7 mtm180 -112.21 155.27 24.26 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-O 120.89 0.376 . . . . 0.0 110.083 -178.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.445 ' HA ' ' O ' ' A' ' 2' ' ' VAL . 36.8 m -78.02 142.01 38.52 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 123.882 0.873 . . . . 0.0 110.533 -176.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.7 m -67.05 153.37 43.82 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 119.144 -1.022 . . . . 0.0 111.312 172.006 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 12.3 p -48.74 -46.65 41.29 Favored 'General case' 0 C--O 1.241 0.622 0 N-CA-C 114.229 1.196 . . . . 0.0 114.229 -173.189 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -90.63 11.79 70.56 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.448 -0.882 . . . . 0.0 112.703 -179.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 78.7 mm-40 -105.28 37.19 2.25 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.276 0.56 . . . . 0.0 111.716 -178.001 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.48 -158.92 30.32 Favored Glycine 0 N--CA 1.423 -2.205 0 C-N-CA 120.091 -1.052 . . . . 0.0 112.32 177.02 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 -122.18 149.44 43.63 Favored 'General case' 0 C--N 1.282 -2.35 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 49.1 t -84.02 97.33 9.23 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.002 -1.111 . . . . 0.0 108.002 179.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.6 p -104.82 124.88 35.37 Favored Pre-proline 0 C--N 1.305 -1.34 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.52 -177.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -67.07 141.74 58.93 Favored 'Trans proline' 0 C--O 1.243 0.762 0 C-N-CA 122.645 2.23 . . . . 0.0 112.951 -176.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 87.9 mt -122.21 148.63 52.57 Favored Pre-proline 0 C--N 1.309 -1.181 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.601 -178.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo -49.29 -64.22 0.24 Allowed 'Trans proline' 0 CA--C 1.545 1.072 0 C-N-CA 123.715 2.943 . . . . 0.0 114.394 -178.198 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -97.16 -40.36 8.84 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.947 0.403 . . . . 0.0 110.987 -174.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 9.2 mp -78.98 0.74 26.38 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 113.737 1.014 . . . . 0.0 113.737 -174.681 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 86.28 -65.33 3.86 Favored Glycine 0 CA--C 1.501 -0.803 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.081 176.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.403 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -176.35 160.43 28.11 Favored Glycine 0 CA--C 1.477 -2.323 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 8.8 p -142.76 157.63 18.39 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 CA-C-N 117.73 0.765 . . . . 0.0 109.922 -178.265 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.603 ' SG ' HG23 ' A' ' 2' ' ' VAL . 59.9 m -88.0 108.73 19.36 Favored 'General case' 0 C--N 1.278 -2.514 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 174.547 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -149.88 163.84 36.97 Favored 'General case' 0 N--CA 1.435 -1.182 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 -175.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 6.9 p . . . . . 0 C--N 1.293 -1.852 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.653 178.786 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.4 p . . . . . 0 C--O 1.243 0.722 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 19.0 m -109.11 168.61 3.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 120.813 0.34 . . . . 0.0 111.147 -179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 29.3 mt -108.02 -176.24 3.0 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.327 -175.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 21.9 pt -56.78 138.83 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 N-CA-C 112.695 0.628 . . . . 0.0 112.695 179.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 85.29 -20.11 19.12 Favored Glycine 0 CA--C 1.506 -0.476 0 CA-C-N 115.707 -0.678 . . . . 0.0 112.694 178.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -80.5 153.73 27.98 Favored 'General case' 0 N--CA 1.429 -1.48 0 CA-C-O 121.252 0.549 . . . . 0.0 109.892 -179.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 4.2 tmt_? -86.31 130.14 34.61 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 114.657 -1.156 . . . . 0.0 109.038 -173.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.4 ' HB2' ' O ' ' A' ' 14' ' ' PRO . 27.8 p -130.29 170.67 13.82 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.242 -176.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -147.42 124.59 11.47 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 177.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 14.6 m120 -71.56 -35.88 70.75 Favored 'General case' 0 C--N 1.298 -1.662 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.424 -175.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -76.3 -56.86 4.25 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.637 -0.71 . . . . 0.0 112.146 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 74.1 mtm180 -93.8 -21.3 19.38 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 115.872 -0.604 . . . . 0.0 112.511 -173.48 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 94.74 163.45 35.24 Favored Glycine 0 N--CA 1.427 -1.947 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 -175.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.4 ' O ' ' HB2' ' A' ' 8' ' ' CYS . 89.7 Cg_endo -89.86 165.68 34.52 Favored 'Cis proline' 0 N--CA 1.451 -0.998 0 C-N-CA 123.353 -1.52 . . . . 0.0 110.76 -1.184 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 69.8 mtm180 -106.86 179.43 4.27 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 176.139 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 26.4 m -73.42 140.75 46.76 Favored 'General case' 0 C--N 1.293 -1.856 0 C-N-CA 122.914 0.486 . . . . 0.0 109.963 -179.085 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 60.9 m -67.83 155.03 40.25 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 173.25 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 29.1 t -60.98 113.5 2.57 Favored 'General case' 0 C--O 1.246 0.899 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 -178.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 102.36 14.39 28.21 Favored Glycine 0 N--CA 1.435 -1.389 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.657 -178.472 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.45 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 83.9 mm-40 -116.8 28.85 8.28 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 -178.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.33 -163.11 35.54 Favored Glycine 0 N--CA 1.433 -1.553 0 C-N-CA 119.689 -1.243 . . . . 0.0 111.756 178.529 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 52.8 m-80 -130.43 152.05 50.25 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 107.756 -1.202 . . . . 0.0 107.756 179.166 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 63.1 m -66.95 98.1 0.53 Allowed 'General case' 0 N--CA 1.439 -1.007 0 O-C-N 124.04 0.837 . . . . 0.0 110.713 176.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.4 m -92.99 111.81 53.19 Favored Pre-proline 0 N--CA 1.411 -2.378 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 175.449 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.37 141.4 31.78 Favored 'Trans proline' 0 N--CA 1.44 -1.634 0 C-N-CA 122.069 1.846 . . . . 0.0 112.977 -173.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 91.8 mt -137.3 117.34 10.47 Favored Pre-proline 0 C--N 1.292 -1.928 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -72.15 51.03 1.63 Allowed 'Trans proline' 0 N--CA 1.485 0.984 0 C-N-CA 124.393 3.395 . . . . 0.0 113.969 -171.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 70.8 m-85 -143.83 -60.51 0.4 Allowed 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.638 ' H ' HD23 ' A' ' 29' ' ' LEU . 2.1 pt? -106.95 0.22 23.6 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.922 -178.208 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 109.46 -76.76 0.22 Allowed Glycine 0 C--N 1.306 -1.123 0 C-N-CA 120.399 -0.905 . . . . 0.0 111.755 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 177.27 159.56 22.63 Favored Glycine 0 N--CA 1.425 -2.057 0 N-CA-C 109.984 -1.247 . . . . 0.0 109.984 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.2 m -133.9 157.14 41.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-O 120.927 0.394 . . . . 0.0 110.697 -179.118 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.45 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 86.3 m -83.67 108.63 16.87 Favored 'General case' 0 C--N 1.296 -1.74 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.77 176.519 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -141.45 155.38 45.86 Favored 'General case' 0 N--CA 1.429 -1.518 0 N-CA-C 109.702 -0.481 . . . . 0.0 109.702 -178.662 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 49.0 t . . . . . 0 C--N 1.3 -1.572 0 N-CA-C 108.293 -1.002 . . . . 0.0 108.293 177.326 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 29.6 p . . . . . 0 CA--C 1.519 -0.246 0 N-CA-C 110.078 -0.341 . . . . 0.0 110.078 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.425 HG23 ' SG ' ' A' ' 33' ' ' CYS . 16.6 m -107.95 168.37 3.42 Favored 'Isoleucine or valine' 0 C--O 1.243 0.743 0 CA-C-O 121.113 0.482 . . . . 0.0 110.946 178.467 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 29.2 mt -108.2 178.54 4.47 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.185 -173.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.506 ' HA ' ' HB2' ' A' ' 33' ' ' CYS . 26.9 pt -59.49 136.27 23.25 Favored 'Isoleucine or valine' 0 C--O 1.236 0.383 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.131 177.073 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 86.99 -13.45 59.4 Favored Glycine 0 C--N 1.311 -0.856 0 CA-C-N 115.843 -0.617 . . . . 0.0 112.596 178.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.455 ' O ' ' HA ' ' A' ' 32' ' ' VAL . 89.9 mt-30 -92.09 159.7 15.56 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 179.582 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.597 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 41.9 ttm180 -85.34 124.61 32.15 Favored 'General case' 0 C--N 1.317 -0.839 0 O-C-N 123.729 0.643 . . . . 0.0 110.805 -175.266 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 23.6 p -123.34 176.26 6.23 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.795 -177.285 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -145.81 125.63 13.49 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 174.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 47.3 m-80 -71.78 -30.0 65.08 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 113.339 0.866 . . . . 0.0 113.339 -175.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -91.37 -47.1 7.66 Favored 'General case' 0 C--N 1.295 -1.761 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 -172.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 51.0 mtp180 -106.1 -23.1 12.7 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 112.593 0.59 . . . . 0.0 112.593 -176.065 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 98.96 169.7 30.94 Favored Glycine 0 N--CA 1.431 -1.689 0 C-N-CA 119.825 -1.179 . . . . 0.0 110.479 -176.373 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -72.49 152.39 97.51 Favored 'Cis proline' 0 C--N 1.333 -0.258 0 CA-C-N 119.474 1.637 . . . . 0.0 112.32 1.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 73.1 mtt180 -105.89 160.77 15.0 Favored 'General case' 0 C--N 1.289 -2.06 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.263 -179.16 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.0 m -69.81 143.32 52.95 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 123.665 0.786 . . . . 0.0 110.953 -177.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 85.2 m -63.3 155.78 27.61 Favored 'General case' 0 C--O 1.238 0.459 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 176.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.7 m -63.57 106.13 0.9 Allowed 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -179.478 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 101.6 29.61 6.19 Favored Glycine 0 N--CA 1.439 -1.142 0 N-CA-C 110.687 -0.965 . . . . 0.0 110.687 -176.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.405 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 23.0 mm-40 -126.7 36.01 4.53 Favored 'General case' 0 CA--C 1.496 -1.098 0 CA-C-O 121.26 0.553 . . . . 0.0 111.506 178.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 76.14 -163.32 53.09 Favored Glycine 0 N--CA 1.42 -2.375 0 C-N-CA 120.469 -0.872 . . . . 0.0 113.138 178.299 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -110.45 145.49 37.55 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 177.444 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 50.3 t -75.69 98.02 3.97 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 176.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.441 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 20.8 t -98.87 126.51 38.3 Favored Pre-proline 0 N--CA 1.427 -1.604 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 -176.725 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 7.8 Cg_exo -72.94 126.45 11.28 Favored 'Trans proline' 0 N--CA 1.45 -1.071 0 C-N-CA 122.714 2.276 . . . . 0.0 112.296 178.468 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.487 HD13 HG22 ' A' ' 32' ' ' VAL . 10.6 mp -121.63 119.79 29.02 Favored Pre-proline 0 C--N 1.306 -1.315 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 176.373 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_exo -37.62 -49.69 1.9 Allowed 'Trans proline' 0 CA--C 1.553 1.438 0 C-N-CA 124.634 3.556 . . . . 0.0 116.673 -174.381 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -89.64 -26.34 20.8 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 120.151 -0.619 . . . . 0.0 112.228 -176.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -94.91 -4.88 46.06 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 121.464 0.65 . . . . 0.0 110.793 -174.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 84.53 -77.65 2.09 Favored Glycine 0 N--CA 1.431 -1.699 0 N-CA-C 109.109 -1.597 . . . . 0.0 109.109 -178.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -168.64 138.2 4.98 Favored Glycine 0 N--CA 1.413 -2.864 0 N-CA-C 107.816 -2.114 . . . . 0.0 107.816 178.258 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.487 HG22 HD13 ' A' ' 26' ' ' LEU . 35.9 m -134.8 146.95 29.83 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.12 0 CA-C-O 121.251 0.548 . . . . 0.0 109.796 -178.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.506 ' HB2' ' HA ' ' A' ' 4' ' ' ILE . 81.1 m -72.81 124.69 25.88 Favored 'General case' 0 C--N 1.294 -1.841 0 CA-C-N 115.305 -0.862 . . . . 0.0 109.138 176.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -142.19 133.94 26.98 Favored 'General case' 0 N--CA 1.425 -1.702 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 -176.031 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.7 m . . . . . 0 C--N 1.306 -1.318 0 O-C-N 123.54 0.525 . . . . 0.0 110.72 179.82 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.4 p . . . . . 0 N--CA 1.452 -0.332 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.554 HG23 ' SG ' ' A' ' 33' ' ' CYS . 19.6 m -107.58 162.82 5.72 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.876 0 CA-C-O 121.188 0.518 . . . . 0.0 112.076 -176.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.402 ' O ' ' HB2' ' A' ' 6' ' ' GLN . 16.4 mt -106.98 -177.11 3.27 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.145 -174.528 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 37.7 pt -59.65 139.42 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.959 0 N-CA-C 112.483 0.549 . . . . 0.0 112.483 -178.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 83.25 -16.74 27.37 Favored Glycine 0 C--N 1.316 -0.542 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.626 179.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.402 ' HB2' ' O ' ' A' ' 3' ' ' LEU . 78.2 mt-30 -82.02 156.83 24.44 Favored 'General case' 0 N--CA 1.428 -1.53 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 178.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.479 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 43.5 ttp180 -85.94 129.61 34.79 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-N 114.618 -1.173 . . . . 0.0 110.451 -173.185 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 24.6 p -126.35 176.16 7.32 Favored 'General case' 0 C--N 1.284 -2.26 0 CA-C-N 115.296 -0.866 . . . . 0.0 110.138 -177.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -146.76 123.09 10.95 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 105.896 -1.89 . . . . 0.0 105.896 173.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 18.7 m120 -58.44 -45.73 87.96 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 114.645 -1.162 . . . . 0.0 112.611 -173.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -92.65 -52.89 4.42 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -175.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -85.72 -24.99 26.72 Favored 'General case' 0 C--N 1.315 -0.9 0 C-N-CA 120.1 -0.64 . . . . 0.0 112.563 -173.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 98.18 169.75 32.01 Favored Glycine 0 N--CA 1.43 -1.743 0 C-N-CA 120.135 -1.031 . . . . 0.0 111.291 -177.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -74.57 164.0 89.1 Favored 'Cis proline' 0 C--N 1.332 -0.334 0 C-N-CA 123.342 -1.524 . . . . 0.0 112.351 0.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 77.0 mtt180 -117.7 164.26 15.24 Favored 'General case' 0 C--N 1.292 -1.895 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.076 -178.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.417 ' HA ' ' O ' ' A' ' 2' ' ' VAL . 28.0 m -71.16 140.72 50.63 Favored 'General case' 0 C--N 1.289 -2.038 0 C-N-CA 123.829 0.852 . . . . 0.0 110.192 -177.348 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.429 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 59.0 m -67.26 151.98 46.54 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 176.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.3 t -67.15 103.66 1.26 Allowed 'General case' 0 N--CA 1.439 -1.005 0 C-N-CA 123.424 0.69 . . . . 0.0 109.181 -177.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 122.92 -12.3 8.67 Favored Glycine 0 N--CA 1.437 -1.267 0 N-CA-C 110.429 -1.068 . . . . 0.0 110.429 -177.384 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.429 ' CG ' ' HB2' ' A' ' 17' ' ' CYS . 84.2 mm-40 -85.78 -45.12 11.91 Favored 'General case' 0 CA--C 1.5 -0.96 0 CA-C-N 115.46 -0.37 . . . . 0.0 110.353 178.661 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 152.71 -161.62 29.61 Favored Glycine 0 N--CA 1.419 -2.45 0 C-N-CA 119.079 -1.534 . . . . 0.0 113.019 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -112.36 147.43 36.4 Favored 'General case' 0 C--N 1.279 -2.475 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 178.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 53.0 t -82.0 105.98 13.55 Favored 'General case' 0 C--N 1.294 -1.83 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.129 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -92.53 117.04 67.45 Favored Pre-proline 0 C--N 1.311 -1.078 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 176.184 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -74.36 148.25 38.13 Favored 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 122.025 1.817 . . . . 0.0 114.114 -174.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 8.1 mp -126.28 132.39 24.3 Favored Pre-proline 0 C--N 1.308 -1.198 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 176.573 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_exo -39.0 -57.2 1.01 Allowed 'Trans proline' 0 CA--C 1.543 0.933 0 C-N-CA 124.611 3.541 . . . . 0.0 115.299 -175.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -93.43 -46.4 7.35 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-O 121.801 0.81 . . . . 0.0 110.327 -178.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 26.7 mt -77.15 0.52 21.36 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 114.339 -1.3 . . . . 0.0 113.189 -167.439 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 87.03 -65.79 3.65 Favored Glycine 0 CA--C 1.492 -1.345 0 N-CA-C 112.201 -0.36 . . . . 0.0 112.201 175.069 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.479 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . 165.02 162.75 16.77 Favored Glycine 0 N--CA 1.412 -2.944 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.8 m -135.46 147.64 28.77 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 177.462 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.554 ' SG ' HG23 ' A' ' 2' ' ' VAL . 94.7 m -80.42 131.47 35.6 Favored 'General case' 0 C--N 1.293 -1.856 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.692 177.24 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.61 168.61 26.59 Favored 'General case' 0 N--CA 1.427 -1.596 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 -178.095 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 4.1 p . . . . . 0 C--O 1.259 1.586 0 C-N-CA 123.919 0.888 . . . . 0.0 113.101 -178.925 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 22.3 p . . . . . 0 N--CA 1.447 -0.606 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.569 HG23 ' SG ' ' A' ' 16' ' ' CYS . 23.8 m -94.15 178.42 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.594 -0.276 . . . . 0.0 110.586 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 27.3 mt -117.84 -176.01 2.95 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 112.667 0.617 . . . . 0.0 112.667 -172.669 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.532 HG13 ' OE1' ' A' ' 20' ' ' GLN . 66.4 mt -56.6 135.88 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 C-N-CA 123.714 0.806 . . . . 0.0 110.764 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 84.04 -6.85 73.4 Favored Glycine 0 C--N 1.313 -0.704 0 C-N-CA 121.447 -0.406 . . . . 0.0 112.693 177.29 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -94.14 150.55 20.22 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 178.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.2 tmm_? -86.76 129.7 34.77 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.5 -172.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 18.5 p -128.33 175.45 8.48 Favored 'General case' 0 C--N 1.297 -1.694 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.175 -175.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -152.9 121.51 6.4 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 106.161 -1.792 . . . . 0.0 106.161 174.456 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.8 m120 -72.17 -26.27 62.01 Favored 'General case' 0 C--N 1.294 -1.843 0 CA-C-O 120.832 0.349 . . . . 0.0 111.091 -174.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -78.74 -56.8 4.14 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.788 -176.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 26.9 mmm180 -106.53 -9.61 16.55 Favored 'General case' 0 C--N 1.312 -1.043 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -174.216 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 90.64 165.51 40.39 Favored Glycine 0 C--N 1.297 -1.622 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -177.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -81.39 170.87 60.26 Favored 'Cis proline' 0 CA--C 1.534 0.486 0 C-N-CA 123.385 -1.506 . . . . 0.0 111.831 0.314 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 78.7 mtm180 -122.76 152.12 40.94 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.14 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.569 ' SG ' HG23 ' A' ' 2' ' ' VAL . 57.9 m -86.01 158.67 19.8 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.068 -176.345 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.445 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 26.4 m -67.28 153.81 42.79 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 178.295 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 18.7 m -46.86 -45.59 20.41 Favored 'General case' 0 CA--C 1.56 1.334 0 N-CA-C 115.188 1.551 . . . . 0.0 115.188 -172.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -97.0 22.01 43.06 Favored Glycine 0 C--N 1.318 -0.472 0 C-N-CA 120.501 -0.857 . . . . 0.0 112.559 -178.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.532 ' OE1' HG13 ' A' ' 4' ' ' ILE . 85.9 mm-40 -105.28 23.28 13.96 Favored 'General case' 0 C--N 1.311 -1.1 0 O-C-N 122.648 -0.324 . . . . 0.0 111.692 -178.602 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 92.65 -177.42 38.88 Favored Glycine 0 N--CA 1.43 -1.7 0 C-N-CA 120.451 -0.881 . . . . 0.0 112.774 177.154 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 33' ' ' CYS . 35.3 t30 -119.16 143.8 47.03 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 179.135 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 92.2 m -63.38 102.04 0.37 Allowed 'General case' 0 C--N 1.316 -0.872 0 O-C-N 123.871 0.732 . . . . 0.0 110.535 178.103 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.7 m -110.1 137.23 20.49 Favored Pre-proline 0 N--CA 1.421 -1.924 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 177.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -67.91 120.85 7.85 Favored 'Trans proline' 0 N--CA 1.448 -1.184 0 C-N-CA 121.699 1.6 . . . . 0.0 112.14 -178.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.41 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 56.5 tp -115.98 104.99 51.91 Favored Pre-proline 0 N--CA 1.42 -1.964 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 176.131 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 18.3 Cg_exo -70.78 56.15 1.79 Allowed 'Trans proline' 0 N--CA 1.479 0.653 0 C-N-CA 124.056 3.171 . . . . 0.0 113.219 -175.53 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -148.06 -63.54 0.26 Allowed 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 125.294 1.438 . . . . 0.0 108.09 179.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -104.03 -19.38 14.22 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.518 -179.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 121.76 -165.01 14.73 Favored Glycine 0 C--N 1.305 -1.167 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -177.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -72.91 125.43 9.82 Favored Glycine 0 CA--C 1.49 -1.481 0 C-N-CA 119.986 -1.102 . . . . 0.0 110.356 177.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 33.2 m -127.62 153.14 36.55 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.327 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -176.733 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.478 ' HA ' ' O ' ' A' ' 22' ' ' ASN . 74.1 m -85.84 116.55 24.16 Favored 'General case' 0 C--N 1.284 -2.246 0 C-N-CA 119.718 -0.793 . . . . 0.0 111.25 178.302 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.54 168.51 22.54 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.256 179.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.1 t . . . . . 0 C--N 1.307 -1.255 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 176.507 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.5 p . . . . . 0 C--O 1.244 0.808 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.405 HG23 ' SG ' ' A' ' 33' ' ' CYS . 27.9 m -116.35 159.44 16.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-O 120.916 0.389 . . . . 0.0 111.243 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 67.8 mt -105.41 -177.83 3.48 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 115.58 -0.737 . . . . 0.0 111.01 -175.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 20.5 pt -56.05 137.34 17.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 178.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 89.15 -14.42 60.79 Favored Glycine 0 C--N 1.316 -0.543 0 CA-C-N 115.761 -0.654 . . . . 0.0 113.288 177.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.438 ' O ' ' HA ' ' A' ' 32' ' ' VAL . 78.0 mt-30 -87.73 162.06 17.26 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-O 121.031 0.443 . . . . 0.0 110.794 -178.453 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.406 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 37.6 ttt180 -84.88 123.59 30.66 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 114.753 -1.112 . . . . 0.0 109.092 -175.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -134.88 167.6 20.59 Favored 'General case' 0 C--N 1.294 -1.82 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.038 -176.702 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -146.55 130.54 17.27 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 175.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 35.7 m-80 -66.32 -40.33 89.86 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 114.753 -1.112 . . . . 0.0 112.977 -171.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -93.04 -52.01 4.78 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -175.113 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 78.4 mtp180 -84.46 -24.68 29.39 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.29 -173.028 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 99.58 163.17 29.22 Favored Glycine 0 N--CA 1.429 -1.818 0 N-CA-C 109.377 -1.489 . . . . 0.0 109.377 -175.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -81.15 159.73 82.94 Favored 'Cis proline' 0 N--CA 1.446 -1.311 0 CA-C-N 119.662 1.731 . . . . 0.0 111.296 0.267 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -107.94 149.93 27.72 Favored 'General case' 0 C--N 1.291 -1.972 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.017 -178.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 45.7 m -65.08 142.45 58.38 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.053 -0.976 . . . . 0.0 108.6 178.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 61.2 m -63.84 144.96 56.64 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 176.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.7 p -53.04 86.54 0.0 OUTLIER 'General case' 0 CA--C 1.546 0.818 0 N-CA-C 113.909 1.077 . . . . 0.0 113.909 -176.144 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.6 26.81 1.54 Allowed Glycine 0 N--CA 1.435 -1.392 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.3 -178.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 23.1 mm-40 -115.87 30.19 7.5 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.427 0.632 . . . . 0.0 111.87 179.133 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.64 -150.5 24.4 Favored Glycine 0 N--CA 1.425 -2.073 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.402 177.164 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 28.8 p-10 -130.64 159.35 37.46 Favored 'General case' 0 C--N 1.287 -2.127 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 179.064 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 85.5 m -77.5 99.27 5.61 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 123.572 0.545 . . . . 0.0 109.798 175.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 14.6 p -90.22 120.47 69.15 Favored Pre-proline 0 N--CA 1.421 -1.914 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 176.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -74.59 134.73 18.94 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 121.982 1.788 . . . . 0.0 113.222 -176.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.0 mt -135.94 129.92 18.34 Favored Pre-proline 0 C--N 1.301 -1.513 0 CA-C-N 115.046 -0.979 . . . . 0.0 108.573 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.79 54.23 2.01 Favored 'Trans proline' 0 CA--C 1.536 0.581 0 C-N-CA 124.031 3.154 . . . . 0.0 113.898 -174.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -143.06 -66.9 0.37 Allowed 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 178.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.618 ' H ' HD23 ' A' ' 29' ' ' LEU . 1.9 pt? -107.45 0.27 22.73 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.496 -0.774 . . . . 0.0 112.369 -178.458 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 109.94 -86.88 0.45 Allowed Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.393 -0.908 . . . . 0.0 111.39 179.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.406 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -152.54 148.83 20.19 Favored Glycine 0 CA--C 1.49 -1.518 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.438 ' HA ' ' O ' ' A' ' 6' ' ' GLN . 28.4 m -128.79 145.79 35.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 120.834 0.349 . . . . 0.0 111.439 -178.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.405 ' SG ' HG23 ' A' ' 2' ' ' VAL . 79.7 m -71.72 121.68 19.31 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 175.598 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -142.33 136.49 29.74 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.025 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 58.1 t . . . . . 0 N--CA 1.438 -1.07 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 177.192 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.4 p . . . . . 0 C--O 1.242 0.694 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.443 HG23 ' SG ' ' A' ' 33' ' ' CYS . 26.1 m -108.87 162.68 6.55 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.166 0.508 . . . . 0.0 111.277 -179.038 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 54.3 mt -105.79 -175.28 2.75 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.737 -175.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 30.5 pt -58.02 129.03 19.48 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 N-CA-C 113.224 0.824 . . . . 0.0 113.224 -178.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.18 -13.92 65.02 Favored Glycine 0 CA--C 1.503 -0.664 0 CA-C-N 115.639 -0.71 . . . . 0.0 112.681 177.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.42 ' HB2' ' HB ' ' A' ' 2' ' ' VAL . 87.5 mt-30 -88.82 159.72 17.59 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.408 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 62.1 ttt180 -86.02 131.37 34.28 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.827 -173.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.7 p -126.2 156.67 39.86 Favored 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.813 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -137.38 126.57 24.58 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 176.202 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 46.9 m-80 -78.98 -31.62 44.96 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 120.485 -0.486 . . . . 0.0 111.893 -178.09 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -72.67 -52.86 13.55 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-O 121.097 0.475 . . . . 0.0 111.727 -174.7 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.423 ' HA ' ' NE ' ' A' ' 12' ' ' ARG . 5.4 mmp_? -108.06 -17.58 14.0 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 113.398 0.888 . . . . 0.0 113.398 -176.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 91.26 168.28 41.5 Favored Glycine 0 N--CA 1.432 -1.6 0 C-N-CA 119.842 -1.17 . . . . 0.0 110.502 -177.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 94.1 Cg_endo -79.25 159.9 89.53 Favored 'Cis proline' 0 C--N 1.329 -0.47 0 CA-C-N 119.082 1.441 . . . . 0.0 111.863 -1.143 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 83.0 mtm180 -109.6 177.0 4.87 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 178.514 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.2 m -70.51 144.45 51.35 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 86.3 m -68.17 145.02 54.73 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 173.585 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.5 t -50.93 99.0 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.236 1.015 . . . . 0.0 112.177 -175.724 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 118.01 -11.33 13.33 Favored Glycine 0 N--CA 1.443 -0.84 0 CA-C-N 115.83 -0.623 . . . . 0.0 112.123 179.3 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.476 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 23.7 mm-40 -86.17 23.55 1.52 Allowed 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 114.674 1.361 . . . . 0.0 114.674 -176.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 101.27 -176.63 26.86 Favored Glycine 0 N--CA 1.427 -1.946 0 C-N-CA 119.439 -1.362 . . . . 0.0 113.934 174.441 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 38.4 m-80 -113.4 150.31 32.88 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 179.407 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 89.1 m -74.52 98.18 3.29 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 123.193 0.308 . . . . 0.0 111.101 179.112 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.9 t -82.42 122.24 78.84 Favored Pre-proline 0 C--N 1.303 -1.42 0 N-CA-C 106.279 -1.749 . . . . 0.0 106.279 175.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -86.4 121.72 1.98 Allowed 'Trans proline' 0 N--CA 1.439 -1.686 0 C-N-CA 122.66 2.24 . . . . 0.0 113.679 -174.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -119.45 148.41 45.56 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 108.369 -0.975 . . . . 0.0 108.369 178.011 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_exo -41.19 -69.3 0.08 OUTLIER 'Trans proline' 0 CA--C 1.548 1.198 0 C-N-CA 124.74 3.627 . . . . 0.0 116.037 -175.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 24.6 p90 -93.01 -17.66 23.61 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 112.966 0.728 . . . . 0.0 112.966 -173.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 96.5 mt -86.64 -13.48 45.49 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.495 179.227 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 81.79 -79.46 1.84 Allowed Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.84 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.408 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -166.34 136.26 4.07 Favored Glycine 0 N--CA 1.426 -1.992 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 179.471 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 36.0 m -126.51 143.44 39.99 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 CA-C-O 120.909 0.385 . . . . 0.0 110.821 -179.006 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.476 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 74.8 m -71.42 114.08 9.12 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.792 178.696 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -148.43 156.41 42.45 Favored 'General case' 0 C--N 1.315 -0.912 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 178.561 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 39.3 t . . . . . 0 C--O 1.255 1.37 0 C-N-CA 123.684 0.794 . . . . 0.0 110.006 -179.315 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.5 p . . . . . 0 C--O 1.24 0.56 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.435 ' HB ' ' HB2' ' A' ' 6' ' ' GLN . 33.9 m -110.75 164.68 6.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 121.185 0.517 . . . . 0.0 110.866 -178.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 48.4 mt -102.47 -179.22 3.92 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.767 -178.286 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 27.3 pt -59.4 133.19 24.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.126 0.489 . . . . 0.0 112.213 178.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 91.1 -10.26 75.47 Favored Glycine 0 C--N 1.316 -0.536 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.98 178.535 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.435 ' HB2' ' HB ' ' A' ' 2' ' ' VAL . 86.7 mt-30 -94.85 157.53 15.88 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 -179.124 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 2.7 tmm_? -85.96 124.55 32.53 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.367 -173.618 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.46 ' HB2' ' HA ' ' A' ' 15' ' ' ARG . 10.4 p -121.36 165.8 15.01 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.009 179.254 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -125.0 124.93 43.06 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 176.296 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -73.48 -33.43 64.82 Favored 'General case' 0 C--N 1.305 -1.365 0 N-CA-C 112.751 0.649 . . . . 0.0 112.751 -171.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -91.17 -50.56 5.77 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 120.542 -0.463 . . . . 0.0 111.928 -175.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 58.4 mtp180 -102.18 -8.67 21.14 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -172.177 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.14 168.36 44.57 Favored Glycine 0 C--N 1.31 -0.909 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.491 178.304 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 90.5 Cg_endo -81.87 166.89 70.91 Favored 'Cis proline' 0 N--CA 1.474 0.327 0 C-N-CA 123.837 -1.318 . . . . 0.0 111.283 -0.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.46 ' HA ' ' HB2' ' A' ' 8' ' ' CYS . 73.4 mtm180 -121.49 -173.79 2.71 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 116.763 -0.199 . . . . 0.0 111.006 178.283 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 33.1 m -60.38 144.46 50.78 Favored 'General case' 0 C--N 1.301 -1.533 0 C-N-CA 123.846 0.859 . . . . 0.0 112.142 -178.302 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 74.4 m -71.97 166.23 22.6 Favored 'General case' 0 C--O 1.243 0.731 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 170.541 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.7 t -67.83 109.82 3.55 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -179.056 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 101.16 26.68 7.71 Favored Glycine 0 N--CA 1.443 -0.886 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 -179.253 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.537 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 86.9 mm-40 -126.06 35.68 4.64 Favored 'General case' 0 C--N 1.318 -0.792 0 O-C-N 122.68 -0.306 . . . . 0.0 111.503 -179.239 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 70.81 -158.59 53.71 Favored Glycine 0 C--O 1.248 0.997 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.407 178.617 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -127.05 158.84 35.91 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 176.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 98.4 m -68.66 104.81 2.08 Favored 'General case' 0 C--N 1.305 -1.366 0 CA-C-O 121.168 0.509 . . . . 0.0 110.779 178.616 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 59.9 t -91.83 120.06 68.14 Favored Pre-proline 0 N--CA 1.426 -1.647 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 175.608 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_exo -67.51 136.86 40.95 Favored 'Trans proline' 0 N--CA 1.445 -1.37 0 C-N-CA 122.459 2.106 . . . . 0.0 111.858 -179.461 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 24.0 tp -132.49 117.01 15.3 Favored Pre-proline 0 C--N 1.29 -2.017 0 N-CA-C 105.271 -2.122 . . . . 0.0 105.271 176.224 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -63.42 51.61 0.14 Allowed 'Trans proline' 0 N--CA 1.502 1.982 0 C-N-CA 125.029 3.819 . . . . 0.0 116.575 -170.726 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -144.34 -64.39 0.36 Allowed 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 177.531 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.641 ' H ' HD23 ' A' ' 29' ' ' LEU . 1.9 pt? -103.7 -3.4 25.11 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.213 -0.903 . . . . 0.0 112.88 -173.148 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 113.94 -103.91 1.39 Allowed Glycine 0 C--N 1.304 -1.216 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -177.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -139.78 152.48 22.63 Favored Glycine 0 N--CA 1.43 -1.724 0 C-N-CA 120.674 -0.774 . . . . 0.0 111.425 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 19.5 m -132.06 139.71 49.63 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.537 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 84.2 m -69.31 128.14 35.53 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.295 179.271 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -164.85 158.36 17.27 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 109.484 -0.562 . . . . 0.0 109.484 -178.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.2 t . . . . . 0 C--O 1.252 1.206 0 O-C-N 124.9 1.375 . . . . 0.0 111.603 177.329 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.6 p . . . . . 0 N--CA 1.456 -0.164 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.48 HG23 ' SG ' ' A' ' 33' ' ' CYS . 15.3 m -105.43 164.59 4.05 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-O 121.094 0.473 . . . . 0.0 111.846 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 21.4 mt -107.39 178.84 4.42 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.244 -173.652 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 40.0 pt -57.85 137.35 20.15 Favored 'Isoleucine or valine' 0 C--O 1.24 0.57 0 CA-C-O 121.571 0.7 . . . . 0.0 112.685 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 92.13 -23.98 24.18 Favored Glycine 0 C--N 1.306 -1.083 0 CA-C-N 115.645 -0.707 . . . . 0.0 112.795 178.661 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 92.3 mt-30 -82.8 155.79 24.01 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -178.316 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.9 tmm_? -85.75 127.18 34.47 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -173.512 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 21.8 p -122.52 172.92 8.02 Favored 'General case' 0 C--N 1.288 -2.107 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.376 -177.109 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -153.35 124.02 7.24 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 177.001 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 93.9 m-20 -72.96 -37.79 66.98 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 112.64 0.607 . . . . 0.0 112.64 -174.475 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -85.6 -47.3 9.98 Favored 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 120.072 -0.651 . . . . 0.0 112.533 -174.656 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 5.1 mmp_? -93.58 -29.21 15.6 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.891 -0.723 . . . . 0.0 112.196 -177.327 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 103.61 162.45 25.14 Favored Glycine 0 N--CA 1.434 -1.471 0 N-CA-C 109.826 -1.31 . . . . 0.0 109.826 -175.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -82.77 157.59 76.47 Favored 'Cis proline' 0 CA--C 1.535 0.536 0 CA-C-N 119.276 1.538 . . . . 0.0 112.432 1.278 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 63.7 mtm180 -107.23 157.04 18.21 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-O 120.853 0.359 . . . . 0.0 110.054 179.7 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 35.6 m -68.51 142.85 55.15 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 124.19 0.996 . . . . 0.0 110.282 -178.654 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.446 ' HB2' ' CG ' ' A' ' 20' ' ' GLN . 54.7 m -67.78 154.4 41.61 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 174.032 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.1 p -54.55 -23.05 15.04 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 115.776 1.769 . . . . 0.0 115.776 -171.196 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -115.83 22.84 11.31 Favored Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 177.483 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.446 ' CG ' ' HB2' ' A' ' 17' ' ' CYS . 86.4 mm-40 -115.56 20.9 14.41 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.254 0.55 . . . . 0.0 110.91 -178.236 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 80.16 -151.6 33.46 Favored Glycine 0 N--CA 1.426 -2.002 0 C-N-CA 120.282 -0.961 . . . . 0.0 113.166 176.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -135.88 168.57 19.07 Favored 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 77.6 m -74.74 124.72 27.3 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 123.648 0.592 . . . . 0.0 111.234 -179.182 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 22.0 t -106.25 116.52 59.22 Favored Pre-proline 0 C--N 1.291 -1.954 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 173.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.427 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 56.4 Cg_endo -80.72 125.01 5.34 Favored 'Trans proline' 0 N--CA 1.445 -1.371 0 C-N-CA 122.583 2.188 . . . . 0.0 112.953 -175.702 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.405 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 4.1 pp -118.72 153.96 52.52 Favored Pre-proline 0 C--N 1.302 -1.47 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.23 178.742 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 5.4 Cg_endo -83.54 49.66 2.99 Favored 'Trans proline' 0 C--O 1.236 0.396 0 C-N-CA 123.53 2.82 . . . . 0.0 113.935 -170.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -141.48 -77.59 0.28 Allowed 'General case' 0 C--N 1.314 -0.959 0 CA-C-O 120.878 0.37 . . . . 0.0 110.915 179.29 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.468 ' H ' HD13 ' A' ' 29' ' ' LEU . 0.0 OUTLIER -106.85 0.88 24.31 Favored 'General case' 0 C--N 1.319 -0.732 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -177.11 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 116.98 -138.62 14.44 Favored Glycine 0 N--CA 1.437 -1.266 0 C-N-CA 120.371 -0.919 . . . . 0.0 111.206 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.427 ' HA2' ' HA ' ' A' ' 25' ' ' PRO . . . -108.92 149.23 17.0 Favored Glycine 0 N--CA 1.428 -1.841 0 C-N-CA 120.395 -0.907 . . . . 0.0 112.52 -178.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.8 m -124.04 146.75 29.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 177.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.48 ' SG ' HG23 ' A' ' 2' ' ' VAL . 74.4 m -71.1 136.7 48.35 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.828 179.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -160.33 146.06 15.16 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 178.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.7 t . . . . . 0 C--N 1.307 -1.258 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 -179.063 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 26.5 p . . . . . 0 N--CA 1.443 -0.778 0 N-CA-C 108.765 -0.828 . . . . 0.0 108.765 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.451 HG23 ' SG ' ' A' ' 33' ' ' CYS . 35.7 m -102.26 169.19 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-O 121.146 0.498 . . . . 0.0 111.088 -178.427 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 26.0 mt -109.84 -176.11 2.92 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.399 -0.818 . . . . 0.0 110.542 -175.432 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.514 HG13 ' OE1' ' A' ' 20' ' ' GLN . 61.5 mt -56.37 133.25 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 C-N-CA 122.681 0.392 . . . . 0.0 111.029 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 87.26 -15.03 56.09 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 116.024 -0.534 . . . . 0.0 113.057 177.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -88.42 159.25 18.09 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 -178.662 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.551 ' HA ' ' O ' ' A' ' 31' ' ' GLY . 85.9 mtm180 -86.63 134.53 33.62 Favored 'General case' 0 CA--C 1.496 -1.098 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.916 -175.523 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.427 ' HB3' ' CG2' ' A' ' 2' ' ' VAL . 24.0 p -139.49 171.34 14.4 Favored 'General case' 0 C--N 1.285 -2.205 0 CA-C-N 114.276 -1.329 . . . . 0.0 109.379 -178.148 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -145.51 125.7 13.8 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 174.427 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -65.79 -32.75 74.46 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -177.308 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -91.16 -52.34 4.87 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -172.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 55.3 mtp180 -92.46 -25.91 18.22 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -176.068 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 90.51 167.92 42.07 Favored Glycine 0 N--CA 1.437 -1.288 0 N-CA-C 110.772 -0.931 . . . . 0.0 110.772 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -76.78 168.84 76.04 Favored 'Cis proline' 0 N--CA 1.475 0.387 0 CA-C-N 119.669 1.735 . . . . 0.0 110.517 -0.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 5.7 mpt_? -116.09 -179.18 3.59 Favored 'General case' 0 C--N 1.291 -1.943 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.267 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 56.7 m -70.71 148.59 47.82 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 178.161 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 60.9 m -69.85 142.86 53.01 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 106.04 -1.837 . . . . 0.0 106.04 170.526 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 16.6 m -62.23 99.23 0.13 Allowed 'General case' 0 C--O 1.243 0.749 0 CA-C-O 121.002 0.429 . . . . 0.0 111.111 -175.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 128.84 -6.59 6.49 Favored Glycine 0 CA--C 1.53 1.014 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.204 -176.372 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.514 ' OE1' HG13 ' A' ' 4' ' ' ILE . 84.8 mm-40 -98.42 10.87 39.82 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 -178.478 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.452 ' HA2' ' HB ' ' A' ' 35' ' ' VAL . . . 103.73 -172.44 20.97 Favored Glycine 0 N--CA 1.442 -0.963 0 C-N-CA 120.009 -1.091 . . . . 0.0 113.442 176.138 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 -117.02 147.16 42.57 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 -179.301 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 96.1 m -72.67 102.21 3.26 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 123.884 0.74 . . . . 0.0 112.018 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.2 p -87.23 119.85 71.08 Favored Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 171.299 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -82.97 141.13 10.42 Favored 'Trans proline' 0 N--CA 1.447 -1.253 0 C-N-CA 121.987 1.791 . . . . 0.0 114.606 -173.141 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 5.8 mp -122.83 122.97 26.98 Favored Pre-proline 0 C--N 1.3 -1.551 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 177.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_exo -36.34 -54.64 0.88 Allowed 'Trans proline' 0 N--CA 1.485 1.015 0 C-N-CA 124.957 3.772 . . . . 0.0 116.012 -175.398 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -111.05 -15.35 13.74 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 113.75 1.018 . . . . 0.0 113.75 -177.647 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -80.0 -30.13 39.58 Favored 'General case' 0 C--N 1.294 -1.836 0 C-N-CA 120.313 -0.555 . . . . 0.0 112.002 174.521 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 114.73 -99.0 0.9 Allowed Glycine 0 N--CA 1.431 -1.664 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.551 ' O ' ' HA ' ' A' ' 7' ' ' ARG . . . -171.64 148.62 11.15 Favored Glycine 0 C--N 1.282 -2.471 0 N-CA-C 108.649 -1.78 . . . . 0.0 108.649 178.147 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 31.5 m -130.47 145.91 34.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 CA-C-N 117.928 0.864 . . . . 0.0 111.484 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.451 ' SG ' HG23 ' A' ' 2' ' ' VAL . 71.9 m -76.11 116.74 17.11 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.896 176.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -141.56 149.19 40.48 Favored 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -179.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.452 ' HB ' ' HA2' ' A' ' 21' ' ' GLY . 4.1 p . . . . . 0 C--N 1.3 -1.544 0 CA-C-O 118.74 -0.647 . . . . 0.0 109.485 177.232 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.0 p . . . . . 0 C--O 1.227 -0.118 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.532 HG23 ' SG ' ' A' ' 33' ' ' CYS . 16.5 m -110.13 161.21 8.68 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -177.54 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 36.0 mt -107.41 -178.96 3.78 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.09 -175.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 24.0 pt -61.13 128.81 23.03 Favored 'Isoleucine or valine' 0 C--O 1.238 0.489 0 N-CA-C 113.282 0.845 . . . . 0.0 113.282 -179.337 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.62 -5.35 73.57 Favored Glycine 0 N--CA 1.443 -0.859 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.767 -179.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 77.5 mt-30 -101.32 156.01 17.7 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 176.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.401 ' NH1' HD22 ' A' ' 29' ' ' LEU . 54.1 mtm180 -86.03 140.75 30.0 Favored 'General case' 0 C--N 1.306 -1.3 0 CA-C-O 121.727 0.775 . . . . 0.0 112.606 -173.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.415 ' SG ' ' N ' ' A' ' 9' ' ' ASP . 1.6 t -133.16 171.68 13.68 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-N 113.68 -1.6 . . . . 0.0 109.321 -175.16 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.415 ' N ' ' SG ' ' A' ' 8' ' ' CYS . 17.1 t70 -161.86 118.73 2.13 Favored 'General case' 0 C--N 1.276 -2.59 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 172.363 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -57.68 -39.57 77.43 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 113.984 1.105 . . . . 0.0 113.984 -175.536 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -91.13 -47.78 7.33 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -175.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 29.1 mmt180 -80.7 -43.0 21.01 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.709 0.766 . . . . 0.0 111.592 -177.012 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 105.46 163.87 23.55 Favored Glycine 0 N--CA 1.425 -2.064 0 N-CA-C 108.337 -1.905 . . . . 0.0 108.337 -172.286 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -79.01 165.85 80.58 Favored 'Cis proline' 0 C--N 1.322 -0.865 0 CA-C-N 119.88 1.84 . . . . 0.0 111.891 -0.002 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 60.5 mtp180 -108.2 153.49 23.11 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 179.412 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 55.9 m -68.01 138.69 56.07 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 55.9 m -65.93 158.28 28.5 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 178.148 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.8 t -60.89 104.43 0.36 Allowed 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 123.194 0.597 . . . . 0.0 110.343 -179.342 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 108.85 17.35 10.4 Favored Glycine 0 N--CA 1.443 -0.897 0 N-CA-C 111.524 -0.631 . . . . 0.0 111.524 -178.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 83.6 mm-40 -111.18 52.19 0.75 Allowed 'General case' 0 C--N 1.307 -1.243 0 O-C-N 122.038 -0.684 . . . . 0.0 111.591 -179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 71.03 -143.4 36.15 Favored Glycine 0 N--CA 1.434 -1.492 0 C-N-CA 120.584 -0.817 . . . . 0.0 112.376 178.079 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 46.4 m-80 -128.94 146.12 51.04 Favored 'General case' 0 C--N 1.289 -2.05 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 176.194 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 42.9 t -83.11 97.12 8.63 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.01 -1.107 . . . . 0.0 108.01 179.036 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.0 p -94.37 114.99 64.72 Favored Pre-proline 0 N--CA 1.432 -1.341 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.353 -179.426 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.485 ' HA ' ' CA ' ' A' ' 31' ' ' GLY . 73.9 Cg_endo -76.72 142.15 22.54 Favored 'Trans proline' 0 N--CA 1.449 -1.136 0 C-N-CA 122.557 2.172 . . . . 0.0 113.605 -176.107 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 5.8 mp -116.06 142.4 29.16 Favored Pre-proline 0 N--CA 1.422 -1.867 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 172.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 62.2 Cg_endo -74.57 53.99 3.3 Favored 'Trans proline' 0 C--N 1.326 -0.65 0 C-N-CA 123.164 2.576 . . . . 0.0 113.464 -177.247 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.46 ' HB3' HD12 ' A' ' 29' ' ' LEU . 70.2 m-85 -139.17 -87.51 0.22 Allowed 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 178.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.46 HD12 ' HB3' ' A' ' 28' ' ' PHE . 4.5 mp -104.66 -28.27 11.33 Favored 'General case' 0 C--N 1.308 -1.226 0 CA-C-O 121.589 0.709 . . . . 0.0 110.47 -176.181 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 167.41 -152.59 21.32 Favored Glycine 0 N--CA 1.418 -2.543 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -179.22 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.485 ' CA ' ' HA ' ' A' ' 25' ' ' PRO . . . -113.42 -172.75 18.36 Favored Glycine 0 N--CA 1.411 -3.033 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.3 p -138.06 152.59 26.22 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.24 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.061 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.532 ' SG ' HG23 ' A' ' 2' ' ' VAL . 63.7 m -89.12 119.43 29.62 Favored 'General case' 0 C--N 1.275 -2.633 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.297 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -147.04 139.56 24.83 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -176.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 C--N 1.306 -1.316 0 CA-C-O 118.867 -0.587 . . . . 0.0 109.978 -179.861 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 27.7 p . . . . . 0 CA--C 1.513 -0.45 0 N-CA-C 109.29 -0.634 . . . . 0.0 109.29 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.458 ' HB ' ' HB2' ' A' ' 6' ' ' GLN . 33.5 m -103.17 152.53 5.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-O 120.953 0.406 . . . . 0.0 111.076 -177.293 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 52.3 mt -97.68 -174.3 2.86 Favored 'General case' 0 N--CA 1.438 -1.043 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.667 -179.273 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 43.2 pt -59.28 142.06 15.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.059 0.457 . . . . 0.0 111.704 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 88.59 -26.07 8.67 Favored Glycine 0 C--N 1.311 -0.82 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.26 178.366 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.458 ' HB2' ' HB ' ' A' ' 2' ' ' VAL . 24.1 mt-30 -79.18 152.92 30.42 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -178.552 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 10.2 mpt_? -86.76 136.86 32.84 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.883 -175.799 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.5 p -130.02 168.27 16.98 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.984 -175.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -132.5 123.68 27.06 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 16.9 m120 -72.73 -26.59 61.63 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -175.685 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -84.17 -56.55 3.6 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-O 121.228 0.537 . . . . 0.0 111.4 -175.112 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 71.9 mtm180 -105.45 -24.14 12.69 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 -170.339 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 95.48 172.48 36.59 Favored Glycine 0 N--CA 1.426 -1.999 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 -172.744 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -72.21 160.54 93.94 Favored 'Cis proline' 0 C--O 1.235 0.373 0 CA-C-N 119.771 1.785 . . . . 0.0 111.574 -0.218 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 57.8 mtm180 -120.18 176.04 5.65 Favored 'General case' 0 C--N 1.291 -1.959 0 CA-C-N 116.495 -0.321 . . . . 0.0 110.17 179.281 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 20.5 m -68.02 144.45 55.12 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 123.607 0.567 . . . . 0.0 109.494 -178.501 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . 0.405 ' HB2' ' HG3' ' A' ' 20' ' ' GLN . 52.9 m -67.9 145.67 54.36 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 105.977 -1.86 . . . . 0.0 105.977 171.333 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 14.6 p -56.43 107.75 0.41 Allowed 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 112.017 0.377 . . . . 0.0 112.017 -177.218 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 115.03 -11.46 20.32 Favored Glycine 0 N--CA 1.444 -0.804 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.497 -177.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.452 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 86.8 mm-40 -91.98 26.61 2.39 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-O 121.321 0.581 . . . . 0.0 111.45 -178.514 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.84 -168.02 37.17 Favored Glycine 0 N--CA 1.415 -2.73 0 C-N-CA 120.54 -0.838 . . . . 0.0 113.074 176.41 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 47.4 m-80 -129.9 153.07 48.68 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 -179.121 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 74.3 m -68.32 104.7 1.93 Allowed 'General case' 0 C--N 1.314 -0.946 0 O-C-N 123.895 0.747 . . . . 0.0 112.602 -176.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.53 117.5 61.78 Favored Pre-proline 0 N--CA 1.434 -1.259 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 175.248 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.443 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 6.1 Cg_exo -77.98 122.36 5.76 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 122.125 1.884 . . . . 0.0 112.198 -179.051 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.423 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 34.9 tp -129.31 109.92 17.86 Favored Pre-proline 0 N--CA 1.427 -1.607 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 175.351 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 35.5 Cg_exo -64.29 51.53 0.18 Allowed 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 125.122 3.881 . . . . 0.0 116.476 -172.464 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -139.16 -53.34 0.56 Allowed 'General case' 0 C--N 1.299 -1.61 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 174.009 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.669 ' H ' HD23 ' A' ' 29' ' ' LEU . 1.9 pt? -107.05 -18.37 13.92 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 114.595 -1.184 . . . . 0.0 111.842 -178.011 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 115.42 -154.97 16.61 Favored Glycine 0 N--CA 1.442 -0.954 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.443 ' HA2' ' HA ' ' A' ' 25' ' ' PRO . . . -101.81 123.94 8.05 Favored Glycine 0 CA--C 1.483 -1.965 0 N-CA-C 110.136 -1.186 . . . . 0.0 110.136 178.352 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 33.3 m -120.12 150.41 22.78 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.047 0 CA-C-O 121.157 0.503 . . . . 0.0 111.601 -174.101 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.452 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 82.0 m -75.13 116.43 15.86 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.152 176.12 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -130.86 136.3 48.51 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.56 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 55.2 t . . . . . 0 C--N 1.315 -0.933 0 CA-C-O 118.778 -0.629 . . . . 0.0 109.366 -179.518 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 28.4 p . . . . . 0 CA--C 1.51 -0.572 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.428 HG23 ' SG ' ' A' ' 33' ' ' CYS . 20.0 m -109.19 164.41 5.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.314 -178.333 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 38.8 mt -103.05 -179.83 4.06 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -177.774 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 34.2 pt -62.64 135.66 26.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.426 0.631 . . . . 0.0 112.683 -178.5 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 90.08 -12.77 66.68 Favored Glycine 0 C--N 1.314 -0.677 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.985 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -92.23 154.22 18.78 Favored 'General case' 0 N--CA 1.435 -1.211 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.368 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.0 mtm180 -86.16 143.41 28.02 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.545 -174.011 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.477 ' HB2' ' O ' ' A' ' 14' ' ' PRO . 26.4 p -144.46 176.13 9.61 Favored 'General case' 0 C--N 1.278 -2.519 0 CA-C-N 114.519 -1.219 . . . . 0.0 108.362 -177.681 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -130.23 124.14 31.8 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -69.29 -27.69 65.62 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 112.645 0.609 . . . . 0.0 112.645 -177.705 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -91.94 -57.05 2.86 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 111.688 0.255 . . . . 0.0 111.688 -175.683 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -96.75 -18.47 19.6 Favored 'General case' 0 C--N 1.312 -1.051 0 N-CA-C 112.756 0.65 . . . . 0.0 112.756 -172.315 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.02 172.99 47.53 Favored Glycine 0 N--CA 1.437 -1.283 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 -174.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.477 ' O ' ' HB2' ' A' ' 8' ' ' CYS . 80.6 Cg_endo -75.77 173.09 59.83 Favored 'Cis proline' 0 C--O 1.23 0.093 0 CA-C-N 120.013 1.907 . . . . 0.0 111.014 -0.538 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.453 ' HA ' ' HB2' ' A' ' 8' ' ' CYS . 73.2 mtm180 -126.59 -173.91 2.99 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 116.678 -0.237 . . . . 0.0 110.437 178.492 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 22.2 m -65.45 146.74 54.5 Favored 'General case' 0 C--N 1.294 -1.826 0 C-N-CA 124.08 0.952 . . . . 0.0 111.591 -179.037 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 62.9 m -66.75 149.65 50.24 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 171.131 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.9 t -62.05 100.48 0.16 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.762 0.315 . . . . 0.0 110.365 -178.075 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 121.35 1.23 11.2 Favored Glycine 0 N--CA 1.444 -0.824 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -177.481 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 27.3 mm-40 -109.76 39.6 2.08 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 120.976 0.417 . . . . 0.0 112.103 179.564 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 74.43 -159.21 52.28 Favored Glycine 0 N--CA 1.423 -2.172 0 C-N-CA 120.308 -0.949 . . . . 0.0 112.628 178.38 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -133.96 148.92 51.22 Favored 'General case' 0 C--N 1.278 -2.5 0 N-CA-C 109.338 -0.615 . . . . 0.0 109.338 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 88.4 m -64.78 112.69 3.36 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 124.112 0.883 . . . . 0.0 111.079 177.677 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.3 p -96.19 124.67 50.81 Favored Pre-proline 0 C--N 1.284 -2.242 0 N-CA-C 106.116 -1.809 . . . . 0.0 106.116 172.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -78.39 145.86 21.52 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 C-N-CA 121.594 1.529 . . . . 0.0 112.585 -177.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.452 ' HB2' ' HB3' ' A' ' 29' ' ' LEU . 3.8 mm? -130.07 146.54 61.89 Favored Pre-proline 0 C--N 1.301 -1.534 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 178.003 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo -41.75 -68.19 0.1 Allowed 'Trans proline' 0 N--CA 1.481 0.791 0 C-N-CA 124.503 3.469 . . . . 0.0 115.111 -177.124 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 33.4 p90 -104.79 -25.22 12.74 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-O 121.074 0.464 . . . . 0.0 112.04 -176.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.452 ' HB3' ' HB2' ' A' ' 26' ' ' LEU . 3.2 tm? -66.05 -32.04 73.28 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.441 179.178 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 101.19 -88.12 0.7 Allowed Glycine 0 N--CA 1.429 -1.822 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 178.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -158.82 147.69 15.64 Favored Glycine 0 N--CA 1.427 -1.927 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 179.279 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.7 p -140.41 148.82 21.91 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.686 0 CA-C-O 121.197 0.522 . . . . 0.0 110.103 178.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.428 ' SG ' HG23 ' A' ' 2' ' ' VAL . 76.9 m -82.2 132.87 35.24 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.51 179.112 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.93 140.73 17.12 Favored 'General case' 0 N--CA 1.425 -1.678 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -178.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.1 m . . . . . 0 C--N 1.307 -1.282 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 176.125 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 24.3 p . . . . . 0 N--CA 1.445 -0.684 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' A' ' 16' ' ' CYS . 30.8 m -96.67 169.2 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 120.936 0.398 . . . . 0.0 111.087 -179.562 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.473 ' HB2' HE22 ' A' ' 6' ' ' GLN . 42.5 mt -114.41 -176.14 2.84 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.788 -176.326 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.3 pp -51.92 145.01 2.56 Favored 'Isoleucine or valine' 0 C--O 1.246 0.917 0 N-CA-C 113.546 0.943 . . . . 0.0 113.546 176.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 80.32 -15.98 15.36 Favored Glycine 0 C--N 1.32 -0.348 0 CA-C-N 115.728 -0.669 . . . . 0.0 113.632 179.383 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.473 HE22 ' HB2' ' A' ' 3' ' ' LEU . 11.5 mt-30 -85.91 157.96 20.04 Favored 'General case' 0 C--N 1.307 -1.271 0 O-C-N 122.384 -0.48 . . . . 0.0 110.136 177.254 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -86.44 125.05 33.43 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.894 -177.245 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.4 p -119.07 163.48 16.93 Favored 'General case' 0 C--N 1.278 -2.538 0 CA-C-N 114.569 -1.196 . . . . 0.0 110.697 -175.318 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -148.15 126.32 12.17 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 174.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -77.78 -22.13 50.61 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 -174.047 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -90.5 -54.81 3.84 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-O 121.255 0.55 . . . . 0.0 111.158 -175.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -100.04 -27.58 13.49 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.112 -0.949 . . . . 0.0 112.271 -172.424 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.0 169.93 27.32 Favored Glycine 0 N--CA 1.432 -1.599 0 N-CA-C 110.141 -1.184 . . . . 0.0 110.141 -174.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -79.85 155.53 88.16 Favored 'Cis proline' 0 N--CA 1.457 -0.655 0 CA-C-N 119.461 1.631 . . . . 0.0 111.704 -0.605 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 66.1 mtt180 -107.45 145.44 33.02 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 -179.358 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.491 ' HA ' ' O ' ' A' ' 2' ' ' VAL . 81.6 m -74.38 149.92 40.29 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.374 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 64.0 m -58.23 141.18 51.52 Favored 'General case' 0 C--N 1.317 -0.821 0 O-C-N 124.223 0.952 . . . . 0.0 109.693 -176.406 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 13.7 t -68.66 97.68 0.82 Allowed 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 -179.023 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 141.01 -19.18 2.71 Favored Glycine 0 N--CA 1.435 -1.428 0 N-CA-C 108.559 -1.817 . . . . 0.0 108.559 -173.662 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 24.9 mm-40 -81.49 -178.98 7.18 Favored 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 123.681 0.792 . . . . 0.0 111.839 177.215 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.54 169.61 19.17 Favored Glycine 0 C--N 1.314 -0.681 0 CA-C-O 121.42 0.456 . . . . 0.0 114.083 -177.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . 0.531 ' O ' ' HA ' ' A' ' 33' ' ' CYS . 9.0 t30 -85.82 139.93 30.87 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 178.72 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 21.4 t -76.25 101.46 5.45 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 -178.276 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.6 t -99.9 113.95 65.41 Favored Pre-proline 0 N--CA 1.426 -1.652 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 -179.302 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.444 ' HA ' ' CA ' ' A' ' 31' ' ' GLY . 3.0 Cg_exo -71.87 121.38 7.56 Favored 'Trans proline' 0 N--CA 1.442 -1.545 0 C-N-CA 122.19 1.927 . . . . 0.0 110.706 179.257 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.1 mt -117.12 122.88 30.67 Favored Pre-proline 0 N--CA 1.425 -1.695 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 178.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -73.65 42.86 0.72 Allowed 'Trans proline' 0 CA--C 1.542 0.878 0 C-N-CA 123.716 2.944 . . . . 0.0 113.102 -176.721 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -135.2 -67.65 0.54 Allowed 'General case' 0 C--N 1.31 -1.14 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 -179.282 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.621 ' H ' HD23 ' A' ' 29' ' ' LEU . 2.3 pt? -107.14 -5.72 17.8 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.669 -178.559 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 111.71 -172.76 15.12 Favored Glycine 0 N--CA 1.432 -1.595 0 N-CA-C 110.129 -1.188 . . . . 0.0 110.129 -175.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.444 ' CA ' ' HA ' ' A' ' 25' ' ' PRO . . . -90.64 132.78 11.45 Favored Glycine 0 CA--C 1.484 -1.894 0 C-N-CA 120.526 -0.845 . . . . 0.0 111.336 179.381 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.4 m -129.88 147.74 33.23 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.938 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -178.239 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.531 ' HA ' ' O ' ' A' ' 22' ' ' ASN . 96.4 m -82.25 120.07 24.9 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.132 178.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -119.76 137.71 53.78 Favored 'General case' 0 N--CA 1.427 -1.589 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 178.428 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--N 1.292 -1.898 0 C-N-CA 121.008 -0.277 . . . . 0.0 111.194 -177.472 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 25.8 p . . . . . 0 N--CA 1.446 -0.648 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.471 HG23 ' SG ' ' A' ' 33' ' ' CYS . 18.6 m -108.37 154.91 9.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 CA-C-O 121.134 0.492 . . . . 0.0 111.513 -179.605 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 57.7 mt -100.33 -176.96 3.37 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.52 -175.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.9 pt -61.13 130.49 25.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.503 0 CA-C-O 121.477 0.656 . . . . 0.0 112.438 -179.114 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 96.59 -22.64 39.12 Favored Glycine 0 C--N 1.311 -0.821 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.841 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -81.02 154.9 26.64 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-O 121.067 0.46 . . . . 0.0 109.794 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.1 tmt_? -86.34 138.15 32.04 Favored 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.349 -173.679 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 17.5 p -137.07 167.89 20.65 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.917 -177.364 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -141.66 120.49 12.7 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 175.41 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -63.37 -35.18 79.56 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.84 -0.618 . . . . 0.0 112.168 -170.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -92.44 -52.54 4.61 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 113.026 0.75 . . . . 0.0 113.026 -175.469 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.4 mtm180 -87.08 -27.81 22.92 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 121.133 0.492 . . . . 0.0 112.306 -174.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.0 163.42 26.76 Favored Glycine 0 N--CA 1.427 -1.966 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 -175.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -78.44 165.93 81.37 Favored 'Cis proline' 0 C--N 1.332 -0.323 0 C-N-CA 123.378 -1.509 . . . . 0.0 112.375 0.569 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 60.1 mtt180 -115.74 163.09 16.34 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.678 -179.358 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 58.4 m -70.14 142.33 52.55 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 123.638 0.775 . . . . 0.0 110.514 -177.39 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 81.9 m -67.39 157.48 34.0 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 174.667 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.1 p -57.64 96.6 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.818 0 C-N-CA 124.207 1.003 . . . . 0.0 112.477 -177.467 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 99.09 34.76 5.02 Favored Glycine 0 N--CA 1.433 -1.566 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.293 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.435 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 23.9 mm-40 -122.58 34.57 5.11 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-O 121.547 0.689 . . . . 0.0 111.013 177.184 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 78.47 -166.38 52.34 Favored Glycine 0 N--CA 1.419 -2.457 0 CA-C-N 114.928 -1.033 . . . . 0.0 112.169 178.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 40.4 m-80 -127.95 157.19 41.26 Favored 'General case' 0 C--N 1.29 -2.016 0 N-CA-C 106.607 -1.627 . . . . 0.0 106.607 -179.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 99.3 m -68.13 97.92 0.74 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 123.819 0.7 . . . . 0.0 111.765 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 7.7 p -82.82 126.62 72.54 Favored Pre-proline 0 N--CA 1.425 -1.699 0 N-CA-C 106.153 -1.795 . . . . 0.0 106.153 174.082 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.41 ' HA ' ' HA2' ' A' ' 31' ' ' GLY . 48.2 Cg_endo -70.3 129.99 17.94 Favored 'Trans proline' 0 N--CA 1.446 -1.288 0 C-N-CA 121.558 1.506 . . . . 0.0 114.283 -174.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.41 HD23 HG22 ' A' ' 32' ' ' VAL . 4.6 mm? -121.42 143.24 37.19 Favored Pre-proline 0 C--N 1.309 -1.187 0 CA-C-N 114.932 -1.031 . . . . 0.0 108.747 178.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_exo -44.26 -63.7 0.31 Allowed 'Trans proline' 0 CA--C 1.546 1.094 0 C-N-CA 123.731 2.954 . . . . 0.0 115.298 -176.744 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -89.65 -25.42 21.27 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 112.599 0.592 . . . . 0.0 112.599 -173.518 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -88.81 -17.97 28.66 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-O 121.362 0.601 . . . . 0.0 111.093 -175.434 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 88.89 -63.59 3.49 Favored Glycine 0 N--CA 1.429 -1.832 0 N-CA-C 109.389 -1.485 . . . . 0.0 109.389 -177.038 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.41 ' HA2' ' HA ' ' A' ' 25' ' ' PRO . . . -165.13 148.18 13.68 Favored Glycine 0 N--CA 1.419 -2.441 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.41 HG22 HD23 ' A' ' 26' ' ' LEU . 14.0 m -131.79 150.97 34.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 176.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.471 ' SG ' HG23 ' A' ' 2' ' ' VAL . 71.7 m -76.32 117.24 17.79 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -142.65 145.47 33.49 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 120.726 -0.389 . . . . 0.0 110.786 -179.733 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 31.6 m . . . . . 0 C--N 1.308 -1.22 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.603 176.963 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 23.4 p . . . . . 0 C--O 1.233 0.217 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.417 HG23 ' SG ' ' A' ' 33' ' ' CYS . 28.8 m -110.54 154.44 12.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-O 120.606 0.241 . . . . 0.0 111.367 -178.583 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 35.5 mt -99.69 -176.36 3.24 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.297 -177.477 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.408 ' HA ' ' O ' ' A' ' 33' ' ' CYS . 33.8 pt -58.14 134.6 22.84 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.73 0 CA-C-O 121.477 0.656 . . . . 0.0 112.489 179.027 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 93.73 -18.72 55.98 Favored Glycine 0 C--N 1.311 -0.828 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.296 178.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLN . . . . . 0.414 ' HB2' ' HB ' ' A' ' 2' ' ' VAL . 23.7 mt-30 -89.66 152.33 21.42 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -179.556 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.462 ' HA ' ' HA ' ' A' ' 32' ' ' VAL . 16.4 ptp180 -86.61 148.71 25.36 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.07 0.462 . . . . 0.0 111.106 -175.317 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 10.2 p -138.56 158.24 44.62 Favored 'General case' 0 C--N 1.298 -1.652 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.611 -174.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -129.06 124.03 33.8 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 176.152 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -79.17 -27.11 42.64 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 120.955 0.407 . . . . 0.0 111.626 -173.107 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -91.1 -42.08 10.68 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-N 115.723 -0.671 . . . . 0.0 112.154 -173.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 83.7 mtm180 -112.54 -13.3 13.35 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 -175.597 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 89.35 165.74 41.33 Favored Glycine 0 N--CA 1.44 -1.094 0 C-N-CA 120.055 -1.069 . . . . 0.0 110.805 -177.408 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -79.85 158.73 88.28 Favored 'Cis proline' 0 N--CA 1.463 -0.284 0 CA-C-N 119.227 1.513 . . . . 0.0 111.195 -0.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 80.9 mtm180 -113.49 172.67 6.83 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 121.03 -0.268 . . . . 0.0 110.502 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.7 m -68.01 141.0 56.37 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 123.634 0.583 . . . . 0.0 109.834 -179.228 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 55.8 m -67.33 140.86 57.29 Favored 'General case' 0 C--N 1.312 -1.042 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 172.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 5.9 p -58.4 94.77 0.02 OUTLIER 'General case' 0 CA--C 1.544 0.73 0 CA-C-O 121.663 0.744 . . . . 0.0 112.794 -177.383 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 132.38 -5.32 5.26 Favored Glycine 0 N--CA 1.438 -1.179 0 CA-C-N 114.853 -1.067 . . . . 0.0 110.644 -176.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . 0.448 ' O ' ' HB3' ' A' ' 33' ' ' CYS . 86.0 mm-40 -101.58 30.09 4.49 Favored 'General case' 0 C--N 1.323 -0.561 0 C-N-CA 123.348 0.659 . . . . 0.0 112.456 -177.483 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 84.44 -171.6 47.89 Favored Glycine 0 N--CA 1.436 -1.352 0 C-N-CA 120.103 -1.046 . . . . 0.0 113.9 175.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -113.44 162.59 15.94 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.747 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 98.8 m -76.87 97.23 4.51 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-O 121.553 0.692 . . . . 0.0 109.689 177.253 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.4 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 43.5 t -93.43 127.91 44.55 Favored Pre-proline 0 N--CA 1.416 -2.14 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 -179.045 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 24' ' ' VAL . 57.5 Cg_endo -85.0 121.01 2.34 Favored 'Trans proline' 0 N--CA 1.427 -2.421 0 C-N-CA 121.953 1.769 . . . . 0.0 112.018 -178.532 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.42 ' HA ' ' HD3' ' A' ' 27' ' ' PRO . 10.3 mp -110.39 124.52 33.08 Favored Pre-proline 0 C--N 1.29 -2.018 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 177.463 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 26' ' ' LEU . 78.2 Cg_exo -53.24 -17.38 8.46 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 C-N-CA 124.448 3.432 . . . . 0.0 115.564 -173.725 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.411 ' HB2' HD12 ' A' ' 29' ' ' LEU . 73.6 m-85 -110.55 -22.74 11.49 Favored 'General case' 0 C--N 1.309 -1.164 0 C-N-CA 120.858 -0.337 . . . . 0.0 111.388 -179.167 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . 0.411 HD12 ' HB2' ' A' ' 28' ' ' PHE . 6.1 mp -106.55 -16.89 14.41 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 112.177 0.436 . . . . 0.0 112.177 -173.76 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 98.94 -104.91 2.98 Favored Glycine 0 N--CA 1.426 -2.006 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 -176.449 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -147.35 127.9 2.79 Favored Glycine 0 C--N 1.295 -1.744 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 176.465 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.462 ' HA ' ' HA ' ' A' ' 7' ' ' ARG . 34.5 m -131.83 154.19 39.88 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 C-N-CA 122.926 0.49 . . . . 0.0 110.187 -175.809 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' CYS . . . . . 0.448 ' HB3' ' O ' ' A' ' 20' ' ' GLN . 74.4 m -74.53 119.69 19.06 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.705 178.033 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -146.53 148.75 32.5 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.752 0.311 . . . . 0.0 110.551 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 17.9 m . . . . . 0 C--N 1.306 -1.291 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.007 176.663 . . . . . . . . 0 0 . 1 stop_ save_